data_6r3c_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6r3c _Structure_validation_residue.Date_analyzed 2019-06-28 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.408 HG11 ' N ' ' A' ' 3' ' ' PHE . 56.3 t . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.302 0.572 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.477 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.461 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.493 HG21 ' N ' ' A' ' 13' ' ' ILE . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.449 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.575 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.442 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.475 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.451 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG13 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.431 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.419 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.466 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.418 ' O ' ' OG ' ' A' ' 40' ' ' SER . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.525 HG13 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.462 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.408 HG21 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.468 ' O ' ' CG2' ' A' ' 52' ' ' THR . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.444 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.52 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.551 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.466 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.514 ' OG ' ' N ' ' A' ' 40' ' ' SER . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo . . . . . 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.186 0.517 . . . . 0.0 109.686 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.551 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.51 HG22 ' N ' ' A' ' 68' ' ' LYS . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.51 ' N ' HG22 ' A' ' 67' ' ' VAL . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.408 ' OD1' ' CD2' ' A' ' 83' ' ' TYR . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.502 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.502 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.443 ' O ' ' HG2' ' A' ' 97' ' ' LYS . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.446 ' HA2' HG21 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.469 ' OD1' HD12 ' A' ' 95' ' ' LEU . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.493 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.464 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.515 HG12 ' CD1' ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.448 HG23 HD13 ' A' ' 102' ' ' ILE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.456 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.521 HG22 ' CB ' ' A' ' 15' ' ' ALA . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.321 0.582 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.461 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.456 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.407 ' HE1' ' CD1' ' A' ' 5' ' ' TYR . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.469 ' O ' ' HA ' ' A' ' 96' ' ' GLU . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.47 HG21 ' O ' ' A' ' 95' ' ' LEU . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.547 ' N ' ' O ' ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.535 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.419 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.458 ' O ' HD22 ' A' ' 151' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' A' ' 146' ' ' ALA . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.512 HG11 ' N ' ' A' ' 3' ' ' PHE . 39.4 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.567 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.567 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.426 HG23 ' HE3' ' A' ' 137' ' ' LYS . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.519 HG21 ' N ' ' A' ' 13' ' ' ILE . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.53 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.421 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.5 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.468 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.452 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.527 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.408 ' N ' HG22 ' A' ' 33' ' ' VAL . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.51 HG21 ' CG2' ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.503 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.404 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 55' ' ' LYS . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.485 ' O ' ' CG2' ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.414 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.432 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.485 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.429 ' N ' HG22 ' A' ' 52' ' ' THR . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.437 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.51 ' CG2' HG21 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.426 ' N ' ' O ' ' A' ' 65' ' ' LYS . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo . . . . . 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.426 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.458 HG11 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.522 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.448 ' OD1' HG23 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.472 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.447 ' HG3' ' N ' ' A' ' 74' ' ' VAL . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.561 HG12 ' CE1' ' A' ' 76' ' ' HIS . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.436 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . 0.561 ' CE1' HG12 ' A' ' 74' ' ' VAL . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.436 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.499 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.443 ' O ' ' O ' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.458 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.458 ' HA2' HG11 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.523 ' CD1' ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.527 ' CD2' ' CD2' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' ' CD1' ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.472 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.505 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.456 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.456 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.441 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 114' ' ' LEU . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.535 ' CD1' ' CD2' ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.458 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.456 ' O ' HG22 ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.456 HG22 ' O ' ' A' ' 106' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 26.5 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.535 ' CD2' ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.456 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.493 ' CE ' HG12 ' A' ' 2' ' ' VAL . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.505 ' CD1' HG12 ' A' ' 98' ' ' ILE . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' ' HD3' ' A' ' 119' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.476 ' HA ' ' O ' ' A' ' 94' ' ' THR . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.527 ' N ' ' O ' ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . 0.527 ' CD2' ' CD2' ' A' ' 95' ' ' LEU . 99.3 m-70 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.452 HG12 ' OE1' ' A' ' 132' ' ' GLN . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.452 ' OE1' HG12 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.44 HG11 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' HG23 ' A' ' 7' ' ' THR . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.535 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.459 HG12 HD11 ' A' ' 18' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.413 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.454 HD21 ' O ' ' A' ' 147' ' ' VAL . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.472 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.421 HG11 ' N ' ' A' ' 3' ' ' PHE . 94.6 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.543 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.543 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.518 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.453 ' HB ' HD21 ' A' ' 114' ' ' LEU . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.557 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.592 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 102' ' ' ILE . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.592 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.463 ' O ' HD11 ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.526 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.445 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.525 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.409 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.495 HG21 ' CG2' ' A' ' 56' ' ' ILE . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.463 ' OG ' ' HA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.511 ' O ' ' CG2' ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.467 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.451 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.511 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.459 HG23 HD11 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.495 ' CG2' HG21 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.463 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo . . . . . 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.137 0.494 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.459 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.464 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.464 ' OD2' ' O ' ' A' ' 68' ' ' LYS . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.474 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.451 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.413 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.562 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.476 ' O ' ' N ' ' A' ' 102' ' ' ILE . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.402 ' O ' HG13 ' A' ' 71' ' ' VAL . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.554 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.455 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.459 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.41 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.41 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.411 HD11 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.454 HD13 ' CA ' ' A' ' 92' ' ' GLY . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.416 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.552 HD12 ' CE2' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.557 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.493 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 89.8 p . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 121.238 0.542 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.493 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.514 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.523 ' CD1' HD22 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 21.0 m120 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.454 ' OH ' HG11 ' A' ' 133' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.458 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.454 HG11 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.427 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.518 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.447 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.495 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.44 ' O ' HD21 ' A' ' 151' ' ' LEU . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.427 ' O ' HD12 ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.462 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.452 ' N ' HD13 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.456 HG13 ' N ' ' A' ' 3' ' ' PHE . 95.1 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.461 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.461 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.444 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 13' ' ' ILE . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.545 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.545 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.536 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.448 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.519 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.523 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.523 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.465 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.526 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.414 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.487 HG21 ' CG2' ' A' ' 56' ' ' ILE . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.461 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.459 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.492 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.492 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.45 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.447 HG12 ' HG2' ' A' ' 70' ' ' ARG . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.459 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.487 ' CG2' HG21 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.452 ' O ' HG21 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.21 0.528 . . . . 0.0 109.596 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 68' ' ' LYS . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.52 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.447 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.481 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.481 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.441 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.406 ' HA2' HG21 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.458 HD13 ' O ' ' A' ' 96' ' ' GLU . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 122' ' ' THR . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.536 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 59.3 p . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.254 0.55 . . . . 0.0 109.541 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.476 HD23 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 15.1 m120 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.462 ' CE1' HG21 ' A' ' 133' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' GLU . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.45 HG23 HG23 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.45 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 25.1 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.462 HG21 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.473 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.473 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.437 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.455 ' O ' HD22 ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.488 HD11 ' N ' ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 86.3 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.335 0.588 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.453 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.453 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.422 HG21 ' HE3' ' A' ' 137' ' ' LYS . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.401 ' O ' ' N ' ' A' ' 114' ' ' LEU . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.4 HG22 HG12 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.532 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.532 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.505 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.47 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.578 ' CE2' HD11 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HG2' ' CD2' ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.491 ' CD2' ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.52 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.432 HG21 HG21 ' A' ' 41' ' ' VAL . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.432 HG21 HG21 ' A' ' 38' ' ' ILE . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.485 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.485 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.469 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.505 ' HB ' ' CG1' ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.505 ' CG1' ' HB ' ' A' ' 56' ' ' ILE . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.42 ' N ' HG22 ' A' ' 67' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.441 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.445 HG11 ' O ' ' A' ' 82' ' ' ASN . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.564 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.483 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.445 ' O ' HG11 ' A' ' 71' ' ' VAL . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.435 ' O ' ' O ' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.475 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.481 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 96' ' ' GLU . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.456 ' O ' HD12 ' A' ' 91' ' ' ILE . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.467 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.504 HD11 ' CE2' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.505 HG22 ' CB ' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.454 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.454 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.446 HD13 HG23 ' A' ' 107' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.401 ' N ' ' O ' ' A' ' 9' ' ' THR . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.518 ' CE2' HG12 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.477 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . 0.575 ' O ' ' CD2' ' A' ' 126' ' ' HIS . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . 0.575 ' CD2' ' O ' ' A' ' 124' ' ' GLY . 85.7 m-70 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.518 HG12 ' CE2' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.422 ' HE3' HG21 ' A' ' 7' ' ' THR . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.414 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.492 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 139' ' ' MET . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.492 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.433 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.549 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.549 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.529 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.5 ' CD1' HD12 ' A' ' 104' ' ' ILE . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.529 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.463 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.404 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.463 ' HB2' HD11 ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.463 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.521 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 57' ' ' SER . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.491 HD13 ' CG2' ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.469 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.413 ' O ' HG12 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.491 ' CG2' HD13 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.438 HD13 ' HB2' ' A' ' 69' ' ' ASP . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG22 ' A' ' 38' ' ' ILE . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.42 ' N ' ' O ' ' A' ' 65' ' ' LYS . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.42 ' O ' ' N ' ' A' ' 58' ' ' PHE . 81.5 tttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.266 0.555 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.472 HG13 ' N ' ' A' ' 68' ' ' LYS . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.438 ' HB2' HD13 ' A' ' 56' ' ' ILE . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.499 ' NH1' HG23 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.51 HG23 ' CZ ' ' A' ' 81' ' ' TYR . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.458 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.51 ' CZ ' HG23 ' A' ' 71' ' ' VAL . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.503 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.564 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.502 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.499 HG23 ' NH1' ' A' ' 70' ' ' ARG . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.47 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.446 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.511 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.511 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.437 ' O ' ' O ' ' A' ' 88' ' ' GLY . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.5 ' CA ' HD13 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.5 HD13 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.449 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.564 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.503 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.485 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.508 HG23 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.457 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.468 ' O ' HG23 ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.449 HD21 HG21 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.481 ' CD1' HG12 ' A' ' 98' ' ' ILE . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.457 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.439 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.426 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.44 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.528 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.514 HD13 ' CG2' ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.434 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.492 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.537 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.537 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.498 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.49 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.552 ' CD1' ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.49 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.404 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.529 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.404 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.529 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.475 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.443 HG12 ' N ' ' A' ' 42' ' ' GLU . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.416 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.444 ' O ' ' CG2' ' A' ' 52' ' ' THR . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.451 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.483 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.444 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.507 HG21 ' CD1' ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' CD1' ' O ' ' A' ' 37' ' ' ALA . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.494 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.43 HG11 ' N ' ' A' ' 68' ' ' LYS . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.483 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.514 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.426 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.413 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.411 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.511 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.511 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 96' ' ' GLU . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.432 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.514 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.498 HG22 ' CB ' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 105' ' ' VAL . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.417 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.404 HD23 HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.407 ' N ' ' O ' ' A' ' 5' ' ' TYR . 16.8 m120 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.434 ' HG2' ' OD1' ' A' ' 4' ' ' ASN . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.432 HG23 ' CG2' ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.45 ' O ' ' HG3' ' A' ' 137' ' ' LYS . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.442 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.531 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.442 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.479 HD11 ' CG2' ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.483 HG12 ' ND1' ' A' ' 121' ' ' HIS . 46.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.401 ' N ' HG13 ' A' ' 2' ' ' VAL . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.473 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.458 ' OG ' ' OE1' ' A' ' 148' ' ' GLU . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.507 ' HB3' ' CG2' ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.585 ' CE2' HD11 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.585 HD11 ' CE2' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.443 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.456 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.521 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.456 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.441 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.502 ' CD1' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.444 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 27' ' ' ASP . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.472 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.475 ' N ' ' O ' ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.475 ' O ' ' CG2' ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.456 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.529 ' HB ' ' CG1' ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.408 ' O ' HG21 ' A' ' 38' ' ' ILE . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.444 ' HD3' ' N ' ' A' ' 39' ' ' SER . 48.9 Cg_endo . . . . . 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.305 0.574 . . . . 0.0 109.875 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.463 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.529 ' CG1' ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.524 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.489 HG21 ' CZ ' ' A' ' 81' ' ' TYR . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.568 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.459 ' OD1' ' HB3' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.504 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.507 HD21 ' CD2' ' A' ' 126' ' ' HIS . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.433 ' O ' HD12 ' A' ' 91' ' ' ILE . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.476 HD11 ' CZ ' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.547 ' CD1' ' CD1' ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.449 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.499 HD11 HG21 ' A' ' 113' ' ' ILE . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.547 ' CD1' ' CD1' ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.452 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.534 ' CG1' ' CD2' ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.563 ' CE2' HG11 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.483 ' ND1' HG12 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 94' ' ' THR . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . 0.507 ' CD2' HD21 ' A' ' 95' ' ' LEU . 96.9 m-70 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.563 HG11 ' CE2' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.474 ' CE ' HG13 ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.444 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.529 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.444 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.529 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.428 ' HA ' HG13 ' A' ' 33' ' ' VAL . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.458 ' OE1' ' OG ' ' A' ' 11' ' ' SER . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.523 ' CD1' HG23 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.409 ' CD2' HD13 ' A' ' 13' ' ' ILE . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.553 HG13 ' CE1' ' A' ' 121' ' ' HIS . 92.0 t . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.494 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.494 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.462 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.541 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.541 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.532 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.629 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.438 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.464 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.416 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.528 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.416 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.528 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.444 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CD1' HG22 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.495 ' HB ' ' NZ ' ' A' ' 54' ' ' LYS . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.424 ' ND2' ' O ' ' A' ' 46' ' ' GLY . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.419 ' HB ' ' HB ' ' A' ' 53' ' ' ILE . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 52' ' ' THR . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.465 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.432 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.465 HG21 ' HA3' ' A' ' 46' ' ' GLY . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.43 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.495 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.525 HG22 ' CD1' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.414 ' N ' HG23 ' A' ' 56' ' ' ILE . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.436 ' O ' HG13 ' A' ' 67' ' ' VAL . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.473 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.453 ' OD1' HG23 ' A' ' 85' ' ' VAL . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.458 HG23 ' OH ' ' A' ' 81' ' ' TYR . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.435 ' O ' HG13 ' A' ' 71' ' ' VAL . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.451 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.405 ' HA2' HG22 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.465 HD11 ' O ' ' A' ' 96' ' ' GLU . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.459 HD12 ' OD1' ' A' ' 93' ' ' ASP . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.465 ' O ' HD11 ' A' ' 91' ' ' ILE . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.429 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.472 HD11 ' CD1' ' A' ' 18' ' ' LEU . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.418 ' C ' HG21 ' A' ' 107' ' ' THR . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.418 HG21 ' C ' ' A' ' 106' ' ' ALA . 13.6 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 77.4 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.293 0.568 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.462 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.429 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.464 HD11 HG22 ' A' ' 116' ' ' ILE . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.412 ' O ' HG11 ' A' ' 2' ' ' VAL . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.553 ' CE1' HG13 ' A' ' 2' ' ' VAL . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 94' ' ' THR . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HG23 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.527 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.527 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.466 ' HB3' HG22 ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.461 ' O ' HD22 ' A' ' 151' ' ' LEU . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.461 HD22 ' O ' ' A' ' 147' ' ' VAL . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.496 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.47 HG11 ' ND1' ' A' ' 121' ' ' HIS . 64.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.501 ' HB3' ' NZ ' ' A' ' 137' ' ' LYS . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 21' ' ' ALA . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.476 ' C ' ' CD1' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' ARG . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.465 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.431 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.488 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.488 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 57' ' ' SER . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.43 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.455 HD12 HG23 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.485 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.485 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.413 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.455 HG23 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.453 HG22 HD11 ' A' ' 56' ' ' ILE . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' HG22 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo . . . . . 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.452 HG12 ' N ' ' A' ' 68' ' ' LYS . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.523 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.425 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.477 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.523 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.456 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.421 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.454 ' O ' HD11 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.456 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.41 HD11 HG23 ' A' ' 102' ' ' ILE . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.496 HG12 ' CD2' ' A' ' 114' ' ' LEU . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.496 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.567 ' CE2' HG12 ' A' ' 133' ' ' VAL . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.47 ' ND1' HG11 ' A' ' 2' ' ' VAL . 84.0 m-70 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.456 HG22 HG23 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.567 HG12 ' CE2' ' A' ' 120' ' ' TYR . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.501 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.433 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.528 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.468 ' HB1' ' CG2' ' A' ' 33' ' ' VAL . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.45 ' O ' HD21 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.489 HD13 ' CG2' ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.45 HD21 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.474 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.474 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.541 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.541 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.541 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.519 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' HG12 ' A' ' 23' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.465 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB3' ' CD1' ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.451 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.444 ' CD1' ' HB3' ' A' ' 25' ' ' ASP . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.534 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.46 HG23 HG23 ' A' ' 41' ' ' VAL . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.46 HG23 HG23 ' A' ' 38' ' ' ILE . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.506 ' N ' ' O ' ' A' ' 53' ' ' ILE . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.509 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.459 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.509 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.492 ' HB2' ' CD1' ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.436 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.417 ' O ' HG21 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo . . . . . 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.44 HG11 ' N ' ' A' ' 68' ' ' LYS . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.44 ' N ' HG11 ' A' ' 67' ' ' VAL . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.452 HG12 ' HB ' ' A' ' 52' ' ' THR . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 71' ' ' VAL . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.415 ' N ' ' O ' ' A' ' 102' ' ' ILE . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.405 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.498 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.498 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.406 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.431 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.431 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD11 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.527 HD11 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.458 ' OD1' HG22 ' A' ' 116' ' ' ILE . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.456 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.503 HD11 ' CE2' ' A' ' 22' ' ' PHE . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.541 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.466 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.459 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 60.7 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.466 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.471 ' CD2' HG22 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.451 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.458 HG22 ' OD1' ' A' ' 100' ' ' ASN . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.403 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 21.6 m120 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.508 ' CE1' HG22 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.516 ' CG2' HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.516 HG23 ' CG2' ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.516 HG12 ' CE ' ' A' ' 137' ' ' LYS . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.516 ' CE ' HG12 ' A' ' 133' ' ' VAL . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.534 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.454 ' O ' HD21 ' A' ' 151' ' ' LEU . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.434 ' O ' HD21 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.516 ' HB3' ' CD1' ' A' ' 13' ' ' ILE . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.468 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.501 HG13 ' ND1' ' A' ' 121' ' ' HIS . 48.5 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.574 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.574 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.532 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.532 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.441 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.575 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.453 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.477 HG23 HD12 ' A' ' 23' ' ' ILE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.472 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.428 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.524 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.428 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.428 HG22 ' CG2' ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.476 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.505 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 53' ' ' ILE . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.477 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.574 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.476 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo . . . . . 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.131 0.491 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.574 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.493 HG13 ' N ' ' A' ' 68' ' ' LYS . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.522 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.446 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.42 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.511 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.463 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.467 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.48 HG21 HD13 ' A' ' 91' ' ' ILE . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.508 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.508 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.511 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.482 HD12 HG21 ' A' ' 98' ' ' ILE . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.411 ' N ' ' O ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.445 HG22 ' HB3' ' A' ' 15' ' ' ALA . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.515 ' HG ' ' N ' ' A' ' 115' ' ' LYS . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.515 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.56 ' CE2' HG12 ' A' ' 133' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.501 ' ND1' HG13 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 94' ' ' THR . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.448 HG11 ' OE1' ' A' ' 132' ' ' GLN . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.448 ' OE1' HG11 ' A' ' 128' ' ' VAL . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.56 HG12 ' CE2' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.515 ' HE3' ' CG1' ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.436 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.406 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.451 ' HB2' HG22 ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.448 HG13 HD23 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.455 ' HA ' HD11 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.523 HD13 ' CG2' ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.513 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.484 HG12 ' ND1' ' A' ' 121' ' ' HIS . 54.9 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.581 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.581 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.465 HG23 ' N ' ' A' ' 13' ' ' ILE . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.546 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.546 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.525 ' HB3' ' CG2' ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.433 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.485 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.469 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.485 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.467 ' HB2' HD13 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.502 ' OD1' ' NZ ' ' A' ' 32' ' ' LYS . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.532 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.502 ' NZ ' ' OD1' ' A' ' 28' ' ' ASN . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.41 ' N ' HG22 ' A' ' 33' ' ' VAL . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.441 ' O ' ' OG ' ' A' ' 40' ' ' SER . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 39' ' ' SER . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.459 HG23 HG22 ' A' ' 38' ' ' ILE . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.457 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.482 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.482 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.457 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.519 ' HB2' ' CD1' ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.519 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.501 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.411 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.445 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.454 HG11 ' HA2' ' A' ' 88' ' ' GLY . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.491 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.498 HG22 ' CZ ' ' A' ' 81' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.419 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.536 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.536 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.455 ' O ' HG23 ' A' ' 71' ' ' VAL . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.487 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.48 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.439 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.454 ' HA2' HG11 ' A' ' 67' ' ' VAL . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.446 HD12 HG22 ' A' ' 91' ' ' ILE . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.503 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.48 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.428 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.525 ' CG2' ' HB3' ' A' ' 15' ' ' ALA . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 13.0 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.443 HD11 HG23 ' A' ' 107' ' ' THR . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 103' ' ' LYS . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.428 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 23.8 m120 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 133' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.484 ' ND1' HG12 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 94' ' ' THR . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.407 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.531 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 139' ' ' MET . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.458 ' HB3' HG21 ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.465 ' O ' HD23 ' A' ' 151' ' ' LEU . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.465 HD23 ' O ' ' A' ' 147' ' ' VAL . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 121' ' ' HIS . 87.1 t . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.292 0.568 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.521 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.46 ' OD1' ' HE3' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.521 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.459 HG22 ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.544 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.544 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.459 ' HB3' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.513 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.457 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.542 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.468 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.525 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.414 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.463 HG21 ' O ' ' A' ' 57' ' ' SER . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.42 HG12 ' N ' ' A' ' 42' ' ' GLU . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.42 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.447 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.459 HD12 ' CG2' ' A' ' 53' ' ' ILE . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.468 ' O ' ' CG2' ' A' ' 52' ' ' THR . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 71' ' ' VAL . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.459 ' CG2' HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.468 ' NZ ' ' OD1' ' A' ' 27' ' ' ASP . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.416 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG21 ' A' ' 38' ' ' ILE . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.566 HG21 ' CZ ' ' A' ' 81' ' ' TYR . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.466 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.412 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.566 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.466 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.402 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.514 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.47 ' O ' ' O ' ' A' ' 88' ' ' GLY . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.463 ' O ' HG23 ' A' ' 122' ' ' THR . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.513 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.469 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.439 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.542 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.45 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 114' ' ' LEU . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 93.2 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.582 ' CD1' ' CD1' ' A' ' 104' ' ' ILE . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.45 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.465 ' CD1' HD12 ' A' ' 144' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.513 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.518 ' CE1' HG13 ' A' ' 2' ' ' VAL . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.475 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.432 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.457 HG13 ' OH ' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.459 ' HE3' HG22 ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.432 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.47 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.579 ' CD1' ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.446 ' HB1' HG23 ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.524 ' HG2' ' CD1' ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.525 ' CD1' HD12 ' A' ' 13' ' ' ILE . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.494 HD21 ' N ' ' A' ' 152' ' ' LEU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.414 HG13 ' N ' ' A' ' 3' ' ' PHE . 49.1 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.574 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.574 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.463 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.419 ' OG ' ' OE2' ' A' ' 148' ' ' GLU . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.553 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.553 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 104' ' ' ILE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.52 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.565 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.535 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.502 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.511 ' CD1' ' O ' ' A' ' 25' ' ' ASP . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.448 HG22 HG22 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.436 HD12 HG21 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.488 ' O ' ' CG2' ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.436 HG21 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.47 ' HB ' HG13 ' A' ' 67' ' ' VAL . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 65' ' ' LYS . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.247 0.546 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.514 HG21 ' N ' ' A' ' 68' ' ' LYS . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.514 ' N ' HG21 ' A' ' 67' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.439 ' OD2' ' O ' ' A' ' 54' ' ' LYS . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.482 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.504 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.46 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 8.3 m120 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.473 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.482 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.504 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.437 ' O ' ' O ' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.465 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.446 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.439 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 HG21 ' A' ' 91' ' ' ILE . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.458 ' O ' HD11 ' A' ' 91' ' ' ILE . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.524 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.513 ' CD1' ' HA ' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.518 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.4 p . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 61.5 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.518 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.473 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.471 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.463 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 22.1 m120 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.524 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.458 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 94' ' ' THR . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.427 ' HA ' ' HE1' ' A' ' 139' ' ' MET . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.463 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.427 ' HE1' ' HA ' ' A' ' 136' ' ' SER . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.53 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.462 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.468 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.452 ' O ' HD23 ' A' ' 151' ' ' LEU . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.53 ' HA ' ' CD1' ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.435 ' O ' ' HB1' ' A' ' 153' ' ' ALA . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.452 HD23 ' O ' ' A' ' 147' ' ' VAL . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 150' ' ' TYR . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.576 HG13 ' CE1' ' A' ' 121' ' ' HIS . 78.8 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.289 0.566 . . . . 0.0 109.563 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.525 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.525 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.433 HG21 ' HG3' ' A' ' 137' ' ' LYS . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.509 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.509 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.524 ' HB2' ' CG2' ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.549 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.57 ' CZ ' HD12 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.466 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.43 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.447 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.405 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.474 HG12 ' CG2' ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.478 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.511 ' N ' ' O ' ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.425 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.469 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.404 ' HA ' HG12 ' A' ' 71' ' ' VAL . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.462 ' HB ' HG11 ' A' ' 71' ' ' VAL . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.523 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.474 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.268 0.556 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 66' ' ' TYR . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.439 ' HB2' ' HB2' ' A' ' 87' ' ' GLU . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.565 HG23 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.434 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.565 ' CE2' HG23 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.444 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 21.0 m120 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 69' ' ' ASP . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.439 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.446 HD13 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.542 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.53 ' CD2' ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.469 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.446 HG12 HD13 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.557 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.444 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.524 ' CG2' ' HB2' ' A' ' 15' ' ' ALA . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.52 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.417 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.452 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.564 ' CE2' HG21 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.576 ' CE1' HG13 ' A' ' 2' ' ' VAL . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . 0.53 ' CD2' ' CD2' ' A' ' 95' ' ' LEU . 97.7 m-70 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.422 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.422 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.564 HG21 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.433 ' HG3' HG21 ' A' ' 7' ' ' THR . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.529 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.529 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.52 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.47 ' CG2' HG13 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.416 ' O ' HD21 ' A' ' 152' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.454 HD21 ' O ' ' A' ' 147' ' ' VAL . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.426 HG11 ' ND1' ' A' ' 121' ' ' HIS . 50.1 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.485 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.438 HG23 ' N ' ' A' ' 10' ' ' THR . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.438 ' N ' HG23 ' A' ' 9' ' ' THR . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.437 ' OG ' ' OE1' ' A' ' 148' ' ' GLU . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.512 HG23 ' N ' ' A' ' 13' ' ' ILE . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.54 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.54 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.528 ' CB ' HG23 ' A' ' 104' ' ' ILE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.43 ' O ' ' HB1' ' A' ' 21' ' ' ALA . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.638 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.565 ' CE2' HD12 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.638 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.457 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.526 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.457 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.515 ' CD1' HG22 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.513 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.503 ' CG1' ' HB2' ' A' ' 55' ' ' LYS . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.476 ' O ' ' CG2' ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.459 ' O ' HG13 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.46 HG22 ' CD1' ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.513 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.503 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.515 HG22 ' CD1' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.45 ' O ' HG21 ' A' ' 38' ' ' ILE . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.458 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.249 0.547 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.408 HG12 ' N ' ' A' ' 68' ' ' LYS . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.508 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.405 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.421 HG12 ' CE1' ' A' ' 76' ' ' HIS . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . 0.421 ' CE1' HG12 ' A' ' 74' ' ' VAL . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.577 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.446 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.508 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.444 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.517 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.517 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.463 ' O ' ' O ' ' A' ' 88' ' ' GLY . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.453 ' O ' HD11 ' A' ' 91' ' ' ILE . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.538 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.496 ' OD1' ' ND2' ' A' ' 118' ' ' ASN . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.45 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.565 HD12 ' CE2' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.528 HG23 ' CB ' ' A' ' 15' ' ' ALA . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.456 ' O ' HG22 ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.456 HG22 ' O ' ' A' ' 106' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.401 ' CD2' HG12 ' A' ' 104' ' ' ILE . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.496 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 1.1 t-20 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CD2' HG12 ' A' ' 98' ' ' ILE . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.477 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 94' ' ' THR . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.417 ' CG2' ' CG2' ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.512 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.512 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 33' ' ' VAL . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.463 ' O ' HD22 ' A' ' 151' ' ' LEU . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.465 ' O ' HD22 ' A' ' 152' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.478 ' CD1' HD21 ' A' ' 29' ' ' LEU . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.468 ' CD2' ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' A' ' 121' ' ' HIS . 62.7 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.541 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.45 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.541 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.417 ' O ' HG23 ' A' ' 113' ' ' ILE . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.521 ' CB ' HG21 ' A' ' 104' ' ' ILE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.471 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.526 HD13 ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.561 ' CE2' HG13 ' A' ' 23' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.526 ' CB ' HD13 ' A' ' 18' ' ' LEU . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.561 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.46 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.527 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.46 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.527 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.457 HG23 HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.476 ' CD1' HG23 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.477 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.423 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.476 HG23 ' CD1' ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.52 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.457 HG23 HG23 ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 38' ' ' ILE . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo . . . . . 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.445 ' HD2' ' OE2' ' A' ' 87' ' ' GLU . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.495 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.522 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.522 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.58 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.431 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 69' ' ' ASP . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.495 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.445 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.403 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.403 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.447 HG22 HD11 ' A' ' 91' ' ' ILE . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.483 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.431 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.58 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.453 ' N ' ' O ' ' A' ' 81' ' ' TYR . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.521 HG21 ' CB ' ' A' ' 15' ' ' ALA . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.474 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.3 p . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 83.6 p . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.474 HG13 ' CG2' ' A' ' 107' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.512 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.456 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 94' ' ' THR . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . 0.434 ' CD2' HD22 ' A' ' 95' ' ' LEU . 97.7 m-70 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.442 HG23 ' CG2' ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.454 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.454 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.465 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.53 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.505 ' N ' HD11 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.456 ' O ' HD22 ' A' ' 151' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.435 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.507 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 3' ' ' PHE . 58.2 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.54 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.54 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.508 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.547 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.547 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.519 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.527 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.544 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.527 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.494 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.51 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.423 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.52 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.431 HG21 HD11 ' A' ' 38' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.51 ' CG2' ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.461 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.467 ' O ' ' CG2' ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.416 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.4 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.467 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.512 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.461 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo . . . . . 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.268 0.556 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.509 HG11 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.512 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.467 HG22 ' CZ ' ' A' ' 81' ' ' TYR . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.46 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.46 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.457 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 12.5 m120 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.544 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.483 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.551 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.408 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.449 ' O ' ' HG2' ' A' ' 97' ' ' LYS . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.585 ' CD1' ' N ' ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.509 ' CA ' HG11 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.504 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 HD12 ' A' ' 91' ' ' ILE . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.457 ' O ' HD11 ' A' ' 91' ' ' ILE . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.408 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.551 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.483 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.467 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' THR . . . . . 0.517 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.5 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.437 ' HA ' HG22 ' A' ' 107' ' ' THR . 80.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.517 HG13 ' CG2' ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.445 ' N ' HG22 ' A' ' 113' ' ' ILE . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.457 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 94' ' ' THR . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.448 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 23.7 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.508 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.524 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.524 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . 0.462 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.494 ' CG2' HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.457 ' HA ' HD11 ' A' ' 13' ' ' ILE . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.523 HD11 ' CD1' ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.456 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.438 HG13 ' N ' ' A' ' 3' ' ' PHE . 45.5 t . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.271 0.558 . . . . 0.0 109.565 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.553 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.553 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.405 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' THR . . . . . 0.415 HG23 ' HG3' ' A' ' 137' ' ' LYS . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.46 HG22 HD11 ' A' ' 13' ' ' ILE . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.539 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.539 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.419 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.526 ' CD2' HD22 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.501 ' CA ' HG22 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.53 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.425 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.53 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.471 HG22 ' CG2' ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.501 HG22 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.449 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . 0.449 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.419 HD13 HG21 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.507 ' O ' ' CG2' ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.507 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.443 HG12 ' HG2' ' A' ' 70' ' ' ARG . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.531 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.267 0.556 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.531 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.436 HG22 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.523 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.455 ' HD3' HG23 ' A' ' 86' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.455 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 10.9 m120 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.518 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.406 ' OH ' HG22 ' A' ' 71' ' ' VAL . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.455 HG23 ' HD3' ' A' ' 70' ' ' ARG . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.518 HD13 HG22 ' A' ' 91' ' ' ILE . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.531 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.456 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.445 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.464 HG22 ' CB ' ' A' ' 15' ' ' ALA . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.467 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.422 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 24.2 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.526 HD22 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.447 HG21 ' OD1' ' A' ' 100' ' ' ASN . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ASN . . . . . 0.471 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 26.0 m120 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.464 ' OH ' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.452 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' LYS . . . . . 0.531 ' N ' ' O ' ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.542 HG12 ' CD1' ' A' ' 5' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 7' ' ' THR . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.4 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.518 ' CG1' HD23 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 153' ' ' ALA . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' LEU . . . . . 0.501 HD21 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 150' ' ' TYR . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.408 HG11 ' N ' ' A' ' 3' ' ' PHE . 56.3 t -135.01 144.18 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -1.137 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.477 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.461 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.493 HG21 ' N ' ' A' ' 13' ' ' ILE . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.449 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.575 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.442 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.475 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.451 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG13 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.431 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.419 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.466 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.418 ' O ' ' OG ' ' A' ' 40' ' ' SER . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.525 HG13 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.462 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.408 HG21 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.468 ' O ' ' CG2' ' A' ' 52' ' ' THR . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.444 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.52 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.551 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.466 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.514 ' OG ' ' N ' ' A' ' 40' ' ' SER . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 159.11 54.46 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -61.95 145.21 53.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.71 13.65 27.26 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.565 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -117.34 173.59 3.07 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.299 -1.118 . . . . 0.0 109.292 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.565 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 47.6 Cg_endo -68.65 -47.13 1.48 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.54 2.16 . . . . 0.0 111.612 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.505 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 48.2 p90 -123.31 152.3 41.56 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.903 . . . . 0.0 109.195 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt -76.36 -44.08 38.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.202 -0.936 . . . . 0.0 109.686 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.551 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.51 HG22 ' N ' ' A' ' 68' ' ' LYS . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.51 ' N ' HG22 ' A' ' 67' ' ' VAL . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.408 ' OD1' ' CD2' ' A' ' 83' ' ' TYR . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.502 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.502 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.443 ' O ' ' HG2' ' A' ' 97' ' ' LYS . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.446 ' HA2' HG21 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.469 ' OD1' HD12 ' A' ' 95' ' ' LEU . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.493 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.464 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.515 HG12 ' CD1' ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.448 HG23 HD13 ' A' ' 102' ' ' ILE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.456 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.521 HG22 ' CB ' ' A' ' 15' ' ' ALA . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.452 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -153.74 122.81 3.16 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.79 -1.48 8.56 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.74 2.293 . . . . 0.0 111.79 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -87.07 -31.68 20.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.276 -0.89 . . . . 0.0 109.647 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -156.54 33.41 0.58 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 81.64 -145.51 25.08 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p -107.25 143.38 35.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -1.152 . . . . 0.0 109.448 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.461 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.456 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.407 ' HE1' ' CD1' ' A' ' 5' ' ' TYR . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.469 ' O ' ' HA ' ' A' ' 96' ' ' GLU . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.47 HG21 ' O ' ' A' ' 95' ' ' LEU . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.547 ' N ' ' O ' ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.535 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.419 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.458 ' O ' HD22 ' A' ' 151' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' A' ' 146' ' ' ALA . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.38 76.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.4 m80 -52.25 -33.01 39.64 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.318 -0.863 . . . . 0.0 109.457 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.5 m -61.59 -30.49 70.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.481 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -72.24 -15.83 61.93 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -72.33 143.43 48.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.234 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -48.94 -51.48 30.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.322 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.372 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.512 HG11 ' N ' ' A' ' 3' ' ' PHE . 39.4 t -128.97 153.21 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -1.122 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.567 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.567 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.426 HG23 ' HE3' ' A' ' 137' ' ' LYS . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.519 HG21 ' N ' ' A' ' 13' ' ' ILE . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.53 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.421 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.5 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.468 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.452 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.527 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.408 ' N ' HG22 ' A' ' 33' ' ' VAL . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.49 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.51 HG21 ' CG2' ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.503 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.404 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 55' ' ' LYS . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.485 ' O ' ' CG2' ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.414 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.432 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.485 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.429 ' N ' HG22 ' A' ' 52' ' ' THR . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.437 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.51 ' CG2' HG21 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.426 ' N ' ' O ' ' A' ' 65' ' ' LYS . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.522 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.0 Cg_endo -70.31 153.55 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -53.32 140.8 25.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.438 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.28 10.9 46.96 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.522 ' CD2' ' HG2' ' A' ' 59' ' ' PRO . 2.8 m-85 -108.61 169.08 6.92 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.238 -1.154 . . . . 0.0 109.487 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.453 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -69.94 -48.15 0.74 Allowed 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.696 2.264 . . . . 0.0 111.739 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.554 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 95.1 m-85 -116.71 152.87 33.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.201 -0.937 . . . . 0.0 109.503 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.426 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt -82.74 -43.08 17.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.458 HG11 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.522 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.448 ' OD1' HG23 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.472 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.447 ' HG3' ' N ' ' A' ' 74' ' ' VAL . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.561 HG12 ' CE1' ' A' ' 76' ' ' HIS . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.436 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.561 ' CE1' HG12 ' A' ' 74' ' ' VAL . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.436 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.499 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.443 ' O ' ' O ' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.458 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.458 ' HA2' HG11 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.554 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.523 ' CD1' ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.527 ' CD2' ' CD2' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' ' CD1' ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.472 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.505 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.456 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.456 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.441 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 114' ' ' LEU . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.535 ' CD1' ' CD2' ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.458 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.456 ' O ' HG22 ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.7 OUTLIER -153.29 122.63 3.24 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.16 -0.85 7.86 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.613 2.209 . . . . 0.0 111.721 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.1 m-20 -79.89 -43.98 21.25 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.217 -0.927 . . . . 0.0 109.691 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -150.87 36.61 0.9 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 87.39 -150.0 22.33 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 26.5 m -104.98 139.85 39.06 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.129 . . . . 0.0 109.414 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.535 ' CD2' ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.456 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.493 ' CE ' HG12 ' A' ' 2' ' ' VAL . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.505 ' CD1' HG12 ' A' ' 98' ' ' ILE . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' ' HD3' ' A' ' 119' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.476 ' HA ' ' O ' ' A' ' 94' ' ' THR . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.527 ' N ' ' O ' ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . 0.527 ' CD2' ' CD2' ' A' ' 95' ' ' LEU . 99.3 m-70 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.452 HG12 ' OE1' ' A' ' 132' ' ' GLN . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.452 ' OE1' HG12 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.44 HG11 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' HG23 ' A' ' 7' ' ' THR . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.535 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.459 HG12 HD11 ' A' ' 18' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.413 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.546 ' CE2' ' CE1' ' A' ' 154' ' ' HIS . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.459 ' HA ' ' CD2' ' A' ' 154' ' ' HIS . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.472 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -65.54 -33.67 76.47 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.546 ' CE1' ' CE2' ' A' ' 150' ' ' TYR . 73.1 m-70 -49.58 -33.64 15.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.0 m -56.98 -31.96 65.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.255 -0.903 . . . . 0.0 109.411 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -71.19 -19.58 62.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.295 -0.878 . . . . 0.0 109.419 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.421 ' HB1' ' O ' ' A' ' 154' ' ' HIS . . . -64.39 -24.38 67.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.873 . . . . 0.0 109.372 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -114.8 129.91 56.77 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 27.2 t30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.549 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.421 HG11 ' N ' ' A' ' 3' ' ' PHE . 94.6 t -131.69 146.15 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -1.155 . . . . 0.0 109.489 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.543 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.543 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.443 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.518 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.453 ' HB ' HD21 ' A' ' 114' ' ' LEU . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.557 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.592 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.552 ' CE2' HD12 ' A' ' 102' ' ' ILE . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.592 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.463 ' O ' HD11 ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.526 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.445 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.525 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.409 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.495 HG21 ' CG2' ' A' ' 56' ' ' ILE . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.463 ' OG ' ' HA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.459 HD11 HG23 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.511 ' O ' ' CG2' ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.467 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.451 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.511 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.459 HG23 HD11 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.495 ' CG2' HG21 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.418 ' CD2' ' CD1' ' A' ' 62' ' ' PHE . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.463 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo -69.73 151.68 69.29 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -52.22 143.46 14.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.464 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.17 10.08 43.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.562 ' CG ' ' HD2' ' A' ' 63' ' ' PRO . 0.2 OUTLIER -113.09 166.78 10.38 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.231 -1.158 . . . . 0.0 109.468 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.562 ' HD2' ' CG ' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.99 -51.67 0.43 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.734 2.289 . . . . 0.0 111.815 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.573 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 95.2 m-85 -109.72 146.38 35.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -0.878 . . . . 0.0 109.408 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -82.59 -36.89 25.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 0.0 109.756 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.459 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.464 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.464 ' OD2' ' O ' ' A' ' 68' ' ' LYS . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.474 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.451 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.413 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.562 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.476 ' O ' ' N ' ' A' ' 102' ' ' ILE . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.402 ' O ' HG13 ' A' ' 71' ' ' VAL . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.554 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.455 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.459 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.57 ' HA3' ' CE2' ' A' ' 64' ' ' PHE . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.573 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.411 HD11 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.454 HD13 ' CA ' ' A' ' 92' ' ' GLY . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.416 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.552 HD12 ' CE2' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.557 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.493 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.448 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 8.7 p -125.09 160.54 54.12 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.448 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.6 Cg_endo -70.52 -51.34 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.714 2.276 . . . . 0.0 111.9 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -132.18 26.08 4.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.579 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.429 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -128.7 25.84 4.66 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.424 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 56.54 -146.13 34.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 89.8 p -118.11 153.47 33.72 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.556 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.493 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.514 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.523 ' CD1' HD22 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 21.0 m120 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.454 ' OH ' HG11 ' A' ' 133' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.458 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.454 HG11 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.427 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.518 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.447 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.495 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.44 ' O ' HD21 ' A' ' 151' ' ' LEU . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.427 ' O ' HD12 ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.462 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.452 ' N ' HD13 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -57.75 -37.83 74.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -47.07 -26.94 1.18 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.557 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 93.9 p -65.6 -29.41 70.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.523 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 9.0 p30 -90.9 2.58 56.07 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.663 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 156' ' ' ASP . . . 43.99 -150.6 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.245 -0.909 . . . . 0.0 109.512 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.11 -37.68 86.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.464 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.1 t30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.504 179.978 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.456 HG13 ' N ' ' A' ' 3' ' ' PHE . 95.1 t -132.49 149.24 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -1.169 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.461 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.461 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.444 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 13' ' ' ILE . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.545 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.545 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.536 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.448 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.519 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.523 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.523 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.465 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.526 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.414 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.487 HG21 ' CG2' ' A' ' 56' ' ' ILE . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.461 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.459 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.492 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.492 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.45 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.447 HG12 ' HG2' ' A' ' 70' ' ' ARG . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.459 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.487 ' CG2' HG21 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.452 ' O ' HG21 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.7 149.05 66.79 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -56.18 139.55 47.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 109.47 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 62' ' ' PHE . . . 147.79 -16.41 1.4 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.469 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 0.0 OUTLIER -126.51 171.86 7.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.297 -1.12 . . . . 0.0 109.21 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.86 -26.86 31.62 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.707 2.271 . . . . 0.0 111.907 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.555 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 74.0 m-85 -104.5 152.3 22.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.319 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp -114.3 -39.01 3.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.188 -0.945 . . . . 0.0 109.596 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 68' ' ' LYS . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.52 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.447 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.481 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.481 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.441 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.406 ' HA2' HG21 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.555 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.458 HD13 ' O ' ' A' ' 96' ' ' GLU . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 122' ' ' THR . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.536 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.445 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 2.8 p -123.63 161.16 47.63 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.452 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 49.2 Cg_endo -70.05 -49.37 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.745 2.297 . . . . 0.0 111.844 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 97.6 m-20 -138.02 26.45 2.71 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.196 -0.94 . . . . 0.0 109.556 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -124.32 19.14 7.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.432 ' O ' HG23 ' A' ' 107' ' ' THR . . . 68.22 -149.76 50.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 59.3 p -119.04 150.21 40.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.136 -1.214 . . . . 0.0 109.541 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.476 HD23 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 15.1 m120 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.462 ' CE1' HG21 ' A' ' 133' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.464 ' O ' ' HA ' ' A' ' 96' ' ' GLU . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.45 HG23 HG23 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.45 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 25.1 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.462 HG21 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.473 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.473 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.437 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.455 ' O ' HD22 ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.488 HD11 ' N ' ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.02 71.47 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -49.61 -32.72 13.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 21.9 m -55.36 -33.14 63.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.392 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -70.38 -20.26 62.96 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.245 -0.91 . . . . 0.0 109.38 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -104.31 140.97 37.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.299 -0.876 . . . . 0.0 109.457 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -109.86 123.27 49.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.497 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 32.2 t-20 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.484 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 86.3 t -134.03 143.6 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -1.17 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.453 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.453 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.422 HG21 ' HE3' ' A' ' 137' ' ' LYS . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.401 ' O ' ' N ' ' A' ' 114' ' ' LEU . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.4 HG22 HG12 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.532 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.532 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.505 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.47 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.578 ' CE2' HD11 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HG2' ' CD2' ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.462 ' O ' ' CD1' ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.491 ' CD2' ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.52 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.432 HG21 HG21 ' A' ' 41' ' ' VAL . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.432 HG21 HG21 ' A' ' 38' ' ' ILE . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.485 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.485 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.469 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.505 ' HB ' ' CG1' ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.41 158.88 54.78 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -55.49 149.71 13.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.63 8.62 51.81 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.458 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 2.3 m-85 -115.16 170.15 5.88 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.431 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.458 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -70.16 -45.06 1.49 Allowed 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.635 2.223 . . . . 0.0 111.645 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.577 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 93.4 m-85 -119.11 156.58 29.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.349 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt -83.11 -39.19 21.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.505 ' CG1' ' HB ' ' A' ' 56' ' ' ILE . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.42 ' N ' HG22 ' A' ' 67' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.441 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.445 HG11 ' O ' ' A' ' 82' ' ' ASN . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.564 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.483 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.445 ' O ' HG11 ' A' ' 71' ' ' VAL . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.435 ' O ' ' O ' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.475 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.577 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.456 HD12 ' O ' ' A' ' 96' ' ' GLU . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.456 ' O ' HD12 ' A' ' 91' ' ' ILE . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.467 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.504 HD11 ' CE2' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.505 HG22 ' CB ' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.454 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p -153.24 122.05 3.18 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -72.03 -2.15 11.12 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.821 2.347 . . . . 0.0 111.896 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -97.75 -13.93 21.13 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.195 -0.941 . . . . 0.0 109.707 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -163.7 29.62 0.24 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 75.29 -146.51 34.68 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.454 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m -106.64 140.57 39.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.323 -1.104 . . . . 0.0 109.506 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.446 HD13 HG23 ' A' ' 107' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.401 ' N ' ' O ' ' A' ' 9' ' ' THR . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.518 ' CE2' HG12 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.477 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . 0.575 ' O ' ' CD2' ' A' ' 126' ' ' HIS . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . 0.575 ' CD2' ' O ' ' A' ' 124' ' ' GLY . 85.7 m-70 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.518 HG12 ' CE2' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.422 ' HE3' HG21 ' A' ' 7' ' ' THR . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.414 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.492 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 139' ' ' MET . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.492 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.433 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.77 -36.63 84.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.468 ' CD2' ' HA ' ' A' ' 151' ' ' LEU . 63.8 m-70 -50.56 -42.42 55.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -0.871 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 94.6 p -60.8 -24.93 66.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.6 -4.41 42.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.633 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -80.0 124.39 28.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.42 ' C ' ' O ' ' A' ' 157' ' ' ALA . 14.4 t80 -44.13 128.11 5.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.902 . . . . 0.0 109.496 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 39.8 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.526 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t -138.91 139.95 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.269 -1.136 . . . . 0.0 109.31 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.549 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.549 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.529 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.5 ' CD1' HD12 ' A' ' 104' ' ' ILE . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.529 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.463 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.404 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.463 ' HB2' HD11 ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.463 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 57' ' ' SER . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.43 HG21 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.491 HD13 ' CG2' ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.469 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.469 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.413 ' O ' HG12 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.491 ' CG2' HD13 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.438 HD13 ' HB2' ' A' ' 69' ' ' ASP . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG22 ' A' ' 38' ' ' ILE . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.42 ' N ' ' O ' ' A' ' 65' ' ' LYS . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.26 153.41 66.64 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.26 140.82 31.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.283 -0.886 . . . . 0.0 109.468 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.46 10.56 53.49 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.471 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -106.59 168.66 7.8 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -69.94 -51.75 0.35 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.664 2.242 . . . . 0.0 111.669 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.563 ' CD1' ' HD3' ' A' ' 90' ' ' PRO . 92.3 m-85 -109.84 151.32 27.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.283 -0.886 . . . . 0.0 109.483 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.42 ' O ' ' N ' ' A' ' 58' ' ' PHE . 81.5 tttt -77.14 -45.7 25.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.472 HG13 ' N ' ' A' ' 68' ' ' LYS . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.438 ' HB2' HD13 ' A' ' 56' ' ' ILE . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.499 ' NH1' HG23 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.51 HG23 ' CZ ' ' A' ' 81' ' ' TYR . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.458 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.51 ' CZ ' HG23 ' A' ' 71' ' ' VAL . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.503 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.564 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.502 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.499 HG23 ' NH1' ' A' ' 70' ' ' ARG . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.47 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.446 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.551 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.563 ' HD3' ' CD1' ' A' ' 64' ' ' PHE . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.437 ' O ' ' O ' ' A' ' 88' ' ' GLY . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.5 ' CA ' HD13 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.5 HD13 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.449 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.564 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.503 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.485 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.508 HG23 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.457 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.468 ' O ' HG23 ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 106' ' ' ALA . 1.2 p -153.43 126.86 4.24 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.91 -0.87 7.67 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 122.745 2.297 . . . . 0.0 111.804 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -83.83 -39.27 20.16 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.302 -0.874 . . . . 0.0 109.452 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.16 37.0 0.7 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 81.32 -146.45 26.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m -104.42 140.11 38.4 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.3 -1.118 . . . . 0.0 109.241 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.449 HD21 HG21 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.481 ' CD1' HG12 ' A' ' 98' ' ' ILE . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.457 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.439 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.426 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.44 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.528 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.427 HG12 HD23 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.514 HD13 ' CG2' ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -56.53 -46.82 80.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -56.98 -41.43 78.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.369 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 29.4 m -55.38 -30.56 60.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.368 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.411 ' O ' ' N ' ' A' ' 158' ' ' TYR . 92.0 m-20 -73.4 -19.43 60.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.384 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . 62.72 -85.08 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.325 -0.859 . . . . 0.0 109.417 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.411 ' N ' ' O ' ' A' ' 156' ' ' ASP . 74.7 m-85 -108.55 119.69 40.26 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.484 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.4 t30 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.471 -179.884 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.1 t -137.69 142.87 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -1.142 . . . . 0.0 109.48 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.434 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.492 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.537 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.537 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.498 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.49 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.552 ' CD1' ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.49 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.404 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.529 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.404 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.529 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.475 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.443 HG12 ' N ' ' A' ' 42' ' ' GLU . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.416 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.444 ' O ' ' CG2' ' A' ' 52' ' ' THR . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.451 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.483 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.444 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.507 HG21 ' CD1' ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.674 ' CD1' ' CE1' ' A' ' 62' ' ' PHE . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.6 159.64 52.12 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -49.28 150.25 1.83 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.401 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.3 5.25 57.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.674 ' CE1' ' CD1' ' A' ' 58' ' ' PHE . 0.4 OUTLIER -108.85 164.17 15.33 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.254 -1.145 . . . . 0.0 109.53 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.57 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.13 -43.73 2.2 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.595 2.197 . . . . 0.0 111.769 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.569 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 95.0 m-85 -116.34 159.01 22.53 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 109.446 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt -78.76 -43.81 24.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.16 -0.963 . . . . 0.0 109.499 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.494 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.43 HG11 ' N ' ' A' ' 68' ' ' LYS . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.483 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.514 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.426 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.413 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.411 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.569 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.564 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 96' ' ' GLU . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.432 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.514 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.498 HG22 ' CB ' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 105' ' ' VAL . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -151.63 122.51 3.7 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.11 -0.33 7.83 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.687 2.258 . . . . 0.0 111.746 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.57 -45.06 12.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.74 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -147.37 36.97 1.16 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 85.09 -145.82 21.65 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p -107.54 151.01 26.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -1.125 . . . . 0.0 109.341 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.404 HD23 HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.407 ' N ' ' O ' ' A' ' 5' ' ' TYR . 16.8 m120 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.434 ' HG2' ' OD1' ' A' ' 4' ' ' ASN . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.432 HG23 ' CG2' ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.45 ' O ' ' HG3' ' A' ' 137' ' ' LYS . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.442 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.531 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.442 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.518 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.479 HD11 ' CG2' ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.13 -38.57 73.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.518 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 79.1 m80 -49.56 -49.11 47.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 80.8 p -56.41 -22.5 32.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.331 -0.855 . . . . 0.0 109.565 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -88.01 0.49 55.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.256 -0.903 . . . . 0.0 109.657 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.407 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -87.09 125.02 33.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.468 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.407 ' C ' ' O ' ' A' ' 157' ' ' ALA . 9.0 t80 -43.36 124.99 3.65 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.792 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.368 179.745 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.483 HG12 ' ND1' ' A' ' 121' ' ' HIS . 46.2 t -135.89 143.89 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -1.142 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.401 ' N ' HG13 ' A' ' 2' ' ' VAL . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.473 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.458 ' OG ' ' OE1' ' A' ' 148' ' ' GLU . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.507 ' HB3' ' CG2' ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.585 ' CE2' HD11 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.585 HD11 ' CE2' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.443 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.456 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.456 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.441 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.502 ' CD1' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.444 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.421 HG22 ' HB3' ' A' ' 27' ' ' ASP . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.472 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.475 ' N ' ' O ' ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.475 ' O ' ' CG2' ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.456 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.529 ' HB ' ' CG1' ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.408 ' O ' HG21 ' A' ' 38' ' ' ILE . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.528 ' HB3' ' CB ' ' A' ' 62' ' ' PHE . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.464 ' O ' ' HB3' ' A' ' 62' ' ' PHE . 48.9 Cg_endo -70.11 169.05 20.27 Favored 'Trans proline' 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' A' ' 59' ' ' PRO . 91.8 mt-10 -42.75 165.78 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.763 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 52.91 59.44 9.35 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.543 ' CE2' ' HA ' ' A' ' 65' ' ' LYS . 46.9 p90 -132.24 155.41 81.32 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.362 -1.081 . . . . 0.0 110.307 -179.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -76.5 -53.83 0.07 OUTLIER 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.587 2.192 . . . . 0.0 111.223 178.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.552 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 98.8 m-85 -116.51 143.65 45.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.295 -0.878 . . . . 0.0 109.375 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.543 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 9.6 mttp -59.07 -63.92 1.13 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.875 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.463 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.529 ' CG1' ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.524 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.489 HG21 ' CZ ' ' A' ' 81' ' ' TYR . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.568 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.459 ' OD1' ' HB3' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.504 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.504 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.476 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.552 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.507 HD21 ' CD2' ' A' ' 126' ' ' HIS . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.433 ' O ' HD12 ' A' ' 91' ' ' ILE . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.476 HD11 ' CZ ' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.547 ' CD1' ' CD1' ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.449 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p -125.11 152.83 71.24 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.76 -15.35 37.04 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.672 2.248 . . . . 0.0 111.748 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -60.3 -28.98 68.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 120.62 19.98 3.63 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -145.44 175.29 25.07 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p -131.69 143.28 50.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.356 -1.084 . . . . 0.0 109.094 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.499 HD11 HG21 ' A' ' 113' ' ' ILE . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.547 ' CD1' ' CD1' ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.452 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.534 ' CG1' ' CD2' ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.563 ' CE2' HG11 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.483 ' ND1' HG12 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 94' ' ' THR . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . 0.507 ' CD2' HD21 ' A' ' 95' ' ' LEU . 96.9 m-70 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.563 HG11 ' CE2' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.474 ' CE ' HG13 ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.444 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.529 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.444 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.529 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.433 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.428 ' HA ' HG13 ' A' ' 33' ' ' VAL . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.458 ' OE1' ' OG ' ' A' ' 11' ' ' SER . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CZ ' ' NE2' ' A' ' 154' ' ' HIS . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.523 ' CD1' HG23 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.409 ' CD2' HD13 ' A' ' 13' ' ' ILE . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.79 71.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.592 ' NE2' ' CZ ' ' A' ' 150' ' ' TYR . 74.7 m-70 -103.8 135.99 44.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.144 -0.973 . . . . 0.0 109.614 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 37.9 m -73.44 -14.57 61.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.481 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -70.19 -16.78 63.11 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.463 ' HB2' ' O ' ' A' ' 151' ' ' LEU . . . -60.58 -26.84 67.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.401 ' O ' ' C ' ' A' ' 159' ' ' ASN . 90.9 m-85 -122.98 127.88 49.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.325 -0.859 . . . . 0.0 109.396 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' TYR . 89.7 m-20 . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.557 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.553 HG13 ' CE1' ' A' ' 121' ' ' HIS . 92.0 t -136.6 145.3 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.247 -1.149 . . . . 0.0 109.551 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.494 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.494 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.462 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.541 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.541 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.451 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.532 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.629 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.438 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.464 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.416 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.528 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.416 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.528 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.444 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.525 ' CD1' HG22 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.495 ' HB ' ' NZ ' ' A' ' 54' ' ' LYS . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.424 ' ND2' ' O ' ' A' ' 46' ' ' GLY . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.419 ' HB ' ' HB ' ' A' ' 53' ' ' ILE . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 52' ' ' THR . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.465 ' HA3' HG21 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.432 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.465 HG21 ' HA3' ' A' ' 46' ' ' GLY . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.43 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.495 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.525 HG22 ' CD1' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.414 ' N ' HG23 ' A' ' 56' ' ' ILE . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -83.76 34.09 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -114.26 172.04 7.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.123 -0.986 . . . . 0.0 109.592 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -87.96 9.03 76.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.467 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 0.6 OUTLIER -49.13 171.86 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.164 -1.198 . . . . 0.0 109.33 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.467 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.26 -29.04 32.99 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.704 2.269 . . . . 0.0 111.792 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.574 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 92.3 m-85 -107.3 157.07 18.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.318 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -118.44 -19.55 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.536 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.436 ' O ' HG13 ' A' ' 67' ' ' VAL . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.473 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.453 ' OD1' HG23 ' A' ' 85' ' ' VAL . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.458 HG23 ' OH ' ' A' ' 81' ' ' TYR . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.435 ' O ' HG13 ' A' ' 71' ' ' VAL . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.451 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.405 ' HA2' HG22 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.574 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.465 HD11 ' O ' ' A' ' 96' ' ' GLU . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.459 HD12 ' OD1' ' A' ' 93' ' ' ASP . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.465 ' O ' HD11 ' A' ' 91' ' ' ILE . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.429 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.472 HD11 ' CD1' ' A' ' 18' ' ' LEU . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.418 ' C ' HG21 ' A' ' 107' ' ' THR . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.459 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 13.6 p -129.49 160.24 65.37 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.7 Cg_endo -70.38 -50.23 0.41 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.755 2.303 . . . . 0.0 112.112 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -129.98 27.24 5.17 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.927 . . . . 0.0 109.691 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.425 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.85 23.11 4.22 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 59.28 -143.76 45.85 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 77.4 p -117.26 151.3 37.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.319 -1.107 . . . . 0.0 109.474 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.462 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.429 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.464 HD11 HG22 ' A' ' 116' ' ' ILE . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.412 ' O ' HG11 ' A' ' 2' ' ' VAL . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.553 ' CE1' HG13 ' A' ' 2' ' ' VAL . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 94' ' ' THR . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HG23 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.527 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.527 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.466 ' HB3' HG22 ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.461 ' O ' HD22 ' A' ' 151' ' ' LEU . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.561 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.461 HD22 ' O ' ' A' ' 147' ' ' VAL . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.496 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.412 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -63.32 -40.35 97.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.561 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 71.0 m-70 -46.9 -24.79 0.65 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 48.7 m -60.66 -30.35 69.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.263 -0.898 . . . . 0.0 109.535 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.412 ' CG ' ' O ' ' A' ' 153' ' ' ALA . 19.3 p30 -87.19 13.67 9.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -0.882 . . . . 0.0 109.507 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.05 141.94 58.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.396 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.413 ' O ' ' C ' ' A' ' 159' ' ' ASN . 23.0 t80 -46.68 -54.3 9.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.31 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' TYR . 69.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.493 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.47 HG11 ' ND1' ' A' ' 121' ' ' HIS . 64.3 t -134.54 136.94 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -1.128 . . . . 0.0 109.334 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.501 ' HB3' ' NZ ' ' A' ' 137' ' ' LYS . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.414 ' O ' ' HB2' ' A' ' 21' ' ' ALA . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.476 ' C ' ' CD1' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' ARG . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.465 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.431 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.488 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.488 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 57' ' ' SER . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.43 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.455 HD12 HG23 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.485 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.485 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.413 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.455 HG23 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.453 HG22 HD11 ' A' ' 56' ' ' ILE . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' HG22 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.5 152.03 65.24 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -55.33 143.07 29.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.81 10.52 40.13 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.414 ' HB3' ' HD2' ' A' ' 63' ' ' PRO . 3.9 m-85 -111.2 167.79 8.53 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.269 -1.136 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 62' ' ' PHE . 49.7 Cg_endo -70.6 -45.09 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.636 2.224 . . . . 0.0 111.603 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -113.11 163.62 14.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.25 -0.906 . . . . 0.0 109.414 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt -95.1 -62.99 1.21 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.465 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.452 HG12 ' N ' ' A' ' 68' ' ' LYS . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.523 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.425 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.477 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.523 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.456 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.421 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.454 ' O ' HD11 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.456 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.41 HD11 HG23 ' A' ' 102' ' ' ILE . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.496 HG12 ' CD2' ' A' ' 114' ' ' LEU . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.436 ' OG1' ' O ' ' A' ' 111' ' ' GLY . 12.7 p -122.42 157.6 58.43 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.401 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 51.2 Cg_endo -70.92 -47.15 0.61 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.716 2.277 . . . . 0.0 112.064 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 88.6 m-20 -133.8 27.23 3.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.209 -0.932 . . . . 0.0 109.688 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.434 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.18 24.5 4.21 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.436 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 58.93 -146.39 42.5 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p -118.81 150.18 40.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -1.149 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.496 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.567 ' CE2' HG12 ' A' ' 133' ' ' VAL . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.47 ' ND1' HG11 ' A' ' 2' ' ' VAL . 84.0 m-70 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.456 HG22 HG23 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.567 HG12 ' CE2' ' A' ' 120' ' ' TYR . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.501 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.433 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.528 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.468 ' HB1' ' CG2' ' A' ' 33' ' ' VAL . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.45 ' O ' HD21 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.489 HD13 ' CG2' ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.45 HD21 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.5 -35.46 80.52 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -50.26 -40.8 49.04 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.601 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.7 p -59.68 -28.27 67.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.216 -0.928 . . . . 0.0 109.658 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.43 -15.28 60.45 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.23 -0.919 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -76.75 146.47 37.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -46.44 -58.04 4.12 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.161 -0.962 . . . . 0.0 109.207 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.412 179.87 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 47.7 t -134.38 139.91 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.197 -1.178 . . . . 0.0 109.423 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.474 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.474 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.541 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.541 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.541 ' CB ' ' CG2' ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.519 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' HG12 ' A' ' 23' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.465 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB3' ' CD1' ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.451 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.444 ' CD1' ' HB3' ' A' ' 25' ' ' ASP . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.534 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.46 HG23 HG23 ' A' ' 41' ' ' VAL . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.46 HG23 HG23 ' A' ' 38' ' ' ILE . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.506 ' N ' ' O ' ' A' ' 53' ' ' ILE . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.509 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.459 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.509 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.492 ' HB2' ' CD1' ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.436 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.417 ' O ' HG21 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.08 149.06 57.85 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -52.64 150.94 4.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.53 14.64 10.29 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.466 ' HB3' ' HD2' ' A' ' 63' ' ' PRO . 2.0 m-85 -135.27 172.16 7.69 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.371 -1.076 . . . . 0.0 109.296 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.51 ' HG2' ' CD1' ' A' ' 64' ' ' PHE . 48.0 Cg_endo -69.23 -43.73 2.9 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.601 2.201 . . . . 0.0 111.714 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.51 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 23.8 p90 -109.9 166.34 11.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.175 -0.953 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -106.48 -37.56 6.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.162 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.44 HG11 ' N ' ' A' ' 68' ' ' LYS . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.44 ' N ' HG11 ' A' ' 67' ' ' VAL . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.452 HG12 ' HB ' ' A' ' 52' ' ' THR . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.424 ' CG2' HG22 ' A' ' 71' ' ' VAL . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.415 ' N ' ' O ' ' A' ' 102' ' ' ILE . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.405 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.498 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.498 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.406 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.461 ' HA3' ' HB3' ' A' ' 64' ' ' PHE . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.431 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD11 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.527 HD11 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.458 ' OD1' HG22 ' A' ' 116' ' ' ILE . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.456 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.503 HD11 ' CE2' ' A' ' 22' ' ' PHE . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.541 ' CG2' ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.466 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.459 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 11.3 p -124.0 160.94 49.67 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.4 Cg_endo -70.97 -46.22 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.714 2.276 . . . . 0.0 112.221 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.434 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 82.9 m-20 -135.44 29.02 3.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 0.0 109.674 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -137.14 34.76 2.16 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.422 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 50.9 -150.43 6.24 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.459 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 60.7 p -113.66 148.92 35.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.22 -1.165 . . . . 0.0 109.45 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.466 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.471 ' CD2' HG22 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.451 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.458 HG22 ' OD1' ' A' ' 100' ' ' ASN . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.403 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 21.6 m120 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.508 ' CE1' HG22 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.516 ' CG2' HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.516 HG23 ' CG2' ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.516 HG12 ' CE ' ' A' ' 137' ' ' LYS . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.516 ' CE ' HG12 ' A' ' 133' ' ' VAL . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.534 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.454 ' O ' HD21 ' A' ' 151' ' ' LEU . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.434 ' O ' HD21 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.516 ' HB3' ' CD1' ' A' ' 13' ' ' ILE . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.468 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.48 -37.72 73.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -53.09 -30.45 36.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.561 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 30.6 m -61.59 -29.95 70.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.216 -0.928 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -75.15 -9.5 58.6 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.28 -0.887 . . . . 0.0 109.684 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.428 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -78.04 148.44 34.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.903 . . . . 0.0 109.455 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.428 ' C ' ' O ' ' A' ' 157' ' ' ALA . 13.8 t80 -44.61 -46.59 10.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.299 -0.875 . . . . 0.0 109.207 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 56.3 m-20 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.446 179.782 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.501 HG13 ' ND1' ' A' ' 121' ' ' HIS . 48.5 t -133.37 142.83 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -1.148 . . . . 0.0 109.518 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.574 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.574 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.532 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.532 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.441 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.575 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.453 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.477 HG23 HD12 ' A' ' 23' ' ' ILE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.472 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.428 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.524 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.428 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.428 HG22 ' CG2' ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.476 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.505 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 53' ' ' ILE . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.477 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.46 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.574 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.476 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo -72.12 53.06 1.97 Allowed 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -125.21 165.31 18.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 109.583 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -83.31 2.59 86.86 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.452 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 1.4 m-85 -46.45 171.64 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.211 -1.17 . . . . 0.0 109.338 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.452 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.84 -29.86 27.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.662 2.241 . . . . 0.0 111.533 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.571 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 97.7 m-85 -111.6 145.93 38.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.335 -0.853 . . . . 0.0 109.247 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -104.47 -18.44 14.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.179 -0.951 . . . . 0.0 109.858 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.574 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.493 HG13 ' N ' ' A' ' 68' ' ' LYS . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.522 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.446 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.42 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.511 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.463 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.467 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.571 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.48 HG21 HD13 ' A' ' 91' ' ' ILE . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.508 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.508 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.511 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.482 HD12 HG21 ' A' ' 98' ' ' ILE . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.411 ' N ' ' O ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.445 HG22 ' HB3' ' A' ' 15' ' ' ALA . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -132.37 122.48 18.08 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.62 -21.51 29.38 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.721 2.28 . . . . 0.0 111.93 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -111.45 19.8 17.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.191 -0.943 . . . . 0.0 109.615 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -168.62 31.4 0.17 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 56.12 -146.29 32.71 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p -109.77 150.43 28.35 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.301 -1.117 . . . . 0.0 109.428 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.515 ' HG ' ' N ' ' A' ' 115' ' ' LYS . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.515 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.56 ' CE2' HG12 ' A' ' 133' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.501 ' ND1' HG13 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 94' ' ' THR . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.448 HG11 ' OE1' ' A' ' 132' ' ' GLN . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.448 ' OE1' HG11 ' A' ' 128' ' ' VAL . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.56 HG12 ' CE2' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.515 ' HE3' ' CG1' ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.436 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.406 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.451 ' HB2' HG22 ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.448 HG13 HD23 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.455 ' HA ' HD11 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.541 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.523 HD13 ' CG2' ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.513 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.77 96.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.541 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 58.7 m-70 -58.11 -39.95 79.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 23.0 t -59.85 -29.76 68.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.452 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -70.5 -20.01 62.88 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.77 -24.39 67.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.399 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -114.48 131.28 56.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.3 t30 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.531 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.484 HG12 ' ND1' ' A' ' 121' ' ' HIS . 54.9 t -136.41 140.46 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -1.151 . . . . 0.0 109.382 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.581 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.581 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.465 HG23 ' N ' ' A' ' 13' ' ' ILE . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.546 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.546 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.525 ' HB3' ' CG2' ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.433 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.485 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.469 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.485 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.467 ' HB2' HD13 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.502 ' OD1' ' NZ ' ' A' ' 32' ' ' LYS . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.532 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.502 ' NZ ' ' OD1' ' A' ' 28' ' ' ASN . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.41 ' N ' HG22 ' A' ' 33' ' ' VAL . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.526 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.441 ' O ' ' OG ' ' A' ' 40' ' ' SER . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 39' ' ' SER . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.459 HG23 HG22 ' A' ' 38' ' ' ILE . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.457 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.482 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.482 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.457 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.519 ' HB2' ' CD1' ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.519 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.501 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.38 151.5 65.55 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.29 141.32 15.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.486 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.03 11.39 37.14 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.526 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.6 m-85 -113.69 169.86 6.01 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.482 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.451 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 50.3 Cg_endo -70.61 -49.48 0.44 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.649 2.233 . . . . 0.0 111.724 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.542 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 97.9 m-85 -113.71 152.45 30.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.237 -0.914 . . . . 0.0 109.463 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.411 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt -83.39 -36.39 24.34 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -0.918 . . . . 0.0 109.51 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.445 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.454 HG11 ' HA2' ' A' ' 88' ' ' GLY . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.491 ' O ' ' CG1' ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.498 HG22 ' CZ ' ' A' ' 81' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.419 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.536 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.536 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.455 ' O ' HG23 ' A' ' 71' ' ' VAL . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.487 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.48 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.439 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.454 ' HA2' HG11 ' A' ' 67' ' ' VAL . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.542 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.446 HD12 HG22 ' A' ' 91' ' ' ILE . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.503 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.48 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.428 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.525 ' CG2' ' HB3' ' A' ' 15' ' ' ALA . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.2 p -154.21 121.92 2.94 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -70.88 -1.08 8.84 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.771 2.314 . . . . 0.0 111.823 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -86.8 -35.11 19.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.204 -0.935 . . . . 0.0 109.636 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.94 33.71 0.8 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 82.43 -146.26 24.68 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 13.0 p -106.91 143.87 34.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -1.131 . . . . 0.0 109.434 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.443 HD11 HG23 ' A' ' 107' ' ' THR . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 103' ' ' LYS . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.428 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 23.8 m120 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 133' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.484 ' ND1' HG12 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 94' ' ' THR . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.407 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.531 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 139' ' ' MET . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.458 ' HB3' HG21 ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.465 ' O ' HD23 ' A' ' 151' ' ' LEU . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.465 HD23 ' O ' ' A' ' 147' ' ' VAL . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.28 -42.48 99.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -49.26 -38.8 28.12 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.276 -0.89 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.8 t -56.86 -32.25 65.62 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.503 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -75.09 -13.75 60.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.556 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -73.18 140.84 47.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.369 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -46.16 -55.46 7.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.202 -0.936 . . . . 0.0 109.273 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.429 179.842 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 121' ' ' HIS . 87.1 t -132.6 144.01 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.211 -1.17 . . . . 0.0 109.597 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.521 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.46 ' OD1' ' HE3' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.521 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.459 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.459 HG22 ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.544 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.544 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.459 ' HB3' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.513 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.528 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.457 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.542 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.468 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.525 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.414 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.562 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.463 HG21 ' O ' ' A' ' 57' ' ' SER . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.42 HG12 ' N ' ' A' ' 42' ' ' GLU . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.42 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.447 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.459 HD12 ' CG2' ' A' ' 53' ' ' ILE . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.468 ' O ' ' CG2' ' A' ' 52' ' ' THR . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.403 ' HA ' HG11 ' A' ' 71' ' ' VAL . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.468 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.459 ' CG2' HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.468 ' NZ ' ' OD1' ' A' ' 27' ' ' ASP . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.416 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG21 ' A' ' 38' ' ' ILE . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.466 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.3 145.98 55.53 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.08 144.26 12.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.217 -0.927 . . . . 0.0 109.352 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.85 16.43 41.88 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.562 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.5 m-85 -114.69 161.65 27.75 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.335 -1.097 . . . . 0.0 109.425 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.93 -30.17 21.92 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.595 2.197 . . . . 0.0 111.829 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.574 ' CD2' ' HD3' ' A' ' 90' ' ' PRO . 45.5 m-85 -118.69 164.33 15.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.658 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt -104.78 -62.81 1.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.566 HG21 ' CZ ' ' A' ' 81' ' ' TYR . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.466 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.412 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.566 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.466 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.402 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.514 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.47 ' O ' ' O ' ' A' ' 88' ' ' GLY . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.463 ' O ' HG23 ' A' ' 122' ' ' THR . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.455 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.513 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.469 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.439 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.542 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.45 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.582 ' CD1' ' CD1' ' A' ' 114' ' ' LEU . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.483 ' OG1' ' N ' ' A' ' 110' ' ' GLY . 11.0 p -109.36 160.06 29.09 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.438 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.0 Cg_endo -69.94 -23.58 29.8 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.818 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -169.23 27.31 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.483 ' N ' ' OG1' ' A' ' 107' ' ' THR . . . -130.19 30.49 3.49 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 67.72 -146.43 46.86 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 93.2 p -125.07 154.67 41.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.358 -1.084 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.582 ' CD1' ' CD1' ' A' ' 104' ' ' ILE . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' CD1' HD12 ' A' ' 144' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.513 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.518 ' CE1' HG13 ' A' ' 2' ' ' VAL . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.475 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.432 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.457 HG13 ' OH ' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.459 ' HE3' HG22 ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.432 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.47 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.579 ' CD1' ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.446 ' HB1' HG23 ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.524 ' HG2' ' CD1' ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.555 ' HA ' ' CD2' ' A' ' 154' ' ' HIS . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.494 HD21 ' N ' ' A' ' 152' ' ' LEU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.427 ' O ' ' C ' ' A' ' 154' ' ' HIS . . . -63.07 -34.2 77.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.555 ' CD2' ' HA ' ' A' ' 151' ' ' LEU . 37.6 m-70 -44.2 -32.48 1.26 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 84.6 p -58.4 -30.85 67.16 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.327 -0.858 . . . . 0.0 109.262 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.418 ' N ' ' O ' ' A' ' 153' ' ' ALA . 81.5 m-20 -70.54 -20.19 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.513 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -107.71 139.4 42.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.616 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.576 ' CD2' ' HB2' ' A' ' 159' ' ' ASN . 3.3 t80 -72.59 131.48 42.52 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.303 -0.873 . . . . 0.0 109.175 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . 0.576 ' HB2' ' CD2' ' A' ' 158' ' ' TYR . 56.7 t30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.529 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.414 HG13 ' N ' ' A' ' 3' ' ' PHE . 49.1 t -134.05 146.26 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.149 -1.206 . . . . 0.0 109.44 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.574 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.574 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.463 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.419 ' OG ' ' OE2' ' A' ' 148' ' ' GLU . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.553 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.553 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 104' ' ' ILE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.52 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.535 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.565 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.535 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.502 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' CD1' ' O ' ' A' ' 25' ' ' ASP . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.45 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.448 HG22 HG22 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.436 HD12 HG21 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.488 ' O ' ' CG2' ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.436 HG21 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.47 ' HB ' HG13 ' A' ' 67' ' ' VAL . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.675 ' CD2' ' CE1' ' A' ' 64' ' ' PHE . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.81 166.01 29.09 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -63.62 139.49 58.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.27 13.33 19.59 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.606 ' CD1' ' CD1' ' A' ' 58' ' ' PHE . 1.5 m-85 -117.03 172.95 3.43 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.308 -1.113 . . . . 0.0 109.357 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.569 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 47.4 Cg_endo -68.22 -48.28 1.32 Allowed 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.652 2.235 . . . . 0.0 111.634 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.675 ' CE1' ' CD2' ' A' ' 58' ' ' PHE . 40.4 p90 -124.33 153.53 41.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 109.328 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm -72.6 -44.25 62.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.913 . . . . 0.0 109.654 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.526 ' HB ' ' CE1' ' A' ' 64' ' ' PHE . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.514 ' N ' HG21 ' A' ' 67' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.439 ' OD2' ' O ' ' A' ' 54' ' ' LYS . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.482 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.504 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.46 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 8.3 m120 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.473 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.482 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.504 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.437 ' O ' ' O ' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.465 ' CG1' ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.446 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.439 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.465 HD12 HG21 ' A' ' 91' ' ' ILE . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.458 ' O ' HD11 ' A' ' 91' ' ' ILE . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.524 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.513 ' CD1' ' HA ' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.518 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.462 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 12.4 p -106.56 160.38 26.48 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.462 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.2 Cg_endo -70.65 -24.16 25.92 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.648 2.232 . . . . 0.0 111.867 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -170.35 28.01 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.213 -0.93 . . . . 0.0 109.507 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.69 29.11 4.07 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 71.96 -145.51 38.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 61.5 p -127.62 148.89 50.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.302 -1.116 . . . . 0.0 109.471 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.518 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.473 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.471 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.463 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 22.1 m120 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.524 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.458 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 94' ' ' THR . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.427 ' HA ' ' HE1' ' A' ' 139' ' ' MET . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.463 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.427 ' HE1' ' HA ' ' A' ' 136' ' ' SER . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.53 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.462 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.468 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.452 ' O ' HD23 ' A' ' 151' ' ' LEU . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.53 ' HA ' ' CD1' ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.589 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.452 HD23 ' O ' ' A' ' 147' ' ' VAL . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 150' ' ' TYR . . . -60.14 -39.55 86.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.589 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 80.5 m-70 -55.7 -38.56 69.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 20.2 m -57.64 -31.14 65.99 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.929 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -73.26 -19.19 61.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.69 144.39 55.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.284 -0.885 . . . . 0.0 109.447 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -60.42 -33.06 71.97 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.33 -0.857 . . . . 0.0 109.524 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 31.3 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.435 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.38 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.576 HG13 ' CE1' ' A' ' 121' ' ' HIS . 78.8 t -134.16 146.25 31.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -1.157 . . . . 0.0 109.563 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.525 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.525 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.433 HG21 ' HG3' ' A' ' 137' ' ' LYS . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.509 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.509 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.524 ' HB2' ' CG2' ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.549 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.57 ' CZ ' HD12 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.466 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.43 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.447 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.482 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 146' ' ' ALA . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.405 ' N ' HG21 ' A' ' 33' ' ' VAL . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.474 HG12 ' CG2' ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.478 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.511 ' N ' ' O ' ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.425 ' O ' ' CG2' ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.469 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.404 ' HA ' HG12 ' A' ' 71' ' ' VAL . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.462 ' HB ' HG11 ' A' ' 71' ' ' VAL . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.523 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.474 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.02 144.06 51.5 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -48.01 144.83 3.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.208 -0.933 . . . . 0.0 109.459 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.63 10.38 50.4 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.449 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -111.7 164.94 13.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -1.15 . . . . 0.0 109.509 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.449 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.2 Cg_endo -68.65 -35.09 17.59 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.757 2.304 . . . . 0.0 111.935 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.558 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 55.0 m-85 -118.85 166.73 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 109.467 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt -100.22 -63.89 1.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 66' ' ' TYR . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.439 ' HB2' ' HB2' ' A' ' 87' ' ' GLU . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.565 HG23 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.434 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.565 ' CE2' HG23 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.444 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 21.0 m120 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 69' ' ' ASP . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.439 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.558 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.446 HD13 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.542 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.53 ' CD2' ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.469 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.446 HG12 HD13 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.557 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.444 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.524 ' CG2' ' HB2' ' A' ' 15' ' ' ALA . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 6.6 p -92.1 160.65 35.1 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.8 Cg_endo -69.9 -27.52 25.71 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.66 2.24 . . . . 0.0 111.776 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -168.58 27.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.271 -0.893 . . . . 0.0 109.552 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.427 ' N ' ' OG1' ' A' ' 107' ' ' THR . . . -129.41 28.33 4.05 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.443 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 77.42 -150.37 36.66 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t -123.01 148.18 45.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.131 -1.217 . . . . 0.0 109.501 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.52 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.521 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.417 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.452 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.564 ' CE2' HG21 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.576 ' CE1' HG13 ' A' ' 2' ' ' VAL . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.542 ' N ' ' O ' ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . 0.53 ' CD2' ' CD2' ' A' ' 95' ' ' LEU . 97.7 m-70 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.422 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.422 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.564 HG21 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.433 ' HG3' HG21 ' A' ' 7' ' ' THR . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.529 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.529 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.52 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.47 ' CG2' HG13 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.416 ' O ' HD21 ' A' ' 152' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.527 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.454 HD21 ' O ' ' A' ' 147' ' ' VAL . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.8 -35.48 80.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.527 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 76.0 m80 -49.38 -40.3 35.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.418 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.4 p -59.06 -30.65 68.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.941 . . . . 0.0 109.241 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -73.95 -16.52 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.364 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.7 145.09 55.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.956 . . . . 0.0 109.405 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.452 ' O ' ' CB ' ' A' ' 159' ' ' ASN . 69.9 m-85 -113.03 120.23 40.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . 0.452 ' CB ' ' O ' ' A' ' 158' ' ' TYR . 46.6 t30 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.426 HG11 ' ND1' ' A' ' 121' ' ' HIS . 50.1 t -133.85 142.09 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.308 -1.113 . . . . 0.0 109.395 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.485 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.438 HG23 ' N ' ' A' ' 10' ' ' THR . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.438 ' N ' HG23 ' A' ' 9' ' ' THR . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.437 ' OG ' ' OE1' ' A' ' 148' ' ' GLU . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.512 HG23 ' N ' ' A' ' 13' ' ' ILE . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.54 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.54 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.528 ' CB ' HG23 ' A' ' 104' ' ' ILE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.43 ' O ' ' HB1' ' A' ' 21' ' ' ALA . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.638 ' CZ ' ' CD1' ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.565 ' CE2' HD12 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.638 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.457 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.526 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.457 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.515 ' CD1' HG22 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.513 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.503 ' CG1' ' HB2' ' A' ' 55' ' ' LYS . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.476 ' O ' ' CG2' ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.459 ' O ' HG13 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.476 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.46 HG22 ' CD1' ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.513 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.503 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.515 HG22 ' CD1' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.45 ' O ' HG21 ' A' ' 38' ' ' ILE . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.458 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.64 157.04 62.0 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -54.47 141.62 30.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.479 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.62 9.36 52.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.522 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.3 m-85 -109.2 161.13 25.01 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.327 -1.101 . . . . 0.0 109.464 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.522 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.3 Cg_endo -70.07 -38.76 6.71 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.766 2.311 . . . . 0.0 111.696 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.57 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 98.0 m-85 -114.08 152.27 31.3 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.412 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt -79.19 -36.69 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.656 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.408 HG12 ' N ' ' A' ' 68' ' ' LYS . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.508 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.405 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.421 HG12 ' CE1' ' A' ' 76' ' ' HIS . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.421 ' CE1' HG12 ' A' ' 74' ' ' VAL . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.577 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.446 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.508 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.444 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.459 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.551 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.57 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.463 ' O ' ' O ' ' A' ' 88' ' ' GLY . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.453 ' O ' HD11 ' A' ' 91' ' ' ILE . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.538 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.496 ' OD1' ' ND2' ' A' ' 118' ' ' ASN . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.45 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.565 HD12 ' CE2' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.528 HG23 ' CB ' ' A' ' 15' ' ' ALA . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.456 ' O ' HG22 ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.6 OUTLIER -153.52 125.04 3.67 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.51 -4.78 15.21 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.639 2.226 . . . . 0.0 111.72 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.23 -33.64 43.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.173 -0.954 . . . . 0.0 109.396 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -157.59 37.3 0.54 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 76.03 -143.9 30.38 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p -103.9 148.21 26.43 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.324 -1.104 . . . . 0.0 109.18 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.401 ' CD2' HG12 ' A' ' 104' ' ' ILE . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.496 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 1.1 t-20 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CD2' HG12 ' A' ' 98' ' ' ILE . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.477 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 94' ' ' THR . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.417 ' CG2' ' CG2' ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.512 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.512 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 33' ' ' VAL . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.463 ' O ' HD22 ' A' ' 151' ' ' LEU . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.465 ' O ' HD22 ' A' ' 152' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.554 ' CZ ' ' NE2' ' A' ' 154' ' ' HIS . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.468 ' CD2' ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' OD1' ' A' ' 156' ' ' ASP . . . -70.65 -28.37 64.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . 0.554 ' NE2' ' CZ ' ' A' ' 150' ' ' TYR . 67.7 m-70 -92.16 -26.99 17.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 109.476 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 87.4 p -52.37 -31.92 36.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.194 -0.941 . . . . 0.0 109.361 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 56.9 p30 -91.73 9.52 32.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -68.5 143.39 54.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.311 -0.868 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -61.23 -36.8 80.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.272 -0.893 . . . . 0.0 109.468 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.47 179.922 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' A' ' 121' ' ' HIS . 62.7 t -133.96 142.6 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.166 -1.197 . . . . 0.0 109.435 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.541 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.45 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.541 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.417 ' O ' HG23 ' A' ' 113' ' ' ILE . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.454 ' O ' ' HA2' ' A' ' 111' ' ' GLY . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.521 ' CB ' HG21 ' A' ' 104' ' ' ILE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.471 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.526 HD13 ' CB ' ' A' ' 22' ' ' PHE . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.561 ' CE2' HG13 ' A' ' 23' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.526 ' CB ' HD13 ' A' ' 18' ' ' LEU . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.561 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.46 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.527 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.46 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.527 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.507 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.457 HG23 HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.476 ' CD1' HG23 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.477 ' HG2' ' N ' ' A' ' 46' ' ' GLY . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.477 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.423 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.476 HG23 ' CD1' ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.52 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.457 HG23 HG23 ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 38' ' ' ILE . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.444 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.8 Cg_endo -69.9 143.47 50.29 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -51.23 143.89 10.39 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.343 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.39 8.35 57.57 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.508 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -106.2 162.76 18.69 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.236 -1.155 . . . . 0.0 109.488 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.508 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.7 Cg_endo -68.92 -30.76 25.78 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.702 2.268 . . . . 0.0 111.795 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.531 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 41.0 m-85 -119.67 158.44 26.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 109.541 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt -96.58 -65.71 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -0.904 . . . . 0.0 109.402 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.445 ' HD2' ' OE2' ' A' ' 87' ' ' GLU . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.495 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.522 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.522 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.58 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.431 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 69' ' ' ASP . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.495 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.445 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.403 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.531 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.447 HG22 HD11 ' A' ' 91' ' ' ILE . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.483 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.431 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.58 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.453 ' N ' ' O ' ' A' ' 81' ' ' TYR . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.521 HG21 ' CB ' ' A' ' 15' ' ' ALA . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.474 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.3 p -109.26 163.84 16.11 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.3 Cg_endo -69.43 -17.62 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.535 2.157 . . . . 0.0 111.629 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.25 -23.63 59.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.354 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 126.81 -53.66 0.79 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 12' ' ' VAL . . . -62.46 -160.28 0.18 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 83.6 p -147.18 157.75 43.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -1.161 . . . . 0.0 109.381 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.474 HG13 ' CG2' ' A' ' 107' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.512 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.456 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 94' ' ' THR . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . 0.434 ' CD2' HD22 ' A' ' 95' ' ' LEU . 97.7 m-70 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.442 HG23 ' CG2' ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.454 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.454 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.465 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.53 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.505 ' N ' HD11 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.476 ' HB3' HG23 ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.456 ' O ' HD22 ' A' ' 151' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.435 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.507 HD21 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.71 -44.57 95.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -90.75 -24.27 20.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 32.5 t -61.11 -29.06 69.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.595 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -105.93 18.33 22.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.92 . . . . 0.0 109.884 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.41 130.41 55.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.053 -1.029 . . . . 0.0 110.014 -179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 27.2 t80 -65.86 132.04 47.71 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.478 -0.764 . . . . 0.0 109.525 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.542 179.786 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 3' ' ' PHE . 58.2 t -132.05 145.9 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -1.157 . . . . 0.0 109.483 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.54 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.54 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.508 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.547 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.547 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.519 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.527 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.544 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.527 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.494 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.51 ' O ' ' CG2' ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.423 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.52 ' O ' ' CG2' ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.431 HG21 HD11 ' A' ' 38' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.51 ' CG2' ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.461 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.467 ' O ' ' CG2' ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.416 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.4 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.467 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.512 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.461 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo -74.24 -168.94 0.52 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' A' ' 59' ' ' PRO . 3.3 mt-10 50.56 177.48 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.849 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -88.73 26.87 7.72 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.468 ' O ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -42.1 165.99 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.452 -1.029 . . . . 0.0 109.701 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.98 -29.73 33.72 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.718 2.279 . . . . 0.0 111.911 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.576 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 79.6 m-85 -106.83 148.33 28.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt -106.1 -40.85 5.53 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.74 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.509 HG11 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.512 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.467 HG22 ' CZ ' ' A' ' 81' ' ' TYR . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.46 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.46 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.457 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 12.5 m120 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.544 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.483 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.551 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.408 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.449 ' O ' ' HG2' ' A' ' 97' ' ' LYS . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.585 ' CD1' ' N ' ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.509 ' CA ' HG11 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.576 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.572 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 HD12 ' A' ' 91' ' ' ILE . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.457 ' O ' HD11 ' A' ' 91' ' ' ILE . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.408 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.551 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.483 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.467 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.517 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.5 p -103.01 163.24 17.92 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.466 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.8 Cg_endo -69.9 -26.1 27.26 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.687 2.258 . . . . 0.0 111.754 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -70.85 -28.95 64.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.335 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 111' ' ' GLY . . . 132.85 -48.55 0.96 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 110' ' ' GLY . . . -58.08 -156.54 0.02 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.437 ' HA ' HG22 ' A' ' 107' ' ' THR . 80.5 p -151.48 157.77 42.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -1.117 . . . . 0.0 109.463 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.517 HG13 ' CG2' ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.445 ' N ' HG22 ' A' ' 113' ' ' ILE . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.457 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 94' ' ' THR . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.448 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 23.7 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.508 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.524 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.524 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . 0.462 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.494 ' CG2' HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.457 ' HA ' HD11 ' A' ' 13' ' ' ILE . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.523 HD11 ' CD1' ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.456 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -61.7 -43.7 98.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -50.55 -39.25 48.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 28.7 m -58.48 -29.49 66.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -72.43 -18.72 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.527 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -78.09 -10.64 59.71 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.154 -0.966 . . . . 0.0 109.513 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.539 ' CD1' ' C ' ' A' ' 158' ' ' TYR . 0.6 OUTLIER -50.15 -39.72 44.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.235 -0.915 . . . . 0.0 109.085 179.844 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . 0.462 ' OXT' ' OD1' ' A' ' 159' ' ' ASN . 28.7 t-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.909 -1.044 . . . . 0.0 109.493 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.438 HG13 ' N ' ' A' ' 3' ' ' PHE . 45.5 t -133.12 149.19 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -1.154 . . . . 0.0 109.565 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.553 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.553 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.405 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' THR . . . . . 0.415 HG23 ' HG3' ' A' ' 137' ' ' LYS . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.46 HG22 HD11 ' A' ' 13' ' ' ILE . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.539 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.539 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.419 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.526 ' CD2' HD22 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.445 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.501 ' CA ' HG22 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . 0.45 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.53 ' HG ' ' CG1' ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.425 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.53 ' CG1' ' HG ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.479 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.471 HG22 ' CG2' ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.501 HG22 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.449 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . 0.449 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.419 HD13 HG21 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.507 ' O ' ' CG2' ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.507 ' CG2' ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.443 HG12 ' HG2' ' A' ' 70' ' ' ARG . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.531 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.471 ' CG2' HG22 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.68 155.35 66.43 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -53.09 141.32 23.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.12 -0.987 . . . . 0.0 109.433 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.01 48.5 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.531 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.6 m-85 -108.41 169.87 6.1 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.296 -1.12 . . . . 0.0 109.491 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.531 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.2 Cg_endo -69.46 -49.7 0.57 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 111.791 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.567 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 96.9 m-85 -119.64 148.86 42.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.247 -0.908 . . . . 0.0 109.495 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp -75.09 -44.79 45.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.698 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.531 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.436 HG22 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.523 ' O ' ' CG2' ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.455 ' HD3' HG23 ' A' ' 86' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.455 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 10.9 m120 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.518 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.406 ' OH ' HG22 ' A' ' 71' ' ' VAL . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.455 HG23 ' HD3' ' A' ' 70' ' ' ARG . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.409 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.567 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.518 HD13 HG22 ' A' ' 91' ' ' ILE . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.531 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.456 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.445 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.464 HG22 ' CB ' ' A' ' 15' ' ' ALA . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.467 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 111' ' ' GLY . 6.7 p -121.15 157.99 54.04 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 48.8 Cg_endo -69.9 -48.02 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.744 2.296 . . . . 0.0 111.918 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.463 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 92.1 m-20 -136.31 26.25 3.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.147 -0.971 . . . . 0.0 109.477 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.406 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -127.42 20.12 5.88 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.442 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 63.02 -147.47 50.47 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.422 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 24.2 p -112.84 146.73 38.36 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.241 -1.153 . . . . 0.0 109.394 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.526 HD22 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.447 HG21 ' OD1' ' A' ' 100' ' ' ASN . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ASN . . . . . 0.471 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 26.0 m120 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.464 ' OH ' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.452 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 94' ' ' THR . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' LYS . . . . . 0.531 ' N ' ' O ' ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.542 HG12 ' CD1' ' A' ' 5' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 7' ' ' THR . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.4 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.518 ' CG1' HD23 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 153' ' ' ALA . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.501 HD21 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 150' ' ' TYR . . . -62.93 -31.25 72.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -56.38 -32.89 65.2 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.9 t -62.86 -21.15 65.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -85.65 5.96 29.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.22 -0.925 . . . . 0.0 109.646 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.1 125.62 39.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.107 -0.996 . . . . 0.0 109.499 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -58.23 129.56 42.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.481 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.423 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 120' ' ' TYR . 56.3 t . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.302 0.572 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.498 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.605 HG23 ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.778 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.457 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.878 ' HD1' HD12 ' A' ' 104' ' ' ILE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.437 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG11 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.415 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.942 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.942 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 57' ' ' SER . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.832 HG22 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.832 ' HG3' HG22 ' A' ' 44' ' ' ILE . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.509 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.748 HG22 HD12 ' A' ' 44' ' ' ILE . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.52 HG23 HG21 ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.522 ' O ' HG23 ' A' ' 38' ' ' ILE . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo . . . . . 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.186 0.517 . . . . 0.0 109.686 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.865 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.496 ' CE ' ' OE1' ' A' ' 87' ' ' GLU . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.685 ' HA ' HG12 ' A' ' 85' ' ' VAL . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.401 ' O ' HG13 ' A' ' 74' ' ' VAL . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.581 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' ASP . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.865 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.708 HD11 HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.555 ' CG ' HG22 ' A' ' 94' ' ' THR . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.645 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.604 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.708 HG12 HD11 ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 82' ' ' ASN . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.878 HD12 ' HD1' ' A' ' 19' ' ' PHE . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 112' ' ' SER . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.321 0.582 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.472 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 65.8 m-20 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.634 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.608 ' CE1' HG11 ' A' ' 2' ' ' VAL . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.62 HG21 HG23 ' A' ' 128' ' ' VAL . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.645 ' HB2' HG23 ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 63.0 m80 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 120' ' ' TYR . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.544 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.416 ' HA ' HD23 ' A' ' 143' ' ' LEU . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.426 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.432 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.73 HG13 HD21 ' A' ' 29' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.653 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 120' ' ' TYR . 39.4 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.59 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.522 HG21 HD22 ' A' ' 144' ' ' LEU . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.716 HG23 ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.716 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.546 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.599 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.482 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.495 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.468 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.94 ' O ' HG22 ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.94 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.655 HD13 HG23 ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.49 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.694 HG22 ' HG3' ' A' ' 45' ' ' GLU . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.898 ' O ' HG23 ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.422 ' O ' HG21 ' A' ' 74' ' ' VAL . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.49 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 HD13 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.572 ' O ' HG23 ' A' ' 38' ' ' ILE . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.475 ' HE1' HG23 ' A' ' 67' ' ' VAL . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo . . . . . 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.437 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.533 HG13 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.429 ' OD1' HG22 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.498 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.463 ' OE2' ' HB3' ' A' ' 50' ' ' PRO . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.451 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.451 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.503 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.498 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.47 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.533 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.491 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.596 HD13 ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.671 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.608 HD23 ' ND1' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.596 ' O ' HD13 ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.506 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.878 ' CD1' HD23 ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.444 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.432 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 15' ' ' ALA . 26.5 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.878 HD23 ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 121' ' ' HIS . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.692 ' O ' HG13 ' A' ' 2' ' ' VAL . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.574 HG21 HG23 ' A' ' 128' ' ' VAL . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.671 ' HB2' HG23 ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.608 ' ND1' HD23 ' A' ' 95' ' ' LEU . 46.8 m80 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.574 HG23 HG21 ' A' ' 122' ' ' THR . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.415 ' OE1' HG13 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.44 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.546 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.632 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.565 ' N ' HD12 ' A' ' 144' ' ' LEU . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.68 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.402 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.637 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.588 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.586 HG13 ' O ' ' A' ' 120' ' ' TYR . 94.6 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.566 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.528 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.562 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.846 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.49 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.761 ' CE1' HD12 ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.761 HD12 ' CE1' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.621 ' O ' HG11 ' A' ' 41' ' ' VAL . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.432 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.909 ' O ' HG22 ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.909 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 57' ' ' SER . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.459 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.869 ' O ' HG23 ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.451 HG23 HD13 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.668 ' HE1' HG23 ' A' ' 67' ' ' VAL . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.459 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo . . . . . 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.137 0.494 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.446 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.668 HG23 ' HE1' ' A' ' 58' ' ' PHE . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.617 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 85' ' ' VAL . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.51 HG21 ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.482 HG22 ' CE2' ' A' ' 81' ' ' TYR . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.567 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.51 ' OH ' HG21 ' A' ' 71' ' ' VAL . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.42 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.425 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.513 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.513 ' HA ' HD13 ' A' ' 91' ' ' ILE . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.846 HG22 ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.504 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 89.8 p . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 121.238 0.542 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.504 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.83 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.522 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.83 ' CD1' HD21 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 83.1 m-20 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.586 ' O ' HG13 ' A' ' 2' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.783 HG21 HG23 ' A' ' 128' ' ' VAL . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.783 HG23 HG21 ' A' ' 122' ' ' THR . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.426 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.426 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.429 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.528 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.456 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.504 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.64 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.503 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.419 HG22 HG11 ' A' ' 33' ' ' VAL . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.418 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.625 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 120' ' ' TYR . 95.1 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.484 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.484 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.439 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.596 HG21 ' HG ' ' A' ' 151' ' ' LEU . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.898 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.595 HD23 HD13 ' A' ' 104' ' ' ILE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.541 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.709 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.541 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.455 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.901 ' O ' HG22 ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.901 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.719 HG23 ' O ' ' A' ' 57' ' ' SER . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.482 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.576 HD12 HG22 ' A' ' 53' ' ' ILE . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.709 ' O ' HG23 ' A' ' 52' ' ' THR . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 44' ' ' ILE . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.482 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.66 HG23 HD13 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.719 ' O ' HG23 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.21 0.528 . . . . 0.0 109.596 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.57 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.954 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.5 ' HA ' HG22 ' A' ' 85' ' ' VAL . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.487 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.487 ' OH ' HG22 ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.954 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.493 ' HB2' ' HD2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.8 HD11 HG12 ' A' ' 98' ' ' ILE . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.59 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.523 ' HG2' HD11 ' A' ' 98' ' ' ILE . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.613 ' HA ' HD13 ' A' ' 91' ' ' ILE . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.8 HG12 HD11 ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.898 HG22 ' HB1' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.254 0.55 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.544 HD21 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.409 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 73.6 m-20 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.528 ' O ' HG13 ' A' ' 2' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.515 ' CE1' HG11 ' A' ' 2' ' ' VAL . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.615 HG21 HG23 ' A' ' 128' ' ' VAL . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.59 ' HB2' HG23 ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 53.1 m80 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.615 HG23 HG21 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 84.0 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.449 HG22 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.439 ' HE3' HG22 ' A' ' 7' ' ' THR . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.617 ' OE2' HD21 ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.672 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.601 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.427 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.631 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 120' ' ' TYR . 86.3 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.335 0.588 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.476 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.476 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.993 HG22 HG23 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.882 HG21 HD13 ' A' ' 151' ' ' LEU . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.747 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.788 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.975 ' HG2' HD22 ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.797 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.639 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.975 HD22 ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.978 ' O ' HG22 ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.978 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.481 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.879 HD12 HG22 ' A' ' 53' ' ' ILE . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.838 ' O ' HG23 ' A' ' 52' ' ' THR . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.491 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.879 HG22 HD12 ' A' ' 44' ' ' ILE . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.604 ' HB ' HG12 ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.44 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.685 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.71 ' O ' HG13 ' A' ' 85' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.627 ' O ' HG23 ' A' ' 53' ' ' ILE . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.614 HH21 HD13 ' A' ' 86' ' ' ILE . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.453 ' N ' ' HG2' ' A' ' 70' ' ' ARG . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.4 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.447 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 68' ' ' LYS . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.614 HD13 HH21 ' A' ' 70' ' ' ARG . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.685 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 97' ' ' LYS . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.501 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.552 ' HA ' HD13 ' A' ' 91' ' ' ILE . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.452 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.788 HG22 ' HB1' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.993 HG23 HG22 ' A' ' 10' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 104' ' ' ILE . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.992 ' OH ' HG13 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.407 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.992 HG13 ' OH ' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.503 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HA ' HD23 ' A' ' 143' ' ' LEU . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.612 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.464 ' N ' HD12 ' A' ' 144' ' ' LEU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.556 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' SER . . . . . 0.594 ' HA ' HD12 ' A' ' 152' ' ' LEU . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.882 HD13 HG21 ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.594 HD12 ' HA ' ' A' ' 149' ' ' SER . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.813 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.445 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.572 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.445 HG21 HD13 ' A' ' 144' ' ' LEU . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.902 HG21 HD13 ' A' ' 151' ' ' LEU . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.769 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.771 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.731 ' HD2' HD12 ' A' ' 104' ' ' ILE . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.446 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.426 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.913 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 56' ' ' ILE . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.409 HG22 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.884 HD12 HG22 ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.798 ' O ' HG23 ' A' ' 52' ' ' THR . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.524 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.798 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.884 HG22 HD12 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.527 HG23 ' CG2' ' A' ' 38' ' ' ILE . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.266 0.555 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.522 HG13 ' HA2' ' A' ' 88' ' ' GLY . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.973 ' O ' HG13 ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.442 ' CZ ' HD13 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 74' ' ' VAL . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.484 ' O ' ' N ' ' A' ' 102' ' ' ILE . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.973 HG13 ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 87' ' ' GLU . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.522 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.527 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.527 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.574 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.487 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.487 HD12 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.574 ' HA ' HD13 ' A' ' 91' ' ' ILE . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.497 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.484 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.769 HG22 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.576 ' CD2' HG23 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.721 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.813 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.635 HG21 HG23 ' A' ' 128' ' ' VAL . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.635 HG23 HG21 ' A' ' 122' ' ' THR . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.438 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.445 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.449 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.537 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.56 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.612 HG13 HD21 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.456 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' SER . . . . . 0.828 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.902 HD13 HG21 ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.828 HD12 ' HA ' ' A' ' 149' ' ' SER . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.1 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.435 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.598 HG22 HG23 ' A' ' 113' ' ' ILE . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.871 HG21 HD13 ' A' ' 151' ' ' LEU . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.741 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.854 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.675 HD23 HD13 ' A' ' 104' ' ' ILE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.481 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.564 HD12 ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.538 ' HB2' HD13 ' A' ' 29' ' ' LEU . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.886 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.886 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.47 HD13 HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.43 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.821 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.452 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.516 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.489 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.516 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG23 ' A' ' 38' ' ' ILE . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' CD1' ' O ' ' A' ' 37' ' ' ALA . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.456 HG13 ' HA2' ' A' ' 88' ' ' GLY . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.947 ' O ' HG13 ' A' ' 85' ' ' VAL . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.489 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.463 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 81' ' ' TYR . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.404 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.947 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.529 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.451 HD13 ' HA ' ' A' ' 97' ' ' LYS . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.486 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.404 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.461 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.499 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.854 HG22 ' HB1' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.417 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.598 HG23 HG22 ' A' ' 10' ' ' THR . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.529 ' CD2' HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.485 ' ND2' ' HG2' ' A' ' 137' ' ' LYS . 73.7 m-20 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.649 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.7 HG21 HG23 ' A' ' 128' ' ' VAL . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 48.8 m80 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.7 HG23 HG21 ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.469 ' OE1' HG13 ' A' ' 128' ' ' VAL . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 120' ' ' TYR . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.45 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.485 ' HG2' ' ND2' ' A' ' 118' ' ' ASN . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.45 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.452 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.715 ' OE2' HD11 ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.715 HD11 ' OE2' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.61 ' N ' HD12 ' A' ' 144' ' ' LEU . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.871 HD13 HG21 ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 120' ' ' TYR . 46.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.483 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.926 HG21 HD13 ' A' ' 151' ' ' LEU . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.608 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.448 ' O ' HD12 ' A' ' 29' ' ' LEU . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.984 ' O ' HG22 ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.984 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.683 ' CG2' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.45 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.573 ' CG1' HG21 ' A' ' 38' ' ' ILE . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.493 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.926 HD12 HG22 ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.822 ' O ' HG23 ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.48 ' H ' HG21 ' A' ' 52' ' ' THR . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.822 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.926 HG22 HD12 ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.695 ' HB ' HG12 ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HD3' ' N ' ' A' ' 39' ' ' SER . 48.9 Cg_endo . . . . . 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.305 0.574 . . . . 0.0 109.875 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.695 HG12 ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 1.017 ' O ' HG13 ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.603 HG22 ' CE2' ' A' ' 81' ' ' TYR . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.603 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.463 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 1.017 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.582 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.596 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.528 HD13 ' CE1' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.706 HD12 HD12 ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.467 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 105' ' ' VAL . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.706 HD12 HD12 ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.582 HG12 HD21 ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.926 ' OH ' HG13 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.625 ' CE1' HG11 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.606 HG21 HG23 ' A' ' 128' ' ' VAL . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.606 HG23 HG21 ' A' ' 122' ' ' THR . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.926 HG13 ' OH ' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.442 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.454 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.538 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.464 ' NE ' ' CG ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.926 HD13 HG21 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 92.0 t . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.517 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.53 HG23 HD13 ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.792 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.763 ' HD2' HD12 ' A' ' 104' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.435 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.723 HD12 ' CE1' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.651 ' O ' HG21 ' A' ' 41' ' ' VAL . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.917 ' O ' HG22 ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.434 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.917 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' HG23 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.651 HG21 ' O ' ' A' ' 27' ' ' ASP . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.433 ' HA ' ' HD2' ' A' ' 54' ' ' LYS . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.783 HG22 ' HG3' ' A' ' 45' ' ' GLU . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.783 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.56 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.737 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.641 HG22 HD12 ' A' ' 44' ' ' ILE . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.503 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.623 HG23 ' CG2' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.48 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.877 HG23 ' HA2' ' A' ' 88' ' ' GLY . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.965 ' O ' HG23 ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.559 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.965 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.465 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.877 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.594 ' CG ' HG22 ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.594 HG22 ' CG ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.488 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.763 HD12 ' HD2' ' A' ' 19' ' ' PHE . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 13.6 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.4 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.293 0.568 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.474 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' TYR . 79.2 m-20 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.489 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.531 HG21 HG23 ' A' ' 128' ' ' VAL . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.411 ' O ' ' HB ' ' A' ' 122' ' ' THR . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.531 HG23 HG21 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.632 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.557 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 120' ' ' TYR . 64.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.511 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.511 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.402 ' O ' ' N ' ' A' ' 112' ' ' SER . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.83 HG21 HD13 ' A' ' 151' ' ' LEU . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.904 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.433 ' O ' ' HG2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.577 ' O ' HG22 ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.452 ' CG2' HG23 ' A' ' 56' ' ' ILE . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.01 HD12 HG22 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.782 ' O ' HG23 ' A' ' 52' ' ' THR . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.782 HG23 ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 1.01 HG22 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo . . . . . 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.458 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.539 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.872 ' O ' HG13 ' A' ' 85' ' ' VAL . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.634 HG22 ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.428 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.481 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.634 ' OH ' HG22 ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.475 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 68' ' ' LYS . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.437 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.539 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.472 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.638 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.557 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' HD13 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.475 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.66 HD12 ' HD2' ' A' ' 19' ' ' PHE . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.497 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.446 ' CD1' HG12 ' A' ' 98' ' ' ILE . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 53.6 m80 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.666 HG21 HG23 ' A' ' 128' ' ' VAL . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.638 ' HB2' HG23 ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.666 HG23 HG21 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.583 ' OE1' HG13 ' A' ' 128' ' ' VAL . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.483 HG12 ' HE3' ' A' ' 137' ' ' LYS . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.507 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.441 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.623 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.473 ' N ' HD12 ' A' ' 144' ' ' LEU . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.552 HG13 HD21 ' A' ' 29' ' ' LEU . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.505 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.83 HD13 HG21 ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.634 HG11 ' CE1' ' A' ' 121' ' ' HIS . 47.7 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.495 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.488 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.415 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.563 HG23 ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.885 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.827 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.486 ' HD1' HD12 ' A' ' 104' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB3' HD13 ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.597 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.748 ' HB ' ' HB1' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.424 HG12 ' CG2' ' A' ' 56' ' ' ILE . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.424 ' O ' ' N ' ' A' ' 55' ' ' LYS . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.016 HD11 ' HB2' ' A' ' 55' ' ' LYS . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.82 ' O ' HG23 ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.429 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.491 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.756 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.82 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 1.016 ' HB2' HD11 ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.424 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' HG23 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo . . . . . 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.423 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.66 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.482 ' HA ' HG12 ' A' ' 85' ' ' VAL . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 81' ' ' TYR . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.494 ' CD1' HG22 ' A' ' 74' ' ' VAL . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.411 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 69' ' ' ASP . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.507 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.66 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.45 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 97' ' ' LYS . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.527 HD12 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 91' ' ' ILE . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.423 ' HA ' ' O ' ' A' ' 117' ' ' SER . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.415 ' O ' ' N ' ' A' ' 81' ' ' TYR . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.885 HG22 ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.474 ' CD2' HG23 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 5' ' ' TYR . 82.1 m-20 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.581 ' CE1' HG13 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.634 ' CE1' HG11 ' A' ' 2' ' ' VAL . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.82 HG21 HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.82 HG23 HG21 ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 120' ' ' TYR . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.492 ' HE2' ' HB3' ' A' ' 5' ' ' TYR . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.403 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.55 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 143' ' ' LEU . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 144' ' ' LEU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.592 ' N ' HD12 ' A' ' 144' ' ' LEU . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.748 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.402 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.546 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 120' ' ' TYR . 48.5 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.596 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.464 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.632 HG22 HG23 ' A' ' 113' ' ' ILE . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.844 HG21 HD13 ' A' ' 151' ' ' LEU . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.732 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.621 ' HB3' ' HB2' ' A' ' 106' ' ' ALA . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.572 HD23 HD13 ' A' ' 104' ' ' ILE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.429 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.93 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.93 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.414 HD13 HG23 ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.494 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.512 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 55' ' ' LYS . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.036 HD11 ' HB2' ' A' ' 55' ' ' LYS . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.76 ' O ' HG23 ' A' ' 52' ' ' THR . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.475 ' H ' HG21 ' A' ' 52' ' ' THR . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.76 HG23 ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 1.036 ' HB2' HD11 ' A' ' 44' ' ' ILE . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo . . . . . 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.131 0.491 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.599 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.592 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 1.034 ' O ' HG13 ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.444 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 1.034 HG13 ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.519 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.47 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.592 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 96' ' ' GLU . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.508 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' HD13 ' A' ' 91' ' ' ILE . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.519 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.482 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.403 ' O ' ' N ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.572 HD13 HD23 ' A' ' 18' ' ' LEU . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.632 HG23 HG22 ' A' ' 10' ' ' THR . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.819 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.524 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.819 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.69 ' O ' HG13 ' A' ' 2' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.549 ' CE1' HG11 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.63 HG21 HG23 ' A' ' 128' ' ' VAL . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.451 ' ND1' HD22 ' A' ' 95' ' ' LEU . 67.8 m80 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.63 HG23 HG21 ' A' ' 122' ' ' THR . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.663 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.571 ' HE3' HG12 ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.445 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.413 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.608 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.853 HG13 HD21 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.434 ' HA ' HD12 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.844 HD13 HG21 ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.553 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 120' ' ' TYR . 54.9 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.605 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.605 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.556 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.646 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.705 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.49 ' HA ' HD13 ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.563 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.501 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.617 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.551 ' O ' HD12 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.99 ' O ' HG22 ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.99 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.695 HD13 HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.409 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.982 HD11 ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.894 ' O ' HG23 ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.894 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.446 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.982 ' HB2' HD11 ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.695 HG23 HD13 ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 38' ' ' ILE . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.526 ' HE1' HG23 ' A' ' 67' ' ' VAL . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.453 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.526 HG23 ' HE1' ' A' ' 58' ' ' PHE . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.962 ' O ' HG13 ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.446 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.53 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.495 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.603 HG22 ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.481 HD13 ' O ' ' A' ' 96' ' ' GLU . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.577 HD22 ' ND1' ' A' ' 126' ' ' HIS . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.603 ' CE ' HG22 ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.705 HD13 HD23 ' A' ' 18' ' ' LEU . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 13.0 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.636 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 84.5 m-20 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.7 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.506 ' CE1' HG11 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.763 HG21 HG23 ' A' ' 128' ' ' VAL . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.577 ' ND1' HD22 ' A' ' 95' ' ' LEU . 70.0 m80 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.763 HG23 HG21 ' A' ' 122' ' ' THR . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.668 HG22 ' CZ ' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.417 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.542 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.439 ' HA ' HD23 ' A' ' 143' ' ' LEU . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.581 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.475 ' N ' HD12 ' A' ' 144' ' ' LEU . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.452 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' SER . . . . . 0.601 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.601 HD12 ' HA ' ' A' ' 149' ' ' SER . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.292 0.568 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.545 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.469 ' HA ' ' HG2' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.545 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.401 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.904 HG21 HD13 ' A' ' 151' ' ' LEU . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.555 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.686 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.54 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.545 HD23 HD12 ' A' ' 104' ' ' ILE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.689 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.659 ' CE1' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.471 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.435 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.441 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.891 ' O ' HG22 ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.891 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.437 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.799 HG22 ' HG3' ' A' ' 45' ' ' GLU . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.799 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.633 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.763 HG23 ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.727 HG22 HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.523 HG23 ' CG2' ' A' ' 38' ' ' ILE . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.498 HG22 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 85' ' ' VAL . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 49' ' ' GLY . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.481 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.443 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.42 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.532 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.472 HD13 ' HA ' ' A' ' 97' ' ' LYS . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.693 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.659 HD13 ' CE1' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.686 HG22 ' CB ' ' A' ' 15' ' ' ALA . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.408 HG21 ' NZ ' ' A' ' 115' ' ' LYS . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.2 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.891 ' CD2' HD13 ' A' ' 144' ' ' LEU . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.701 HD11 HD21 ' A' ' 114' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.735 ' CE1' HG13 ' A' ' 133' ' ' VAL . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.719 HG21 HG23 ' A' ' 128' ' ' VAL . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.693 ' HB2' HG23 ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 45.3 m80 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.719 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.404 ' HE2' ' OE1' ' A' ' 131' ' ' GLU . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.404 ' OE1' ' HE2' ' A' ' 129' ' ' LYS . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.735 HG13 ' CE1' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.401 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.443 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.479 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.891 HD13 ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 143' ' ' LEU . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.749 ' HA ' HD11 ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.904 HD13 HG21 ' A' ' 13' ' ' ILE . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.522 HG13 ' O ' ' A' ' 120' ' ' TYR . 49.1 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.597 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 22.4 t30 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.464 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.407 HG21 HD13 ' A' ' 144' ' ' LEU . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' ILE . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.754 HD11 ' HA ' ' A' ' 148' ' ' GLU . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.488 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.76 ' CD1' HD12 ' A' ' 104' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.545 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.59 ' O ' HG21 ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.438 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.764 ' O ' HG22 ' A' ' 33' ' ' VAL . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.594 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.59 HG21 ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.796 HD12 HG22 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.854 ' O ' HG23 ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.854 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.796 HG22 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.594 HG23 ' CG2' ' A' ' 38' ' ' ILE . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 65' ' ' LYS . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.247 0.546 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.809 HG23 ' HA2' ' A' ' 88' ' ' GLY . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.932 ' O ' HG13 ' A' ' 85' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.599 ' O ' HG23 ' A' ' 53' ' ' ILE . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.525 HG22 ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 56.3 m-20 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.479 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.525 ' OH ' HG22 ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.932 HG13 ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.468 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.434 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.809 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.56 HD13 ' HA ' ' A' ' 97' ' ' LYS . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.56 ' HA ' HD13 ' A' ' 91' ' ' ILE . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.504 HD13 ' HE2' ' A' ' 22' ' ' PHE . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.76 HD12 ' CD1' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.527 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.4 p . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.5 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.527 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.476 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.473 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.528 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.482 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.675 HG21 HG23 ' A' ' 128' ' ' VAL . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.675 HG23 HG21 ' A' ' 122' ' ' THR . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.464 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 143' ' ' LEU . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.539 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.693 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.754 ' HA ' HD11 ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.607 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.491 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 78.8 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.289 0.566 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.405 ' CG ' ' HE3' ' A' ' 119' ' ' LYS . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.546 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 113' ' ' ILE . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.452 HG23 HD13 ' A' ' 13' ' ' ILE . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.517 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.517 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.508 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.574 ' CE2' HD13 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.884 ' O ' HG22 ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.884 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.561 ' CG2' HG23 ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.468 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.799 HD12 HG22 ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.771 ' O ' HG23 ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.46 ' H ' HG21 ' A' ' 52' ' ' THR . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.832 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.799 HG22 HD12 ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.561 HG23 ' CG2' ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.268 0.556 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 56' ' ' ILE . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.7 ' O ' HG13 ' A' ' 85' ' ' VAL . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.656 ' O ' HG23 ' A' ' 53' ' ' ILE . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.832 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.468 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.52 ' HE3' HD22 ' A' ' 82' ' ' ASN . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.597 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.52 HD22 ' HE3' ' A' ' 80' ' ' LYS . 74.3 m-20 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.574 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 68' ' ' LYS . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.42 ' HA ' ' HE2' ' A' ' 97' ' ' LYS . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.543 HD11 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.708 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.726 HD23 ' ND1' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.543 HG12 HD11 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.574 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.574 HD13 ' CE2' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 114' ' ' LEU . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.53 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 10' ' ' THR . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.627 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.442 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.405 ' HE3' ' CG ' ' A' ' 4' ' ' ASN . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 95' ' ' LEU . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.708 ' HB2' HG23 ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.726 ' ND1' HD23 ' A' ' 95' ' ' LEU . 62.2 m80 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.512 HG23 HG21 ' A' ' 122' ' ' THR . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.43 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.535 HG22 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.619 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.575 ' N ' HD12 ' A' ' 144' ' ' LEU . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.53 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.84 HG22 HG11 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.407 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.627 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.663 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.687 HG13 ' O ' ' A' ' 120' ' ' TYR . 50.1 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.507 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.44 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.489 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.912 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.696 ' CE2' HD12 ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.517 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.551 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.696 HD12 ' CE2' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.443 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.9 ' O ' HG22 ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.9 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.614 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.838 HG22 ' HG3' ' A' ' 45' ' ' GLU . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.698 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.859 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.798 HG22 HD12 ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.502 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.512 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.614 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.459 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.249 0.547 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.454 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.997 ' O ' HG23 ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.698 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.416 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.583 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.452 ' HE1' HD11 ' A' ' 102' ' ' ILE . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.402 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.434 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.477 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.534 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 97' ' ' LYS . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.545 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.401 ' HA ' HD23 ' A' ' 95' ' ' LEU . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.503 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.539 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.402 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.48 ' HA ' ' O ' ' A' ' 117' ' ' SER . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.459 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.551 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.525 HD12 ' HD1' ' A' ' 19' ' ' PHE . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.422 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.422 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.406 ' HA ' HD23 ' A' ' 114' ' ' LEU . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.412 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.687 ' O ' HG13 ' A' ' 2' ' ' VAL . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.804 HG21 HG23 ' A' ' 128' ' ' VAL . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.545 ' HB2' HG23 ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.804 HG23 HG21 ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.44 ' HE3' HG22 ' A' ' 7' ' ' THR . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 143' ' ' LEU . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 150' ' ' TYR . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.473 ' CE1' HD21 ' A' ' 29' ' ' LEU . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.665 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.597 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.49 HG11 ' CE1' ' A' ' 121' ' ' HIS . 62.7 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.564 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.449 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.564 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 144' ' ' LEU . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.519 HG23 HG12 ' A' ' 113' ' ' ILE . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.563 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.478 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.474 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.885 ' HD2' HD12 ' A' ' 104' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.711 ' HE2' HD13 ' A' ' 102' ' ' ILE . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.58 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.487 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.818 ' O ' HG22 ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.487 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.818 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.42 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.547 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.756 ' O ' HG23 ' A' ' 52' ' ' THR . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.697 ' H ' HG21 ' A' ' 52' ' ' THR . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.756 HG23 ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.512 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.547 HG23 ' CG2' ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo . . . . . 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.75 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.649 HG22 ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.639 HG22 ' CD1' ' A' ' 81' ' ' TYR . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.649 ' OH ' HG22 ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.6 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.435 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.75 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.443 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.421 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.587 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.6 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.711 HD13 ' HE2' ' A' ' 22' ' ' PHE . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.885 HD12 ' HD2' ' A' ' 19' ' ' PHE . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.479 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.3 p . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.459 ' HA ' HG23 ' A' ' 107' ' ' THR . 83.6 p . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.519 HG12 HG23 ' A' ' 10' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.514 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.502 ' OH ' HG13 ' A' ' 133' ' ' VAL . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' HG11 ' A' ' 2' ' ' VAL . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.618 HG21 HG23 ' A' ' 128' ' ' VAL . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' HIS . . . . . 0.44 ' ND1' HD23 ' A' ' 95' ' ' LEU . 45.7 m80 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.618 HG23 HG21 ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.464 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.464 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.502 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.478 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.478 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.455 ' HA ' HD23 ' A' ' 143' ' ' LEU . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.431 ' N ' HD12 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.717 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 29' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.405 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.624 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.555 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.2 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.562 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.5 t30 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' THR . . . . . 0.789 HG22 ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 113' ' ' ILE . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.536 ' OG ' HD12 ' A' ' 13' ' ' ILE . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.846 HD13 HD12 ' A' ' 151' ' ' LEU . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.559 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.538 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.781 ' CD2' HD21 ' A' ' 114' ' ' LEU . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HA ' HD13 ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.809 ' HZ ' HD13 ' A' ' 102' ' ' ILE . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.552 ' O ' HG21 ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.409 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 56' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.552 HG21 ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 53' ' ' ILE . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.847 ' O ' HG23 ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.419 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.847 HG23 ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.505 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.454 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo . . . . . 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.268 0.556 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.586 HG13 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.493 ' HA ' HG12 ' A' ' 85' ' ' VAL . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.505 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 73.8 m-20 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.463 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 98' ' ' ILE . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.809 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.586 ' CA ' HG13 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.522 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 97' ' ' LYS . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.485 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.626 HD12 ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.422 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.57 ' HE2' HG22 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 85' ' ' VAL . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.809 HD13 ' HZ ' ' A' ' 22' ' ' PHE . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.525 HD13 HD23 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 112' ' ' SER . 1.5 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.636 ' HA ' HG23 ' A' ' 107' ' ' THR . 80.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.574 HG13 HG22 ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.781 HD21 ' CD2' ' A' ' 18' ' ' LEU . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.613 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.6 HG21 HG23 ' A' ' 128' ' ' VAL . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.6 HG23 HG21 ' A' ' 122' ' ' THR . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 78.3 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.406 HG13 ' OH ' ' A' ' 120' ' ' TYR . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.789 ' HE3' HG22 ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 143' ' ' LEU . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.846 HG13 HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.615 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.846 HD12 HD13 ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.535 HG13 ' O ' ' A' ' 120' ' ' TYR . 45.5 t . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.271 0.558 . . . . 0.0 109.565 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.577 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.709 HG22 HG23 ' A' ' 113' ' ' ILE . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.422 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.738 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.86 ' HD1' HD12 ' A' ' 104' ' ' ILE . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.496 ' CA ' HG21 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ASN . . . . . 0.461 ' HB3' ' HE2' ' A' ' 32' ' ' LYS . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.935 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.461 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.935 HG22 ' O ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.566 HG21 HG23 ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.496 HG21 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASN . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.851 HD12 HG22 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.818 ' O ' HG23 ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.475 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' H ' HG21 ' A' ' 52' ' ' THR . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.851 HG22 HD12 ' A' ' 44' ' ' ILE . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.535 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.566 HG23 HG21 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.407 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.267 0.556 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.535 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.587 HG23 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 1.015 ' O ' HG23 ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.443 ' HG2' HG12 ' A' ' 53' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 67.1 m-20 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.523 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 1.015 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.439 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.587 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.411 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.465 HG12 ' HB3' ' A' ' 96' ' ' GLU . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.635 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.465 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.475 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.59 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.86 HD12 ' HD1' ' A' ' 19' ' ' PHE . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.477 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.709 HG23 HG22 ' A' ' 10' ' ' THR . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.738 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.572 ' CE2' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.475 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.594 HG21 HG23 ' A' ' 128' ' ' VAL . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' LYS . . . . . 0.635 ' HB2' HG23 ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.594 HG23 HG21 ' A' ' 122' ' ' THR . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.572 HG13 ' CE2' ' A' ' 120' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.492 ' O ' HG23 ' A' ' 147' ' ' VAL . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.528 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.922 HG13 HD21 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLU . . . . . 0.449 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.601 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 120' ' ' TYR . 56.3 t -135.01 144.18 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -1.137 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.498 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.605 HG23 ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.778 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.457 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.878 ' HD1' HD12 ' A' ' 104' ' ' ILE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.437 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG11 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.415 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.942 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.942 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 57' ' ' SER . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.832 HG22 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.832 ' HG3' HG22 ' A' ' 44' ' ' ILE . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.509 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.748 HG22 HD12 ' A' ' 44' ' ' ILE . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.52 HG23 HG21 ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.522 ' O ' HG23 ' A' ' 38' ' ' ILE . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 159.11 54.46 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -61.95 145.21 53.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.71 13.65 27.26 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.582 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -117.34 173.59 3.07 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.299 -1.118 . . . . 0.0 109.292 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.582 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 47.6 Cg_endo -68.65 -47.13 1.48 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.54 2.16 . . . . 0.0 111.612 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.514 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 48.2 p90 -123.31 152.3 41.56 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.903 . . . . 0.0 109.195 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt -76.36 -44.08 38.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.202 -0.936 . . . . 0.0 109.686 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.865 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.496 ' CE ' ' OE1' ' A' ' 87' ' ' GLU . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.685 ' HA ' HG12 ' A' ' 85' ' ' VAL . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.401 ' O ' HG13 ' A' ' 74' ' ' VAL . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.581 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' ASP . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.865 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 64' ' ' PHE . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.708 HD11 HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.555 ' CG ' HG22 ' A' ' 94' ' ' THR . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.645 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.604 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.708 HG12 HD11 ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 82' ' ' ASN . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.878 HD12 ' HD1' ' A' ' 19' ' ' PHE . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 112' ' ' SER . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.452 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -153.74 122.81 3.16 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.79 -1.48 8.56 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.74 2.293 . . . . 0.0 111.79 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -87.07 -31.68 20.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.276 -0.89 . . . . 0.0 109.647 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -156.54 33.41 0.58 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 81.64 -145.51 25.08 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p -107.25 143.38 35.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -1.152 . . . . 0.0 109.448 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.472 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 65.8 m-20 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.634 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.608 ' CE1' HG11 ' A' ' 2' ' ' VAL . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.62 HG21 HG23 ' A' ' 128' ' ' VAL . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.645 ' HB2' HG23 ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 63.0 m80 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 120' ' ' TYR . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.544 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.416 ' HA ' HD23 ' A' ' 143' ' ' LEU . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.426 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.432 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.73 HG13 HD21 ' A' ' 29' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.653 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.38 76.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.4 m80 -52.25 -33.01 39.64 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.318 -0.863 . . . . 0.0 109.457 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.5 m -61.59 -30.49 70.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.481 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -72.24 -15.83 61.93 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -72.33 143.43 48.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.234 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -48.94 -51.48 30.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.322 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.372 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 120' ' ' TYR . 39.4 t -128.97 153.21 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -1.122 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.59 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.522 HG21 HD22 ' A' ' 144' ' ' LEU . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.716 HG23 ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.716 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.546 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.599 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.482 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.495 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.468 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.94 ' O ' HG22 ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.94 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.49 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.655 HD13 HG23 ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.49 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.694 HG22 ' HG3' ' A' ' 45' ' ' GLU . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.898 ' O ' HG23 ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.422 ' O ' HG21 ' A' ' 74' ' ' VAL . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.49 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 HD13 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.572 ' O ' HG23 ' A' ' 38' ' ' ILE . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.475 ' HE1' HG23 ' A' ' 67' ' ' VAL . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.0 Cg_endo -70.31 153.55 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -53.32 140.8 25.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.438 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.28 10.9 46.96 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.532 ' CD2' ' HG2' ' A' ' 59' ' ' PRO . 2.8 m-85 -108.61 169.08 6.92 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.238 -1.154 . . . . 0.0 109.487 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.475 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -69.94 -48.15 0.74 Allowed 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.696 2.264 . . . . 0.0 111.739 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.541 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 95.1 m-85 -116.71 152.87 33.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.201 -0.937 . . . . 0.0 109.503 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.437 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt -82.74 -43.08 17.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.533 HG13 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.429 ' OD1' HG22 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.498 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.463 ' OE2' ' HB3' ' A' ' 50' ' ' PRO . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.451 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.451 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.503 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.498 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.47 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.533 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.491 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.596 HD13 ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.671 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.608 HD23 ' ND1' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.596 ' O ' HD13 ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.506 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.878 ' CD1' HD23 ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.444 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.7 OUTLIER -153.29 122.63 3.24 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.16 -0.85 7.86 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.613 2.209 . . . . 0.0 111.721 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.1 m-20 -79.89 -43.98 21.25 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.217 -0.927 . . . . 0.0 109.691 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -150.87 36.61 0.9 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 87.39 -150.0 22.33 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 15' ' ' ALA . 26.5 m -104.98 139.85 39.06 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.129 . . . . 0.0 109.414 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.878 HD23 ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 121' ' ' HIS . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.692 ' O ' HG13 ' A' ' 2' ' ' VAL . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.574 HG21 HG23 ' A' ' 128' ' ' VAL . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.671 ' HB2' HG23 ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.608 ' ND1' HD23 ' A' ' 95' ' ' LEU . 46.8 m80 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.574 HG23 HG21 ' A' ' 122' ' ' THR . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.415 ' OE1' HG13 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.44 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.546 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.632 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.565 ' N ' HD12 ' A' ' 144' ' ' LEU . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.68 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.402 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.637 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.588 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -65.54 -33.67 76.47 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -49.58 -33.64 15.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.0 m -56.98 -31.96 65.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.255 -0.903 . . . . 0.0 109.411 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -71.19 -19.58 62.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.295 -0.878 . . . . 0.0 109.419 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -64.39 -24.38 67.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.873 . . . . 0.0 109.372 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -114.8 129.91 56.77 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 27.2 t30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.549 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.586 HG13 ' O ' ' A' ' 120' ' ' TYR . 94.6 t -131.69 146.15 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -1.155 . . . . 0.0 109.489 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.566 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.528 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.562 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.846 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.49 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.761 ' CE1' HD12 ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.761 HD12 ' CE1' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.621 ' O ' HG11 ' A' ' 41' ' ' VAL . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.432 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.909 ' O ' HG22 ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.909 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 57' ' ' SER . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.459 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.869 ' O ' HG23 ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.451 HG23 HD13 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.668 ' HE1' HG23 ' A' ' 67' ' ' VAL . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.459 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo -69.73 151.68 69.29 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -52.22 143.46 14.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.464 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.17 10.08 43.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.585 ' CG ' ' HD2' ' A' ' 63' ' ' PRO . 0.2 OUTLIER -113.09 166.78 10.38 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.231 -1.158 . . . . 0.0 109.468 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.585 ' HD2' ' CG ' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.99 -51.67 0.43 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.734 2.289 . . . . 0.0 111.815 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.586 ' CE2' ' HA3' ' A' ' 89' ' ' GLY . 95.2 m-85 -109.72 146.38 35.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -0.878 . . . . 0.0 109.408 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -82.59 -36.89 25.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 0.0 109.756 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.446 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.668 HG23 ' HE1' ' A' ' 58' ' ' PHE . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.617 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 85' ' ' VAL . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.51 HG21 ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.482 HG22 ' CE2' ' A' ' 81' ' ' TYR . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.567 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.51 ' OH ' HG21 ' A' ' 71' ' ' VAL . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.42 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.586 ' HA3' ' CE2' ' A' ' 64' ' ' PHE . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.576 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.513 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.513 ' HA ' HD13 ' A' ' 91' ' ' ILE . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.846 HG22 ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.504 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.466 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 8.7 p -125.09 160.54 54.12 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.466 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.6 Cg_endo -70.52 -51.34 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.714 2.276 . . . . 0.0 111.9 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -132.18 26.08 4.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.579 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.429 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -128.7 25.84 4.66 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 56.54 -146.13 34.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 89.8 p -118.11 153.47 33.72 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.556 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.504 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.83 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.522 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.83 ' CD1' HD21 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 83.1 m-20 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.586 ' O ' HG13 ' A' ' 2' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.783 HG21 HG23 ' A' ' 128' ' ' VAL . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.783 HG23 HG21 ' A' ' 122' ' ' THR . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.426 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.426 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.429 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.528 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.456 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.504 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.64 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.503 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.419 HG22 HG11 ' A' ' 33' ' ' VAL . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.418 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.625 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -57.75 -37.83 74.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -47.07 -26.94 1.18 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.557 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 93.9 p -65.6 -29.41 70.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.523 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 9.0 p30 -90.9 2.58 56.07 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.663 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 156' ' ' ASP . . . 43.99 -150.6 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.245 -0.909 . . . . 0.0 109.512 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.11 -37.68 86.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.464 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.1 t30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.504 179.978 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 120' ' ' TYR . 95.1 t -132.49 149.24 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -1.169 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.484 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.484 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.439 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.596 HG21 ' HG ' ' A' ' 151' ' ' LEU . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.898 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.595 HD23 HD13 ' A' ' 104' ' ' ILE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.541 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.709 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.541 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.455 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.901 ' O ' HG22 ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.901 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.719 HG23 ' O ' ' A' ' 57' ' ' SER . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.482 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.576 HD12 HG22 ' A' ' 53' ' ' ILE . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.709 ' O ' HG23 ' A' ' 52' ' ' THR . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 44' ' ' ILE . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.482 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.66 HG23 HD13 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.719 ' O ' HG23 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.7 149.05 66.79 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -56.18 139.55 47.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 109.47 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 62' ' ' PHE . . . 147.79 -16.41 1.4 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.503 ' HB3' ' HD2' ' A' ' 63' ' ' PRO . 0.0 OUTLIER -126.51 171.86 7.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.297 -1.12 . . . . 0.0 109.21 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.86 -26.86 31.62 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.707 2.271 . . . . 0.0 111.907 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.571 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 74.0 m-85 -104.5 152.3 22.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.319 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp -114.3 -39.01 3.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.188 -0.945 . . . . 0.0 109.596 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.57 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.954 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.5 ' HA ' HG22 ' A' ' 85' ' ' VAL . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.487 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.487 ' OH ' HG22 ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.954 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.493 ' HB2' ' HD2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.571 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.8 HD11 HG12 ' A' ' 98' ' ' ILE . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.59 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.523 ' HG2' HD11 ' A' ' 98' ' ' ILE . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.613 ' HA ' HD13 ' A' ' 91' ' ' ILE . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.8 HG12 HD11 ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.898 HG22 ' HB1' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.463 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 2.8 p -123.63 161.16 47.63 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.2 Cg_endo -70.05 -49.37 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.745 2.297 . . . . 0.0 111.844 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 97.6 m-20 -138.02 26.45 2.71 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.196 -0.94 . . . . 0.0 109.556 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -124.32 19.14 7.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 107' ' ' THR . . . 68.22 -149.76 50.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -119.04 150.21 40.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.136 -1.214 . . . . 0.0 109.541 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.544 HD21 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.409 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 73.6 m-20 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.528 ' O ' HG13 ' A' ' 2' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.515 ' CE1' HG11 ' A' ' 2' ' ' VAL . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.615 HG21 HG23 ' A' ' 128' ' ' VAL . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.59 ' HB2' HG23 ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 53.1 m80 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.615 HG23 HG21 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 84.0 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.449 HG22 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.439 ' HE3' HG22 ' A' ' 7' ' ' THR . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.617 ' OE2' HD21 ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.672 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.601 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.427 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.631 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.02 71.47 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -49.61 -32.72 13.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 21.9 m -55.36 -33.14 63.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.392 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -70.38 -20.26 62.96 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.245 -0.91 . . . . 0.0 109.38 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -104.31 140.97 37.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.299 -0.876 . . . . 0.0 109.457 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -109.86 123.27 49.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.497 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 32.2 t-20 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.484 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 120' ' ' TYR . 86.3 t -134.03 143.6 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -1.17 . . . . 0.0 109.453 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.476 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.476 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.993 HG22 HG23 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.882 HG21 HD13 ' A' ' 151' ' ' LEU . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.747 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.788 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.975 ' HG2' HD22 ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.797 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.639 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.975 HD22 ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.978 ' O ' HG22 ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.978 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.481 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.879 HD12 HG22 ' A' ' 53' ' ' ILE . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.838 ' O ' HG23 ' A' ' 52' ' ' THR . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.491 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.879 HG22 HD12 ' A' ' 44' ' ' ILE . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.604 ' HB ' HG12 ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.41 158.88 54.78 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -55.49 149.71 13.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.63 8.62 51.81 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.474 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 2.3 m-85 -115.16 170.15 5.88 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.431 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.474 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -70.16 -45.06 1.49 Allowed 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.635 2.223 . . . . 0.0 111.645 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.6 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 93.4 m-85 -119.11 156.58 29.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.349 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt -83.11 -39.19 21.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.44 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.685 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.71 ' O ' HG13 ' A' ' 85' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.627 ' O ' HG23 ' A' ' 53' ' ' ILE . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.614 HH21 HD13 ' A' ' 86' ' ' ILE . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.453 ' N ' ' HG2' ' A' ' 70' ' ' ARG . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.4 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.447 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 68' ' ' LYS . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.614 HD13 HH21 ' A' ' 70' ' ' ARG . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.685 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.6 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.576 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 97' ' ' LYS . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.501 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.552 ' HA ' HD13 ' A' ' 91' ' ' ILE . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.452 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.788 HG22 ' HB1' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p -153.24 122.05 3.18 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -72.03 -2.15 11.12 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.821 2.347 . . . . 0.0 111.896 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -97.75 -13.93 21.13 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.195 -0.941 . . . . 0.0 109.707 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -163.7 29.62 0.24 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 75.29 -146.51 34.68 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m -106.64 140.57 39.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.323 -1.104 . . . . 0.0 109.506 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.993 HG23 HG22 ' A' ' 10' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 104' ' ' ILE . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.992 ' OH ' HG13 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.407 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.992 HG13 ' OH ' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.503 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HA ' HD23 ' A' ' 143' ' ' LEU . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.612 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.464 ' N ' HD12 ' A' ' 144' ' ' LEU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.556 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.594 ' HA ' HD12 ' A' ' 152' ' ' LEU . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.882 HD13 HG21 ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.594 HD12 ' HA ' ' A' ' 149' ' ' SER . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.77 -36.63 84.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 33.2 m80 -50.56 -42.42 55.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -0.871 . . . . 0.0 109.494 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 94.6 p -60.8 -24.93 66.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.6 -4.41 42.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.633 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -80.0 124.39 28.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.42 ' C ' ' O ' ' A' ' 157' ' ' ALA . 14.4 t80 -44.13 128.11 5.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.902 . . . . 0.0 109.496 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 39.8 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.526 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.813 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t -138.91 139.95 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.269 -1.136 . . . . 0.0 109.31 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.445 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.572 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.445 HG21 HD13 ' A' ' 144' ' ' LEU . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.902 HG21 HD13 ' A' ' 151' ' ' LEU . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.769 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.771 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.731 ' HD2' HD12 ' A' ' 104' ' ' ILE . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.446 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.426 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.913 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 56' ' ' ILE . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.409 HG22 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.884 HD12 HG22 ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.798 ' O ' HG23 ' A' ' 52' ' ' THR . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.524 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.798 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.884 HG22 HD12 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.527 HG23 ' CG2' ' A' ' 38' ' ' ILE . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.26 153.41 66.64 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.26 140.82 31.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.283 -0.886 . . . . 0.0 109.468 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.46 10.56 53.49 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.489 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -106.59 168.66 7.8 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.489 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -69.94 -51.75 0.35 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.664 2.242 . . . . 0.0 111.669 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 90' ' ' PRO . 92.3 m-85 -109.84 151.32 27.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.283 -0.886 . . . . 0.0 109.483 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -77.14 -45.7 25.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.522 HG13 ' HA2' ' A' ' 88' ' ' GLY . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.973 ' O ' HG13 ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.442 ' CZ ' HD13 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 74' ' ' VAL . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.484 ' O ' ' N ' ' A' ' 102' ' ' ILE . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.973 HG13 ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 87' ' ' GLU . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.522 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.557 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.559 ' HD3' ' CD1' ' A' ' 64' ' ' PHE . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.574 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.487 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.487 HD12 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.574 ' HA ' HD13 ' A' ' 91' ' ' ILE . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.497 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.484 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.769 HG22 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p -153.43 126.86 4.24 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.91 -0.87 7.67 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 122.745 2.297 . . . . 0.0 111.804 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -83.83 -39.27 20.16 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.302 -0.874 . . . . 0.0 109.452 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.16 37.0 0.7 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 81.32 -146.45 26.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m -104.42 140.11 38.4 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.3 -1.118 . . . . 0.0 109.241 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.576 ' CD2' HG23 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.721 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.813 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.635 HG21 HG23 ' A' ' 128' ' ' VAL . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.635 HG23 HG21 ' A' ' 122' ' ' THR . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.438 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.445 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.449 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.537 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.56 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.612 HG13 HD21 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.456 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.828 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.902 HD13 HG21 ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.828 HD12 ' HA ' ' A' ' 149' ' ' SER . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -56.53 -46.82 80.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -56.98 -41.43 78.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.369 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 29.4 m -55.38 -30.56 60.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.368 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.45 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 92.0 m-20 -73.4 -19.43 60.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.384 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 156' ' ' ASP . . . 62.72 -85.08 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.325 -0.859 . . . . 0.0 109.417 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.411 ' N ' ' O ' ' A' ' 156' ' ' ASP . 74.7 m-85 -108.55 119.69 40.26 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.484 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.4 t30 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.471 -179.884 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.1 t -137.69 142.87 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -1.142 . . . . 0.0 109.48 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.435 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.598 HG22 HG23 ' A' ' 113' ' ' ILE . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.871 HG21 HD13 ' A' ' 151' ' ' LEU . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.741 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.854 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.675 HD23 HD13 ' A' ' 104' ' ' ILE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.481 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.564 HD12 ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.538 ' HB2' HD13 ' A' ' 29' ' ' LEU . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.886 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.886 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.47 HD13 HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.43 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.821 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.452 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.516 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.489 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.516 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG23 ' A' ' 38' ' ' ILE . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.674 ' CD1' ' CE1' ' A' ' 62' ' ' PHE . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.6 159.64 52.12 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -49.28 150.25 1.83 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.401 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.3 5.25 57.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.674 ' CE1' ' CD1' ' A' ' 58' ' ' PHE . 0.4 OUTLIER -108.85 164.17 15.33 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.254 -1.145 . . . . 0.0 109.53 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.585 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.13 -43.73 2.2 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.595 2.197 . . . . 0.0 111.769 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.583 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 95.0 m-85 -116.34 159.01 22.53 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 109.446 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt -78.76 -43.81 24.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.16 -0.963 . . . . 0.0 109.499 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.456 HG13 ' HA2' ' A' ' 88' ' ' GLY . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.947 ' O ' HG13 ' A' ' 85' ' ' VAL . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.489 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.463 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 81' ' ' TYR . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.404 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.947 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.583 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.451 HD13 ' HA ' ' A' ' 97' ' ' LYS . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.486 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.404 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.461 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.499 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.854 HG22 ' HB1' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -151.63 122.51 3.7 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.11 -0.33 7.83 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.687 2.258 . . . . 0.0 111.746 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.57 -45.06 12.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.74 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -147.37 36.97 1.16 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 85.09 -145.82 21.65 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p -107.54 151.01 26.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -1.125 . . . . 0.0 109.341 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.598 HG23 HG22 ' A' ' 10' ' ' THR . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.529 ' CD2' HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.485 ' ND2' ' HG2' ' A' ' 137' ' ' LYS . 73.7 m-20 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.649 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.7 HG21 HG23 ' A' ' 128' ' ' VAL . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 48.8 m80 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.7 HG23 HG21 ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.469 ' OE1' HG13 ' A' ' 128' ' ' VAL . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 120' ' ' TYR . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.45 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.485 ' HG2' ' ND2' ' A' ' 118' ' ' ASN . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.45 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.452 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.715 ' OE2' HD11 ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.715 HD11 ' OE2' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.61 ' N ' HD12 ' A' ' 144' ' ' LEU . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.871 HD13 HG21 ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.13 -38.57 73.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -49.56 -49.11 47.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 80.8 p -56.41 -22.5 32.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.331 -0.855 . . . . 0.0 109.565 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -88.01 0.49 55.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.256 -0.903 . . . . 0.0 109.657 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.407 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -87.09 125.02 33.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.468 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.407 ' C ' ' O ' ' A' ' 157' ' ' ALA . 9.0 t80 -43.36 124.99 3.65 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.792 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.368 179.745 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 120' ' ' TYR . 46.2 t -135.89 143.89 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -1.142 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.483 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.926 HG21 HD13 ' A' ' 151' ' ' LEU . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.608 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.448 ' O ' HD12 ' A' ' 29' ' ' LEU . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.984 ' O ' HG22 ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.984 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.683 ' CG2' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.45 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.573 ' CG1' HG21 ' A' ' 38' ' ' ILE . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.493 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.926 HD12 HG22 ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.822 ' O ' HG23 ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.48 ' H ' HG21 ' A' ' 52' ' ' THR . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.822 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.926 HG22 HD12 ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.695 ' HB ' HG12 ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.546 ' HB3' ' CB ' ' A' ' 62' ' ' PHE . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.465 ' O ' ' HB3' ' A' ' 62' ' ' PHE . 48.9 Cg_endo -70.11 169.05 20.27 Favored 'Trans proline' 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' A' ' 59' ' ' PRO . 91.8 mt-10 -42.75 165.78 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.763 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 52.91 59.44 9.35 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 65' ' ' LYS . 46.9 p90 -132.24 155.41 81.32 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.362 -1.081 . . . . 0.0 110.307 -179.221 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -76.5 -53.83 0.07 OUTLIER 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.587 2.192 . . . . 0.0 111.223 178.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.547 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 98.8 m-85 -116.51 143.65 45.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.295 -0.878 . . . . 0.0 109.375 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 9.6 mttp -59.07 -63.92 1.13 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.875 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.695 HG12 ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 1.017 ' O ' HG13 ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.603 HG22 ' CE2' ' A' ' 81' ' ' TYR . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.603 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.463 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 1.017 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.582 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.487 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.596 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.528 HD13 ' CE1' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.706 HD12 HD12 ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.467 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p -125.11 152.83 71.24 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.76 -15.35 37.04 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.672 2.248 . . . . 0.0 111.748 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -60.3 -28.98 68.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 120.62 19.98 3.63 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -145.44 175.29 25.07 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p -131.69 143.28 50.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.356 -1.084 . . . . 0.0 109.094 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 105' ' ' VAL . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.706 HD12 HD12 ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.582 HG12 HD21 ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.926 ' OH ' HG13 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.625 ' CE1' HG11 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.606 HG21 HG23 ' A' ' 128' ' ' VAL . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.606 HG23 HG21 ' A' ' 122' ' ' THR . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.926 HG13 ' OH ' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.442 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.454 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.538 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.464 ' NE ' ' CG ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CZ ' ' NE2' ' A' ' 154' ' ' HIS . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.926 HD13 HG21 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.79 71.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.592 ' NE2' ' CZ ' ' A' ' 150' ' ' TYR . 74.7 m-70 -103.8 135.99 44.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.144 -0.973 . . . . 0.0 109.614 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 37.9 m -73.44 -14.57 61.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.481 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -70.19 -16.78 63.11 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 151' ' ' LEU . . . -60.58 -26.84 67.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.51 ' OH ' HD13 ' A' ' 13' ' ' ILE . 90.9 m-85 -122.98 127.88 49.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.325 -0.859 . . . . 0.0 109.396 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' TYR . 89.7 m-20 . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.557 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.6 145.3 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.247 -1.149 . . . . 0.0 109.551 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.517 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.53 HG23 HD13 ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.792 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.763 ' HD2' HD12 ' A' ' 104' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.435 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.723 HD12 ' CE1' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.651 ' O ' HG21 ' A' ' 41' ' ' VAL . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.917 ' O ' HG22 ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.434 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.917 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' HG23 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.651 HG21 ' O ' ' A' ' 27' ' ' ASP . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.433 ' HA ' ' HD2' ' A' ' 54' ' ' LYS . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.783 HG22 ' HG3' ' A' ' 45' ' ' GLU . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.783 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.56 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.737 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.641 HG22 HD12 ' A' ' 44' ' ' ILE . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.503 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.623 HG23 ' CG2' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -83.76 34.09 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -114.26 172.04 7.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.123 -0.986 . . . . 0.0 109.592 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -87.96 9.03 76.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.484 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 0.6 OUTLIER -49.13 171.86 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.164 -1.198 . . . . 0.0 109.33 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.26 -29.04 32.99 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.704 2.269 . . . . 0.0 111.792 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.596 ' CE2' ' HA2' ' A' ' 89' ' ' GLY . 92.3 m-85 -107.3 157.07 18.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.318 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -118.44 -19.55 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.536 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.48 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.877 HG23 ' HA2' ' A' ' 88' ' ' GLY . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.965 ' O ' HG23 ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.559 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.965 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.465 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.877 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.596 ' HA2' ' CE2' ' A' ' 64' ' ' PHE . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.594 ' CG ' HG22 ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.594 HG22 ' CG ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.488 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.763 HD12 ' HD2' ' A' ' 19' ' ' PHE . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.478 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 13.6 p -129.49 160.24 65.37 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.478 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.7 Cg_endo -70.38 -50.23 0.41 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.755 2.303 . . . . 0.0 112.112 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -129.98 27.24 5.17 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.927 . . . . 0.0 109.691 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.425 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.85 23.11 4.22 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 59.28 -143.76 45.85 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.4 p -117.26 151.3 37.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.319 -1.107 . . . . 0.0 109.474 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.474 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' TYR . 79.2 m-20 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.489 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.531 HG21 HG23 ' A' ' 128' ' ' VAL . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.411 ' O ' ' HB ' ' A' ' 122' ' ' THR . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.531 HG23 HG21 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.527 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.632 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.557 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.412 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -63.32 -40.35 97.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.527 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 34.5 m80 -46.9 -24.79 0.65 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 48.7 m -60.66 -30.35 69.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.263 -0.898 . . . . 0.0 109.535 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.412 ' CG ' ' O ' ' A' ' 153' ' ' ALA . 19.3 p30 -87.19 13.67 9.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -0.882 . . . . 0.0 109.507 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.05 141.94 58.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.396 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.413 ' O ' ' C ' ' A' ' 159' ' ' ASN . 23.0 t80 -46.68 -54.3 9.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.31 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ASN . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' TYR . 69.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.493 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 120' ' ' TYR . 64.3 t -134.54 136.94 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -1.128 . . . . 0.0 109.334 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.511 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.511 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.83 HG21 HD13 ' A' ' 151' ' ' LEU . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.904 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.433 ' O ' ' HG2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.577 ' O ' HG22 ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.452 ' CG2' HG23 ' A' ' 56' ' ' ILE . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.01 HD12 HG22 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.782 ' O ' HG23 ' A' ' 52' ' ' THR . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.782 HG23 ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 1.01 HG22 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.5 152.03 65.24 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -55.33 143.07 29.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.81 10.52 40.13 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -111.2 167.79 8.53 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.269 -1.136 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.6 -45.09 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.636 2.224 . . . . 0.0 111.603 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -113.11 163.62 14.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.25 -0.906 . . . . 0.0 109.414 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt -95.1 -62.99 1.21 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.465 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.458 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.539 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.872 ' O ' HG13 ' A' ' 85' ' ' VAL . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.634 HG22 ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.428 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.481 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.634 ' OH ' HG22 ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.475 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 68' ' ' LYS . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.437 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.539 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.472 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.638 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.557 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' HD13 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.475 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.66 HD12 ' HD2' ' A' ' 19' ' ' PHE . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.434 ' OG1' ' C ' ' A' ' 110' ' ' GLY . 12.7 p -122.42 157.6 58.43 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.401 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 51.2 Cg_endo -70.92 -47.15 0.61 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.716 2.277 . . . . 0.0 112.064 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 88.6 m-20 -133.8 27.23 3.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.209 -0.932 . . . . 0.0 109.688 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.434 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.18 24.5 4.21 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 58.93 -146.39 42.5 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p -118.81 150.18 40.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -1.149 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.497 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.446 ' CD1' HG12 ' A' ' 98' ' ' ILE . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 53.6 m80 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.666 HG21 HG23 ' A' ' 128' ' ' VAL . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.638 ' HB2' HG23 ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.666 HG23 HG21 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.583 ' OE1' HG13 ' A' ' 128' ' ' VAL . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.483 HG12 ' HE3' ' A' ' 137' ' ' LYS . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.507 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.441 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.623 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.473 ' N ' HD12 ' A' ' 144' ' ' LEU . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.552 HG13 HD21 ' A' ' 29' ' ' LEU . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.505 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.83 HD13 HG21 ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.5 -35.46 80.52 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -50.26 -40.8 49.04 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.601 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.7 p -59.68 -28.27 67.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.216 -0.928 . . . . 0.0 109.658 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.43 -15.28 60.45 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.23 -0.919 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -76.75 146.47 37.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -46.44 -58.04 4.12 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.161 -0.962 . . . . 0.0 109.207 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.412 179.87 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.634 HG11 ' CE1' ' A' ' 121' ' ' HIS . 47.7 t -134.38 139.91 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.197 -1.178 . . . . 0.0 109.423 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.495 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.488 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.415 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.563 HG23 ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.885 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.827 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.486 ' HD1' HD12 ' A' ' 104' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB3' HD13 ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.597 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.748 ' HB ' ' HB1' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.424 HG12 ' CG2' ' A' ' 56' ' ' ILE . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.424 ' O ' ' N ' ' A' ' 55' ' ' LYS . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.016 HD11 ' HB2' ' A' ' 55' ' ' LYS . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.82 ' O ' HG23 ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.429 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.491 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.756 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.82 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 1.016 ' HB2' HD11 ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.424 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' HG23 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.08 149.06 57.85 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -52.64 150.94 4.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.53 14.64 10.29 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.459 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 2.0 m-85 -135.27 172.16 7.69 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.371 -1.076 . . . . 0.0 109.296 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.518 ' HG2' ' CD1' ' A' ' 64' ' ' PHE . 48.0 Cg_endo -69.23 -43.73 2.9 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.601 2.201 . . . . 0.0 111.714 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.518 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 23.8 p90 -109.9 166.34 11.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.175 -0.953 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -106.48 -37.56 6.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.162 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.423 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.66 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.482 ' HA ' HG12 ' A' ' 85' ' ' VAL . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 81' ' ' TYR . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.494 ' CD1' HG22 ' A' ' 74' ' ' VAL . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.411 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 69' ' ' ASP . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.507 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.66 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.498 ' HA3' ' HB3' ' A' ' 64' ' ' PHE . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 97' ' ' LYS . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.527 HD12 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 91' ' ' ILE . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.423 ' HA ' ' O ' ' A' ' 117' ' ' SER . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.415 ' O ' ' N ' ' A' ' 81' ' ' TYR . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.885 HG22 ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.477 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 11.3 p -124.0 160.94 49.67 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.477 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.4 Cg_endo -70.97 -46.22 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.714 2.276 . . . . 0.0 112.221 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.434 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 82.9 m-20 -135.44 29.02 3.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 0.0 109.674 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -137.14 34.76 2.16 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 50.9 -150.43 6.24 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -113.66 148.92 35.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.22 -1.165 . . . . 0.0 109.45 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.474 ' CD2' HG23 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 5' ' ' TYR . 82.1 m-20 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.581 ' CE1' HG13 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.634 ' CE1' HG11 ' A' ' 2' ' ' VAL . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.82 HG21 HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.82 HG23 HG21 ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 120' ' ' TYR . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.492 ' HE2' ' HB3' ' A' ' 5' ' ' TYR . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.403 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.55 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 143' ' ' LEU . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 144' ' ' LEU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.592 ' N ' HD12 ' A' ' 144' ' ' LEU . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.748 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.402 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.546 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.48 -37.72 73.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -53.09 -30.45 36.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.561 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 30.6 m -61.59 -29.95 70.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.216 -0.928 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -75.15 -9.5 58.6 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.28 -0.887 . . . . 0.0 109.684 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.428 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -78.04 148.44 34.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.903 . . . . 0.0 109.455 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.428 ' C ' ' O ' ' A' ' 157' ' ' ALA . 13.8 t80 -44.61 -46.59 10.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.299 -0.875 . . . . 0.0 109.207 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 56.3 m-20 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.446 179.782 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 120' ' ' TYR . 48.5 t -133.37 142.83 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -1.148 . . . . 0.0 109.518 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.596 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.464 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.632 HG22 HG23 ' A' ' 113' ' ' ILE . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.844 HG21 HD13 ' A' ' 151' ' ' LEU . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.732 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.621 ' HB3' ' HB2' ' A' ' 106' ' ' ALA . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.572 HD23 HD13 ' A' ' 104' ' ' ILE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.429 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.93 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.93 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.414 HD13 HG23 ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.494 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.512 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 55' ' ' LYS . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.036 HD11 ' HB2' ' A' ' 55' ' ' LYS . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.76 ' O ' HG23 ' A' ' 52' ' ' THR . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.475 ' H ' HG21 ' A' ' 52' ' ' THR . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.76 HG23 ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 1.036 ' HB2' HD11 ' A' ' 44' ' ' ILE . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo -72.12 53.06 1.97 Allowed 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -125.21 165.31 18.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 109.583 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -83.31 2.59 86.86 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.462 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 1.4 m-85 -46.45 171.64 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.211 -1.17 . . . . 0.0 109.338 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.84 -29.86 27.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.662 2.241 . . . . 0.0 111.533 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 97.7 m-85 -111.6 145.93 38.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.335 -0.853 . . . . 0.0 109.247 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -104.47 -18.44 14.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.179 -0.951 . . . . 0.0 109.858 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.599 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.592 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 1.034 ' O ' HG13 ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.444 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 1.034 HG13 ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.519 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.47 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.592 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 96' ' ' GLU . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.508 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' HD13 ' A' ' 91' ' ' ILE . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.519 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.482 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.403 ' O ' ' N ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.572 HD13 HD23 ' A' ' 18' ' ' LEU . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -132.37 122.48 18.08 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.62 -21.51 29.38 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.721 2.28 . . . . 0.0 111.93 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -111.45 19.8 17.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.191 -0.943 . . . . 0.0 109.615 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -168.62 31.4 0.17 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.43 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 56.12 -146.29 32.71 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p -109.77 150.43 28.35 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.301 -1.117 . . . . 0.0 109.428 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.632 HG23 HG22 ' A' ' 10' ' ' THR . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.819 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.524 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.819 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.69 ' O ' HG13 ' A' ' 2' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.549 ' CE1' HG11 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.63 HG21 HG23 ' A' ' 128' ' ' VAL . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.451 ' ND1' HD22 ' A' ' 95' ' ' LEU . 67.8 m80 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.63 HG23 HG21 ' A' ' 122' ' ' THR . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.663 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.571 ' HE3' HG12 ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.445 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.413 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.608 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.853 HG13 HD21 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.434 ' HA ' HD12 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.541 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.844 HD13 HG21 ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.553 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.77 96.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.541 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 58.7 m-70 -58.11 -39.95 79.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 23.0 t -59.85 -29.76 68.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.452 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -70.5 -20.01 62.88 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.77 -24.39 67.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.399 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -114.48 131.28 56.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.3 t30 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.531 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 120' ' ' TYR . 54.9 t -136.41 140.46 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -1.151 . . . . 0.0 109.382 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.605 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.605 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.556 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.646 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.705 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.49 ' HA ' HD13 ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.563 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.501 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.617 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.551 ' O ' HD12 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.99 ' O ' HG22 ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.99 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.526 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.695 HD13 HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.409 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.982 HD11 ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.894 ' O ' HG23 ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.894 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.446 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.982 ' HB2' HD11 ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.695 HG23 HD13 ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 38' ' ' ILE . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.526 ' HE1' HG23 ' A' ' 67' ' ' VAL . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.38 151.5 65.55 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.29 141.32 15.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.486 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.03 11.39 37.14 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.526 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.6 m-85 -113.69 169.86 6.01 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.482 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.47 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 50.3 Cg_endo -70.61 -49.48 0.44 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.649 2.233 . . . . 0.0 111.724 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.529 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 97.9 m-85 -113.71 152.45 30.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.237 -0.914 . . . . 0.0 109.463 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt -83.39 -36.39 24.34 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -0.918 . . . . 0.0 109.51 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.453 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.526 HG23 ' HE1' ' A' ' 58' ' ' PHE . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.962 ' O ' HG13 ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.446 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.53 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.495 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.603 HG22 ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.481 HD13 ' O ' ' A' ' 96' ' ' GLU . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.577 HD22 ' ND1' ' A' ' 126' ' ' HIS . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.603 ' CE ' HG22 ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.705 HD13 HD23 ' A' ' 18' ' ' LEU . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.2 p -154.21 121.92 2.94 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -70.88 -1.08 8.84 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.771 2.314 . . . . 0.0 111.823 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -86.8 -35.11 19.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.204 -0.935 . . . . 0.0 109.636 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.94 33.71 0.8 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 82.43 -146.26 24.68 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 13.0 p -106.91 143.87 34.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -1.131 . . . . 0.0 109.434 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.636 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 84.5 m-20 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.7 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.506 ' CE1' HG11 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.763 HG21 HG23 ' A' ' 128' ' ' VAL . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.577 ' ND1' HD22 ' A' ' 95' ' ' LEU . 70.0 m80 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.763 HG23 HG21 ' A' ' 122' ' ' THR . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.668 HG22 ' CZ ' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.417 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.542 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.439 ' HA ' HD23 ' A' ' 143' ' ' LEU . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.581 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.475 ' N ' HD12 ' A' ' 144' ' ' LEU . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.452 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.601 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.601 HD12 ' HA ' ' A' ' 149' ' ' SER . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.28 -42.48 99.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -49.26 -38.8 28.12 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.276 -0.89 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.8 t -56.86 -32.25 65.62 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.503 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -75.09 -13.75 60.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.556 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -73.18 140.84 47.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.369 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -46.16 -55.46 7.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.202 -0.936 . . . . 0.0 109.273 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.429 179.842 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.1 t -132.6 144.01 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.211 -1.17 . . . . 0.0 109.597 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.545 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.469 ' HA ' ' HG2' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.545 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.401 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.904 HG21 HD13 ' A' ' 151' ' ' LEU . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.555 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.686 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.54 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.545 HD23 HD12 ' A' ' 104' ' ' ILE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.689 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.659 ' CE1' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.471 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.435 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.441 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.891 ' O ' HG22 ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.891 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.562 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.437 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.799 HG22 ' HG3' ' A' ' 45' ' ' GLU . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.799 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.633 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.763 HG23 ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.727 HG22 HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.523 HG23 ' CG2' ' A' ' 38' ' ' ILE . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.481 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.3 145.98 55.53 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.08 144.26 12.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.217 -0.927 . . . . 0.0 109.352 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.85 16.43 41.88 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.562 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.5 m-85 -114.69 161.65 27.75 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.335 -1.097 . . . . 0.0 109.425 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.93 -30.17 21.92 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.595 2.197 . . . . 0.0 111.829 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.57 ' CD2' ' HD3' ' A' ' 90' ' ' PRO . 45.5 m-85 -118.69 164.33 15.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.658 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt -104.78 -62.81 1.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.498 HG22 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 85' ' ' VAL . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 49' ' ' GLY . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.481 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.443 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.42 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.532 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.472 HD13 ' HA ' ' A' ' 97' ' ' LYS . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.693 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.659 HD13 ' CE1' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.686 HG22 ' CB ' ' A' ' 15' ' ' ALA . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.408 HG21 ' NZ ' ' A' ' 115' ' ' LYS . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.459 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 11.0 p -109.36 160.06 29.09 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.0 Cg_endo -69.94 -23.58 29.8 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.818 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -169.23 27.31 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.422 ' N ' ' OG1' ' A' ' 107' ' ' THR . . . -130.19 30.49 3.49 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 107' ' ' THR . . . 67.72 -146.43 46.86 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.2 p -125.07 154.67 41.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.358 -1.084 . . . . 0.0 109.508 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.891 ' CD2' HD13 ' A' ' 144' ' ' LEU . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.701 HD11 HD21 ' A' ' 114' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.735 ' CE1' HG13 ' A' ' 133' ' ' VAL . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.719 HG21 HG23 ' A' ' 128' ' ' VAL . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.693 ' HB2' HG23 ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 45.3 m80 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.719 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.404 ' HE2' ' OE1' ' A' ' 131' ' ' GLU . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.404 ' OE1' ' HE2' ' A' ' 129' ' ' LYS . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.735 HG13 ' CE1' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.401 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.443 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.479 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.891 HD13 ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 143' ' ' LEU . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.749 ' HA ' HD11 ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.904 HD13 HG21 ' A' ' 13' ' ' ILE . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.427 ' O ' ' C ' ' A' ' 154' ' ' HIS . . . -63.07 -34.2 77.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.563 ' CD2' ' HA ' ' A' ' 151' ' ' LEU . 37.6 m-70 -44.2 -32.48 1.26 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 84.6 p -58.4 -30.85 67.16 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.327 -0.858 . . . . 0.0 109.262 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.418 ' N ' ' O ' ' A' ' 153' ' ' ALA . 81.5 m-20 -70.54 -20.19 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.513 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -107.71 139.4 42.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.616 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.59 ' CD2' ' HB2' ' A' ' 159' ' ' ASN . 3.3 t80 -72.59 131.48 42.52 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.303 -0.873 . . . . 0.0 109.175 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ASN . . . . . 0.59 ' HB2' ' CD2' ' A' ' 158' ' ' TYR . 56.7 t30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.529 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.522 HG13 ' O ' ' A' ' 120' ' ' TYR . 49.1 t -134.05 146.26 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.149 -1.206 . . . . 0.0 109.44 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.597 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 22.4 t30 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.464 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.407 HG21 HD13 ' A' ' 144' ' ' LEU . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' ILE . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.754 HD11 ' HA ' ' A' ' 148' ' ' GLU . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.488 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.76 ' CD1' HD12 ' A' ' 104' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.545 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.59 ' O ' HG21 ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.438 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.764 ' O ' HG22 ' A' ' 33' ' ' VAL . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.594 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.59 HG21 ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.796 HD12 HG22 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.854 ' O ' HG23 ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.854 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.796 HG22 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.594 HG23 ' CG2' ' A' ' 38' ' ' ILE . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.675 ' CD2' ' CE1' ' A' ' 64' ' ' PHE . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.81 166.01 29.09 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -63.62 139.49 58.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.27 13.33 19.59 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.606 ' CD1' ' CD1' ' A' ' 58' ' ' PHE . 1.5 m-85 -117.03 172.95 3.43 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.308 -1.113 . . . . 0.0 109.357 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.587 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 47.4 Cg_endo -68.22 -48.28 1.32 Allowed 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.652 2.235 . . . . 0.0 111.634 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.675 ' CE1' ' CD2' ' A' ' 58' ' ' PHE . 40.4 p90 -124.33 153.53 41.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 109.328 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm -72.6 -44.25 62.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.913 . . . . 0.0 109.654 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.809 HG23 ' HA2' ' A' ' 88' ' ' GLY . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.932 ' O ' HG13 ' A' ' 85' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.599 ' O ' HG23 ' A' ' 53' ' ' ILE . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.525 HG22 ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 56.3 m-20 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.479 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.525 ' OH ' HG22 ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.932 HG13 ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.468 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.434 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.809 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.56 HD13 ' HA ' ' A' ' 97' ' ' LYS . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.56 ' HA ' HD13 ' A' ' 91' ' ' ILE . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.504 HD13 ' HE2' ' A' ' 22' ' ' PHE . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.76 HD12 ' CD1' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.527 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.484 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 12.4 p -106.56 160.38 26.48 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.484 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.2 Cg_endo -70.65 -24.16 25.92 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.648 2.232 . . . . 0.0 111.867 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -170.35 28.01 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.213 -0.93 . . . . 0.0 109.507 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.69 29.11 4.07 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 71.96 -145.51 38.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.5 p -127.62 148.89 50.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.302 -1.116 . . . . 0.0 109.471 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.527 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.476 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.473 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.528 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.482 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.675 HG21 HG23 ' A' ' 128' ' ' VAL . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.675 HG23 HG21 ' A' ' 122' ' ' THR . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.464 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 143' ' ' LEU . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.539 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.693 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.754 ' HA ' HD11 ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.589 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.607 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.491 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -60.14 -39.55 86.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.589 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 80.5 m-70 -55.7 -38.56 69.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 20.2 m -57.64 -31.14 65.99 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.929 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -73.26 -19.19 61.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.69 144.39 55.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.284 -0.885 . . . . 0.0 109.447 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -60.42 -33.06 71.97 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.33 -0.857 . . . . 0.0 109.524 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 31.3 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.435 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.38 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 78.8 t -134.16 146.25 31.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -1.157 . . . . 0.0 109.563 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.405 ' CG ' ' HE3' ' A' ' 119' ' ' LYS . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.546 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 113' ' ' ILE . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.452 HG23 HD13 ' A' ' 13' ' ' ILE . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.517 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.517 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.508 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.574 ' CE2' HD13 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.884 ' O ' HG22 ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.884 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.561 ' CG2' HG23 ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.468 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.799 HD12 HG22 ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.771 ' O ' HG23 ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.46 ' H ' HG21 ' A' ' 52' ' ' THR . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.832 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.799 HG22 HD12 ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.561 HG23 ' CG2' ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.02 144.06 51.5 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -48.01 144.83 3.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.208 -0.933 . . . . 0.0 109.459 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.63 10.38 50.4 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.466 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -111.7 164.94 13.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -1.15 . . . . 0.0 109.509 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.466 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.2 Cg_endo -68.65 -35.09 17.59 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.757 2.304 . . . . 0.0 111.935 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.562 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 55.0 m-85 -118.85 166.73 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 109.467 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt -100.22 -63.89 1.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 56' ' ' ILE . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.7 ' O ' HG13 ' A' ' 85' ' ' VAL . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.656 ' O ' HG23 ' A' ' 53' ' ' ILE . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.832 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.468 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.52 ' HE3' HD22 ' A' ' 82' ' ' ASN . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.597 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.52 HD22 ' HE3' ' A' ' 80' ' ' LYS . 74.3 m-20 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.574 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 68' ' ' LYS . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.42 ' HA ' ' HE2' ' A' ' 97' ' ' LYS . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.562 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.543 HD11 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.708 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.726 HD23 ' ND1' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.543 HG12 HD11 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.574 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.574 HD13 ' CE2' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 114' ' ' LEU . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.53 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.6 HG23 ' O ' ' A' ' 111' ' ' GLY . 6.6 p -92.1 160.65 35.1 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.8 Cg_endo -69.9 -27.52 25.71 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.66 2.24 . . . . 0.0 111.776 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -168.58 27.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.271 -0.893 . . . . 0.0 109.552 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -129.41 28.33 4.05 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 107' ' ' THR . . . 77.42 -150.37 36.66 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t -123.01 148.18 45.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.131 -1.217 . . . . 0.0 109.501 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 10' ' ' THR . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.627 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.442 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.405 ' HE3' ' CG ' ' A' ' 4' ' ' ASN . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 95' ' ' LEU . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.708 ' HB2' HG23 ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.726 ' ND1' HD23 ' A' ' 95' ' ' LEU . 62.2 m80 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.512 HG23 HG21 ' A' ' 122' ' ' THR . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.43 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.535 HG22 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.619 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.575 ' N ' HD12 ' A' ' 144' ' ' LEU . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.53 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.84 HG22 HG11 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.407 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.527 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.627 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.663 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.8 -35.48 80.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.527 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 76.0 m80 -49.38 -40.3 35.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.418 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.4 p -59.06 -30.65 68.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.941 . . . . 0.0 109.241 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -73.95 -16.52 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.364 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.7 145.09 55.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.956 . . . . 0.0 109.405 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.452 ' O ' ' CB ' ' A' ' 159' ' ' ASN . 69.9 m-85 -113.03 120.23 40.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ASN . . . . . 0.452 ' CB ' ' O ' ' A' ' 158' ' ' TYR . 46.6 t30 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.687 HG13 ' O ' ' A' ' 120' ' ' TYR . 50.1 t -133.85 142.09 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.308 -1.113 . . . . 0.0 109.395 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.507 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.44 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.489 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.912 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.696 ' CE2' HD12 ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.517 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.551 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.696 HD12 ' CE2' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.443 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.9 ' O ' HG22 ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.9 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.614 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.838 HG22 ' HG3' ' A' ' 45' ' ' GLU . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.698 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.859 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.798 HG22 HD12 ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.502 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.512 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.614 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.459 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.64 157.04 62.0 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -54.47 141.62 30.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.479 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.62 9.36 52.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.541 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.3 m-85 -109.2 161.13 25.01 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.327 -1.101 . . . . 0.0 109.464 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.541 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.3 Cg_endo -70.07 -38.76 6.71 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.766 2.311 . . . . 0.0 111.696 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.56 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 98.0 m-85 -114.08 152.27 31.3 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.412 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt -79.19 -36.69 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.656 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.454 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.997 ' O ' HG23 ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.698 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.416 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.583 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.452 ' HE1' HD11 ' A' ' 102' ' ' ILE . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.402 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.434 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.477 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.556 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 97' ' ' LYS . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.545 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.401 ' HA ' HD23 ' A' ' 95' ' ' LEU . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.503 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.539 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.402 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.48 ' HA ' ' O ' ' A' ' 117' ' ' SER . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.459 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.551 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.525 HD12 ' HD1' ' A' ' 19' ' ' PHE . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.422 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.6 OUTLIER -153.52 125.04 3.67 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.51 -4.78 15.21 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.639 2.226 . . . . 0.0 111.72 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.23 -33.64 43.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.173 -0.954 . . . . 0.0 109.396 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -157.59 37.3 0.54 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 76.03 -143.9 30.38 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p -103.9 148.21 26.43 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.324 -1.104 . . . . 0.0 109.18 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.406 ' HA ' HD23 ' A' ' 114' ' ' LEU . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.412 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.687 ' O ' HG13 ' A' ' 2' ' ' VAL . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.804 HG21 HG23 ' A' ' 128' ' ' VAL . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.545 ' HB2' HG23 ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.804 HG23 HG21 ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.44 ' HE3' HG22 ' A' ' 7' ' ' THR . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 143' ' ' LEU . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 150' ' ' TYR . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.501 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.665 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.597 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' OD1' ' A' ' 156' ' ' ASP . . . -70.65 -28.37 64.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' HIS . . . . . 0.501 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 67.7 m-70 -92.16 -26.99 17.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 109.476 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 87.4 p -52.37 -31.92 36.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.194 -0.941 . . . . 0.0 109.361 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 56.9 p30 -91.73 9.52 32.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -68.5 143.39 54.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.311 -0.868 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -61.23 -36.8 80.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.272 -0.893 . . . . 0.0 109.468 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.47 179.922 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.49 HG11 ' CE1' ' A' ' 121' ' ' HIS . 62.7 t -133.96 142.6 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.166 -1.197 . . . . 0.0 109.435 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.449 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.564 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 144' ' ' LEU . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.519 HG23 HG12 ' A' ' 113' ' ' ILE . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' O ' ' HA2' ' A' ' 111' ' ' GLY . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.563 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.478 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.474 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.885 ' HD2' HD12 ' A' ' 104' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.711 ' HE2' HD13 ' A' ' 102' ' ' ILE . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.58 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.487 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.818 ' O ' HG22 ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.487 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.818 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.42 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.507 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.547 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.756 ' O ' HG23 ' A' ' 52' ' ' THR . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.697 ' H ' HG21 ' A' ' 52' ' ' THR . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.756 HG23 ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.512 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.547 HG23 ' CG2' ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.458 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.8 Cg_endo -69.9 143.47 50.29 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -51.23 143.89 10.39 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.343 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.39 8.35 57.57 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.527 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -106.2 162.76 18.69 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.236 -1.155 . . . . 0.0 109.488 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.527 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.7 Cg_endo -68.92 -30.76 25.78 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.702 2.268 . . . . 0.0 111.795 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.528 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 41.0 m-85 -119.67 158.44 26.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 109.541 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt -96.58 -65.71 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -0.904 . . . . 0.0 109.402 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.75 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.649 HG22 ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.639 HG22 ' CD1' ' A' ' 81' ' ' TYR . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.649 ' OH ' HG22 ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.6 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.435 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.75 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.443 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.421 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.587 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.6 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.711 HD13 ' HE2' ' A' ' 22' ' ' PHE . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.885 HD12 ' HD2' ' A' ' 19' ' ' PHE . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 1.3 p -109.26 163.84 16.11 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.3 Cg_endo -69.43 -17.62 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.535 2.157 . . . . 0.0 111.629 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.25 -23.63 59.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.354 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 126.81 -53.66 0.79 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 12' ' ' VAL . . . -62.46 -160.28 0.18 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.459 ' HA ' HG23 ' A' ' 107' ' ' THR . 83.6 p -147.18 157.75 43.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -1.161 . . . . 0.0 109.381 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.519 HG12 HG23 ' A' ' 10' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.514 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.502 ' OH ' HG13 ' A' ' 133' ' ' VAL . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' HG11 ' A' ' 2' ' ' VAL . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.618 HG21 HG23 ' A' ' 128' ' ' VAL . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' HIS . . . . . 0.44 ' ND1' HD23 ' A' ' 95' ' ' LEU . 45.7 m80 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.618 HG23 HG21 ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.464 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.464 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.502 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.478 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.478 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.455 ' HA ' HD23 ' A' ' 143' ' ' LEU . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.431 ' N ' HD12 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.717 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 29' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.405 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.624 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.555 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.71 -44.57 95.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -90.75 -24.27 20.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 32.5 t -61.11 -29.06 69.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.595 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -105.93 18.33 22.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.92 . . . . 0.0 109.884 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.41 130.41 55.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.053 -1.029 . . . . 0.0 110.014 -179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 27.2 t80 -65.86 132.04 47.71 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.478 -0.764 . . . . 0.0 109.525 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.542 179.786 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.2 t -132.05 145.9 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -1.157 . . . . 0.0 109.483 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.562 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.5 t30 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' THR . . . . . 0.789 HG22 ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 113' ' ' ILE . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.536 ' OG ' HD12 ' A' ' 13' ' ' ILE . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' O ' ' HA2' ' A' ' 111' ' ' GLY . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.846 HD13 HD12 ' A' ' 151' ' ' LEU . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.559 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.538 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.781 ' CD2' HD21 ' A' ' 114' ' ' LEU . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HA ' HD13 ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.809 ' HZ ' HD13 ' A' ' 102' ' ' ILE . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.552 ' O ' HG21 ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.409 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 56' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.552 HG21 ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 53' ' ' ILE . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.847 ' O ' HG23 ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.419 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.847 HG23 ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.505 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.454 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo -74.24 -168.94 0.52 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' A' ' 59' ' ' PRO . 3.3 mt-10 50.56 177.48 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.849 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -88.73 26.87 7.72 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.468 ' O ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -42.1 165.99 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.452 -1.029 . . . . 0.0 109.701 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.98 -29.73 33.72 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.718 2.279 . . . . 0.0 111.911 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.578 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 79.6 m-85 -106.83 148.33 28.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt -106.1 -40.85 5.53 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.74 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.586 HG13 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.493 ' HA ' HG12 ' A' ' 85' ' ' VAL . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.505 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 73.8 m-20 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.463 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 98' ' ' ILE . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.809 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.586 ' CA ' HG13 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.578 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 97' ' ' LYS . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.485 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.626 HD12 ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.422 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.57 ' HE2' HG22 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 85' ' ' VAL . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.809 HD13 ' HZ ' ' A' ' 22' ' ' PHE . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.525 HD13 HD23 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 112' ' ' SER . 1.5 p -103.01 163.24 17.92 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.49 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.8 Cg_endo -69.9 -26.1 27.26 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.687 2.258 . . . . 0.0 111.754 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -70.85 -28.95 64.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.335 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 111' ' ' GLY . . . 132.85 -48.55 0.96 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 110' ' ' GLY . . . -58.08 -156.54 0.02 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.636 ' HA ' HG23 ' A' ' 107' ' ' THR . 80.5 p -151.48 157.77 42.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -1.117 . . . . 0.0 109.463 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.574 HG13 HG22 ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.781 HD21 ' CD2' ' A' ' 18' ' ' LEU . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.613 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.6 HG21 HG23 ' A' ' 128' ' ' VAL . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.6 HG23 HG21 ' A' ' 122' ' ' THR . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 78.3 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.406 HG13 ' OH ' ' A' ' 120' ' ' TYR . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.789 ' HE3' HG22 ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 143' ' ' LEU . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.846 HG13 HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.615 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.846 HD12 HD13 ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -61.7 -43.7 98.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -50.55 -39.25 48.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 28.7 m -58.48 -29.49 66.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -72.43 -18.72 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.527 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -78.09 -10.64 59.71 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.154 -0.966 . . . . 0.0 109.513 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.539 ' CD1' ' C ' ' A' ' 158' ' ' TYR . 0.6 OUTLIER -50.15 -39.72 44.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.235 -0.915 . . . . 0.0 109.085 179.844 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ASN . . . . . 0.462 ' OXT' ' OD1' ' A' ' 159' ' ' ASN . 28.7 t-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.909 -1.044 . . . . 0.0 109.493 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.535 HG13 ' O ' ' A' ' 120' ' ' TYR . 45.5 t -133.12 149.19 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -1.154 . . . . 0.0 109.565 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.577 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.709 HG22 HG23 ' A' ' 113' ' ' ILE . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.422 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.738 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.86 ' HD1' HD12 ' A' ' 104' ' ' ILE . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.496 ' CA ' HG21 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASN . . . . . 0.461 ' HB3' ' HE2' ' A' ' 32' ' ' LYS . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.935 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.461 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.935 HG22 ' O ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.479 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.566 HG21 HG23 ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.496 HG21 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASN . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.851 HD12 HG22 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.818 ' O ' HG23 ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' H ' HG21 ' A' ' 52' ' ' THR . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.851 HG22 HD12 ' A' ' 44' ' ' ILE . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.535 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.566 HG23 HG21 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.407 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.68 155.35 66.43 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -53.09 141.32 23.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.12 -0.987 . . . . 0.0 109.433 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.01 48.5 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.55 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.6 m-85 -108.41 169.87 6.1 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.296 -1.12 . . . . 0.0 109.491 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.55 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.2 Cg_endo -69.46 -49.7 0.57 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 111.791 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.551 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 96.9 m-85 -119.64 148.86 42.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.247 -0.908 . . . . 0.0 109.495 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp -75.09 -44.79 45.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.698 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.535 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.587 HG23 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 1.015 ' O ' HG23 ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.443 ' HG2' HG12 ' A' ' 53' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 67.1 m-20 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.523 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 1.015 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.439 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.587 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.418 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.465 HG12 ' HB3' ' A' ' 96' ' ' GLU . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.635 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.465 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.475 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.59 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.86 HD12 ' HD1' ' A' ' 19' ' ' PHE . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.477 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' THR . . . . . 0.421 HG23 ' O ' ' A' ' 111' ' ' GLY . 6.7 p -121.15 157.99 54.04 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 48.8 Cg_endo -69.9 -48.02 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.744 2.296 . . . . 0.0 111.918 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.463 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 92.1 m-20 -136.31 26.25 3.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.147 -0.971 . . . . 0.0 109.477 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.406 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -127.42 20.12 5.88 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.421 ' O ' HG23 ' A' ' 107' ' ' THR . . . 63.02 -147.47 50.47 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.2 p -112.84 146.73 38.36 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.241 -1.153 . . . . 0.0 109.394 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.709 HG23 HG22 ' A' ' 10' ' ' THR . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.738 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.572 ' CE2' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.475 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.594 HG21 HG23 ' A' ' 128' ' ' VAL . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' LYS . . . . . 0.635 ' HB2' HG23 ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.594 HG23 HG21 ' A' ' 122' ' ' THR . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.572 HG13 ' CE2' ' A' ' 120' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.492 ' O ' HG23 ' A' ' 147' ' ' VAL . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.528 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.922 HG13 HD21 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.449 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.601 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.93 -31.25 72.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -56.38 -32.89 65.2 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.9 t -62.86 -21.15 65.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -85.65 5.96 29.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.22 -0.925 . . . . 0.0 109.646 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.1 125.62 39.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.107 -0.996 . . . . 0.0 109.499 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -58.23 129.56 42.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.481 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.423 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 120' ' ' TYR . 56.3 t . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.302 0.572 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.498 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.605 HG23 ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.778 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.457 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.878 ' HD1' HD12 ' A' ' 104' ' ' ILE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.437 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG11 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.415 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.942 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.942 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 57' ' ' SER . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.832 HG22 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.832 ' HG3' HG22 ' A' ' 44' ' ' ILE . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.509 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.748 HG22 HD12 ' A' ' 44' ' ' ILE . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.52 HG23 HG21 ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.522 ' O ' HG23 ' A' ' 38' ' ' ILE . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo . . . . . 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.186 0.517 . . . . 0.0 109.686 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.865 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.496 ' CE ' ' OE1' ' A' ' 87' ' ' GLU . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.685 ' HA ' HG12 ' A' ' 85' ' ' VAL . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.401 ' O ' HG13 ' A' ' 74' ' ' VAL . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.581 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' ASP . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.865 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.708 HD11 HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.555 ' CG ' HG22 ' A' ' 94' ' ' THR . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.645 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.604 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.708 HG12 HD11 ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 82' ' ' ASN . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.878 HD12 ' HD1' ' A' ' 19' ' ' PHE . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 112' ' ' SER . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.321 0.582 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.472 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.634 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.608 ' CE1' HG11 ' A' ' 2' ' ' VAL . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.62 HG21 HG23 ' A' ' 128' ' ' VAL . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.645 ' HB2' HG23 ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 120' ' ' TYR . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.544 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.416 ' HA ' HD23 ' A' ' 143' ' ' LEU . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.426 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.432 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.73 HG13 HD21 ' A' ' 29' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.653 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 120' ' ' TYR . 39.4 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.59 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.522 HG21 HD22 ' A' ' 144' ' ' LEU . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.716 HG23 ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.716 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.546 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.599 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.482 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.495 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.468 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.94 ' O ' HG22 ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.94 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.655 HD13 HG23 ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.49 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.694 HG22 ' HG3' ' A' ' 45' ' ' GLU . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.898 ' O ' HG23 ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.422 ' O ' HG21 ' A' ' 74' ' ' VAL . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.49 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 HD13 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.572 ' O ' HG23 ' A' ' 38' ' ' ILE . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.475 ' HE1' HG23 ' A' ' 67' ' ' VAL . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo . . . . . 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.437 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.533 HG13 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.429 ' OD1' HG22 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.498 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.463 ' OE2' ' HB3' ' A' ' 50' ' ' PRO . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.451 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.451 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.503 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.498 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.47 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.533 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.491 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.596 HD13 ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.671 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.808 HD23 ' CD2' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.596 ' O ' HD13 ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.506 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.878 ' CD1' HD23 ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.444 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.432 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 15' ' ' ALA . 26.5 m . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.878 HD23 ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 121' ' ' HIS . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.692 ' O ' HG13 ' A' ' 2' ' ' VAL . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.574 HG21 HG23 ' A' ' 128' ' ' VAL . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.671 ' HB2' HG23 ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.808 ' CD2' HD23 ' A' ' 95' ' ' LEU . 99.3 m-70 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.574 HG23 HG21 ' A' ' 122' ' ' THR . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.415 ' OE1' HG13 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.44 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.546 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.632 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.565 ' N ' HD12 ' A' ' 144' ' ' LEU . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.68 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.402 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.637 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.588 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.586 HG13 ' O ' ' A' ' 120' ' ' TYR . 94.6 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.566 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.528 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.562 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.846 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.49 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.761 ' CE1' HD12 ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.761 HD12 ' CE1' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.621 ' O ' HG11 ' A' ' 41' ' ' VAL . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.432 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.909 ' O ' HG22 ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.909 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 57' ' ' SER . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.459 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.869 ' O ' HG23 ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.451 HG23 HD13 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.668 ' HE1' HG23 ' A' ' 67' ' ' VAL . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.459 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo . . . . . 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.137 0.494 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.446 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.668 HG23 ' HE1' ' A' ' 58' ' ' PHE . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.617 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 85' ' ' VAL . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.51 HG21 ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.482 HG22 ' CE2' ' A' ' 81' ' ' TYR . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.567 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.51 ' OH ' HG21 ' A' ' 71' ' ' VAL . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.42 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.425 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.513 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.513 ' HA ' HD13 ' A' ' 91' ' ' ILE . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.846 HG22 ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.504 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 89.8 p . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 121.238 0.542 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.504 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.83 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.522 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.83 ' CD1' HD21 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 21.0 m120 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.586 ' O ' HG13 ' A' ' 2' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.783 HG21 HG23 ' A' ' 128' ' ' VAL . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.783 HG23 HG21 ' A' ' 122' ' ' THR . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.426 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.426 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.429 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.528 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.456 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.504 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.64 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.503 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.419 HG22 HG11 ' A' ' 33' ' ' VAL . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.418 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.625 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 120' ' ' TYR . 95.1 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.484 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.484 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.439 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.596 HG21 ' HG ' ' A' ' 151' ' ' LEU . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.898 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.595 HD23 HD13 ' A' ' 104' ' ' ILE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.541 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.709 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.541 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.455 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.901 ' O ' HG22 ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.901 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.719 HG23 ' O ' ' A' ' 57' ' ' SER . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.482 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.576 HD12 HG22 ' A' ' 53' ' ' ILE . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.709 ' O ' HG23 ' A' ' 52' ' ' THR . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 44' ' ' ILE . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.482 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.66 HG23 HD13 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.719 ' O ' HG23 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo . . . . . 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.21 0.528 . . . . 0.0 109.596 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.57 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.954 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.5 ' HA ' HG22 ' A' ' 85' ' ' VAL . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.487 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.487 ' OH ' HG22 ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.954 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.493 ' HB2' ' HD2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.8 HD11 HG12 ' A' ' 98' ' ' ILE . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.59 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.523 ' HG2' HD11 ' A' ' 98' ' ' ILE . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.613 ' HA ' HD13 ' A' ' 91' ' ' ILE . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.8 HG12 HD11 ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.898 HG22 ' HB1' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.254 0.55 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.544 HD21 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.409 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 15.1 m120 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.528 ' O ' HG13 ' A' ' 2' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.515 ' CE1' HG11 ' A' ' 2' ' ' VAL . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.615 HG21 HG23 ' A' ' 128' ' ' VAL . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.59 ' HB2' HG23 ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.615 HG23 HG21 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 25.1 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.449 HG22 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.439 ' HE3' HG22 ' A' ' 7' ' ' THR . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.617 ' OE2' HD21 ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.672 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.601 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.427 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.631 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 120' ' ' TYR . 86.3 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.335 0.588 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.476 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.476 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.993 HG22 HG23 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.882 HG21 HD13 ' A' ' 151' ' ' LEU . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.747 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.788 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.975 ' HG2' HD22 ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.797 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.639 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.975 HD22 ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.978 ' O ' HG22 ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.978 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.481 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.879 HD12 HG22 ' A' ' 53' ' ' ILE . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.838 ' O ' HG23 ' A' ' 52' ' ' THR . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.491 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.879 HG22 HD12 ' A' ' 44' ' ' ILE . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.604 ' HB ' HG12 ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.44 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.685 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.71 ' O ' HG13 ' A' ' 85' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.627 ' O ' HG23 ' A' ' 53' ' ' ILE . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.614 HH21 HD13 ' A' ' 86' ' ' ILE . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.453 ' N ' ' HG2' ' A' ' 70' ' ' ARG . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.4 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.447 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 68' ' ' LYS . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.614 HD13 HH21 ' A' ' 70' ' ' ARG . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.685 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 97' ' ' LYS . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.501 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.552 ' HA ' HD13 ' A' ' 91' ' ' ILE . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.452 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.788 HG22 ' HB1' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.993 HG23 HG22 ' A' ' 10' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 104' ' ' ILE . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.992 ' OH ' HG13 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.575 ' O ' ' CD2' ' A' ' 126' ' ' HIS . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.575 ' CD2' ' O ' ' A' ' 124' ' ' GLY . 85.7 m-70 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.407 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.992 HG13 ' OH ' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.503 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HA ' HD23 ' A' ' 143' ' ' LEU . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.612 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.464 ' N ' HD12 ' A' ' 144' ' ' LEU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.556 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . 0.594 ' HA ' HD12 ' A' ' 152' ' ' LEU . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.882 HD13 HG21 ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.594 HD12 ' HA ' ' A' ' 149' ' ' SER . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.813 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.445 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.572 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.445 HG21 HD13 ' A' ' 144' ' ' LEU . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.902 HG21 HD13 ' A' ' 151' ' ' LEU . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.769 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.771 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.731 ' HD2' HD12 ' A' ' 104' ' ' ILE . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.446 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.426 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.913 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 56' ' ' ILE . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.409 HG22 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.884 HD12 HG22 ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.798 ' O ' HG23 ' A' ' 52' ' ' THR . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.524 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.798 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.884 HG22 HD12 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.527 HG23 ' CG2' ' A' ' 38' ' ' ILE . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.266 0.555 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.522 HG13 ' HA2' ' A' ' 88' ' ' GLY . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.973 ' O ' HG13 ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.442 ' CZ ' HD13 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 74' ' ' VAL . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.484 ' O ' ' N ' ' A' ' 102' ' ' ILE . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.973 HG13 ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 87' ' ' GLU . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.522 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.527 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.527 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.574 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.487 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.487 HD12 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.574 ' HA ' HD13 ' A' ' 91' ' ' ILE . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.497 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.484 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.769 HG22 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.576 ' CD2' HG23 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.721 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.813 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.635 HG21 HG23 ' A' ' 128' ' ' VAL . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.635 HG23 HG21 ' A' ' 122' ' ' THR . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.438 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.445 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.449 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.537 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.56 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.612 HG13 HD21 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.456 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . 0.828 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.902 HD13 HG21 ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.828 HD12 ' HA ' ' A' ' 149' ' ' SER . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.1 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.435 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.598 HG22 HG23 ' A' ' 113' ' ' ILE . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.871 HG21 HD13 ' A' ' 151' ' ' LEU . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.741 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.854 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.675 HD23 HD13 ' A' ' 104' ' ' ILE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.481 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.564 HD12 ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.538 ' HB2' HD13 ' A' ' 29' ' ' LEU . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.886 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.886 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.47 HD13 HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.43 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.821 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.452 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.516 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.489 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.516 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG23 ' A' ' 38' ' ' ILE . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.516 ' CD1' ' O ' ' A' ' 37' ' ' ALA . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo . . . . . 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.456 HG13 ' HA2' ' A' ' 88' ' ' GLY . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.947 ' O ' HG13 ' A' ' 85' ' ' VAL . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.489 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.463 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 81' ' ' TYR . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.404 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.947 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.529 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.451 HD13 ' HA ' ' A' ' 97' ' ' LYS . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.486 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.404 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.461 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.499 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.854 HG22 ' HB1' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.417 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.3 p . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.598 HG23 HG22 ' A' ' 10' ' ' THR . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.529 ' CD2' HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.407 ' N ' ' O ' ' A' ' 5' ' ' TYR . 16.8 m120 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.649 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.7 HG21 HG23 ' A' ' 128' ' ' VAL . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.452 ' CD2' HD23 ' A' ' 95' ' ' LEU . 99.3 m-70 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.7 HG23 HG21 ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.469 ' OE1' HG13 ' A' ' 128' ' ' VAL . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 120' ' ' TYR . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.45 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.45 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.452 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.715 ' OE2' HD11 ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.715 HD11 ' OE2' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.61 ' N ' HD12 ' A' ' 144' ' ' LEU . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.871 HD13 HG21 ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 120' ' ' TYR . 46.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.483 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.926 HG21 HD13 ' A' ' 151' ' ' LEU . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.608 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.448 ' O ' HD12 ' A' ' 29' ' ' LEU . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.984 ' O ' HG22 ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.984 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.683 ' CG2' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.45 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.573 ' CG1' HG21 ' A' ' 38' ' ' ILE . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.493 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.926 HD12 HG22 ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.822 ' O ' HG23 ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.48 ' H ' HG21 ' A' ' 52' ' ' THR . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.822 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.926 HG22 HD12 ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.695 ' HB ' HG12 ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.45 ' HD3' ' N ' ' A' ' 39' ' ' SER . 48.9 Cg_endo . . . . . 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.305 0.574 . . . . 0.0 109.875 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.695 HG12 ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 1.017 ' O ' HG13 ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.603 HG22 ' CE2' ' A' ' 81' ' ' TYR . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.603 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.463 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 1.017 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.582 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.596 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.528 HD13 ' CE1' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.706 HD12 HD12 ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.467 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 105' ' ' VAL . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.706 HD12 HD12 ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.582 HG12 HD21 ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.926 ' OH ' HG13 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.625 ' CE1' HG11 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.606 HG21 HG23 ' A' ' 128' ' ' VAL . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.407 ' CD2' HD23 ' A' ' 95' ' ' LEU . 96.9 m-70 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.606 HG23 HG21 ' A' ' 122' ' ' THR . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.926 HG13 ' OH ' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.422 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.442 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.454 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.538 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.464 ' NE ' ' CG ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.926 HD13 HG21 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 92.0 t . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.517 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.53 HG23 HD13 ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.792 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.763 ' HD2' HD12 ' A' ' 104' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.435 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.723 HD12 ' CE1' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.651 ' O ' HG21 ' A' ' 41' ' ' VAL . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.917 ' O ' HG22 ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.434 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.917 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' HG23 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.651 HG21 ' O ' ' A' ' 27' ' ' ASP . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.433 ' HA ' ' HD2' ' A' ' 54' ' ' LYS . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.783 HG22 ' HG3' ' A' ' 45' ' ' GLU . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.783 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.56 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.737 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.641 HG22 HD12 ' A' ' 44' ' ' ILE . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.503 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.623 HG23 ' CG2' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.48 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.877 HG23 ' HA2' ' A' ' 88' ' ' GLY . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.965 ' O ' HG23 ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.559 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.965 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.465 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.877 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.594 ' CG ' HG22 ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.594 HG22 ' CG ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.488 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.763 HD12 ' HD2' ' A' ' 19' ' ' PHE . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 13.6 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.4 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.293 0.568 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.474 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.3 m120 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.489 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.531 HG21 HG23 ' A' ' 128' ' ' VAL . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.411 ' O ' ' HB ' ' A' ' 122' ' ' THR . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.531 HG23 HG21 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.632 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.557 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 120' ' ' TYR . 64.3 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.511 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.511 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.402 ' O ' ' N ' ' A' ' 112' ' ' SER . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.83 HG21 HD13 ' A' ' 151' ' ' LEU . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.904 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.433 ' O ' ' HG2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.577 ' O ' HG22 ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.452 ' CG2' HG23 ' A' ' 56' ' ' ILE . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.01 HD12 HG22 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.782 ' O ' HG23 ' A' ' 52' ' ' THR . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.782 HG23 ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 1.01 HG22 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo . . . . . 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.458 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.539 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.872 ' O ' HG13 ' A' ' 85' ' ' VAL . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.634 HG22 ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.428 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.481 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.634 ' OH ' HG22 ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.475 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 68' ' ' LYS . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.437 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.539 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.472 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.638 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.557 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' HD13 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.475 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.66 HD12 ' HD2' ' A' ' 19' ' ' PHE . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.497 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.446 ' CD1' HG12 ' A' ' 98' ' ' ILE . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.0 m-70 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.666 HG21 HG23 ' A' ' 128' ' ' VAL . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.638 ' HB2' HG23 ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.666 HG23 HG21 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.583 ' OE1' HG13 ' A' ' 128' ' ' VAL . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.483 HG12 ' HE3' ' A' ' 137' ' ' LYS . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.507 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.441 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.623 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.473 ' N ' HD12 ' A' ' 144' ' ' LEU . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.552 HG13 HD21 ' A' ' 29' ' ' LEU . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.505 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.83 HD13 HG21 ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.634 HG11 ' CE1' ' A' ' 121' ' ' HIS . 47.7 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.495 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.488 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.415 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.563 HG23 ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.885 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.827 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.486 ' HD1' HD12 ' A' ' 104' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB3' HD13 ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.597 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.748 ' HB ' ' HB1' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.424 HG12 ' CG2' ' A' ' 56' ' ' ILE . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.424 ' O ' ' N ' ' A' ' 55' ' ' LYS . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.016 HD11 ' HB2' ' A' ' 55' ' ' LYS . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.82 ' O ' HG23 ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.429 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.491 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.756 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.82 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 1.016 ' HB2' HD11 ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.424 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' HG23 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo . . . . . 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.423 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.66 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.482 ' HA ' HG12 ' A' ' 85' ' ' VAL . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 81' ' ' TYR . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.494 ' CD1' HG22 ' A' ' 74' ' ' VAL . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.411 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 69' ' ' ASP . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.507 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.66 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.45 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 97' ' ' LYS . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.527 HD12 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 91' ' ' ILE . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.423 ' HA ' ' O ' ' A' ' 117' ' ' SER . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.415 ' O ' ' N ' ' A' ' 81' ' ' TYR . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.885 HG22 ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.474 ' CD2' HG23 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.403 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 21.6 m120 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.581 ' CE1' HG13 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.634 ' CE1' HG11 ' A' ' 2' ' ' VAL . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.82 HG21 HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.82 HG23 HG21 ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 120' ' ' TYR . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.492 ' HE2' ' HB3' ' A' ' 5' ' ' TYR . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.403 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.55 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 143' ' ' LEU . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 144' ' ' LEU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.592 ' N ' HD12 ' A' ' 144' ' ' LEU . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.748 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.402 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.546 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 120' ' ' TYR . 48.5 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.596 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.464 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.632 HG22 HG23 ' A' ' 113' ' ' ILE . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.844 HG21 HD13 ' A' ' 151' ' ' LEU . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.732 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.621 ' HB3' ' HB2' ' A' ' 106' ' ' ALA . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.572 HD23 HD13 ' A' ' 104' ' ' ILE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.429 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.93 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.93 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.414 HD13 HG23 ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.494 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.512 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 55' ' ' LYS . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.036 HD11 ' HB2' ' A' ' 55' ' ' LYS . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.76 ' O ' HG23 ' A' ' 52' ' ' THR . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.475 ' H ' HG21 ' A' ' 52' ' ' THR . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.76 HG23 ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 1.036 ' HB2' HD11 ' A' ' 44' ' ' ILE . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo . . . . . 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.131 0.491 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.599 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.592 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 1.034 ' O ' HG13 ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.444 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 1.034 HG13 ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.519 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.47 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.592 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 96' ' ' GLU . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.706 HD22 ' HD2' ' A' ' 126' ' ' HIS . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' HD13 ' A' ' 91' ' ' ILE . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.519 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.482 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.403 ' O ' ' N ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.572 HD13 HD23 ' A' ' 18' ' ' LEU . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.632 HG23 HG22 ' A' ' 10' ' ' THR . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.819 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.524 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.819 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.69 ' O ' HG13 ' A' ' 2' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.549 ' CE1' HG11 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.63 HG21 HG23 ' A' ' 128' ' ' VAL . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.706 ' HD2' HD22 ' A' ' 95' ' ' LEU . 98.5 m-70 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.63 HG23 HG21 ' A' ' 122' ' ' THR . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.663 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.571 ' HE3' HG12 ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.445 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.413 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.608 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.853 HG13 HD21 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.434 ' HA ' HD12 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.844 HD13 HG21 ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.553 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 120' ' ' TYR . 54.9 t . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.605 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.605 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.556 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.646 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.705 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.49 ' HA ' HD13 ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.563 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.501 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.617 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.551 ' O ' HD12 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.99 ' O ' HG22 ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.99 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.695 HD13 HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.409 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.982 HD11 ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.894 ' O ' HG23 ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.894 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.446 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.982 ' HB2' HD11 ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.695 HG23 HD13 ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 38' ' ' ILE . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.526 ' HE1' HG23 ' A' ' 67' ' ' VAL . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.453 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.526 HG23 ' HE1' ' A' ' 58' ' ' PHE . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.962 ' O ' HG13 ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.446 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.53 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.495 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.603 HG22 ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.481 HD13 ' O ' ' A' ' 96' ' ' GLU . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.793 HD22 ' CD2' ' A' ' 126' ' ' HIS . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.603 ' CE ' HG22 ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.705 HD13 HD23 ' A' ' 18' ' ' LEU . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 13.0 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.636 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 23.8 m120 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.7 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.506 ' CE1' HG11 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.763 HG21 HG23 ' A' ' 128' ' ' VAL . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.793 ' CD2' HD22 ' A' ' 95' ' ' LEU . 85.8 m-70 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.763 HG23 HG21 ' A' ' 122' ' ' THR . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.668 HG22 ' CZ ' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.417 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.542 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.439 ' HA ' HD23 ' A' ' 143' ' ' LEU . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.581 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.475 ' N ' HD12 ' A' ' 144' ' ' LEU . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.452 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . 0.601 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.601 HD12 ' HA ' ' A' ' 149' ' ' SER . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.292 0.568 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.545 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.469 ' HA ' ' HG2' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.545 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.401 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.904 HG21 HD13 ' A' ' 151' ' ' LEU . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.555 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.686 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.54 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.545 HD23 HD12 ' A' ' 104' ' ' ILE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.689 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.659 ' CE1' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.471 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.435 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.441 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.891 ' O ' HG22 ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.891 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.437 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.799 HG22 ' HG3' ' A' ' 45' ' ' GLU . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.799 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.633 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.763 HG23 ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.727 HG22 HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.523 HG23 ' CG2' ' A' ' 38' ' ' ILE . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.498 HG22 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 85' ' ' VAL . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 49' ' ' GLY . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.481 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.443 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.42 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.532 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.472 HD13 ' HA ' ' A' ' 97' ' ' LYS . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.693 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.659 HD13 ' CE1' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.686 HG22 ' CB ' ' A' ' 15' ' ' ALA . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.408 HG21 ' NZ ' ' A' ' 115' ' ' LYS . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.2 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.891 ' CD2' HD13 ' A' ' 144' ' ' LEU . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.701 HD11 HD21 ' A' ' 114' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.735 ' CE1' HG13 ' A' ' 133' ' ' VAL . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.719 HG21 HG23 ' A' ' 128' ' ' VAL . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.693 ' HB2' HG23 ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.408 ' CD2' HD23 ' A' ' 95' ' ' LEU . 96.7 m-70 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.719 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.404 ' HE2' ' OE1' ' A' ' 131' ' ' GLU . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.404 ' OE1' ' HE2' ' A' ' 129' ' ' LYS . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.735 HG13 ' CE1' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.401 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.443 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.479 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.891 HD13 ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 143' ' ' LEU . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.749 ' HA ' HD11 ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.904 HD13 HG21 ' A' ' 13' ' ' ILE . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.522 HG13 ' O ' ' A' ' 120' ' ' TYR . 49.1 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.597 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.464 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.407 HG21 HD13 ' A' ' 144' ' ' LEU . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' ILE . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.754 HD11 ' HA ' ' A' ' 148' ' ' GLU . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.488 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.76 ' CD1' HD12 ' A' ' 104' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.545 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.59 ' O ' HG21 ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.438 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.764 ' O ' HG22 ' A' ' 33' ' ' VAL . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.594 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.59 HG21 ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.796 HD12 HG22 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.854 ' O ' HG23 ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.854 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.796 HG22 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.594 HG23 ' CG2' ' A' ' 38' ' ' ILE . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 65' ' ' LYS . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.247 0.546 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.809 HG23 ' HA2' ' A' ' 88' ' ' GLY . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.932 ' O ' HG13 ' A' ' 85' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.599 ' O ' HG23 ' A' ' 53' ' ' ILE . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.525 HG22 ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 8.3 m120 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.479 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.525 ' OH ' HG22 ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.932 HG13 ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.468 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.434 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.809 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.56 HD13 ' HA ' ' A' ' 97' ' ' LYS . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.56 ' HA ' HD13 ' A' ' 91' ' ' ILE . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.504 HD13 ' HE2' ' A' ' 22' ' ' PHE . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.76 HD12 ' CD1' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.527 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 12.4 p . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.5 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.527 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.476 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.473 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.463 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 22.1 m120 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.528 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.482 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.675 HG21 HG23 ' A' ' 128' ' ' VAL . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.675 HG23 HG21 ' A' ' 122' ' ' THR . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.464 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 143' ' ' LEU . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.539 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.693 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.754 ' HA ' HD11 ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.607 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.491 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 78.8 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.289 0.566 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.405 ' CG ' ' HE3' ' A' ' 119' ' ' LYS . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.546 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 113' ' ' ILE . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.452 HG23 HD13 ' A' ' 13' ' ' ILE . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.517 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.517 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.508 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.574 ' CE2' HD13 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.884 ' O ' HG22 ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.884 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.561 ' CG2' HG23 ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.468 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.799 HD12 HG22 ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.771 ' O ' HG23 ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.46 ' H ' HG21 ' A' ' 52' ' ' THR . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.832 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.799 HG22 HD12 ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.561 HG23 ' CG2' ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo . . . . . 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.268 0.556 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 56' ' ' ILE . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.7 ' O ' HG13 ' A' ' 85' ' ' VAL . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.656 ' O ' HG23 ' A' ' 53' ' ' ILE . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.832 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.468 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.597 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.432 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 21.0 m120 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.574 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 68' ' ' LYS . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.42 ' HA ' ' HE2' ' A' ' 97' ' ' LYS . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.543 HD11 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.708 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.926 HD23 ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.543 HG12 HD11 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.574 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.432 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.574 HD13 ' CE2' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 114' ' ' LEU . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.53 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 10' ' ' THR . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.627 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.442 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.405 ' HE3' ' CG ' ' A' ' 4' ' ' ASN . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 95' ' ' LEU . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.708 ' HB2' HG23 ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.926 ' CD2' HD23 ' A' ' 95' ' ' LEU . 97.7 m-70 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.512 HG23 HG21 ' A' ' 122' ' ' THR . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.43 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.535 HG22 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.619 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.575 ' N ' HD12 ' A' ' 144' ' ' LEU . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.53 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.84 HG22 HG11 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.407 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.627 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.663 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.687 HG13 ' O ' ' A' ' 120' ' ' TYR . 50.1 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.507 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.44 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.489 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.912 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.696 ' CE2' HD12 ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.517 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.551 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.696 HD12 ' CE2' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.443 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.9 ' O ' HG22 ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.9 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.614 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.838 HG22 ' HG3' ' A' ' 45' ' ' GLU . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.698 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.859 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.798 HG22 HD12 ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.502 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.512 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.614 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.459 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.249 0.547 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.454 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.997 ' O ' HG23 ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.698 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.416 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.583 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.452 ' HE1' HD11 ' A' ' 102' ' ' ILE . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.402 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.434 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.477 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.534 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 97' ' ' LYS . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.545 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.622 HD22 ' HD2' ' A' ' 126' ' ' HIS . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.503 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.539 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.402 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.496 ' OD1' ' ND2' ' A' ' 118' ' ' ASN . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.459 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.551 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.525 HD12 ' HD1' ' A' ' 19' ' ' PHE . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.422 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.422 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.406 ' HA ' HD23 ' A' ' 114' ' ' LEU . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.412 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.496 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 1.1 t-20 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.687 ' O ' HG13 ' A' ' 2' ' ' VAL . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.804 HG21 HG23 ' A' ' 128' ' ' VAL . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.545 ' HB2' HG23 ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.622 ' HD2' HD22 ' A' ' 95' ' ' LEU . 98.6 m-70 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.804 HG23 HG21 ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.44 ' HE3' HG22 ' A' ' 7' ' ' THR . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 143' ' ' LEU . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 150' ' ' TYR . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.473 ' CE1' HD21 ' A' ' 29' ' ' LEU . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.665 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.597 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.49 HG11 ' CE1' ' A' ' 121' ' ' HIS . 62.7 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.564 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.449 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.564 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 144' ' ' LEU . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.519 HG23 HG12 ' A' ' 113' ' ' ILE . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.563 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.478 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.474 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.885 ' HD2' HD12 ' A' ' 104' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.711 ' HE2' HD13 ' A' ' 102' ' ' ILE . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.58 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.487 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.818 ' O ' HG22 ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.487 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.818 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.42 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.547 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.756 ' O ' HG23 ' A' ' 52' ' ' THR . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.697 ' H ' HG21 ' A' ' 52' ' ' THR . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.756 HG23 ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.512 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.547 HG23 ' CG2' ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo . . . . . 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.75 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.649 HG22 ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.639 HG22 ' CD1' ' A' ' 81' ' ' TYR . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.649 ' OH ' HG22 ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.6 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.435 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.75 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.443 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.421 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.64 HD23 ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.6 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.711 HD13 ' HE2' ' A' ' 22' ' ' PHE . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.885 HD12 ' HD2' ' A' ' 19' ' ' PHE . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.479 ' CG2' HG13 ' A' ' 113' ' ' ILE . 1.3 p . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.459 ' HA ' HG23 ' A' ' 107' ' ' THR . 83.6 p . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.519 HG12 HG23 ' A' ' 10' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.514 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.502 ' OH ' HG13 ' A' ' 133' ' ' VAL . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' HG11 ' A' ' 2' ' ' VAL . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.618 HG21 HG23 ' A' ' 128' ' ' VAL . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . 0.64 ' CD2' HD23 ' A' ' 95' ' ' LEU . 97.7 m-70 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.618 HG23 HG21 ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.464 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.464 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.502 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.478 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.478 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.455 ' HA ' HD23 ' A' ' 143' ' ' LEU . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.431 ' N ' HD12 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.717 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 29' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.405 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.624 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.555 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.2 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.562 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . 0.789 HG22 ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 113' ' ' ILE . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.536 ' OG ' HD12 ' A' ' 13' ' ' ILE . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.846 HD13 HD12 ' A' ' 151' ' ' LEU . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.559 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.538 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.781 ' CD2' HD21 ' A' ' 114' ' ' LEU . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HA ' HD13 ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.809 ' HZ ' HD13 ' A' ' 102' ' ' ILE . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.552 ' O ' HG21 ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.409 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 56' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.552 HG21 ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 53' ' ' ILE . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.847 ' O ' HG23 ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.419 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.847 HG23 ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.505 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.454 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo . . . . . 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.268 0.556 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.586 HG13 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.493 ' HA ' HG12 ' A' ' 85' ' ' VAL . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.505 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 12.5 m120 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.463 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 98' ' ' ILE . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.809 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.586 ' CA ' HG13 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.522 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 97' ' ' LYS . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.485 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.626 HD12 ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.422 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.57 ' HE2' HG22 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 85' ' ' VAL . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.809 HD13 ' HZ ' ' A' ' 22' ' ' PHE . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.525 HD13 HD23 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 112' ' ' SER . 1.5 p . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.636 ' HA ' HG23 ' A' ' 107' ' ' THR . 80.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.574 HG13 HG22 ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.781 HD21 ' CD2' ' A' ' 18' ' ' LEU . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.613 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.6 HG21 HG23 ' A' ' 128' ' ' VAL . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.6 HG23 HG21 ' A' ' 122' ' ' THR . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 23.7 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.406 HG13 ' OH ' ' A' ' 120' ' ' TYR . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.789 ' HE3' HG22 ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 143' ' ' LEU . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.846 HG13 HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.615 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.846 HD12 HD13 ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.535 HG13 ' O ' ' A' ' 120' ' ' TYR . 45.5 t . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.271 0.558 . . . . 0.0 109.565 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.577 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.709 HG22 HG23 ' A' ' 113' ' ' ILE . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.422 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.738 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.86 ' HD1' HD12 ' A' ' 104' ' ' ILE . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.496 ' CA ' HG21 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ASN . . . . . 0.461 ' HB3' ' HE2' ' A' ' 32' ' ' LYS . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.935 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.461 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.935 HG22 ' O ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.566 HG21 HG23 ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.496 HG21 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.851 HD12 HG22 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.818 ' O ' HG23 ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.475 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' H ' HG21 ' A' ' 52' ' ' THR . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.851 HG22 HD12 ' A' ' 44' ' ' ILE . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.535 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.566 HG23 HG21 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.407 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo . . . . . 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.267 0.556 . . . . 0.0 109.698 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.535 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.587 HG23 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 1.015 ' O ' HG23 ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.443 ' HG2' HG12 ' A' ' 53' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 10.9 m120 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.523 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 1.015 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.439 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.587 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.411 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.465 HG12 ' HB3' ' A' ' 96' ' ' GLU . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.635 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.465 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.475 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.59 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.86 HD12 ' HD1' ' A' ' 19' ' ' PHE . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.477 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.709 HG23 HG22 ' A' ' 10' ' ' THR . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.738 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ASN . . . . . 0.471 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 26.0 m120 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.572 ' CE2' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.475 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.594 HG21 HG23 ' A' ' 128' ' ' VAL . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' LYS . . . . . 0.635 ' HB2' HG23 ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.594 HG23 HG21 ' A' ' 122' ' ' THR . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.572 HG13 ' CE2' ' A' ' 120' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.492 ' O ' HG23 ' A' ' 147' ' ' VAL . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.528 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.922 HG13 HD21 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLU . . . . . 0.449 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.601 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 120' ' ' TYR . 56.3 t -135.01 144.18 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -1.137 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.498 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 87.9 m-85 -92.93 135.65 33.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.322 -0.861 . . . . 0.0 109.279 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -121.17 121.11 37.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.721 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -122.05 140.31 52.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.351 -0.843 . . . . 0.0 109.227 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.0 mt-10 -127.19 139.61 52.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 109.768 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.1 p -129.16 151.59 49.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.303 -0.873 . . . . 0.0 109.275 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -126.51 138.42 53.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.666 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.472 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 21.2 p -139.67 154.69 47.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.436 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.4 m -124.75 145.69 49.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -0.948 . . . . 0.0 109.564 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.7 t -144.65 134.96 24.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 m -63.59 -33.82 63.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.605 HG23 ' HD2' ' A' ' 14' ' ' PRO . 25.4 mm -53.56 142.8 40.19 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -70.25 143.11 47.54 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.542 2.161 . . . . 0.0 111.751 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.778 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -64.5 -36.33 83.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.342 -0.849 . . . . 0.0 109.725 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.93 76.74 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.217 -0.927 . . . . 0.0 109.657 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.457 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.4 mtt180 -74.44 -43.0 58.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.223 -0.923 . . . . 0.0 109.619 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.475 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.1 tp -67.44 -33.81 75.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.878 ' HD1' HD12 ' A' ' 104' ' ' ILE . 72.4 t80 -65.06 -48.26 74.43 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.24 -0.912 . . . . 0.0 109.545 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 35.0 mttp -61.03 -48.33 82.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.132 -0.98 . . . . 0.0 109.517 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.76 -40.86 69.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.494 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 71.6 t80 -66.66 -29.3 69.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.605 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 44.2 mm -100.48 -62.57 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.211 -0.93 . . . . 0.0 109.691 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.437 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 47.0 mt -64.11 -36.84 85.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -0.939 . . . . 0.0 109.715 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 83.0 m-20 -110.21 20.28 18.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.616 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.25 -30.54 69.39 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' CA ' HG11 ' A' ' 41' ' ' VAL . 96.3 m-20 -72.17 -42.54 65.79 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.415 ' C ' ' HD2' ' A' ' 31' ' ' PRO . 10.4 m-20 -86.62 -46.53 10.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.152 -0.967 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.942 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.8 tp -57.16 -35.68 69.84 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.279 -0.888 . . . . 0.0 109.677 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.6 m-30 -51.86 -63.78 1.89 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.2 -0.938 . . . . 0.0 109.585 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.0 Cg_endo -71.05 -35.72 8.5 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.687 2.258 . . . . 0.0 111.909 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.5 mttt -62.95 -43.91 97.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.679 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.942 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.1 m -81.57 -30.32 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.227 -0.921 . . . . 0.0 109.668 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 73.1 24.83 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.226 -0.921 . . . . 0.0 109.607 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.03 -16.98 36.58 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.591 2.194 . . . . 0.0 111.715 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -75.02 -18.47 60.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.76 -47.91 7.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.392 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 57' ' ' SER . 77.1 mt -128.39 120.0 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.259 -0.9 . . . . 0.0 109.444 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 t -60.58 -39.21 87.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.514 ' N ' ' OG ' ' A' ' 57' ' ' SER . 58.2 m -168.79 154.31 6.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.515 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 27' ' ' ASP . 9.1 p -123.72 134.51 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.515 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.509 ' O ' ' N ' ' A' ' 55' ' ' LYS . 73.9 tt0 -125.76 148.13 49.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.226 -0.921 . . . . 0.0 109.438 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG3' ' A' ' 54' ' ' LYS . 91.8 m-20 -98.77 105.88 18.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.201 -0.937 . . . . 0.0 109.417 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.832 HG22 ' HG3' ' A' ' 45' ' ' GLU . 79.8 mt -61.19 -56.31 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.832 ' HG3' HG22 ' A' ' 44' ' ' ILE . 93.5 mt-10 -146.48 164.26 33.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.49 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.509 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.58 163.37 39.26 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -124.42 32.42 5.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.123 . . . . 0.0 109.408 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.12 -8.53 49.45 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -85.32 -173.16 49.59 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.54 139.88 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.722 2.281 . . . . 0.0 111.815 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.44 13.75 69.93 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 45' ' ' GLU . 71.3 m -88.75 137.37 32.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.469 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.748 HG22 HD12 ' A' ' 44' ' ' ILE . 65.6 mt -109.41 134.7 50.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.503 ' HD2' ' CG2' ' A' ' 41' ' ' VAL . 36.5 ttpt -128.71 131.78 47.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.516 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' HE3' ' CD2' ' A' ' 66' ' ' TYR . 15.7 tttp -90.31 135.1 33.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.219 -0.926 . . . . 0.0 109.454 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.52 HG23 HG21 ' A' ' 38' ' ' ILE . 78.2 mt -114.99 126.89 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.204 -0.935 . . . . 0.0 109.448 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.522 ' O ' HG23 ' A' ' 38' ' ' ILE . 91.1 p -98.76 154.36 18.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.354 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.4 m-85 -128.34 147.35 63.36 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.213 -0.929 . . . . 0.0 109.483 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 159.11 54.46 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.731 2.288 . . . . 0.0 111.852 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -61.95 145.21 53.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.71 13.65 27.26 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.582 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -117.34 173.59 3.07 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.299 -1.118 . . . . 0.0 109.292 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.582 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 47.6 Cg_endo -68.65 -47.13 1.48 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.54 2.16 . . . . 0.0 111.612 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.514 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 48.2 p90 -123.31 152.3 41.56 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.256 -0.903 . . . . 0.0 109.195 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 tttt -76.36 -44.08 38.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.202 -0.936 . . . . 0.0 109.686 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' ' HE3' ' A' ' 55' ' ' LYS . 38.3 p90 -145.65 163.28 35.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.517 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.865 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.8 p -138.81 147.47 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.496 ' CE ' ' OE1' ' A' ' 87' ' ' GLU . 86.3 mttt -85.95 136.96 33.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -0.92 . . . . 0.0 109.477 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.685 ' HA ' HG12 ' A' ' 85' ' ' VAL . 19.8 t70 -127.74 143.75 51.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -129.28 145.86 51.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.233 -0.917 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.35 132.39 46.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 93.5 m-20 -83.1 -48.6 10.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.575 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.448 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 87.5 tt0 178.93 140.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.937 . . . . 0.0 109.506 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.401 ' O ' HG13 ' A' ' 74' ' ' VAL . 4.3 p -122.82 128.36 75.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.919 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -104.3 108.6 20.08 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -64.68 -41.67 95.89 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.229 -0.92 . . . . 0.0 109.487 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.2 m -64.36 -40.76 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.309 -0.87 . . . . 0.0 109.416 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.8 m-20 -92.59 6.49 47.08 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.581 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 91.6 m-85 44.72 27.08 0.23 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.482 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 24.9 tttt -96.46 132.69 41.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.571 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.435 ' O ' ' N ' ' A' ' 102' ' ' ILE . 74.0 t80 -133.91 119.42 19.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.277 -0.889 . . . . 0.0 109.473 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 44.5 p-10 -125.06 148.81 48.33 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.467 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.408 ' CD2' ' OD1' ' A' ' 69' ' ' ASP . 36.8 p90 -150.03 155.11 39.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.547 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.6 p -139.04 156.6 47.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.369 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' ASP . 13.7 m -119.36 134.28 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.232 -0.917 . . . . 0.0 109.533 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.462 HG13 ' N ' ' A' ' 87' ' ' GLU . 21.9 pt -99.64 -34.55 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.332 -0.855 . . . . 0.0 109.413 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.496 ' OE1' ' CE ' ' A' ' 68' ' ' LYS . 86.6 tt0 -117.06 125.5 51.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.493 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.865 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -143.75 165.88 27.11 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 64' ' ' PHE . . . -56.11 -71.27 0.76 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.86 0.99 5.62 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.705 2.27 . . . . 0.0 111.927 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.708 HD11 HG12 ' A' ' 98' ' ' ILE . 54.7 mt -112.32 137.8 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.615 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.75 -124.41 4.82 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.555 ' CG ' HG22 ' A' ' 94' ' ' THR . 19.9 p-10 -70.83 -38.92 73.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -1.166 . . . . 0.0 109.091 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.645 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -168.47 24.95 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.319 -0.863 . . . . 0.0 109.546 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.604 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.5 mp -69.66 -32.59 71.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.109 -0.995 . . . . 0.0 109.942 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 94.3 mt-10 -158.06 56.23 0.47 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.155 -0.966 . . . . 0.0 109.813 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.0 tttt -64.62 132.94 51.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.156 -0.965 . . . . 0.0 108.614 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.708 HG12 HD11 ' A' ' 91' ' ' ILE . 9.3 mm -108.97 129.99 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.216 -0.927 . . . . 0.0 110.45 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 34.5 t -131.06 111.12 11.72 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.9 m-20 -113.19 150.66 31.98 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.063 -1.023 . . . . 0.0 110.352 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 82' ' ' ASN . 95.9 mt-10 -122.09 135.48 54.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.43 -0.794 . . . . 0.0 108.903 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 72.2 mt -118.09 136.55 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.099 -1.0 . . . . 0.0 109.933 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 17.3 tttt -133.78 129.47 36.65 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.358 -0.839 . . . . 0.0 109.096 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.878 HD12 ' HD1' ' A' ' 19' ' ' PHE . 55.1 mt -110.12 135.07 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -0.957 . . . . 0.0 109.619 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 112' ' ' SER . 16.7 t -135.91 139.45 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.296 -0.877 . . . . 0.0 109.486 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.3 143.33 30.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.452 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -153.74 122.81 3.16 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.79 -1.48 8.56 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.74 2.293 . . . . 0.0 111.79 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -87.07 -31.68 20.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.276 -0.89 . . . . 0.0 109.647 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -156.54 33.41 0.58 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 81.64 -145.51 25.08 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 12.1 p -107.25 143.38 35.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -1.152 . . . . 0.0 109.448 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 18.0 mt -105.07 132.04 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.307 -0.87 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.472 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 79.0 mt -102.29 138.48 39.17 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.327 -0.858 . . . . 0.0 109.477 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 53.1 mttp -122.27 115.09 21.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.29 -0.881 . . . . 0.0 109.316 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -118.59 130.62 73.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.0 m -117.28 138.88 51.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.317 -0.865 . . . . 0.0 109.157 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -114.54 136.75 52.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.227 -0.921 . . . . 0.0 109.703 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.1 mttt -128.78 136.28 50.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.337 -0.852 . . . . 0.0 109.299 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.634 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.8 m-85 -115.81 131.82 56.82 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.608 ' CE1' HG11 ' A' ' 2' ' ' VAL . 93.0 m-70 -116.41 133.31 56.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.62 HG21 HG23 ' A' ' 128' ' ' VAL . 44.5 p -131.32 137.63 48.88 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.174 -0.954 . . . . 0.0 109.785 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.645 ' HB2' HG23 ' A' ' 94' ' ' THR . 32.3 tttt -49.46 -37.35 25.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.533 -0.73 . . . . 0.0 109.459 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.89 -51.98 0.74 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -60.26 -32.88 71.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.229 -1.16 . . . . 0.0 109.501 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -104.51 140.03 38.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.48 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -118.55 163.42 16.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.266 -0.896 . . . . 0.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 122' ' ' THR . 33.6 t -107.46 136.72 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -85.61 143.48 28.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.27 -0.894 . . . . 0.0 109.505 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.53 -39.85 85.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.256 -0.903 . . . . 0.0 109.492 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -55.08 -45.64 75.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.867 . . . . 0.0 109.431 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -54.31 -40.09 67.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.348 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 120' ' ' TYR . 47.9 t -65.88 -39.92 86.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.286 -0.884 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 60.1 mttm -55.1 -45.68 75.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.464 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.74 -43.86 94.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -64.48 -37.97 89.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.235 -0.916 . . . . 0.0 109.497 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.3 tttm -58.52 -45.97 87.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.384 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -60.45 -41.37 93.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.284 -0.885 . . . . 0.0 109.325 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 62.7 ttp -62.09 -41.87 98.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.202 -0.936 . . . . 0.0 109.298 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.28 -43.42 95.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.544 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 81.8 tt0 -67.66 -32.69 73.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.159 . . . . 0.0 109.326 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -66.02 -31.2 71.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.216 -0.928 . . . . 0.0 109.194 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.416 ' HA ' HD23 ' A' ' 143' ' ' LEU . 35.3 mt -69.07 -51.18 41.5 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.6 pp -70.7 -29.97 66.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.426 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 16.5 ttm180 -64.77 -45.31 86.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.264 -0.897 . . . . 0.0 109.332 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.432 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.73 -35.72 81.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.283 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.73 HG13 HD21 ' A' ' 29' ' ' LEU . 75.9 t -61.89 -48.64 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.184 -0.947 . . . . 0.0 109.362 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -55.24 -43.53 74.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.305 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 86.3 p -61.09 -34.03 74.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -0.878 . . . . 0.0 109.277 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -61.7 -43.08 99.55 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.324 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.653 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -63.4 -38.49 91.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.368 -0.833 . . . . 0.0 109.325 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.497 ' CD2' ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.25 -20.4 59.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.287 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.38 76.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.4 m80 -52.25 -33.01 39.64 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.318 -0.863 . . . . 0.0 109.457 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.5 m -61.59 -30.49 70.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.481 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -72.24 -15.83 61.93 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -72.33 143.43 48.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.234 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -48.94 -51.48 30.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.322 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.372 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 120' ' ' TYR . 39.4 t -128.97 153.21 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -1.122 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.59 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.1 m-85 -113.71 136.86 52.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.44 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -123.34 115.14 21.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 91.9 m-85 -118.91 137.09 53.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.224 -0.922 . . . . 0.0 109.406 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 95.5 mt-10 -121.01 138.96 53.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.468 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.9 p -132.78 156.13 47.65 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.514 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -123.43 141.02 52.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.265 -0.897 . . . . 0.0 109.426 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.522 HG21 HD22 ' A' ' 144' ' ' LEU . 47.3 m -134.84 140.99 46.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 12.5 m -123.62 147.13 47.64 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.938 . . . . 0.0 109.417 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 18.9 m -147.98 145.87 28.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.955 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.8 m -72.72 -26.3 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.31 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.716 HG23 ' HD2' ' A' ' 14' ' ' PRO . 19.0 mm -59.65 143.93 85.82 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.427 -0.796 . . . . 0.0 109.347 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.716 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.3 Cg_endo -69.74 134.55 28.3 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.531 2.154 . . . . 0.0 111.768 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -59.8 -33.61 71.94 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.796 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.43 76.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.132 -0.98 . . . . 0.0 109.704 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.434 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.8 mtt180 -75.77 -44.95 38.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.225 -0.922 . . . . 0.0 109.749 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.546 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.0 tp -67.37 -37.92 83.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.914 . . . . 0.0 109.586 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 75.5 t80 -60.98 -48.94 79.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.137 -0.977 . . . . 0.0 109.491 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.0 mttp -61.5 -51.06 70.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.599 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -71.59 -33.77 69.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.156 -0.965 . . . . 0.0 109.852 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 73.1 t80 -77.05 -24.38 52.0 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.923 . . . . 0.0 109.617 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.482 HG13 ' CZ ' ' A' ' 19' ' ' PHE . 35.5 mm -102.8 -60.5 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.623 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.495 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.5 mp -69.83 -34.05 73.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.59 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 47.2 m-20 -112.46 24.93 11.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.147 -0.97 . . . . 0.0 109.563 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -73.16 -40.07 51.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 87.1 m-20 -70.91 -37.23 72.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -1.135 . . . . 0.0 109.484 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.468 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 85.9 m-20 -79.07 -48.47 14.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.422 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.94 ' O ' HG22 ' A' ' 33' ' ' VAL . 66.8 mt -66.28 -30.37 70.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.488 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.43 -63.71 1.13 Allowed Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.354 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.547 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.5 Cg_endo -71.72 -40.08 3.04 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.65 2.233 . . . . 0.0 111.775 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.468 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 23.7 mmtp -63.27 -46.29 87.5 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.924 . . . . 0.0 109.633 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.94 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.8 m -77.95 -23.12 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.597 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.21 73.59 13.14 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.242 -0.911 . . . . 0.0 109.577 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.14 -19.48 34.28 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.69 2.26 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.49 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -74.9 -15.54 60.7 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.446 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.33 -47.94 6.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.507 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.655 HD13 HG23 ' A' ' 56' ' ' ILE . 92.5 mt -130.08 120.12 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.882 . . . . 0.0 109.432 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.9 m -57.44 -38.82 75.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.195 -0.94 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 78.7 p -165.26 154.91 12.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.296 -0.877 . . . . 0.0 109.404 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.49 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 95.8 t -118.45 134.84 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.535 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.1 tt0 -135.46 147.29 48.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.309 -0.87 . . . . 0.0 109.312 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 -98.89 109.59 22.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.199 -0.938 . . . . 0.0 109.478 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.694 HG22 ' HG3' ' A' ' 45' ' ' GLU . 75.1 mt -63.9 -51.47 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.261 -0.9 . . . . 0.0 109.337 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.898 ' O ' HG23 ' A' ' 52' ' ' THR . 94.1 mt-10 -141.92 166.95 23.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.239 -0.913 . . . . 0.0 109.415 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 81.46 -174.37 54.3 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 34.9 t-20 -153.07 39.18 0.52 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.152 -1.205 . . . . 0.0 109.449 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.422 ' O ' HG21 ' A' ' 74' ' ' VAL . . . 99.03 8.49 53.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -108.28 -173.0 21.67 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 49.0 Cg_endo -69.86 141.68 45.47 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.661 2.241 . . . . 0.0 111.764 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 80.57 12.68 82.66 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 45' ' ' GLU . 52.7 m -88.53 137.81 31.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -1.137 . . . . 0.0 109.409 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 61.8 mt -108.47 132.47 56.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.303 -0.873 . . . . 0.0 109.536 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.49 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 5.1 ttpm? -118.6 127.82 53.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.261 -0.899 . . . . 0.0 109.509 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.452 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 36.2 ttpt -90.53 128.43 36.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.287 -0.883 . . . . 0.0 109.301 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 HD13 ' A' ' 38' ' ' ILE . 85.9 mt -110.33 136.46 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.473 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.572 ' O ' HG23 ' A' ' 38' ' ' ILE . 24.5 t -110.07 154.64 22.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.248 -0.907 . . . . 0.0 109.46 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.475 ' HE1' HG23 ' A' ' 67' ' ' VAL . 58.1 m-85 -120.45 145.17 40.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.281 -0.887 . . . . 0.0 109.482 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.0 Cg_endo -70.31 153.55 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.652 2.235 . . . . 0.0 111.764 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -53.32 140.8 25.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.438 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.28 10.9 46.96 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.532 ' CD2' ' HG2' ' A' ' 59' ' ' PRO . 2.8 m-85 -108.61 169.08 6.92 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.238 -1.154 . . . . 0.0 109.487 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.475 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -69.94 -48.15 0.74 Allowed 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.696 2.264 . . . . 0.0 111.739 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.541 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 95.1 m-85 -116.71 152.87 33.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.201 -0.937 . . . . 0.0 109.503 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.437 ' O ' ' N ' ' A' ' 58' ' ' PHE . 61.2 mttt -82.74 -43.08 17.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.4 p90 -153.03 164.76 37.4 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.913 . . . . 0.0 109.485 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.533 HG13 ' HA2' ' A' ' 88' ' ' GLY . 14.8 t -143.77 157.49 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.348 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.3 mttt -98.18 141.82 30.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.188 -0.945 . . . . 0.0 109.606 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.429 ' OD1' HG22 ' A' ' 85' ' ' VAL . 21.6 t70 -137.8 147.77 44.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -134.03 146.16 50.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.907 . . . . 0.0 109.53 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.7 t -93.16 138.37 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.498 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 96.9 m-20 -84.15 -42.73 15.72 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.256 -0.902 . . . . 0.0 109.511 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.463 ' OE2' ' HB3' ' A' ' 50' ' ' PRO . 39.7 tp10 -178.45 155.44 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.478 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.435 ' N ' ' HG3' ' A' ' 73' ' ' GLU . 40.9 t -121.12 134.65 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.413 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.451 ' HB3' ' HB2' ' A' ' 78' ' ' ASN . 93.4 m-20 -122.29 77.46 1.4 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.498 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -56.42 -38.73 71.96 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.332 -0.855 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 37.4 m -65.54 -38.28 89.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.451 ' HB2' ' HB3' ' A' ' 75' ' ' ASP . 78.8 m-20 -96.68 12.22 32.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.258 -0.901 . . . . 0.0 109.465 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.503 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 93.8 m-85 44.05 30.4 0.42 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.159 -0.963 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 6.5 ttpm? -108.84 133.82 52.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.218 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ILE . 72.7 t80 -132.41 119.75 21.08 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.278 -0.889 . . . . 0.0 109.281 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.498 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 40.2 p-10 -121.28 143.03 49.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.923 . . . . 0.0 109.776 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 39.7 p90 -148.32 157.93 43.79 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.198 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.3 p -147.5 157.89 43.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.141 -0.974 . . . . 0.0 109.602 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.0 t -105.06 132.2 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.461 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.7 pt -106.85 -23.81 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.525 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.47 ' CB ' ' HD2' ' A' ' 68' ' ' LYS . 95.8 mt-10 -134.53 122.19 22.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.208 -0.932 . . . . 0.0 109.568 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.533 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -145.17 157.16 27.25 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.491 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -53.73 -59.62 9.49 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.41 -3.47 13.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.708 2.272 . . . . 0.0 111.898 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.596 HD13 ' O ' ' A' ' 96' ' ' GLU . 50.1 mt -118.87 138.54 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.255 -0.903 . . . . 0.0 109.621 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.23 -142.06 10.71 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -58.57 -44.93 89.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.232 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.671 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -158.72 20.93 0.21 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.266 -0.896 . . . . 0.0 109.51 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.808 HD23 ' CD2' ' A' ' 126' ' ' HIS . 7.1 mp -66.75 -32.78 74.3 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.128 -0.983 . . . . 0.0 109.97 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.596 ' O ' HD13 ' A' ' 91' ' ' ILE . 81.7 mt-10 -159.9 49.86 0.3 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 23.3 ttpp -64.76 132.68 50.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 108.662 179.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.506 HG12 ' CD1' ' A' ' 120' ' ' TYR . 64.1 mt -114.33 137.41 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.069 -1.02 . . . . 0.0 110.201 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 24.2 m -123.73 130.91 53.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 108.891 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 117' ' ' SER . 84.5 m-20 -123.84 137.43 54.66 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.111 -0.993 . . . . 0.0 110.081 -179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -121.24 123.84 43.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.316 -0.865 . . . . 0.0 108.962 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' TYR . 64.5 mt -110.99 137.85 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.122 -0.986 . . . . 0.0 109.957 -179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 70.1 tttt -131.46 130.08 42.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.464 -0.773 . . . . 0.0 109.042 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.878 ' CD1' HD23 ' A' ' 114' ' ' LEU . 19.1 mm -108.33 130.24 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 109.761 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.444 ' O ' ' HB3' ' A' ' 112' ' ' SER . 18.8 t -133.93 136.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.379 179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.87 139.67 31.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.465 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.7 OUTLIER -153.29 122.63 3.24 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.185 -0.947 . . . . 0.0 109.514 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.16 -0.85 7.86 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.613 2.209 . . . . 0.0 111.721 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.1 m-20 -79.89 -43.98 21.25 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.217 -0.927 . . . . 0.0 109.691 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -150.87 36.61 0.9 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 87.39 -150.0 22.33 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 15' ' ' ALA . 26.5 m -104.98 139.85 39.06 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.129 . . . . 0.0 109.414 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 24.2 mt -104.43 130.32 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.878 HD23 ' CD1' ' A' ' 104' ' ' ILE . 5.0 mp -107.87 127.81 54.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.335 -0.853 . . . . 0.0 109.38 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -103.78 117.96 35.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.262 -0.899 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 59.9 mt -116.87 130.1 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.504 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 31.3 t -120.04 135.75 54.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.377 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -111.92 140.41 46.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.915 . . . . 0.0 109.573 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 121' ' ' HIS . 17.0 tttt -135.27 130.25 34.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.353 -0.842 . . . . 0.0 109.219 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.692 ' O ' HG13 ' A' ' 2' ' ' VAL . 74.7 m-85 -111.63 135.98 51.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.777 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 58.3 m-70 -118.22 135.64 54.14 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.35 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.574 HG21 HG23 ' A' ' 128' ' ' VAL . 69.0 p -132.06 137.49 47.8 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.131 -0.98 . . . . 0.0 109.706 179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.671 ' HB2' HG23 ' A' ' 94' ' ' THR . 20.0 tttt -53.88 -34.21 58.76 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.45 -0.781 . . . . 0.0 109.48 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.98 -48.71 0.89 Allowed Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.8 -29.47 70.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.244 -1.15 . . . . 0.0 109.574 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.808 ' CD2' HD23 ' A' ' 95' ' ' LEU . 99.3 m-70 -111.66 137.37 49.63 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.251 -0.906 . . . . 0.0 109.406 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -116.76 161.07 19.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.457 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.574 HG23 HG21 ' A' ' 122' ' ' THR . 26.5 t -106.01 133.95 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.318 -0.864 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 91.1 mttt -82.73 145.36 29.63 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.293 -0.879 . . . . 0.0 109.533 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.87 -39.93 75.23 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.307 -0.87 . . . . 0.0 109.453 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -58.84 -41.87 87.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 109.407 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.415 ' OE1' HG13 ' A' ' 128' ' ' VAL . 63.0 tt0 -52.53 -37.12 56.92 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.236 -0.915 . . . . 0.0 109.166 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.44 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.2 t -73.75 -34.03 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.372 -0.83 . . . . 0.0 109.298 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 17.7 mttp -60.62 -40.62 92.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 109.421 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.38 -47.39 73.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.472 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.7 t -61.71 -39.67 92.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -0.868 . . . . 0.0 109.447 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.7 tttm -57.89 -46.77 84.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.9 . . . . 0.0 109.348 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.423 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 96.3 mt-10 -59.78 -42.25 92.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.262 -0.899 . . . . 0.0 109.353 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.0 mtp -59.28 -39.65 83.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -59.94 -45.76 95.3 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.546 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -64.14 -32.53 74.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -1.116 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 79.9 m -68.68 -31.69 70.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.25 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.6 mt -71.22 -47.23 58.55 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.335 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.632 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.78 -33.48 66.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.388 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.565 ' N ' HD12 ' A' ' 144' ' ' LEU . 67.0 ttt-85 -61.43 -44.41 97.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.68 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -62.87 -37.71 87.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.843 . . . . 0.0 109.455 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.402 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 74.2 t -61.58 -48.58 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.38 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -52.62 -47.49 66.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.191 -0.943 . . . . 0.0 109.3 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.5 p -56.92 -33.9 67.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.296 -0.877 . . . . 0.0 109.347 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.546 ' CE2' ' CE1' ' A' ' 154' ' ' HIS . 73.9 t80 -63.24 -40.65 98.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.637 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.8 -38.64 91.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.252 -0.905 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.588 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -74.92 -21.07 59.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.861 . . . . 0.0 109.341 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -65.54 -33.67 76.47 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.546 ' CE1' ' CE2' ' A' ' 150' ' ' TYR . 73.1 m-70 -49.58 -33.64 15.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.0 m -56.98 -31.96 65.59 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.255 -0.903 . . . . 0.0 109.411 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -71.19 -19.58 62.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.295 -0.878 . . . . 0.0 109.419 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -64.39 -24.38 67.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.873 . . . . 0.0 109.372 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -114.8 129.91 56.77 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.453 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 27.2 t30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.549 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.586 HG13 ' O ' ' A' ' 120' ' ' TYR . 94.6 t -131.69 146.15 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -1.155 . . . . 0.0 109.489 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.566 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 88.2 m-85 -101.8 132.89 47.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -0.859 . . . . 0.0 109.367 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -118.23 121.14 39.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.547 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 94.5 m-85 -123.7 138.96 54.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.363 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 88.2 mt-10 -121.02 143.04 49.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.528 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 5.4 p -127.71 152.87 47.18 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.212 -0.93 . . . . 0.0 109.466 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -129.53 130.9 46.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.29 -0.881 . . . . 0.0 109.544 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.7 m -137.12 143.23 42.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.892 . . . . 0.0 109.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 22.6 m -117.07 140.74 49.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.453 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.0 p -142.47 148.65 38.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.496 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.97 -31.49 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.244 -0.91 . . . . 0.0 109.397 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.562 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 32.3 mm -53.81 142.29 44.43 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.55 141.72 42.7 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.614 2.209 . . . . 0.0 111.728 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.846 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -61.67 -35.15 77.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 0.0 109.79 -179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.79 -48.91 79.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.173 -0.954 . . . . 0.0 109.82 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.49 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 59.9 ttm-85 -69.77 -41.4 75.2 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.875 . . . . 0.0 109.691 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.5 tp -71.53 -34.57 70.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.226 -0.921 . . . . 0.0 109.659 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.761 ' CE1' HD12 ' A' ' 23' ' ' ILE . 42.4 t80 -63.01 -40.81 98.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 0.0 109.644 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 24' ' ' LEU . 46.7 mttt -73.58 -51.03 18.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.648 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.443 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -67.95 -46.69 70.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.759 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.9 t80 -60.34 -31.47 70.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.291 -0.881 . . . . 0.0 109.833 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.761 HD12 ' CE1' ' A' ' 19' ' ' PHE . 64.8 mt -100.6 -63.5 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.945 . . . . 0.0 109.757 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 20' ' ' LYS . 41.9 mt -62.12 -38.44 88.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.178 -0.951 . . . . 0.0 109.663 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' HB2' ' CD1' ' A' ' 29' ' ' LEU . 62.5 m-20 -108.49 19.7 19.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.528 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -67.85 -42.09 86.99 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.621 ' O ' HG11 ' A' ' 41' ' ' VAL . 89.7 m-20 -70.24 -40.41 74.47 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -1.12 . . . . 0.0 109.567 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.432 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 82.4 m-20 -75.21 -40.85 58.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.181 -0.95 . . . . 0.0 109.526 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.909 ' O ' HG22 ' A' ' 33' ' ' VAL . 22.8 mt -73.8 -32.64 63.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.332 -0.855 . . . . 0.0 109.572 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 0.9 OUTLIER -43.39 -63.81 0.92 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.641 -179.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.534 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.6 Cg_endo -71.82 -43.67 1.2 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.726 2.284 . . . . 0.0 111.959 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 23.5 mttt -60.23 -43.2 96.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.772 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.909 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.4 m -77.94 -29.73 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.607 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.5 75.56 11.23 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.133 -0.979 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.96 -21.37 37.39 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.716 2.277 . . . . 0.0 111.78 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -73.69 -20.3 60.58 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.301 -0.874 . . . . 0.0 109.433 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.67 -47.42 8.68 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.558 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 57' ' ' SER . 92.9 mt -129.28 120.7 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.255 -0.903 . . . . 0.0 109.536 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.459 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 55.7 m -60.76 -40.67 93.36 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.89 . . . . 0.0 109.389 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.5 t -166.58 141.7 4.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.465 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 27' ' ' ASP . 5.9 p -113.04 138.23 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.466 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 55' ' ' LYS . 94.9 mt-10 -129.58 157.44 42.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.931 . . . . 0.0 109.443 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.1 m-20 -101.07 105.56 16.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.326 -0.859 . . . . 0.0 109.481 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.584 HD12 HG22 ' A' ' 53' ' ' ILE . 74.7 mt -62.43 -54.26 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.264 -0.898 . . . . 0.0 109.415 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.869 ' O ' HG23 ' A' ' 52' ' ' THR . 80.1 tt0 -140.65 157.21 45.79 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.305 -0.872 . . . . 0.0 109.508 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.21 178.95 52.79 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -131.68 29.62 4.47 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -1.109 . . . . 0.0 109.491 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.6 3.71 46.56 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.86 -164.33 32.66 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.47 135.65 31.71 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.787 2.325 . . . . 0.0 111.92 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.24 29.72 55.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 45' ' ' GLU . 78.2 m -104.31 135.65 45.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -1.092 . . . . 0.0 109.599 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.584 HG22 HD12 ' A' ' 44' ' ' ILE . 64.0 mt -109.86 131.44 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.283 -0.886 . . . . 0.0 109.433 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 48.2 mttp -118.23 140.06 50.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.208 -0.933 . . . . 0.0 109.468 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.491 ' N ' ' O ' ' A' ' 42' ' ' GLU . 23.9 tttp -95.67 128.37 42.48 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.407 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.451 HG23 HD13 ' A' ' 38' ' ' ILE . 94.9 mt -108.11 138.68 33.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -116.91 151.1 37.34 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.458 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.668 ' HE1' HG23 ' A' ' 67' ' ' VAL . 66.3 m-85 -117.43 148.77 43.45 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.215 -0.928 . . . . 0.0 109.569 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.459 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 48.8 Cg_endo -69.73 151.68 69.29 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.707 2.271 . . . . 0.0 111.735 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -52.22 143.46 14.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.464 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.17 10.08 43.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.585 ' CG ' ' HD2' ' A' ' 63' ' ' PRO . 0.2 OUTLIER -113.09 166.78 10.38 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.231 -1.158 . . . . 0.0 109.468 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.585 ' HD2' ' CG ' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.99 -51.67 0.43 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.734 2.289 . . . . 0.0 111.815 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.586 ' CE2' ' HA3' ' A' ' 89' ' ' GLY . 95.2 m-85 -109.72 146.38 35.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -0.878 . . . . 0.0 109.408 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -82.59 -36.89 25.76 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 0.0 109.756 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.446 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 35.6 p90 -152.92 161.55 42.41 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.687 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.668 HG23 ' HE1' ' A' ' 58' ' ' PHE . 22.0 t -134.53 161.97 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.228 179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.617 ' O ' HG13 ' A' ' 85' ' ' VAL . 96.5 mttt -112.85 132.29 55.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.138 -0.976 . . . . 0.0 109.563 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 85' ' ' VAL . 89.2 m-20 -137.31 159.29 42.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.87 . . . . 0.0 109.495 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 72.0 ttt180 -140.69 154.5 46.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.484 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.51 HG21 ' OH ' ' A' ' 81' ' ' TYR . 44.8 t -98.66 138.13 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.307 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -81.4 -48.93 11.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.674 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 48.4 tp10 -171.93 150.26 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.174 -0.954 . . . . 0.0 109.63 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.482 HG22 ' CE2' ' A' ' 81' ' ' TYR . 43.8 t -119.52 131.41 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.445 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.45 93.74 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.479 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -62.69 -42.55 99.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.205 -0.934 . . . . 0.0 109.473 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.5 m -65.36 -39.01 91.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.349 -0.844 . . . . 0.0 109.457 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 79' ' ' PHE . 74.2 m-20 -91.73 5.59 49.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.917 . . . . 0.0 109.572 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.567 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 67.6 m-85 44.4 32.07 0.67 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.141 -0.974 . . . . 0.0 109.393 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 18.1 ttpt -109.02 125.51 52.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -0.905 . . . . 0.0 109.645 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.51 ' OH ' HG21 ' A' ' 71' ' ' VAL . 60.8 t80 -117.19 120.71 39.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.253 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -121.39 137.83 54.53 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.187 -0.946 . . . . 0.0 109.719 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.0 p90 -143.82 159.25 42.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.28 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 93.2 p -141.71 160.26 40.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.152 -0.968 . . . . 0.0 109.659 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 69' ' ' ASP . 56.9 t -107.17 135.94 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.347 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 1.5 mt -104.21 -68.62 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 0.0 109.399 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -100.03 118.51 36.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.281 -0.887 . . . . 0.0 109.544 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.42 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -132.53 173.5 20.81 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.586 ' HA3' ' CE2' ' A' ' 64' ' ' PHE . . . -66.03 -63.23 4.13 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.576 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.7 Cg_endo -71.38 -1.92 10.43 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.792 2.328 . . . . 0.0 111.952 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.513 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.3 mt -114.14 143.58 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.197 -0.94 . . . . 0.0 109.448 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 94' ' ' THR . . . -143.19 -121.82 1.64 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -65.48 68.36 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.317 -1.108 . . . . 0.0 109.659 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.509 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.32 60.3 3.91 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 109.58 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.67 -9.49 13.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.438 -0.788 . . . . 0.0 109.406 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 96' ' ' GLU . 78.6 tt0 -177.85 47.71 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.748 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.513 ' HA ' HD13 ' A' ' 91' ' ' ILE . 18.3 ttmt -64.75 134.89 55.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.139 -0.976 . . . . 0.0 108.898 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 56.9 mt -115.36 126.77 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.131 -0.981 . . . . 0.0 110.064 -179.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 31.1 t -119.84 122.92 42.39 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 66.2 m-20 -117.13 144.03 45.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.129 -179.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -120.7 140.44 51.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.426 -0.796 . . . . 0.0 108.87 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.489 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 76.1 mt -121.03 135.91 59.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.083 -1.011 . . . . 0.0 109.994 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -133.26 126.06 30.68 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.445 -0.784 . . . . 0.0 108.956 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.846 HG22 ' CB ' ' A' ' 15' ' ' ALA . 60.6 mt -114.54 135.25 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.968 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.504 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 5.3 m -130.65 142.46 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.383 -0.823 . . . . 0.0 109.293 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.68 147.02 27.35 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.185 -0.947 . . . . 0.0 109.688 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.466 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 8.7 p -125.09 160.54 54.12 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.858 . . . . 0.0 109.294 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.466 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.6 Cg_endo -70.52 -51.34 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.714 2.276 . . . . 0.0 111.9 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -132.18 26.08 4.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.579 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.429 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -128.7 25.84 4.66 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 56.54 -146.13 34.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 89.8 p -118.11 153.47 33.72 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.556 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.504 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 72.9 mt -115.77 129.35 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.314 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.83 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -102.44 142.63 33.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.219 -0.925 . . . . 0.0 109.688 -179.875 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.522 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 97.6 mttt -134.38 118.99 18.05 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.402 -0.812 . . . . 0.0 109.209 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.83 ' CD1' HD21 ' A' ' 114' ' ' LEU . 56.1 mt -122.76 133.35 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.191 -0.943 . . . . 0.0 109.866 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 37.9 t -115.64 132.86 56.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.153 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 21.0 m120 -107.56 135.55 48.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.13 -0.981 . . . . 0.0 109.838 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 61.7 mttt -127.44 137.3 52.67 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.363 -0.836 . . . . 0.0 109.263 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.586 ' O ' HG13 ' A' ' 2' ' ' VAL . 96.5 m-85 -119.78 134.71 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.131 -0.981 . . . . 0.0 109.737 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 93.7 m-70 -119.88 129.06 54.2 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.259 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.783 HG21 HG23 ' A' ' 128' ' ' VAL . 18.2 p -126.49 145.12 50.63 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.194 -0.941 . . . . 0.0 109.533 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 94' ' ' THR . 20.1 tptt -55.82 -37.28 68.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.27 -0.893 . . . . 0.0 109.414 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.34 -51.74 0.78 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -59.67 -33.46 71.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.282 -1.128 . . . . 0.0 109.527 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -107.28 141.02 39.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.441 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -112.53 164.33 13.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.783 HG23 HG21 ' A' ' 122' ' ' THR . 39.9 t -99.55 135.47 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.201 -0.937 . . . . 0.0 109.457 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.426 ' HB3' ' HG3' ' A' ' 132' ' ' GLN . 16.3 tttt -82.22 133.75 35.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.43 -37.63 67.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.276 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.17 -44.4 97.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.217 -0.927 . . . . 0.0 109.38 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.426 ' HG3' ' HB3' ' A' ' 129' ' ' LYS . 95.8 mt-30 -56.37 -31.14 63.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.353 -0.842 . . . . 0.0 109.286 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' OH ' ' A' ' 120' ' ' TYR . 90.1 t -70.57 -42.1 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 21.6 tttt -58.51 -38.22 77.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.433 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.429 ' O ' ' HG3' ' A' ' 139' ' ' MET . . . -62.93 -50.03 72.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.457 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 m -65.76 -37.15 85.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.528 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 85.9 tttt -63.9 -41.27 97.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.25 -0.906 . . . . 0.0 109.463 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -65.9 -37.62 86.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.229 -0.919 . . . . 0.0 109.456 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.456 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.9 mtt -61.54 -42.08 98.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.263 -0.898 . . . . 0.0 109.315 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.76 -44.22 98.22 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.504 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 46.1 tp10 -65.49 -34.68 78.83 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.232 -1.158 . . . . 0.0 109.356 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.6 m -68.03 -31.53 71.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 139' ' ' MET . 26.8 mt -71.71 -46.58 58.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.495 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.64 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.6 pp -73.57 -33.47 64.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.463 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.1 tpt85 -59.81 -45.19 93.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.916 . . . . 0.0 109.339 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.503 ' HB1' ' O ' ' A' ' 33' ' ' VAL . . . -63.25 -38.51 91.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.304 -0.872 . . . . 0.0 109.452 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.419 HG22 HG11 ' A' ' 33' ' ' VAL . 76.0 t -61.35 -47.86 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.163 -0.961 . . . . 0.0 109.349 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.418 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 85.1 tt0 -53.86 -47.37 71.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.171 -0.956 . . . . 0.0 109.313 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.3 m -57.22 -33.27 67.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.295 -0.878 . . . . 0.0 109.365 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 78.4 t80 -64.36 -42.36 96.25 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.314 -0.866 . . . . 0.0 109.425 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.625 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -62.06 -34.65 76.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.271 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.3 mp -74.66 -26.23 59.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.332 -0.855 . . . . 0.0 109.379 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -57.75 -37.83 74.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -47.07 -26.94 1.18 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.557 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 93.9 p -65.6 -29.41 70.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.523 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 9.0 p30 -90.9 2.58 56.07 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.663 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 156' ' ' ASP . . . 43.99 -150.6 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.245 -0.909 . . . . 0.0 109.512 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.11 -37.68 86.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.464 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.1 t30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.504 179.978 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 120' ' ' TYR . 95.1 t -132.49 149.24 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -1.169 . . . . 0.0 109.47 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.484 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -100.82 135.76 41.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.364 -0.835 . . . . 0.0 109.481 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -123.59 118.35 27.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.194 -0.941 . . . . 0.0 109.607 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.484 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 98.9 m-85 -119.3 137.82 53.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.286 -0.884 . . . . 0.0 109.39 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.7 mt-10 -122.62 143.89 49.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.161 -0.962 . . . . 0.0 109.716 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.439 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.6 p -129.87 156.64 44.04 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.852 . . . . 0.0 109.297 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -126.8 137.12 53.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.986 . . . . 0.0 109.648 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 50.3 m -139.07 140.2 37.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.372 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 18.9 m -122.52 141.05 52.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.9 p -144.26 153.59 42.2 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.369 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 21.7 m -74.24 -27.03 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -0.93 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.596 HG21 ' HG ' ' A' ' 151' ' ' LEU . 22.0 mm -58.08 141.81 81.06 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.356 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.8 Cg_endo -71.11 142.85 42.96 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.528 2.152 . . . . 0.0 111.693 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.898 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -63.88 -31.94 73.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.324 -0.86 . . . . 0.0 109.721 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.04 -49.0 79.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.45 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 92.6 mtt-85 -73.18 -38.65 66.08 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.595 HD23 HD13 ' A' ' 104' ' ' ILE . 1.9 tp -67.85 -37.74 82.27 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.206 -0.934 . . . . 0.0 109.645 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.541 ' CE2' HG13 ' A' ' 23' ' ' ILE . 61.6 t80 -65.7 -40.74 92.6 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.679 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 87.2 mttt -68.03 -45.03 75.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.19 -0.944 . . . . 0.0 109.605 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.709 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -78.63 -37.51 41.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -0.903 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.64 -25.9 61.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.668 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.541 HG13 ' CE2' ' A' ' 19' ' ' PHE . 30.7 mm -101.45 -63.91 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.678 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.455 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.2 mt -64.93 -40.45 95.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.187 -0.946 . . . . 0.0 109.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 57.4 m-20 -104.16 17.56 23.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.925 . . . . 0.0 109.393 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.474 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.71 -34.22 86.74 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 93.2 m-20 -73.61 -35.46 65.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.26 -1.141 . . . . 0.0 109.387 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -82.61 -40.2 21.14 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.901 ' O ' HG22 ' A' ' 33' ' ' VAL . 67.9 mt -69.91 -37.79 76.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.549 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.5 m-85 -44.65 -63.78 1.04 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.496 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.549 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.3 Cg_endo -72.15 -41.57 1.86 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.662 2.241 . . . . 0.0 111.794 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.3 tptm -61.82 -42.98 99.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.865 . . . . 0.0 109.739 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.901 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -78.06 -29.4 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.58 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.84 74.57 11.17 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.245 -0.909 . . . . 0.0 109.496 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.84 -18.98 36.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.65 2.233 . . . . 0.0 111.773 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -74.53 -16.75 60.82 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.883 . . . . 0.0 109.526 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.01 -48.56 7.12 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.247 -0.908 . . . . 0.0 109.389 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.719 HG23 ' O ' ' A' ' 57' ' ' SER . 85.1 mt -127.65 119.93 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 61.7 m -57.65 -40.38 79.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.9 m -166.09 153.17 9.77 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.404 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -120.87 129.42 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.158 -0.964 . . . . 0.0 109.561 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.419 ' O ' ' N ' ' A' ' 55' ' ' LYS . 55.4 tt0 -125.2 143.99 50.67 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.307 -0.871 . . . . 0.0 109.379 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.482 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 34.5 t-20 -94.51 110.63 22.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.53 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.576 HD12 HG22 ' A' ' 53' ' ' ILE . 81.6 mt -65.17 -58.0 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.192 -0.942 . . . . 0.0 109.489 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.709 ' O ' HG23 ' A' ' 52' ' ' THR . 83.5 tt0 -143.36 159.57 42.12 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.212 -0.93 . . . . 0.0 109.529 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 95.66 164.36 34.29 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -125.38 28.8 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.75 -5.69 40.38 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.04 -170.41 42.85 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.97 142.55 47.31 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.664 2.243 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.88 9.63 82.39 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLU . 54.5 m -83.55 135.27 34.7 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.297 -1.12 . . . . 0.0 109.497 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 44' ' ' ILE . 27.0 mt -109.32 129.26 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.492 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.482 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 57.4 mttt -123.5 132.18 53.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.527 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.419 ' N ' ' O ' ' A' ' 42' ' ' GLU . 84.0 tttt -92.34 126.67 37.52 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.912 . . . . 0.0 109.35 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.66 HG23 HD13 ' A' ' 38' ' ' ILE . 86.9 mt -107.71 135.91 44.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.719 ' O ' HG23 ' A' ' 38' ' ' ILE . 66.2 m -110.08 151.15 27.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -0.894 . . . . 0.0 109.419 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.511 ' N ' ' O ' ' A' ' 65' ' ' LYS . 11.6 m-85 -124.77 148.68 60.17 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.18 -0.95 . . . . 0.0 109.536 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -69.7 149.05 66.79 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.763 2.308 . . . . 0.0 111.618 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -56.18 139.55 47.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 109.47 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 62' ' ' PHE . . . 147.79 -16.41 1.4 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.503 ' HB3' ' HD2' ' A' ' 63' ' ' PRO . 0.0 OUTLIER -126.51 171.86 7.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.297 -1.12 . . . . 0.0 109.21 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 62' ' ' PHE . 47.8 Cg_endo -68.86 -26.86 31.62 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.707 2.271 . . . . 0.0 111.907 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.571 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 74.0 m-85 -104.5 152.3 22.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.198 -0.939 . . . . 0.0 109.319 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 58' ' ' PHE . 20.8 mttp -114.3 -39.01 3.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.188 -0.945 . . . . 0.0 109.596 -179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 34.8 p90 -138.49 165.29 27.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.57 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.4 p -144.67 148.43 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.316 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.954 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -90.69 139.04 31.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.179 -0.951 . . . . 0.0 109.568 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.5 ' HA ' HG22 ' A' ' 85' ' ' VAL . 60.4 t0 -142.79 144.15 32.47 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.2 -0.938 . . . . 0.0 109.387 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.438 ' HG2' HG12 ' A' ' 53' ' ' ILE . 75.5 mtp180 -130.12 155.23 46.54 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.181 -0.95 . . . . 0.0 109.524 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.487 HG22 ' OH ' ' A' ' 81' ' ' TYR . 39.6 t -99.16 132.62 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.415 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 93.9 m-20 -77.84 -48.54 16.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.284 -0.885 . . . . 0.0 109.498 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.1 tt0 176.87 144.48 0.09 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.5 p -123.18 132.26 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.47 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD2' ' ND2' ' A' ' 78' ' ' ASN . 46.6 t0 -103.56 109.79 21.6 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.234 -0.917 . . . . 0.0 109.528 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -66.34 -40.39 89.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.153 -0.967 . . . . 0.0 109.415 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 65.5 m -65.37 -46.52 79.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.457 ' ND2' ' OD2' ' A' ' 75' ' ' ASP . 89.8 m-20 -91.96 7.55 41.63 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.556 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.427 ' N ' ' O ' ' A' ' 75' ' ' ASP . 79.0 m-85 45.3 28.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.996 . . . . 0.0 109.377 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -92.16 129.33 38.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.487 ' OH ' HG22 ' A' ' 71' ' ' VAL . 74.6 t80 -126.25 119.68 28.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.225 -0.922 . . . . 0.0 109.382 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -119.44 139.74 51.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.8 p90 -146.67 158.39 43.9 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.32 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 80.1 p -152.0 163.71 38.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.262 -0.899 . . . . 0.0 109.562 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.954 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.0 t -113.23 127.41 70.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.398 -0.814 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.446 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.0 pt -95.75 -25.22 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.493 ' HB2' ' HD2' ' A' ' 68' ' ' LYS . 95.4 mt-10 -135.97 115.54 12.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -0.913 . . . . 0.0 109.388 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.39 161.03 22.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.571 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -51.83 -65.63 3.09 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.64 1.69 5.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.688 2.258 . . . . 0.0 111.971 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.8 HD11 HG12 ' A' ' 98' ' ' ILE . 56.8 mt -112.88 136.99 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.17 -0.956 . . . . 0.0 109.772 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.98 -126.06 5.39 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.975 -1.65 . . . . 0.0 108.975 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -67.51 -43.55 80.59 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -1.182 . . . . 0.0 108.958 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.59 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.2 OUTLIER -166.56 24.78 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.421 -0.799 . . . . 0.0 109.35 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -65.57 -37.53 86.94 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.129 -0.982 . . . . 0.0 110.112 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.523 ' HG2' HD11 ' A' ' 98' ' ' ILE . 74.0 tt0 -157.37 53.64 0.49 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.067 -1.021 . . . . 0.0 109.751 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.613 ' HA ' HD13 ' A' ' 91' ' ' ILE . 10.7 ttpt -64.6 132.24 49.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.916 . . . . 0.0 108.838 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.8 HG12 HD11 ' A' ' 91' ' ' ILE . 7.2 mm -104.41 136.81 36.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.173 -0.955 . . . . 0.0 110.205 -179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 46.2 t -136.5 116.68 13.46 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 85.9 m-20 -115.88 151.86 34.51 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.098 -1.001 . . . . 0.0 110.311 -179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.1 mt-10 -127.45 128.83 46.42 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.477 ' N ' ' O ' ' A' ' 81' ' ' TYR . 69.8 mt -113.85 134.85 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.108 -0.995 . . . . 0.0 109.984 -179.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 71.9 tttt -133.44 134.25 43.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.406 -0.809 . . . . 0.0 109.103 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.898 HG22 ' HB1' ' A' ' 15' ' ' ALA . 64.9 mt -114.1 129.1 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.731 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.2 t -120.48 143.45 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -0.861 . . . . 0.0 109.303 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -109.48 145.08 36.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.591 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.463 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 2.8 p -123.63 161.16 47.63 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.283 -0.885 . . . . 0.0 109.457 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.2 Cg_endo -70.05 -49.37 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.745 2.297 . . . . 0.0 111.844 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.452 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 97.6 m-20 -138.02 26.45 2.71 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.196 -0.94 . . . . 0.0 109.556 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -124.32 19.14 7.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 107' ' ' THR . . . 68.22 -149.76 50.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -119.04 150.21 40.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.136 -1.214 . . . . 0.0 109.541 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 66.5 mt -115.14 127.67 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.432 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.544 HD21 ' CD2' ' A' ' 18' ' ' LEU . 92.2 mt -102.59 137.13 41.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 41.2 mttm -123.53 118.68 27.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.238 -0.914 . . . . 0.0 109.432 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.409 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 70.0 mt -122.02 133.78 67.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.494 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 22.7 t -121.71 132.2 54.5 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.365 -0.834 . . . . 0.0 109.447 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.459 ' N ' ' O ' ' A' ' 5' ' ' TYR . 15.1 m120 -107.88 133.32 52.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.186 -0.946 . . . . 0.0 109.611 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 35.9 mttt -125.78 136.1 52.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.329 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.528 ' O ' HG13 ' A' ' 2' ' ' VAL . 88.7 m-85 -115.11 133.59 55.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.563 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.515 ' CE1' HG11 ' A' ' 2' ' ' VAL . 96.7 m-70 -117.43 134.52 54.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.325 -0.859 . . . . 0.0 109.317 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.615 HG21 HG23 ' A' ' 128' ' ' VAL . 52.9 p -133.49 137.95 45.9 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.158 -0.964 . . . . 0.0 109.794 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.59 ' HB2' HG23 ' A' ' 94' ' ' THR . 42.9 tttt -50.63 -37.3 39.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.499 -0.751 . . . . 0.0 109.484 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.5 -44.85 1.08 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -63.55 -27.75 69.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.191 -1.182 . . . . 0.0 109.542 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -111.25 139.3 46.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.58 164.32 14.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.155 -0.966 . . . . 0.0 109.436 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.615 HG23 HG21 ' A' ' 122' ' ' THR . 38.3 t -110.5 134.02 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 80.1 mttt -85.4 149.29 25.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.324 -0.86 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.06 -37.64 85.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.535 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -58.87 -46.03 88.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.285 -0.885 . . . . 0.0 109.421 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 25.1 mt-30 -52.48 -35.77 53.55 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.09 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.449 HG22 ' CE1' ' A' ' 120' ' ' TYR . 47.3 t -73.57 -33.78 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.275 -0.891 . . . . 0.0 109.265 179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -60.84 -41.36 95.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.34 -43.17 91.75 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 30.6 t -65.37 -37.99 88.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.353 -0.842 . . . . 0.0 109.49 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.439 ' HE3' HG22 ' A' ' 7' ' ' THR . 63.6 tttt -58.36 -45.58 87.92 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.441 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.11 -40.4 95.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.1 mtp -62.28 -39.5 93.13 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.51 -43.37 98.9 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.617 ' OE2' HD21 ' A' ' 144' ' ' LEU . 77.1 mm-40 -66.03 -34.0 77.08 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -1.096 . . . . 0.0 109.385 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 76.9 m -63.95 -32.62 74.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.5 mt -72.33 -47.61 48.42 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.33 -0.856 . . . . 0.0 109.394 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.672 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -74.91 -34.52 62.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.332 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.601 ' N ' HD12 ' A' ' 144' ' ' LEU . 75.7 ttt180 -60.36 -40.23 90.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.313 -0.867 . . . . 0.0 109.349 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.89 -39.92 87.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.286 -0.884 . . . . 0.0 109.391 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.427 ' O ' ' CD2' ' A' ' 151' ' ' LEU . 77.9 t -61.05 -48.4 89.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.342 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.21 -45.74 79.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.276 -0.89 . . . . 0.0 109.303 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 85.7 p -58.84 -34.11 71.2 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.348 -0.845 . . . . 0.0 109.334 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -62.01 -43.26 99.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.631 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -61.46 -37.35 83.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.233 -0.917 . . . . 0.0 109.308 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.478 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.6 mp -72.0 -26.67 62.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.02 71.47 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.89 . . . . 0.0 109.362 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -49.61 -32.72 13.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 21.9 m -55.36 -33.14 63.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.392 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -70.38 -20.26 62.96 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.245 -0.91 . . . . 0.0 109.38 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -104.31 140.97 37.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.299 -0.876 . . . . 0.0 109.457 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -109.86 123.27 49.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.497 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 32.2 t-20 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.484 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 120' ' ' TYR . 86.3 t -134.03 143.6 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -1.17 . . . . 0.0 109.453 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.476 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 72.5 m-85 -98.49 137.09 37.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -0.943 . . . . 0.0 109.368 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.455 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 79.0 m-20 -120.63 125.61 48.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.918 . . . . 0.0 109.637 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.476 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 97.9 m-85 -126.19 144.95 50.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.284 -0.885 . . . . 0.0 109.345 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -131.03 140.21 50.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.264 -0.898 . . . . 0.0 109.691 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 18.1 p -128.48 156.61 42.96 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.342 -0.849 . . . . 0.0 109.249 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -129.31 127.47 41.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.119 -0.988 . . . . 0.0 109.646 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 37.4 m -138.97 138.74 37.57 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.993 HG22 HG23 ' A' ' 113' ' ' ILE . 50.2 p -119.14 158.92 24.97 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.202 -0.936 . . . . 0.0 109.508 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.3 m -152.2 143.41 23.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.22 -0.925 . . . . 0.0 109.426 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.5 m -64.86 -30.26 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.226 -0.921 . . . . 0.0 109.5 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.882 HG21 HD13 ' A' ' 151' ' ' LEU . 25.6 mm -53.84 143.95 38.32 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.405 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.747 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.26 146.87 58.33 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.548 2.165 . . . . 0.0 111.637 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.788 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -68.98 -35.83 77.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.97 -49.25 77.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.158 -0.963 . . . . 0.0 109.471 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 96.2 mtt180 -70.2 -46.13 65.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -0.934 . . . . 0.0 109.43 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.525 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 2.1 tp -63.0 -46.34 88.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.309 -0.869 . . . . 0.0 109.454 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 49.1 t80 -53.98 -39.6 66.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.17 -0.956 . . . . 0.0 109.369 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.975 ' HG2' HD22 ' A' ' 24' ' ' LEU . 4.6 mtmp? -75.85 -59.32 2.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.904 . . . . 0.0 109.607 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.797 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -61.53 -25.26 67.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.231 -0.918 . . . . 0.0 109.697 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 69.4 t80 -84.14 -34.79 23.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.15 -0.969 . . . . 0.0 109.649 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.639 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 54.9 mt -108.27 -63.58 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.906 . . . . 0.0 109.382 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.975 HD22 ' HG2' ' A' ' 20' ' ' LYS . 8.7 mp -49.96 -61.57 2.07 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.149 -0.97 . . . . 0.0 109.397 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -101.67 28.74 5.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.262 -0.899 . . . . 0.0 109.473 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 22' ' ' PHE . . . -74.11 -30.66 60.69 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 97.0 m-20 -69.14 -42.43 75.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -1.126 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -77.87 -40.21 40.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.892 . . . . 0.0 109.346 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.978 ' O ' HG22 ' A' ' 33' ' ' VAL . 52.7 mt -69.27 -32.7 72.05 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.545 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -45.47 -64.01 1.04 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.36 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.545 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.2 Cg_endo -72.18 -38.48 3.73 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.714 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -63.23 -47.4 82.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.256 -0.903 . . . . 0.0 109.557 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.978 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.94 -23.33 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.654 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.75 73.54 10.46 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.178 -0.951 . . . . 0.0 109.475 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.65 -15.76 33.77 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.636 2.224 . . . . 0.0 111.761 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -82.04 -13.48 57.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.31 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.38 -44.52 7.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.481 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.2 mt -133.76 119.89 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -0.916 . . . . 0.0 109.322 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.4 t -61.79 -36.31 80.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 109.622 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 p -164.13 153.21 13.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.936 . . . . 0.0 109.605 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 75.2 t -117.47 137.19 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 55' ' ' LYS . 74.1 mm-40 -134.08 152.28 51.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.245 -0.909 . . . . 0.0 109.419 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.0 m-20 -102.0 105.4 16.16 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.141 -0.974 . . . . 0.0 109.66 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.879 HD12 HG22 ' A' ' 53' ' ' ILE . 78.7 mt -59.77 -60.56 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.149 -0.969 . . . . 0.0 109.258 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.838 ' O ' HG23 ' A' ' 52' ' ' THR . 81.9 tt0 -140.13 158.24 44.35 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.344 -0.848 . . . . 0.0 109.407 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.491 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 84.53 179.29 51.42 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -154.69 47.2 0.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -1.119 . . . . 0.0 109.479 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.61 6.05 50.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -104.08 -178.62 25.38 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.43 138.76 36.38 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.642 2.228 . . . . 0.0 111.91 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.52 16.8 72.6 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 45' ' ' GLU . 63.3 m -85.43 139.21 31.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.138 -1.213 . . . . 0.0 109.543 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.879 HG22 HD12 ' A' ' 44' ' ' ILE . 65.8 mt -114.45 132.57 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.395 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.0 mttt -119.35 136.49 54.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.311 -0.868 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 42' ' ' GLU . 39.1 ttpt -93.14 129.82 39.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.604 ' HB ' HG12 ' A' ' 67' ' ' VAL . 79.8 mt -108.65 143.53 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.6 m -114.29 153.65 29.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.21 -0.931 . . . . 0.0 109.518 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.439 ' N ' ' O ' ' A' ' 65' ' ' LYS . 19.5 m-85 -127.41 137.62 31.06 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.41 158.88 54.78 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.733 2.289 . . . . 0.0 111.789 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -55.49 149.71 13.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.915 . . . . 0.0 109.524 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.63 8.62 51.81 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.474 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 2.3 m-85 -115.16 170.15 5.88 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.22 -1.165 . . . . 0.0 109.431 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.474 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -70.16 -45.06 1.49 Allowed 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.635 2.223 . . . . 0.0 111.645 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.6 ' CD1' ' HA3' ' A' ' 89' ' ' GLY . 93.4 m-85 -119.11 156.58 29.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.259 -0.9 . . . . 0.0 109.349 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.439 ' O ' ' N ' ' A' ' 58' ' ' PHE . 60.1 mttt -83.11 -39.19 21.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.714 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.44 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -149.54 164.01 36.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.811 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.685 HG23 ' HA2' ' A' ' 88' ' ' GLY . 11.9 p -140.9 147.05 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.161 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.71 ' O ' HG13 ' A' ' 85' ' ' VAL . 20.2 mttt -108.99 147.2 32.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.101 -0.999 . . . . 0.0 109.666 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.627 ' O ' HG23 ' A' ' 53' ' ' ILE . 52.6 p30 -146.53 173.97 11.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.864 . . . . 0.0 109.407 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.614 HH21 HD13 ' A' ' 86' ' ' ILE . 31.5 ttm180 -140.84 155.81 46.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 0.0 109.685 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.453 ' N ' ' HG2' ' A' ' 70' ' ' ARG . 44.6 t -100.64 140.53 19.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.285 -0.884 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 94.2 m-20 -82.36 -45.05 15.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 109.549 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 179.73 154.37 0.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.355 -0.841 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.4 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 33.9 t -120.42 132.73 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 79' ' ' PHE . 92.8 m-20 -117.84 89.36 3.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.517 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -59.29 -44.19 92.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.432 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.9 m -61.14 -44.39 97.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.256 -0.903 . . . . 0.0 109.397 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.6 m-20 -92.69 7.32 44.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.224 -0.922 . . . . 0.0 109.512 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 97.4 m-85 44.75 26.92 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.251 -0.906 . . . . 0.0 109.598 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -95.82 130.28 42.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.414 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 102' ' ' ILE . 68.9 t80 -124.6 120.34 31.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -120.02 141.7 49.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.447 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.6 p90 -153.04 154.57 35.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.336 -0.853 . . . . 0.0 109.375 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.6 p -143.25 157.78 44.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.216 -0.927 . . . . 0.0 109.496 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 68' ' ' LYS . 43.0 t -104.47 130.61 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.324 -0.86 . . . . 0.0 109.416 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.614 HD13 HH21 ' A' ' 70' ' ' ARG . 46.2 pt -105.2 -31.1 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -0.863 . . . . 0.0 109.44 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 94.2 mt-10 -127.47 109.17 11.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.685 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -131.01 161.95 23.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.6 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -60.65 -57.67 17.76 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.576 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -73.57 2.53 5.7 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.671 2.248 . . . . 0.0 111.764 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.552 HD13 ' HA ' ' A' ' 97' ' ' LYS . 58.0 mt -124.92 133.13 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.273 -0.892 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.78 -129.73 6.79 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -63.91 -48.35 76.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.18 -1.188 . . . . 0.0 109.074 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -160.47 22.64 0.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.271 179.9 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.501 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.8 mp -61.15 -39.05 88.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.179 -0.951 . . . . 0.0 109.853 -179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -157.1 50.38 0.46 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.183 -0.948 . . . . 0.0 109.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.552 ' HA ' HD13 ' A' ' 91' ' ' ILE . 22.8 ttpt -64.39 132.14 49.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.13 -0.982 . . . . 0.0 108.455 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.7 mt -115.91 126.43 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.145 -0.972 . . . . 0.0 110.445 -178.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 40.1 t -111.61 123.39 50.13 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 117' ' ' SER . 88.0 m-20 -115.61 140.24 49.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 110.294 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.7 mt-10 -119.16 132.84 56.01 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.452 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 71.5 mt -116.41 137.57 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.079 -1.013 . . . . 0.0 110.056 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 39.0 tttt -133.05 124.92 28.53 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.36 -0.838 . . . . 0.0 109.101 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.788 HG22 ' HB1' ' A' ' 15' ' ' ALA . 53.5 mt -106.48 137.31 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.862 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 112' ' ' SER . 16.2 t -136.91 137.39 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.299 -0.876 . . . . 0.0 109.206 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -100.63 141.36 33.6 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.262 -0.899 . . . . 0.0 109.718 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.5 p -153.24 122.05 3.18 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -72.03 -2.15 11.12 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.821 2.347 . . . . 0.0 111.896 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -97.75 -13.93 21.13 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.195 -0.941 . . . . 0.0 109.707 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -163.7 29.62 0.24 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 75.29 -146.51 34.68 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 27.8 m -106.64 140.57 39.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.323 -1.104 . . . . 0.0 109.506 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.993 HG23 HG22 ' A' ' 10' ' ' THR . 26.4 mt -101.63 134.27 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.258 -0.902 . . . . 0.0 109.639 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 104' ' ' ILE . 79.0 mt -110.13 137.75 47.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.541 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 1.8 mtpt -124.69 123.34 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -0.887 . . . . 0.0 109.279 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 74.7 mt -123.02 134.57 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.771 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 49.9 m -118.08 145.44 44.84 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.135 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -125.97 137.86 53.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 109.859 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -131.17 142.03 50.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 108.967 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.992 ' OH ' HG13 ' A' ' 133' ' ' VAL . 92.6 m-85 -117.6 128.64 55.14 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.078 -1.014 . . . . 0.0 109.843 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.4 m-70 -111.18 131.12 55.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 109.167 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 94' ' ' THR . 44.4 p -121.79 138.28 54.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.226 -0.922 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 40.0 tttp -49.46 -57.63 6.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.493 -0.754 . . . . 0.0 109.393 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.575 ' O ' ' CD2' ' A' ' 126' ' ' HIS . . . 166.89 164.78 23.16 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 36.8 m-20 46.64 25.41 0.42 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.139 -1.212 . . . . 0.0 109.547 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.575 ' CD2' ' O ' ' A' ' 124' ' ' GLY . 85.7 m-70 -126.76 149.42 49.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -126.4 143.52 51.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.342 -0.849 . . . . 0.0 109.44 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 t -98.83 131.14 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.542 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.407 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 91.0 mttt -75.85 142.3 42.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.18 91.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.215 -0.928 . . . . 0.0 109.451 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -56.17 -38.35 70.79 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.202 -0.936 . . . . 0.0 109.406 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 93.8 mt-30 -62.99 -33.25 75.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.358 -0.839 . . . . 0.0 109.498 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.992 HG13 ' OH ' ' A' ' 120' ' ' TYR . 48.2 t -70.64 -43.6 77.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.231 -0.918 . . . . 0.0 109.479 -179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -57.95 -39.79 78.95 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.142 -0.973 . . . . 0.0 109.489 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.56 -50.77 72.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.229 -0.919 . . . . 0.0 109.495 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.434 ' HA ' ' HE2' ' A' ' 139' ' ' MET . 0.6 OUTLIER -62.27 -35.05 77.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 50.3 tttt -67.29 -33.61 75.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.35 -44.5 83.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.434 ' HE2' ' HA ' ' A' ' 136' ' ' SER . 69.0 mtm -61.2 -37.35 82.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.259 -0.901 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.15 -42.81 99.36 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.503 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 80.8 tt0 -68.47 -30.33 69.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.242 -1.152 . . . . 0.0 109.357 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 93.6 m -70.05 -31.7 69.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.358 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.432 ' HA ' HD23 ' A' ' 143' ' ' LEU . 33.5 mt -70.81 -50.15 38.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.302 -0.874 . . . . 0.0 109.554 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.612 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.4 pp -66.76 -33.3 75.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.563 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.464 ' N ' HD12 ' A' ' 144' ' ' LEU . 51.3 mtp180 -68.83 -40.64 79.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.171 -0.956 . . . . 0.0 109.337 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.58 -42.65 91.48 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.375 -0.828 . . . . 0.0 109.456 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.0 t -62.82 -48.16 89.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.417 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.556 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.7 tt0 -57.12 -45.84 83.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 109.392 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.594 ' HA ' HD12 ' A' ' 152' ' ' LEU . 85.5 p -55.14 -39.49 69.51 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.311 -0.868 . . . . 0.0 109.494 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -63.16 -46.15 88.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.265 -0.897 . . . . 0.0 109.53 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.882 HD13 HG21 ' A' ' 13' ' ' ILE . 31.9 mt -62.81 -33.48 75.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.26 -0.9 . . . . 0.0 109.44 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.594 HD12 ' HA ' ' A' ' 149' ' ' SER . 9.0 mt -73.97 -23.53 59.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.421 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.77 -36.63 84.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.533 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.477 ' CD2' ' HA ' ' A' ' 151' ' ' LEU . 63.8 m-70 -50.56 -42.42 55.42 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -0.871 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 94.6 p -60.8 -24.93 66.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.6 -4.41 42.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.633 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -80.0 124.39 28.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.42 ' C ' ' O ' ' A' ' 157' ' ' ALA . 14.4 t80 -44.13 128.11 5.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.902 . . . . 0.0 109.496 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 39.8 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.526 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.813 HG11 ' CE1' ' A' ' 121' ' ' HIS . 39.4 t -138.91 139.95 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.269 -1.136 . . . . 0.0 109.31 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 71.3 m-85 -89.82 139.49 30.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.132 -0.98 . . . . 0.0 109.428 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.445 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 91.1 m-20 -120.13 109.64 15.69 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.3 -0.875 . . . . 0.0 109.621 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.572 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 90.4 m-85 -114.77 131.12 56.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 109.298 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.2 tt0 -120.95 147.3 45.64 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.196 -0.94 . . . . 0.0 109.236 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 16.2 p -129.24 158.56 38.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.386 -0.821 . . . . 0.0 109.368 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -132.99 132.95 42.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.954 . . . . 0.0 109.511 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.445 HG21 HD13 ' A' ' 144' ' ' LEU . 56.0 m -135.8 142.1 44.83 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.394 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.9 m -118.04 144.31 45.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.313 -0.867 . . . . 0.0 109.416 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.2 m -147.14 141.01 25.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.193 -0.942 . . . . 0.0 109.548 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.9 m -67.26 -27.52 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.174 -0.954 . . . . 0.0 109.345 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.902 HG21 HD13 ' A' ' 151' ' ' LEU . 49.0 mm -55.88 142.87 63.09 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.321 -0.862 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.631 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.1 Cg_endo -69.98 145.13 54.95 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.57 2.18 . . . . 0.0 111.843 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.769 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -68.63 -28.34 66.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.666 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.13 -49.22 73.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.227 -0.921 . . . . 0.0 109.575 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.461 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 86.6 mtt180 -78.58 -43.06 27.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 109.525 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.771 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.2 tm? -64.42 -35.47 81.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -0.887 . . . . 0.0 109.401 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.731 ' HD2' HD12 ' A' ' 104' ' ' ILE . 58.7 t80 -69.91 -45.1 68.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.595 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 92.9 mttt -62.82 -47.57 82.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -0.913 . . . . 0.0 109.824 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.07 -42.47 63.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.118 -0.989 . . . . 0.0 109.755 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 77.8 t80 -66.19 -26.75 67.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.217 -0.927 . . . . 0.0 109.742 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 19' ' ' PHE . 37.0 mm -102.12 -63.66 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 109.694 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.446 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 55.4 mt -61.67 -38.72 88.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.18 -0.95 . . . . 0.0 109.717 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.514 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 86.9 m-20 -107.15 17.69 22.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.231 -0.918 . . . . 0.0 109.509 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.546 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.62 -29.29 67.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -69.09 -41.23 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -1.142 . . . . 0.0 109.476 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.426 ' O ' ' HD2' ' A' ' 31' ' ' PRO . 11.5 m-20 -92.68 -45.01 8.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.179 -0.95 . . . . 0.0 109.513 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.913 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.4 tp -60.31 -27.81 67.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.511 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.546 ' CG ' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -57.5 -63.06 4.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.383 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.9 Cg_endo -71.03 -37.87 5.68 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.686 2.257 . . . . 0.0 111.734 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 82.2 mttt -59.49 -45.2 92.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.347 -0.846 . . . . 0.0 109.516 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -83.74 -30.99 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.569 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.69 72.99 41.75 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.203 -0.935 . . . . 0.0 109.556 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.67 -15.82 33.7 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.614 2.209 . . . . 0.0 111.716 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -75.06 -15.57 60.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -0.942 . . . . 0.0 109.395 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.21 -47.71 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.243 -0.911 . . . . 0.0 109.367 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 56' ' ' ILE . 81.6 mt -130.27 119.82 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.373 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.7 t -58.06 -41.71 83.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.472 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.7 t -164.02 149.82 10.95 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.292 -0.88 . . . . 0.0 109.454 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.409 HG22 HG21 ' A' ' 38' ' ' ILE . 91.5 t -115.49 136.16 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.903 . . . . 0.0 109.613 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -133.43 153.66 51.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.861 . . . . 0.0 109.453 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -101.41 105.46 16.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.195 -0.941 . . . . 0.0 109.614 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.884 HD12 HG22 ' A' ' 53' ' ' ILE . 82.8 mt -61.67 -60.32 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.284 -0.885 . . . . 0.0 109.404 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.798 ' O ' HG23 ' A' ' 52' ' ' THR . 82.6 tt0 -140.05 157.67 45.28 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.192 -0.943 . . . . 0.0 109.413 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.471 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 88.62 173.93 47.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -136.42 36.2 2.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.379 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.59 -14.39 42.36 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.524 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.21 -176.33 41.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -70.53 143.85 48.3 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.703 2.269 . . . . 0.0 111.864 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.59 5.85 89.58 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.798 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -75.18 138.23 41.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -1.167 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.884 HG22 HD12 ' A' ' 44' ' ' ILE . 38.9 mt -110.68 129.64 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -120.0 133.18 55.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -90.33 123.62 34.24 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.213 -0.929 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.527 HG23 ' CG2' ' A' ' 38' ' ' ILE . 69.4 mt -105.14 136.63 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 67.4 m -110.61 149.68 30.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.292 -0.88 . . . . 0.0 109.487 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 7.1 m-30 -108.87 143.24 27.17 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.422 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.26 153.41 66.64 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.713 2.275 . . . . 0.0 111.841 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.26 140.82 31.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.283 -0.886 . . . . 0.0 109.468 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.46 10.56 53.49 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.489 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -106.59 168.66 7.8 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.487 179.966 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.489 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.4 Cg_endo -69.94 -51.75 0.35 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.664 2.242 . . . . 0.0 111.669 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 90' ' ' PRO . 92.3 m-85 -109.84 151.32 27.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.283 -0.886 . . . . 0.0 109.483 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -77.14 -45.7 25.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.55 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -148.15 170.33 18.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.608 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.522 HG13 ' HA2' ' A' ' 88' ' ' GLY . 40.4 t -145.41 158.51 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.402 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.973 ' O ' HG13 ' A' ' 85' ' ' VAL . 24.8 tttt -100.69 134.76 43.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.553 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -133.11 142.22 48.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.288 -0.882 . . . . 0.0 109.397 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.442 ' CZ ' HD13 ' A' ' 86' ' ' ILE . 42.8 mtm180 -129.3 154.95 46.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.2 -0.937 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.1 p -107.11 133.71 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 51.6 t0 -80.81 -48.32 12.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 178.34 140.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.19 -0.944 . . . . 0.0 109.399 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 74' ' ' VAL . 5.8 p -121.91 129.22 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.254 -0.904 . . . . 0.0 109.513 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -102.18 109.93 21.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.449 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -66.07 -42.95 88.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.268 -0.895 . . . . 0.0 109.387 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 75.0 m -63.64 -38.74 92.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.203 -0.936 . . . . 0.0 109.487 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 79' ' ' PHE . 87.0 m-20 -93.01 4.78 53.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.501 ' C ' ' CE2' ' A' ' 19' ' ' PHE . 76.3 m-85 44.33 27.51 0.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 19.8 tttt -99.9 130.71 46.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.484 ' O ' ' N ' ' A' ' 102' ' ' ILE . 76.2 t80 -124.67 119.69 29.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.316 -0.865 . . . . 0.0 109.385 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 16.6 m120 -121.26 134.1 55.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.655 -179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 37.6 p90 -144.44 156.15 44.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.351 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 82.8 p -142.36 159.6 41.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.215 -0.928 . . . . 0.0 109.574 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.973 HG13 ' O ' ' A' ' 68' ' ' LYS . 66.6 t -116.16 123.19 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 87' ' ' GLU . 26.8 pt -101.61 -32.25 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.487 ' N ' HG13 ' A' ' 86' ' ' ILE . 85.1 tt0 -118.92 122.05 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.467 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.522 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -149.9 159.38 28.07 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.557 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -56.16 -57.88 16.98 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.559 ' HD3' ' CD1' ' A' ' 64' ' ' PHE . 51.1 Cg_endo -71.67 -1.83 10.45 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.785 2.323 . . . . 0.0 111.858 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.574 HD13 ' HA ' ' A' ' 97' ' ' LYS . 61.7 mt -120.32 142.34 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.269 -0.894 . . . . 0.0 109.257 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.487 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -139.51 -126.88 2.38 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -64.61 74.01 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.312 -1.111 . . . . 0.0 109.716 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.481 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 49.32 57.61 6.3 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.341 -0.849 . . . . 0.0 109.637 179.644 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.487 HD12 ' CA ' ' A' ' 92' ' ' GLY . 2.0 mt -107.96 -17.89 13.94 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.491 -0.756 . . . . 0.0 109.26 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.468 ' OE1' ' NE2' ' A' ' 132' ' ' GLN . 81.4 tt0 -172.6 48.29 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.526 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.574 ' HA ' HD13 ' A' ' 91' ' ' ILE . 5.1 ttpp -64.7 135.99 56.47 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.274 -0.891 . . . . 0.0 108.969 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.5 mt -120.77 122.9 69.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.144 -0.972 . . . . 0.0 110.106 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.2 t -109.85 128.43 55.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 108.821 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 83.9 m-20 -120.65 136.19 54.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.113 -0.992 . . . . 0.0 110.086 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.497 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 96.5 mt-10 -118.73 128.53 54.58 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.843 . . . . 0.0 108.826 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.484 ' N ' ' O ' ' A' ' 81' ' ' TYR . 73.4 mt -114.33 132.86 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.055 -1.028 . . . . 0.0 109.918 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 53.9 tttt -133.75 124.75 27.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 109.188 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.769 HG22 ' CB ' ' A' ' 15' ' ' ALA . 34.4 mt -108.27 132.52 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.696 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 112' ' ' SER . 21.8 t -133.84 138.7 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.362 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.4 143.94 26.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.243 -0.911 . . . . 0.0 109.489 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.449 ' CG2' ' C ' ' A' ' 106' ' ' ALA . 1.2 p -153.43 126.86 4.24 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.419 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.91 -0.87 7.67 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 122.745 2.297 . . . . 0.0 111.804 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -83.83 -39.27 20.16 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.302 -0.874 . . . . 0.0 109.452 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.16 37.0 0.7 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 81.32 -146.45 26.25 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.0 m -104.42 140.11 38.4 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.3 -1.118 . . . . 0.0 109.241 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 28.2 mt -102.13 133.02 46.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.309 -0.87 . . . . 0.0 109.572 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.576 ' CD2' HG23 ' A' ' 104' ' ' ILE . 84.9 mt -99.74 137.95 37.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.82 . . . . 0.0 109.333 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 54.8 mttt -125.5 115.77 20.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.471 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.3 mt -117.93 129.94 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 46.7 t -116.0 121.53 42.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.481 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.484 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.4 m120 -104.22 141.55 36.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.171 -0.956 . . . . 0.0 109.69 -179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 22.6 mttp -132.74 145.6 51.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -0.854 . . . . 0.0 108.939 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.721 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.5 m-85 -123.54 128.67 50.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.046 -1.034 . . . . 0.0 109.731 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.813 ' CE1' HG11 ' A' ' 2' ' ' VAL . 86.9 m-70 -115.16 125.66 53.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.244 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.635 HG21 HG23 ' A' ' 128' ' ' VAL . 21.8 p -122.73 144.27 49.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.444 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 94' ' ' THR . 15.3 tptt -59.25 -35.86 74.44 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.341 -0.85 . . . . 0.0 109.53 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.78 -54.32 0.72 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 49.7 t0 -56.63 -34.13 66.97 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.138 -1.213 . . . . 0.0 109.538 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -107.2 137.44 45.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.918 . . . . 0.0 109.558 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -114.98 162.47 16.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.922 . . . . 0.0 109.434 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.635 HG23 HG21 ' A' ' 122' ' ' THR . 21.8 t -106.94 135.95 43.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -83.84 146.48 28.08 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.66 -40.62 92.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -55.76 -42.28 75.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.269 -0.895 . . . . 0.0 109.532 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.468 ' NE2' ' OE1' ' A' ' 96' ' ' GLU . 62.7 tt0 -55.86 -38.17 69.74 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 40.4 t -65.16 -40.86 90.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.438 ' O ' ' HG2' ' A' ' 138' ' ' GLU . 20.8 mmtt -57.25 -40.76 78.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.192 -0.943 . . . . 0.0 109.469 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.445 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -57.79 -46.98 83.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.897 . . . . 0.0 109.534 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 29.6 t -68.8 -37.21 79.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 109.542 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -63.48 -48.91 75.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 134' ' ' LYS . 76.0 mm-40 -58.73 -41.41 86.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.402 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.449 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 96.3 mmm -64.27 -37.39 87.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.351 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.68 -41.93 99.67 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.537 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.0 tt0 -68.84 -34.35 75.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -1.127 . . . . 0.0 109.355 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 67.8 m -66.11 -31.25 72.0 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -0.874 . . . . 0.0 109.389 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 139' ' ' MET . 38.8 mt -73.61 -47.86 36.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.43 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.56 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.3 pp -73.78 -31.95 63.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 56.2 ttt85 -63.46 -41.64 98.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.296 -0.878 . . . . 0.0 109.404 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.89 -36.42 78.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -0.864 . . . . 0.0 109.436 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.612 HG13 HD21 ' A' ' 29' ' ' LEU . 67.8 t -60.64 -48.36 88.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.381 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.456 ' HG2' HD11 ' A' ' 152' ' ' LEU . 84.5 tt0 -60.11 -49.14 78.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.419 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.828 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.4 m -51.86 -39.85 59.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.344 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.71 -49.38 77.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.363 -0.836 . . . . 0.0 109.469 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.902 HD13 HG21 ' A' ' 13' ' ' ILE . 29.1 mt -62.85 -32.98 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.346 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.828 HD12 ' HA ' ' A' ' 149' ' ' SER . 14.4 mt -68.85 -30.07 68.52 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.32 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -56.53 -46.82 80.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.912 . . . . 0.0 109.478 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -56.98 -41.43 78.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.369 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 29.4 m -55.38 -30.56 60.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.368 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.45 ' O ' ' HB3' ' A' ' 157' ' ' ALA . 92.0 m-20 -73.4 -19.43 60.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.89 . . . . 0.0 109.384 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 156' ' ' ASP . . . 62.72 -85.08 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.325 -0.859 . . . . 0.0 109.417 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.411 ' N ' ' O ' ' A' ' 156' ' ' ASP . 74.7 m-85 -108.55 119.69 40.26 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.484 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.4 t30 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.471 -179.884 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.1 t -137.69 142.87 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -1.142 . . . . 0.0 109.48 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 83.9 m-85 -90.61 135.53 33.65 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.357 -0.839 . . . . 0.0 109.582 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.435 ' OD1' ' HG2' ' A' ' 119' ' ' LYS . 85.6 m-20 -123.15 120.09 32.17 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.907 . . . . 0.0 109.48 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 92.1 m-85 -120.29 143.16 48.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.424 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.2 mt-10 -128.03 137.92 52.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 30.7 p -127.93 159.48 34.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.246 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -130.37 133.08 46.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.256 -0.903 . . . . 0.0 109.731 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.6 m -139.21 137.87 36.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.273 -0.892 . . . . 0.0 109.23 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.598 HG22 HG23 ' A' ' 113' ' ' ILE . 72.6 p -118.45 156.1 29.63 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 0.0 109.723 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.5 t -154.33 145.55 22.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.236 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 m -67.07 -24.7 32.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.176 -0.952 . . . . 0.0 109.559 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.871 HG21 HD13 ' A' ' 151' ' ' LEU . 24.2 mm -58.97 143.9 83.06 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.741 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.2 Cg_endo -69.53 147.68 64.91 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.633 2.222 . . . . 0.0 111.762 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.854 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -69.37 -26.17 64.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.862 . . . . 0.0 109.825 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -70.94 -49.43 45.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.455 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 19.4 ttt180 -66.65 -44.46 81.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.429 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.675 HD23 HD13 ' A' ' 104' ' ' ILE . 1.4 tp -68.49 -43.11 77.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.911 . . . . 0.0 109.372 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 23' ' ' ILE . 61.2 t80 -54.0 -36.34 62.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.759 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 24' ' ' LEU . 78.3 mttt -80.01 -62.95 1.53 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.24 -0.913 . . . . 0.0 110.16 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.481 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.78 -30.02 68.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.008 -1.058 . . . . 0.0 109.983 -179.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.523 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 64.3 t80 -79.13 -33.85 43.84 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.096 -1.003 . . . . 0.0 109.535 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.564 HD12 ' CE2' ' A' ' 19' ' ' PHE . 69.4 mt -106.21 -63.72 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 20' ' ' LYS . 7.3 mp -53.45 -45.83 69.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.398 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.538 ' HB2' HD13 ' A' ' 29' ' ' LEU . 4.3 m-20 -110.06 20.36 18.0 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.323 -0.861 . . . . 0.0 109.638 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.54 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -65.37 -28.14 73.25 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -73.53 -30.8 63.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.126 -1.22 . . . . 0.0 109.511 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -86.85 -49.75 7.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.646 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.886 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -66.8 -30.64 70.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.183 -0.948 . . . . 0.0 109.556 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-30 -47.89 -63.69 1.39 Allowed Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 109.42 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.3 Cg_endo -72.05 -40.3 2.62 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.698 2.265 . . . . 0.0 111.705 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -62.01 -43.04 99.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.23 -0.918 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.886 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.67 -31.26 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.74 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 76.63 12.76 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.939 . . . . 0.0 109.664 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.77 -16.7 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.696 2.264 . . . . 0.0 111.752 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -78.03 -8.74 58.59 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.445 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 58' ' ' PHE . . . -98.69 -44.75 6.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.289 -0.882 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.47 HD13 HG23 ' A' ' 56' ' ' ILE . 91.2 mt -134.5 120.11 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.318 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.7 m -60.24 -35.84 76.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.91 . . . . 0.0 109.633 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.1 t -167.45 148.13 5.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.243 -0.911 . . . . 0.0 109.589 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -113.64 139.52 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 109.483 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.43 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -139.56 157.85 45.12 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.353 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 92.2 m-20 -101.27 105.59 16.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.584 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 84.8 mt -59.49 -53.8 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.355 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.821 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.23 158.43 43.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.377 -0.827 . . . . 0.0 109.353 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.452 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 88.63 178.86 46.48 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -131.09 27.48 4.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -1.12 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.516 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.71 -17.78 35.6 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -72.95 -169.25 14.26 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.8 Cg_endo -69.69 144.44 54.37 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.797 2.331 . . . . 0.0 111.809 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.489 ' HA2' ' NE ' ' A' ' 70' ' ' ARG . . . 77.7 18.64 77.08 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 45' ' ' GLU . 90.6 m -94.02 133.84 37.06 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.149 -1.206 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 62.4 mt -108.41 131.18 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 23.4 mttm -116.13 137.72 51.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.145 -0.972 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.516 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 75.0 tttt -89.64 127.24 35.88 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 38' ' ' ILE . 67.8 mt -112.88 128.12 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.281 -0.887 . . . . 0.0 109.465 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.463 ' O ' HG23 ' A' ' 38' ' ' ILE . 96.2 p -109.26 154.96 21.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.674 ' CD1' ' CE1' ' A' ' 62' ' ' PHE . 65.5 m-85 -121.36 146.44 44.85 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.6 159.64 52.12 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.679 2.253 . . . . 0.0 111.751 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -49.28 150.25 1.83 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.401 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.3 5.25 57.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.674 ' CE1' ' CD1' ' A' ' 58' ' ' PHE . 0.4 OUTLIER -108.85 164.17 15.33 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.254 -1.145 . . . . 0.0 109.53 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.585 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.13 -43.73 2.2 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.595 2.197 . . . . 0.0 111.769 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.583 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 95.0 m-85 -116.34 159.01 22.53 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 109.446 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.8 tptt -78.76 -43.81 24.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.16 -0.963 . . . . 0.0 109.499 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 39.0 p90 -152.36 165.01 36.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.287 -0.883 . . . . 0.0 109.417 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.456 HG13 ' HA2' ' A' ' 88' ' ' GLY . 16.7 t -133.72 160.5 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.323 -0.861 . . . . 0.0 109.364 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.947 ' O ' HG13 ' A' ' 85' ' ' VAL . 39.9 mttm -101.64 140.23 36.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -0.893 . . . . 0.0 109.262 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 70' ' ' ARG . 59.6 t0 -135.8 146.16 47.26 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.207 -0.933 . . . . 0.0 109.451 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.489 ' NE ' ' HA2' ' A' ' 51' ' ' GLY . 36.3 ttt180 -130.6 151.9 50.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.392 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.7 t -101.24 142.35 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.146 -0.971 . . . . 0.0 109.475 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.463 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.6 m-20 -82.95 -48.8 10.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.868 . . . . 0.0 109.469 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.2 tt0 178.16 149.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.179 -0.951 . . . . 0.0 109.381 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 81' ' ' TYR . 23.7 t -118.19 131.57 70.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.2 -0.938 . . . . 0.0 109.624 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 79' ' ' PHE . 35.1 t0 -113.26 98.34 7.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.343 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -63.04 -35.64 80.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.567 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 61.5 m -64.69 -45.71 85.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -0.95 . . . . 0.0 109.422 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -97.87 9.55 42.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.471 ' N ' ' O ' ' A' ' 75' ' ' ASP . 82.3 m-85 43.9 30.15 0.37 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.265 -0.897 . . . . 0.0 109.71 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 7.5 ttpm? -92.99 130.16 38.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.142 -0.974 . . . . 0.0 109.425 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 102' ' ' ILE . 73.0 t80 -123.48 120.28 32.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.494 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -119.81 141.52 49.43 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -150.63 157.18 42.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.335 -0.853 . . . . 0.0 109.341 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.404 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 83.6 p -151.86 159.29 43.9 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.174 -0.953 . . . . 0.0 109.585 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.947 HG13 ' O ' ' A' ' 68' ' ' LYS . 45.7 t -103.95 129.55 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.26 -0.9 . . . . 0.0 109.335 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 87' ' ' GLU . 29.6 pt -105.04 -30.17 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -0.893 . . . . 0.0 109.558 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 47.2 tp10 -126.04 112.89 16.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.915 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.456 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -134.74 157.7 23.11 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.583 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -62.1 -58.07 14.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 52.2 Cg_endo -72.08 0.88 6.59 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.775 2.316 . . . . 0.0 111.877 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.451 HD13 ' HA ' ' A' ' 97' ' ' LYS . 51.8 mt -120.14 142.39 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.905 . . . . 0.0 109.56 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.26 -135.5 7.33 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -63.22 -44.93 93.89 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -1.209 . . . . 0.0 109.082 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -161.99 23.43 0.11 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.317 -0.864 . . . . 0.0 109.345 179.802 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.494 ' O ' ' CG ' ' A' ' 96' ' ' GLU . 6.5 mp -64.76 -33.96 77.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.206 -0.934 . . . . 0.0 110.171 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.494 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 68.5 mt-10 -160.45 48.1 0.25 Allowed 'General case' 0 C--N 1.303 -1.445 0 O-C-N 120.979 -1.076 . . . . 0.0 110.004 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.486 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 24.2 ttpt -64.98 132.26 48.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.111 -0.993 . . . . 0.0 108.86 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 57.9 mt -114.68 132.32 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 110.043 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.404 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 30.9 t -127.61 121.51 30.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.388 -0.82 . . . . 0.0 108.794 179.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.461 ' HA ' ' O ' ' A' ' 117' ' ' SER . 44.9 m-20 -116.74 146.88 42.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.048 -1.033 . . . . 0.0 110.221 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.0 mt-10 -118.26 141.53 48.42 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 108.949 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.499 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.9 mt -124.32 136.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.166 -0.959 . . . . 0.0 109.945 -179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 54.5 tttp -133.55 132.11 40.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.106 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.854 HG22 ' HB1' ' A' ' 15' ' ' ALA . 32.7 mt -118.58 130.83 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.19 -0.944 . . . . 0.0 109.619 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.71 136.8 53.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.422 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.417 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -90.36 143.7 26.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.927 . . . . 0.0 109.459 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -151.63 122.51 3.7 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.162 -0.961 . . . . 0.0 109.576 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.11 -0.33 7.83 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.687 2.258 . . . . 0.0 111.746 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.57 -45.06 12.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.74 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -147.37 36.97 1.16 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 85.09 -145.82 21.65 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.4 p -107.54 151.01 26.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -1.125 . . . . 0.0 109.341 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.598 HG23 HG22 ' A' ' 10' ' ' THR . 37.6 mt -110.86 132.22 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.303 -0.873 . . . . 0.0 109.451 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.529 ' CD2' HG23 ' A' ' 104' ' ' ILE . 72.8 mt -104.04 138.17 40.95 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -0.88 . . . . 0.0 109.556 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 34.7 mttt -122.92 112.73 18.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.268 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 60.9 mt -117.08 132.4 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.165 -0.96 . . . . 0.0 109.688 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 27.8 m -121.45 142.41 50.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -0.851 . . . . 0.0 109.18 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.407 ' N ' ' O ' ' A' ' 5' ' ' TYR . 16.8 m120 -114.04 143.29 45.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.277 -0.89 . . . . 0.0 109.81 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 17.9 mttm -134.56 138.8 44.9 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.219 179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.649 ' O ' HG13 ' A' ' 2' ' ' VAL . 84.7 m-85 -121.61 131.13 53.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.115 -0.991 . . . . 0.0 109.827 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 82.8 m-70 -114.61 132.27 56.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.413 -0.804 . . . . 0.0 109.264 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.7 HG21 HG23 ' A' ' 128' ' ' VAL . 44.0 p -128.23 137.35 51.98 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.122 -0.986 . . . . 0.0 109.738 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 12.2 ttmt -52.64 -33.09 45.18 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.486 -0.759 . . . . 0.0 109.453 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.95 -49.88 0.89 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -62.6 -23.26 66.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -1.138 . . . . 0.0 109.548 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.452 ' CD2' HD23 ' A' ' 95' ' ' LEU . 99.3 m-70 -116.65 138.52 51.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.265 -0.897 . . . . 0.0 109.372 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -114.28 162.16 16.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.251 -0.906 . . . . 0.0 109.506 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.7 HG23 HG21 ' A' ' 122' ' ' THR . 24.1 t -103.71 135.26 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 109.423 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -89.36 148.67 23.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.273 -0.892 . . . . 0.0 109.54 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.16 -36.84 73.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -59.19 -36.52 75.51 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.469 ' OE1' HG13 ' A' ' 128' ' ' VAL . 59.7 tt0 -64.06 -34.91 79.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.175 -0.953 . . . . 0.0 109.523 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 120' ' ' TYR . 57.8 t -71.4 -42.54 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.45 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 98.7 mttt -56.43 -40.74 75.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.312 -0.868 . . . . 0.0 109.467 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.05 -50.54 65.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.887 . . . . 0.0 109.571 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.82 -36.43 83.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 53.8 mtmt -60.27 -49.14 78.78 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.322 -0.861 . . . . 0.0 109.581 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.45 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 93.6 mt-10 -60.67 -44.51 96.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.59 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.452 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 64.0 mtt -52.6 -39.46 61.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.421 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -64.36 -46.15 91.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.715 ' OE2' HD11 ' A' ' 144' ' ' LEU . 45.3 tp10 -66.08 -33.13 75.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.23 -1.159 . . . . 0.0 109.554 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.4 m -65.42 -32.58 74.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.409 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 139' ' ' MET . 48.8 mt -74.18 -47.16 37.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -0.887 . . . . 0.0 109.594 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.715 HD11 ' OE2' ' A' ' 141' ' ' GLU . 4.1 pp -74.09 -32.02 63.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.199 -0.938 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.61 ' N ' HD12 ' A' ' 144' ' ' LEU . 15.9 tpt180 -65.16 -38.48 90.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 109.46 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -69.65 -31.71 69.96 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.465 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 71.3 t -71.87 -39.24 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 152' ' ' LEU . 84.9 tt0 -62.21 -46.43 88.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.8 p -60.46 -40.53 91.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.905 . . . . 0.0 109.552 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.518 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 71.9 t80 -63.98 -39.93 95.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.645 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.871 HD13 HG21 ' A' ' 13' ' ' ILE . 62.9 mt -59.49 -38.56 81.2 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.56 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.488 ' CD1' ' O ' ' A' ' 148' ' ' GLU . 7.0 mp -74.01 -25.89 60.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.125 -0.985 . . . . 0.0 109.525 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.13 -38.57 73.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.523 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.518 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 79.1 m80 -49.56 -49.11 47.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 80.8 p -56.41 -22.5 32.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.331 -0.855 . . . . 0.0 109.565 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -88.01 0.49 55.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.256 -0.903 . . . . 0.0 109.657 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.407 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -87.09 125.02 33.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.468 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.407 ' C ' ' O ' ' A' ' 157' ' ' ALA . 9.0 t80 -43.36 124.99 3.65 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.338 -0.851 . . . . 0.0 109.792 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.063 -0.97 . . . . 0.0 109.368 179.745 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 120' ' ' TYR . 46.2 t -135.89 143.89 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -1.142 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -93.9 133.37 37.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -124.64 120.34 31.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.163 -0.961 . . . . 0.0 109.621 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -118.13 138.25 52.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.383 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -116.51 140.7 49.08 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.111 -0.993 . . . . 0.0 109.668 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.483 ' OG1' ' HB ' ' A' ' 116' ' ' ILE . 29.9 p -142.08 160.67 39.77 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.279 -0.888 . . . . 0.0 109.247 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 89.0 mt-10 -140.0 144.61 37.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.602 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' ' N ' ' A' ' 114' ' ' LEU . 11.5 m -136.13 139.37 42.88 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 65.4 p -91.6 154.06 19.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.258 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.8 m -147.61 126.79 12.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.166 -0.959 . . . . 0.0 109.647 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.86 -26.87 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.192 -0.942 . . . . 0.0 109.142 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.926 HG21 HD13 ' A' ' 151' ' ' LEU . 27.8 mm -67.0 142.6 97.45 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.313 -0.867 . . . . 0.0 109.162 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 45.4 Cg_endo -67.92 131.91 25.17 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.425 2.083 . . . . 0.0 111.825 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.608 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -52.29 -33.9 44.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.354 -0.841 . . . . 0.0 110.004 -179.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.72 -49.47 77.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.687 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.465 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 73.5 mtt180 -74.97 -37.38 61.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.53 ' O ' ' CB ' ' A' ' 22' ' ' PHE . 1.4 tp -71.42 -38.24 71.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -0.841 . . . . 0.0 109.366 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD12 ' A' ' 23' ' ' ILE . 36.8 t80 -62.87 -42.62 99.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.454 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 27.6 mttt -73.01 -44.14 61.33 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.903 . . . . 0.0 109.771 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.439 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -75.43 -44.23 45.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.236 -0.915 . . . . 0.0 109.727 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.53 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 61.9 t80 -64.67 -24.71 67.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.202 -0.936 . . . . 0.0 109.791 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 21.7 mt -104.76 -63.82 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.179 -0.951 . . . . 0.0 109.954 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 42.6 mt -63.69 -37.46 87.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.658 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.448 ' O ' HD12 ' A' ' 29' ' ' LEU . 84.3 m-20 -106.92 18.16 22.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.91 . . . . 0.0 109.433 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.508 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.71 -39.57 48.03 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.455 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 92.3 m-20 -69.17 -37.39 78.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.307 -1.113 . . . . 0.0 109.495 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.444 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 81.3 m-20 -80.12 -44.59 19.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.39 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.984 ' O ' HG22 ' A' ' 33' ' ' VAL . 31.0 mt -70.9 -31.43 68.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.492 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.0 OUTLIER -44.33 -63.77 1.01 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.275 -0.891 . . . . 0.0 109.49 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.548 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.9 Cg_endo -71.97 -37.71 4.67 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.731 2.287 . . . . 0.0 111.839 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 25.9 mttt -65.07 -46.34 81.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.26 -0.9 . . . . 0.0 109.629 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.984 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.9 m -77.75 -27.77 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 109.622 -179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.02 73.38 12.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.952 . . . . 0.0 109.529 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.42 -18.88 33.62 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.672 2.248 . . . . 0.0 111.698 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -73.73 -15.04 61.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.312 -0.868 . . . . 0.0 109.473 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.5 -46.84 6.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.683 ' CG2' HG23 ' A' ' 56' ' ' ILE . 95.1 mt -129.44 119.98 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.45 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.45 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 22.0 t -63.96 -37.66 88.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.284 -0.885 . . . . 0.0 109.669 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -167.27 147.15 5.31 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -0.951 . . . . 0.0 109.521 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.573 ' CG1' HG21 ' A' ' 38' ' ' ILE . 35.7 m -119.62 140.8 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.452 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.493 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -136.08 157.83 45.89 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -96.82 105.77 17.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.25 -0.906 . . . . 0.0 109.535 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.926 HD12 HG22 ' A' ' 53' ' ' ILE . 84.4 mt -62.88 -51.12 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.822 ' O ' HG23 ' A' ' 52' ' ' THR . 97.7 mt-10 -146.6 153.94 40.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.65 174.53 48.31 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -128.33 33.14 4.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -1.127 . . . . 0.0 109.479 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.48 ' H ' HG21 ' A' ' 52' ' ' THR . . . 106.03 -14.27 44.7 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -76.75 -170.33 32.03 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.2 Cg_endo -69.84 140.8 43.24 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.667 2.244 . . . . 0.0 111.753 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.32 11.01 81.34 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.822 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.4 m -86.94 135.33 33.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.121 . . . . 0.0 109.502 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.926 HG22 HD12 ' A' ' 44' ' ' ILE . 68.5 mt -112.16 135.06 52.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.394 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -119.75 140.63 50.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.612 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.493 ' N ' ' O ' ' A' ' 42' ' ' GLU . 20.5 tttt -92.25 132.47 36.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -0.888 . . . . 0.0 109.349 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.695 ' HB ' HG12 ' A' ' 67' ' ' VAL . 86.2 mt -112.15 137.66 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.19 -0.944 . . . . 0.0 109.538 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 49.6 m -111.66 155.02 24.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.252 -0.905 . . . . 0.0 109.533 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.546 ' HB3' ' CB ' ' A' ' 62' ' ' PHE . 6.2 m-85 -115.58 131.5 23.62 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.191 -0.943 . . . . 0.0 109.649 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.465 ' O ' ' HB3' ' A' ' 62' ' ' PHE . 48.9 Cg_endo -70.11 169.05 20.27 Favored 'Trans proline' 0 C--O 1.213 -0.756 0 C-N-CA 122.755 2.303 . . . . 0.0 111.818 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.458 ' O ' ' O ' ' A' ' 59' ' ' PRO . 91.8 mt-10 -42.75 165.78 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.763 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 52.91 59.44 9.35 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 65' ' ' LYS . 46.9 p90 -132.24 155.41 81.32 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.362 -1.081 . . . . 0.0 110.307 -179.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -76.5 -53.83 0.07 OUTLIER 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.587 2.192 . . . . 0.0 111.223 178.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.547 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 98.8 m-85 -116.51 143.65 45.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.295 -0.878 . . . . 0.0 109.375 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 9.6 mttp -59.07 -63.92 1.13 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.875 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.7 p90 -137.47 170.76 15.53 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.278 -0.889 . . . . 0.0 109.753 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.695 HG12 ' HB ' ' A' ' 56' ' ' ILE . 12.7 p -144.45 146.11 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.293 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 1.017 ' O ' HG13 ' A' ' 85' ' ' VAL . 47.6 mttm -85.57 139.67 31.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -0.903 . . . . 0.0 109.689 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 62.2 t0 -129.22 138.49 51.72 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -131.91 149.15 52.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.543 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.6 p -104.87 137.81 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.874 . . . . 0.0 109.415 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 46.0 t0 -79.43 -47.07 16.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.887 . . . . 0.0 109.523 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.452 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 84.2 tt0 -178.36 154.05 0.79 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.605 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.603 HG22 ' CE2' ' A' ' 81' ' ' TYR . 37.9 t -116.94 133.32 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.527 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -116.96 90.37 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -61.63 -40.4 94.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.875 . . . . 0.0 109.552 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.3 m -62.83 -40.49 97.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 79' ' ' PHE . 76.7 m-20 -93.2 7.01 46.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.215 -0.928 . . . . 0.0 109.474 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.575 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 91.4 m-85 44.8 31.92 0.73 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 4.1 ttpm? -111.38 134.05 53.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.263 -0.898 . . . . 0.0 109.607 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.603 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.8 t80 -124.38 120.3 31.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.912 . . . . 0.0 109.304 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.463 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 75.8 m-20 -116.19 140.93 48.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.736 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 35.5 p90 -147.04 158.26 43.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.327 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 83.2 p -148.81 159.98 43.64 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.136 -0.978 . . . . 0.0 109.68 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 1.017 HG13 ' O ' ' A' ' 68' ' ' LYS . 50.7 t -107.6 133.53 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.233 -0.917 . . . . 0.0 109.415 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 87' ' ' GLU . 23.3 pt -100.88 -35.4 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.445 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.518 ' N ' HG13 ' A' ' 86' ' ' ILE . 84.9 tt0 -124.58 111.99 16.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.196 -0.94 . . . . 0.0 109.46 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.582 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -129.03 152.08 19.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.487 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -47.93 -63.06 3.77 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.4 Cg_endo -71.28 -3.02 12.11 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.691 2.261 . . . . 0.0 111.897 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' A' ' 88' ' ' GLY . 47.6 mt -114.81 143.31 24.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -0.907 . . . . 0.0 109.578 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -116.9 -128.23 4.09 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.32 -44.52 87.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.172 -1.193 . . . . 0.0 109.069 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.534 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -164.93 24.12 0.06 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 109.434 179.803 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.596 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.6 mp -65.08 -38.9 92.26 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.079 -1.013 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -155.16 51.26 0.59 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.982 -1.073 . . . . 0.0 110.057 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 14.5 tttt -64.73 132.12 48.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.087 -1.008 . . . . 0.0 108.551 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 64.6 mt -119.78 129.91 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.065 -1.022 . . . . 0.0 110.188 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 47.3 t -120.84 118.96 31.32 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 74.3 m-20 -110.09 146.75 34.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.164 -0.96 . . . . 0.0 110.178 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.4 mt-10 -124.51 135.43 53.18 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.528 HD13 ' CE1' ' A' ' 22' ' ' PHE . 72.9 mt -117.37 133.17 64.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.047 -1.033 . . . . 0.0 109.903 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 14.8 tttp -133.65 122.45 23.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.815 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.706 HD12 HD12 ' A' ' 114' ' ' LEU . 19.2 mm -103.67 137.65 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.13 -0.981 . . . . 0.0 109.774 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.467 ' HB ' ' HB ' ' A' ' 113' ' ' ILE . 15.4 t -126.1 139.71 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.374 -0.829 . . . . 0.0 109.348 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -111.79 136.62 50.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.226 -0.921 . . . . 0.0 109.553 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . . . . . . . . . 17.3 p -125.11 152.83 71.24 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.467 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.76 -15.35 37.04 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.672 2.248 . . . . 0.0 111.748 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -60.3 -28.98 68.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 120.62 19.98 3.63 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -145.44 175.29 25.07 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.41 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 11.3 p -131.69 143.28 50.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.356 -1.084 . . . . 0.0 109.094 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 105' ' ' VAL . 56.2 mt -102.68 140.49 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.611 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.706 HD12 HD12 ' A' ' 104' ' ' ILE . 8.6 tt -120.17 139.09 53.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.908 . . . . 0.0 109.461 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 95.9 mttt -124.34 121.44 34.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.277 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.582 HG12 HD21 ' A' ' 114' ' ' LEU . 24.7 mt -114.26 134.74 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.214 -0.928 . . . . 0.0 109.589 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 34.7 t -117.43 123.13 45.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.17 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -105.41 137.32 43.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.956 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 15.7 mttt -132.65 136.85 46.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.316 -0.865 . . . . 0.0 109.096 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.926 ' OH ' HG13 ' A' ' 133' ' ' VAL . 88.9 m-85 -120.39 132.41 55.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.138 -0.976 . . . . 0.0 109.69 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.625 ' CE1' HG11 ' A' ' 2' ' ' VAL . 78.1 m-70 -117.59 131.49 56.67 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.35 -0.844 . . . . 0.0 109.268 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.606 HG21 HG23 ' A' ' 128' ' ' VAL . 37.1 p -130.6 137.57 49.71 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.164 -0.96 . . . . 0.0 109.785 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.534 ' N ' ' O ' ' A' ' 94' ' ' THR . 25.2 tttt -49.86 -35.55 23.7 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.507 -0.746 . . . . 0.0 109.431 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.87 -45.23 1.12 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -64.39 -27.56 69.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.357 -1.084 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.407 ' CD2' HD23 ' A' ' 95' ' ' LEU . 96.9 m-70 -111.22 139.37 46.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.194 -0.941 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.93 163.21 15.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.533 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.606 HG23 HG21 ' A' ' 122' ' ' THR . 38.9 t -108.67 135.07 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.429 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.425 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 84.3 mttt -89.34 148.71 23.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.228 -0.92 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.58 -42.94 89.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.869 . . . . 0.0 109.538 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -56.24 -44.95 80.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.192 -0.942 . . . . 0.0 109.433 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.425 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.3 mt-30 -52.5 -36.83 56.02 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.29 -0.881 . . . . 0.0 109.127 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.926 HG13 ' OH ' ' A' ' 120' ' ' TYR . 42.0 t -73.44 -33.56 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.422 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 23.8 mttm -60.65 -40.37 91.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.213 -0.929 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.42 -48.32 78.29 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.407 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -63.12 -36.81 84.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.377 -0.827 . . . . 0.0 109.637 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.442 ' HG3' ' O ' ' A' ' 133' ' ' VAL . 25.1 mttt -60.98 -40.38 93.24 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.666 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 98.1 mt-10 -65.08 -41.25 95.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.245 -0.909 . . . . 0.0 109.642 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.454 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 49.7 ttm -62.89 -40.83 98.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.256 -0.903 . . . . 0.0 109.517 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -62.2 -39.61 97.9 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.538 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 39.4 tp10 -71.87 -29.56 64.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -1.159 . . . . 0.0 109.55 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 96.0 m -72.97 -31.48 64.57 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -0.934 . . . . 0.0 109.26 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 139' ' ' MET . 34.2 mt -69.98 -45.24 67.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.823 . . . . 0.0 109.554 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.5 pp -73.2 -31.56 64.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.145 -0.972 . . . . 0.0 109.719 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.464 ' NE ' ' CG ' ' A' ' 141' ' ' GLU . 88.9 mtt180 -68.54 -36.41 78.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.205 -0.935 . . . . 0.0 109.423 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -68.24 -37.76 81.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.58 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 69.5 t -64.72 -45.93 93.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.965 . . . . 0.0 109.565 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -60.16 -41.7 93.37 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.284 -0.885 . . . . 0.0 109.572 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.5 m -58.8 -37.97 77.53 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.187 -0.946 . . . . 0.0 109.604 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CZ ' ' NE2' ' A' ' 154' ' ' HIS . 74.2 t80 -63.24 -51.31 66.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.23 -0.919 . . . . 0.0 109.75 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.926 HD13 HG21 ' A' ' 13' ' ' ILE . 23.0 mt -56.93 -42.79 80.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.181 -0.95 . . . . 0.0 109.577 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . . . . . . . . . 75.7 mt -74.91 -25.56 59.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.528 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.79 71.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.536 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.592 ' NE2' ' CZ ' ' A' ' 150' ' ' TYR . 74.7 m-70 -103.8 135.99 44.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.144 -0.973 . . . . 0.0 109.614 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 37.9 m -73.44 -14.57 61.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.481 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -70.19 -16.78 63.11 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 151' ' ' LEU . . . -60.58 -26.84 67.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.51 ' OH ' HD13 ' A' ' 13' ' ' ILE . 90.9 m-85 -122.98 127.88 49.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.325 -0.859 . . . . 0.0 109.396 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' TYR . 89.7 m-20 . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.069 -0.967 . . . . 0.0 109.557 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 92.0 t -136.6 145.3 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.247 -1.149 . . . . 0.0 109.551 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.517 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 89.6 m-85 -97.75 137.05 37.21 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.416 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.04 120.82 33.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.517 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 95.5 m-85 -122.49 141.07 52.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.275 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.5 mt-10 -129.17 135.29 48.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.942 . . . . 0.0 109.763 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 32.2 p -129.53 156.13 44.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.295 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -135.57 138.8 43.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.125 -0.985 . . . . 0.0 109.61 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.474 ' OG1' ' HB2' ' A' ' 114' ' ' LEU . 17.0 p -137.44 157.83 45.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.31 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 27.7 m -123.16 143.94 49.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.634 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.6 p -140.52 149.59 42.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.324 -0.86 . . . . 0.0 109.353 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.53 HG23 HD13 ' A' ' 13' ' ' ILE . 12.4 m -74.47 -27.81 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.504 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.7 mm -58.89 141.75 85.35 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.322 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.55 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.1 147.88 61.67 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.568 2.179 . . . . 0.0 111.756 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.84 -30.41 70.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 109.758 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.01 -49.2 71.14 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.108 -0.995 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.454 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 97.9 mtt180 -76.82 -38.45 53.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -0.903 . . . . 0.0 109.546 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.792 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.62 -35.76 73.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.613 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.763 ' HD2' HD12 ' A' ' 104' ' ' ILE . 52.5 t80 -68.24 -40.6 81.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.153 -0.967 . . . . 0.0 109.652 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 56.8 mttt -75.57 -46.9 29.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.155 -0.965 . . . . 0.0 109.82 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.435 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -71.08 -40.88 71.32 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.998 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.532 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 65.0 t80 -70.4 -24.74 62.99 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.183 -0.948 . . . . 0.0 109.837 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.723 HD12 ' CE1' ' A' ' 19' ' ' PHE . 59.9 mt -106.0 -63.85 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.109 -0.995 . . . . 0.0 109.894 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 40.0 mt -61.64 -44.05 97.71 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 67.8 m-20 -101.12 13.53 34.87 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.579 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.564 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -71.52 -42.24 56.03 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.651 ' O ' HG21 ' A' ' 41' ' ' VAL . 85.9 m-20 -63.08 -40.42 97.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.246 -1.15 . . . . 0.0 109.569 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.434 ' O ' ' HG2' ' A' ' 32' ' ' LYS . 54.1 t30 -80.8 -48.17 12.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -0.952 . . . . 0.0 109.504 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.917 ' O ' HG22 ' A' ' 33' ' ' VAL . 70.1 mt -64.88 -34.08 77.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.564 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.2 m-85 -43.68 -63.0 1.15 Allowed Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.186 -0.946 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.526 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.6 Cg_endo -70.35 -44.89 1.46 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.822 2.348 . . . . 0.0 111.904 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.434 ' HG2' ' O ' ' A' ' 28' ' ' ASN . 18.1 mmtt -60.21 -44.01 95.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.168 -0.957 . . . . 0.0 109.639 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.917 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -79.21 -29.85 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.557 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.63 72.71 17.33 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.544 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.4 ' N ' ' O ' ' A' ' 31' ' ' PRO . 48.4 Cg_endo -70.2 -18.67 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.609 2.206 . . . . 0.0 111.663 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -74.65 -17.19 60.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.325 -0.859 . . . . 0.0 109.37 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.01 -47.61 6.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.277 -0.889 . . . . 0.0 109.335 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' HG23 ' A' ' 56' ' ' ILE . 73.8 mt -127.87 120.16 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.287 -0.883 . . . . 0.0 109.368 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -66.3 -34.22 77.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.423 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.2 t -168.45 147.72 4.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.651 HG21 ' O ' ' A' ' 27' ' ' ASP . 34.0 m -122.04 140.07 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -135.98 142.47 44.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.298 -0.876 . . . . 0.0 109.403 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.433 ' HA ' ' HD2' ' A' ' 54' ' ' LYS . 43.4 t30 -90.63 109.6 20.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.212 -0.93 . . . . 0.0 109.446 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.783 HG22 ' HG3' ' A' ' 45' ' ' GLU . 94.7 mt -67.05 -48.2 79.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.27 -0.894 . . . . 0.0 109.444 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.783 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.8 mt-10 -151.11 159.48 44.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.264 -0.897 . . . . 0.0 109.496 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.56 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.81 168.56 40.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -130.41 33.28 4.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.172 -1.193 . . . . 0.0 109.515 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.76 6.78 56.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -106.63 -167.95 22.64 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.3 Cg_endo -68.32 138.53 43.09 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.728 2.285 . . . . 0.0 111.702 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.21 29.73 40.01 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.737 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.7 m -103.01 137.35 41.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -1.128 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.641 HG22 HD12 ' A' ' 44' ' ' ILE . 24.2 mm -105.64 134.19 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.381 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.503 ' NZ ' ' HB ' ' A' ' 41' ' ' VAL . 18.6 tptm -124.39 131.34 53.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.582 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 61.4 tttt -99.37 130.18 45.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.279 -0.888 . . . . 0.0 109.418 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.623 HG23 ' CG2' ' A' ' 38' ' ' ILE . 86.3 mt -116.98 140.68 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.932 . . . . 0.0 109.468 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.8 t -110.11 152.08 26.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -0.89 . . . . 0.0 109.363 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -120.1 125.86 27.11 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.916 . . . . 0.0 109.673 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -83.76 34.09 0.52 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.733 2.288 . . . . 0.0 112.031 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -114.26 172.04 7.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.123 -0.986 . . . . 0.0 109.592 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -87.96 9.03 76.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.484 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 0.6 OUTLIER -49.13 171.86 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.164 -1.198 . . . . 0.0 109.33 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.26 -29.04 32.99 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.704 2.269 . . . . 0.0 111.792 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.596 ' CE2' ' HA2' ' A' ' 89' ' ' GLY . 92.3 m-85 -107.3 157.07 18.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.913 . . . . 0.0 109.318 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -118.44 -19.55 8.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.536 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.48 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.0 p90 -148.03 159.87 43.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.26 -0.9 . . . . 0.0 109.624 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.877 HG23 ' HA2' ' A' ' 88' ' ' GLY . 12.5 p -137.15 146.25 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.357 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.965 ' O ' HG23 ' A' ' 85' ' ' VAL . 46.7 mttm -92.46 138.11 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.593 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -133.52 163.33 29.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -0.91 . . . . 0.0 109.378 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.508 ' NH1' ' OD2' ' A' ' 72' ' ' ASP . 70.6 ttp85 -139.79 148.98 42.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.865 . . . . 0.0 109.558 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -100.01 135.98 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.356 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.508 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 82.9 m-20 -81.3 -48.73 11.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.24 -0.913 . . . . 0.0 109.632 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 88.1 tt0 177.6 147.32 0.13 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.187 -0.946 . . . . 0.0 109.496 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.9 p -126.27 127.87 71.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.447 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 79' ' ' PHE . 88.6 m-20 -102.45 109.03 20.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.265 -0.897 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -64.62 -44.91 89.04 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.32 -0.863 . . . . 0.0 109.448 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 54.9 m -64.64 -41.86 95.84 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.414 ' O ' ' C ' ' A' ' 79' ' ' PHE . 79.4 m-20 -90.46 4.73 50.19 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.559 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 86.9 m-85 44.11 28.51 0.27 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.474 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -97.65 126.39 42.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.1 t80 -121.01 119.61 33.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.218 -0.926 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -118.54 137.67 53.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.611 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.2 p90 -150.19 159.58 44.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.269 -0.894 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 81.7 p -153.86 164.14 38.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.177 -0.952 . . . . 0.0 109.55 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.965 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.6 p -111.9 138.94 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.205 -0.935 . . . . 0.0 109.369 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.5 pt -112.9 -26.36 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.465 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 94.3 mt-10 -128.5 119.16 24.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.877 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -142.09 170.72 24.85 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.596 ' HA2' ' CE2' ' A' ' 64' ' ' PHE . . . -63.05 -68.15 1.78 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -71.07 2.4 4.31 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.737 2.291 . . . . 0.0 112.023 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 40.8 mt -116.85 136.06 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.106 -0.996 . . . . 0.0 109.645 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.51 -131.61 6.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.074 -1.61 . . . . 0.0 109.074 179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.594 ' CG ' HG22 ' A' ' 94' ' ' THR . 22.1 p-10 -66.95 -42.87 84.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.214 -1.168 . . . . 0.0 109.091 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.594 HG22 ' CG ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -158.99 21.19 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.326 -0.859 . . . . 0.0 109.421 179.903 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.488 HD12 ' N ' ' A' ' 95' ' ' LEU . 6.9 mp -62.34 -43.83 97.91 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.184 -0.948 . . . . 0.0 110.045 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -154.09 50.5 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.02 -1.05 . . . . 0.0 109.981 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 32.8 ttpt -64.66 132.63 50.25 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.079 -1.013 . . . . 0.0 108.726 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 62.2 mt -119.29 129.81 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.081 -1.012 . . . . 0.0 110.336 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 48.9 m -119.1 132.63 56.02 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 87.8 m-20 -122.96 138.25 54.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.018 -1.051 . . . . 0.0 110.352 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -115.32 137.63 51.83 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 81' ' ' TYR . 68.6 mt -120.79 135.61 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.062 -1.024 . . . . 0.0 110.178 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 40.6 tttt -133.88 128.26 34.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.38 -0.825 . . . . 0.0 109.071 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.763 HD12 ' HD2' ' A' ' 19' ' ' PHE . 66.6 mt -109.47 135.69 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.0 t -127.67 137.95 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.262 -0.899 . . . . 0.0 109.271 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -102.09 147.62 26.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.197 -0.939 . . . . 0.0 109.636 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.478 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 13.6 p -129.49 160.24 65.37 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.892 . . . . 0.0 109.284 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.478 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.7 Cg_endo -70.38 -50.23 0.41 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.755 2.303 . . . . 0.0 112.112 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -129.98 27.24 5.17 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.927 . . . . 0.0 109.691 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.425 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.85 23.11 4.22 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 59.28 -143.76 45.85 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.4 p -117.26 151.3 37.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.319 -1.107 . . . . 0.0 109.474 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 72.1 mt -113.19 129.77 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.474 ' HB2' ' OG1' ' A' ' 9' ' ' THR . 69.2 mt -103.97 138.62 40.27 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.658 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.454 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 28.0 mttt -127.44 118.51 24.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.298 -0.876 . . . . 0.0 109.2 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.4 mt -120.29 135.1 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.145 -0.972 . . . . 0.0 109.892 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -117.66 139.23 51.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.104 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' TYR . 20.3 m120 -115.77 139.36 50.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.169 -0.957 . . . . 0.0 109.943 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 55.0 mttm -131.57 137.85 48.62 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.456 -0.777 . . . . 0.0 108.971 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -119.72 131.01 55.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.13 -0.981 . . . . 0.0 109.764 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.489 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.2 m-70 -114.52 134.49 54.98 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.277 -0.889 . . . . 0.0 109.32 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.531 HG21 HG23 ' A' ' 128' ' ' VAL . 56.6 p -130.03 138.03 50.56 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.126 -0.984 . . . . 0.0 109.731 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 16.4 tttp -52.28 -35.2 49.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.469 -0.769 . . . . 0.0 109.493 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.33 -46.9 1.0 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -64.95 -31.38 72.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -1.175 . . . . 0.0 109.555 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.411 ' O ' ' HB ' ' A' ' 122' ' ' THR . 97.4 m-70 -110.95 141.28 44.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.255 -0.903 . . . . 0.0 109.49 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -118.11 164.67 14.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 109.55 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.531 HG23 HG21 ' A' ' 122' ' ' THR . 22.2 t -102.19 135.52 38.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.873 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 26.3 mtmt -86.33 143.67 27.75 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.539 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.12 -36.68 82.51 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.464 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -57.07 -41.91 79.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -60.99 -35.28 76.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.384 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 95.1 t -68.74 -39.66 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -57.57 -47.58 81.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.578 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.28 -44.07 96.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.524 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.5 t -59.67 -39.75 85.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.229 -0.919 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 25.2 tttm -60.71 -39.93 90.38 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.298 -0.876 . . . . 0.0 109.477 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -61.23 -43.21 99.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.298 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.8 mmm -62.95 -44.73 95.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.88 . . . . 0.0 109.382 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.14 -40.09 93.17 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.8 mt-10 -70.73 -33.28 70.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -1.162 . . . . 0.0 109.394 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -63.45 -31.06 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 109.271 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 143' ' ' LEU . 24.1 mt -69.85 -49.74 49.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 109.733 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.5 pp -71.52 -30.62 66.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.103 -0.998 . . . . 0.0 109.68 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 56.5 mtp180 -66.7 -40.05 88.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 109.374 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -65.84 -43.82 87.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.869 . . . . 0.0 109.465 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 73.3 t -59.55 -48.56 86.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.893 . . . . 0.0 109.437 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.4 mt-10 -54.88 -47.83 73.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.216 -0.928 . . . . 0.0 109.318 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.1 t -56.92 -34.44 67.95 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.24 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.561 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 71.8 t80 -61.37 -43.41 98.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.333 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.632 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -61.54 -39.82 92.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.353 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.557 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -70.63 -23.38 62.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 109.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.412 ' O ' ' CG ' ' A' ' 156' ' ' ASP . . . -63.32 -40.35 97.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.561 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 71.0 m-70 -46.9 -24.79 0.65 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 48.7 m -60.66 -30.35 69.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.263 -0.898 . . . . 0.0 109.535 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.412 ' CG ' ' O ' ' A' ' 153' ' ' ALA . 19.3 p30 -87.19 13.67 9.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -0.882 . . . . 0.0 109.507 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.05 141.94 58.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.396 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.413 ' O ' ' C ' ' A' ' 159' ' ' ASN . 23.0 t80 -46.68 -54.3 9.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.31 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' TYR . 69.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.493 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 120' ' ' TYR . 64.3 t -134.54 136.94 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -1.128 . . . . 0.0 109.334 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.511 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 39.9 m-85 -95.37 151.64 19.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 109.608 -179.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -131.96 124.86 30.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.333 -0.854 . . . . 0.0 109.485 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.511 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 59.4 m-85 -131.55 111.47 11.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.527 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 24.5 pt-20 -116.16 154.65 29.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.89 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 61.8 p -134.83 163.6 29.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.601 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -125.28 127.13 46.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.312 -0.867 . . . . 0.0 109.405 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 75.9 m -129.08 149.55 50.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.0 m -122.65 137.78 54.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.158 -0.964 . . . . 0.0 109.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 22.6 p -137.65 146.64 44.11 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.426 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.4 m -78.62 -21.64 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.503 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.83 HG21 HD13 ' A' ' 151' ' ' LEU . 28.4 mm -56.87 144.47 67.19 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.377 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.1 Cg_endo -69.58 134.88 29.47 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.553 2.169 . . . . 0.0 111.645 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.525 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -63.23 -24.4 67.86 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.228 -0.92 . . . . 0.0 109.72 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.74 -49.56 67.98 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.114 -0.992 . . . . 0.0 109.556 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 83.5 mtt-85 -78.68 -39.51 36.55 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.904 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.91 -35.83 79.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.331 -0.856 . . . . 0.0 109.478 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 23' ' ' ILE . 58.9 t80 -69.81 -43.43 72.08 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.203 -0.936 . . . . 0.0 109.831 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' LEU . 75.6 mttt -73.85 -47.51 37.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.124 -0.985 . . . . 0.0 109.984 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.89 -48.46 65.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.163 -0.961 . . . . 0.0 109.943 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.477 ' HB3' ' O ' ' A' ' 18' ' ' LEU . 66.0 t80 -65.1 -24.7 67.51 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.983 . . . . 0.0 109.891 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 19' ' ' PHE . 54.4 mt -103.77 -64.17 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.084 -1.01 . . . . 0.0 109.763 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.507 ' N ' ' O ' ' A' ' 20' ' ' LYS . 36.5 mt -61.46 -38.86 88.75 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.107 -0.996 . . . . 0.0 109.321 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 90.9 m-20 -107.57 18.84 20.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.364 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.53 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -72.5 -24.59 75.99 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -73.85 -42.63 60.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -1.097 . . . . 0.0 109.497 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.433 ' O ' ' HG2' ' A' ' 31' ' ' PRO . 21.0 m-20 -88.77 -39.68 13.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.247 -0.908 . . . . 0.0 109.525 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.577 ' O ' HG22 ' A' ' 33' ' ' VAL . 12.1 tp -63.86 -35.4 80.5 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -0.907 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 2.0 m-30 -48.72 -61.32 3.37 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.0 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.1 Cg_endo -70.47 -44.07 1.76 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.844 2.363 . . . . 0.0 111.574 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 5.3 tttm -51.77 -43.25 62.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.87 . . . . 0.0 109.641 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.4 m -87.99 -35.03 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.183 -0.948 . . . . 0.0 109.719 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -131.25 68.71 81.82 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.077 -1.014 . . . . 0.0 109.855 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 31' ' ' PRO . 51.4 Cg_endo -71.55 -15.45 30.7 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.508 2.139 . . . . 0.0 111.537 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -80.07 -14.79 58.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.282 -0.886 . . . . 0.0 109.305 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -94.64 -44.86 7.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -0.91 . . . . 0.0 109.263 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.452 ' CG2' HG23 ' A' ' 56' ' ' ILE . 85.3 mt -127.5 119.82 53.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.306 -0.871 . . . . 0.0 109.222 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.6 t -58.67 -37.38 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.189 -0.945 . . . . 0.0 109.503 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 32.7 t -170.7 147.54 2.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 109.416 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.3 t -110.88 136.92 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.228 -0.92 . . . . 0.0 109.641 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -135.75 155.08 50.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.312 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 84.4 m-20 -102.71 105.5 15.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.9 . . . . 0.0 109.667 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.01 HD12 HG22 ' A' ' 53' ' ' ILE . 82.3 mt -55.68 -61.18 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.245 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.782 ' O ' HG23 ' A' ' 52' ' ' THR . 80.3 tt0 -140.46 157.14 45.96 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 91.39 172.53 43.06 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -130.65 28.98 4.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.233 -1.157 . . . . 0.0 109.376 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.33 -19.39 26.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -71.11 -171.88 12.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -71.13 146.9 52.98 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.636 2.224 . . . . 0.0 111.975 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.99 15.18 81.89 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.782 HG23 ' O ' ' A' ' 45' ' ' GLU . 67.2 m -86.93 137.48 32.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.08 -1.247 . . . . 0.0 109.479 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 1.01 HG22 HD12 ' A' ' 44' ' ' ILE . 72.2 mt -108.51 132.05 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.5 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 17.8 mttp -118.91 142.51 47.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.342 -0.849 . . . . 0.0 109.398 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.6 tttp -102.37 127.38 49.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.488 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.458 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 73.4 mt -108.16 132.8 54.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.458 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 38' ' ' ILE . 56.4 m -110.96 154.88 23.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.446 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' LYS . 9.6 m-85 -120.83 147.76 46.85 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.91 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.5 152.03 65.24 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.264 . . . . 0.0 111.721 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -55.33 143.07 29.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.81 10.52 40.13 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -111.2 167.79 8.53 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.269 -1.136 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.6 -45.09 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.636 2.224 . . . . 0.0 111.603 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -113.11 163.62 14.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.25 -0.906 . . . . 0.0 109.414 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' N ' ' A' ' 58' ' ' PHE . 36.4 tttt -95.1 -62.99 1.21 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.465 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.458 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 38.8 p90 -136.72 165.69 25.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.539 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.0 t -139.42 157.57 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.872 ' O ' HG13 ' A' ' 85' ' ' VAL . 54.1 mttp -97.99 134.15 41.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.536 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -128.37 144.95 51.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.372 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 49.3 ttp180 -134.0 144.69 48.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.634 HG22 ' OH ' ' A' ' 81' ' ' TYR . 37.4 t -98.83 133.47 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.488 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.428 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 91.7 m-20 -79.33 -48.2 14.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.234 -0.916 . . . . 0.0 109.574 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.6 tt0 179.53 141.57 0.13 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 0.0 109.395 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -123.95 131.63 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.3 -0.875 . . . . 0.0 109.562 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -110.47 103.93 12.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.33 -0.856 . . . . 0.0 109.384 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 63.2 m170 -62.49 -41.41 98.78 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.561 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 60.9 m -58.01 -44.47 87.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' A' ' 79' ' ' PHE . 86.1 m-20 -93.23 9.11 37.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.474 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.481 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.3 m-85 44.27 28.94 0.32 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.248 -0.908 . . . . 0.0 109.699 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -101.83 127.61 48.56 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.107 -0.995 . . . . 0.0 109.456 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.634 ' OH ' HG22 ' A' ' 71' ' ' VAL . 73.0 t80 -121.27 119.65 32.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.219 -0.926 . . . . 0.0 109.387 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.9 m-20 -117.92 131.73 56.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.571 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.529 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 38.7 p90 -145.27 152.32 39.76 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.284 -0.885 . . . . 0.0 109.344 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.475 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 86.9 p -145.98 156.56 43.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -0.926 . . . . 0.0 109.538 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 68' ' ' LYS . 48.7 t -96.88 137.51 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.331 -0.856 . . . . 0.0 109.356 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.437 HG13 ' N ' ' A' ' 87' ' ' GLU . 28.8 pt -109.35 -28.05 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.207 -0.933 . . . . 0.0 109.33 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 85.2 tt0 -134.77 117.24 15.76 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.351 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.539 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -139.01 159.51 25.56 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.502 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.08 -59.25 10.97 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 50.5 Cg_endo -72.25 -4.49 15.31 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.736 2.291 . . . . 0.0 111.733 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.454 ' O ' ' O ' ' A' ' 88' ' ' GLY . 40.2 mt -117.59 150.19 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.269 -0.894 . . . . 0.0 109.548 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.472 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -121.58 -133.7 4.4 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -65.82 -45.76 81.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -1.15 . . . . 0.0 109.123 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.638 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -157.57 20.46 0.28 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.365 -0.835 . . . . 0.0 109.447 179.851 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.557 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.5 mp -63.41 -44.31 95.0 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.203 -0.935 . . . . 0.0 110.028 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' HD13 ' A' ' 91' ' ' ILE . 69.1 tt0 -154.03 50.2 0.65 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.962 -1.086 . . . . 0.0 109.956 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 27.0 ttpt -64.62 132.33 49.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.173 -0.954 . . . . 0.0 108.715 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 45.9 mt -117.93 133.82 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -0.994 . . . . 0.0 110.333 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.475 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 42.4 t -120.54 120.62 36.35 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.529 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 68.6 m-20 -110.15 143.89 39.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.169 -0.957 . . . . 0.0 110.127 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 43.5 mt-10 -127.94 125.69 40.02 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 66.1 mt -113.12 137.71 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 110.119 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -132.02 128.39 38.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.401 -0.812 . . . . 0.0 109.006 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.66 HD12 ' HD2' ' A' ' 19' ' ' PHE . 67.8 mt -110.54 135.63 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.958 . . . . 0.0 109.81 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.91 139.69 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.253 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -103.53 139.96 38.16 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 109.632 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.434 ' OG1' ' C ' ' A' ' 110' ' ' GLY . 12.7 p -122.42 157.6 58.43 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.281 -0.887 . . . . 0.0 109.348 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.401 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 51.2 Cg_endo -70.92 -47.15 0.61 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.716 2.277 . . . . 0.0 112.064 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 88.6 m-20 -133.8 27.23 3.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.209 -0.932 . . . . 0.0 109.688 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.434 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -131.18 24.5 4.21 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 58.93 -146.39 42.5 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 66.1 p -118.81 150.18 40.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -1.149 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 84.8 mt -110.09 133.83 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 109.27 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.497 ' CD2' HG12 ' A' ' 104' ' ' ILE . 96.4 mt -111.28 135.07 52.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.167 -0.958 . . . . 0.0 109.536 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -128.98 129.21 45.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.375 -0.828 . . . . 0.0 109.172 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.465 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 52.7 mt -125.32 126.18 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.21 -0.931 . . . . 0.0 109.806 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 28.6 t -113.77 131.19 56.3 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.365 -0.834 . . . . 0.0 109.064 179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -121.43 149.57 42.83 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.971 . . . . 0.0 110.032 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.3 mttp -137.08 140.43 41.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.379 -0.825 . . . . 0.0 108.826 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.446 ' CD1' HG12 ' A' ' 98' ' ' ILE . 93.9 m-85 -114.48 127.72 55.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.055 . . . . 0.0 109.758 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.0 m-70 -109.74 133.16 53.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.353 -0.842 . . . . 0.0 109.227 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.666 HG21 HG23 ' A' ' 128' ' ' VAL . 52.3 p -130.86 137.82 49.54 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.159 -0.963 . . . . 0.0 109.649 179.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.638 ' HB2' HG23 ' A' ' 94' ' ' THR . 50.2 tttt -53.46 -36.15 61.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.55 -0.719 . . . . 0.0 109.39 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.32 -50.62 0.86 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -59.91 -25.51 65.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -1.123 . . . . 0.0 109.636 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -112.54 138.21 49.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.958 . . . . 0.0 109.434 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -114.39 158.49 21.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.666 HG23 HG21 ' A' ' 122' ' ' THR . 17.5 t -109.31 133.5 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -0.882 . . . . 0.0 109.493 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 75.1 mttt -86.01 147.72 26.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.492 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -54.95 -39.88 69.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.865 . . . . 0.0 109.404 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -55.65 -44.89 77.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.583 ' OE1' HG13 ' A' ' 128' ' ' VAL . 93.8 mt-30 -52.93 -39.96 63.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.483 HG12 ' HE3' ' A' ' 137' ' ' LYS . 46.1 t -68.0 -39.4 81.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.309 -0.869 . . . . 0.0 109.608 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -54.53 -43.97 72.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.654 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 139' ' ' MET . . . -59.37 -48.39 81.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.255 -0.903 . . . . 0.0 109.646 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 25.2 t -64.99 -33.38 75.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.507 ' NZ ' ' HB3' ' A' ' 5' ' ' TYR . 42.3 mttt -64.67 -42.0 95.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.568 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -67.06 -40.2 87.04 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 109.568 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.441 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 95.6 mmm -58.11 -39.52 78.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.14 -41.2 95.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 82.5 tt0 -70.0 -29.75 66.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.292 -1.122 . . . . 0.0 109.415 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.8 m -71.94 -31.11 66.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.225 -0.922 . . . . 0.0 109.297 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 139' ' ' MET . 35.3 mt -73.41 -46.25 49.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.301 -0.874 . . . . 0.0 109.475 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.623 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -73.11 -31.52 64.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.566 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.473 ' N ' HD12 ' A' ' 144' ' ' LEU . 16.7 ttp180 -64.92 -43.56 92.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.243 -0.91 . . . . 0.0 109.496 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -65.05 -33.73 76.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.552 HG13 HD21 ' A' ' 29' ' ' LEU . 54.8 t -68.08 -48.4 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.154 -0.966 . . . . 0.0 109.542 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.505 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.3 tt0 -58.53 -41.39 85.39 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 23.2 t -59.71 -39.69 85.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.305 -0.872 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 68.1 t80 -65.5 -43.47 90.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.83 HD13 HG21 ' A' ' 13' ' ' ILE . 40.1 mt -63.75 -35.94 82.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.223 -0.923 . . . . 0.0 109.475 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 148' ' ' GLU . 4.1 mm? -74.77 -19.35 60.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -63.5 -35.46 80.52 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.253 -0.904 . . . . 0.0 109.574 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -50.26 -40.8 49.04 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.601 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.7 p -59.68 -28.27 67.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.216 -0.928 . . . . 0.0 109.658 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.43 -15.28 60.45 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.23 -0.919 . . . . 0.0 109.613 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -76.75 146.47 37.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -46.44 -58.04 4.12 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.161 -0.962 . . . . 0.0 109.207 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.412 179.87 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.634 HG11 ' CE1' ' A' ' 121' ' ' HIS . 47.7 t -134.38 139.91 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.197 -1.178 . . . . 0.0 109.423 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.495 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 84.5 m-85 -93.33 134.52 35.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.49 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -120.88 121.73 38.72 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 94.2 m-85 -122.0 140.16 52.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.456 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.488 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.8 mt-10 -125.26 141.14 52.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.271 -0.893 . . . . 0.0 109.627 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 28.3 p -125.11 156.42 38.32 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.421 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -124.88 135.93 53.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.201 -0.937 . . . . 0.0 109.544 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.415 ' HB ' ' HB2' ' A' ' 114' ' ' LEU . 53.0 m -139.76 142.05 36.79 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.387 -0.82 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.8 m -119.48 143.92 47.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.16 -0.963 . . . . 0.0 109.559 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.2 p -149.94 152.54 35.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.282 -0.886 . . . . 0.0 109.402 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.82 -29.66 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 109.376 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.563 HG23 ' HD2' ' A' ' 14' ' ' PRO . 28.4 mm -53.57 142.27 41.95 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.192 -0.942 . . . . 0.0 109.323 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 13' ' ' ILE . 49.5 Cg_endo -70.72 148.41 58.81 Favored 'Trans proline' 0 C--O 1.216 -0.602 0 C-N-CA 122.558 2.172 . . . . 0.0 111.88 -179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.885 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -74.78 -18.66 60.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.309 -0.87 . . . . 0.0 109.623 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.47 -48.48 33.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.618 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.1 mtt180 -75.6 -40.36 56.59 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.296 -0.877 . . . . 0.0 109.493 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.827 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -65.48 -42.3 92.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.165 -0.959 . . . . 0.0 109.356 179.961 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.486 ' HD1' HD12 ' A' ' 104' ' ' ILE . 63.3 t80 -63.12 -42.13 99.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.481 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 42.5 mttp -70.13 -45.8 66.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.207 -0.933 . . . . 0.0 109.698 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -77.17 -28.65 54.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.96 . . . . 0.0 109.752 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.519 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 70.6 t80 -79.0 -23.67 44.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.09 -1.006 . . . . 0.0 109.228 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 19' ' ' PHE . 40.0 mm -105.68 -62.39 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.321 -0.862 . . . . 0.0 109.428 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 46.7 mt -64.13 -36.93 85.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.305 -0.872 . . . . 0.0 109.333 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.478 ' HB3' HD13 ' A' ' 29' ' ' LEU . 67.0 m-20 -111.84 18.82 18.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.324 -0.86 . . . . 0.0 109.327 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.466 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -69.45 -29.88 71.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -72.62 -33.8 66.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -1.11 . . . . 0.0 109.525 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 78.4 m-20 -85.8 -40.71 15.74 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.92 . . . . 0.0 109.264 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.597 ' O ' HG22 ' A' ' 33' ' ' VAL . 6.4 mp -71.09 -33.65 70.39 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.267 179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.541 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.1 m-30 -44.39 -63.75 1.02 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.257 -0.902 . . . . 0.0 109.232 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.541 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.3 Cg_endo -71.49 -46.4 0.64 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.521 2.148 . . . . 0.0 111.424 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 21.0 tttt -48.66 -44.16 37.38 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.848 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.748 ' HB ' ' HB1' ' A' ' 146' ' ' ALA . 3.2 m -84.67 -33.31 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 110.053 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.32 75.83 38.84 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.16 -0.963 . . . . 0.0 109.881 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -72.78 -13.86 26.87 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.443 2.095 . . . . 0.0 111.269 179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -86.08 -9.34 56.88 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.395 -0.816 . . . . 0.0 109.418 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.537 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -96.53 -43.07 7.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 108.923 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.424 HG12 ' CG2' ' A' ' 56' ' ' ILE . 97.0 mt -129.48 119.71 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.362 -0.837 . . . . 0.0 109.095 179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.9 t -63.71 -28.56 69.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.93 . . . . 0.0 109.871 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.3 t -174.86 146.79 0.94 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.128 -0.982 . . . . 0.0 109.589 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.2 t -112.15 132.43 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.424 ' O ' ' N ' ' A' ' 55' ' ' LYS . 38.6 tt0 -130.08 147.36 51.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.862 . . . . 0.0 109.291 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 77.8 m-20 -100.65 116.8 33.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.016 HD11 ' HB2' ' A' ' 55' ' ' LYS . 23.6 mm -70.11 -47.7 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.404 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.82 ' O ' HG23 ' A' ' 52' ' ' THR . 96.8 mt-10 -154.72 151.81 29.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.328 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.429 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 91.87 177.01 42.5 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -135.06 37.55 3.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -1.2 . . . . 0.0 109.667 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.491 ' H ' HG21 ' A' ' 52' ' ' THR . . . 103.39 -11.6 54.54 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.756 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -77.44 -172.07 37.22 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 51.3 Cg_endo -71.34 140.25 36.55 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.735 2.29 . . . . 0.0 111.912 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 83.3 2.79 90.31 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.82 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -75.09 133.98 41.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.087 -1.243 . . . . 0.0 109.504 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 44' ' ' ILE . 44.8 mt -107.96 126.38 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.212 -0.93 . . . . 0.0 109.509 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 31.7 mttm -121.06 139.63 53.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.498 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 1.016 ' HB2' HD11 ' A' ' 44' ' ' ILE . 23.7 tttm -98.6 127.6 44.59 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.197 -0.939 . . . . 0.0 109.411 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.424 ' CG2' HG12 ' A' ' 38' ' ' ILE . 89.4 mt -103.6 131.11 52.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.576 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.402 ' O ' HG23 ' A' ' 38' ' ' ILE . 32.3 t -103.51 155.15 18.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.315 -0.866 . . . . 0.0 109.544 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 37' ' ' ALA . 53.5 m-85 -132.25 144.89 55.0 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.245 -0.909 . . . . 0.0 109.557 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.08 149.06 57.85 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.759 2.306 . . . . 0.0 111.774 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -52.64 150.94 4.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.194 -0.941 . . . . 0.0 109.5 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.53 14.64 10.29 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.459 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 2.0 m-85 -135.27 172.16 7.69 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.371 -1.076 . . . . 0.0 109.296 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.518 ' HG2' ' CD1' ' A' ' 64' ' ' PHE . 48.0 Cg_endo -69.23 -43.73 2.9 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.601 2.201 . . . . 0.0 111.714 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.518 ' CD1' ' HG2' ' A' ' 63' ' ' PRO . 23.8 p90 -109.9 166.34 11.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.175 -0.953 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -106.48 -37.56 6.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.162 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.423 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 40.6 p90 -143.5 162.51 35.65 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.44 -0.787 . . . . 0.0 109.076 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.66 HG13 ' HA2' ' A' ' 88' ' ' GLY . 17.2 t -138.27 150.84 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.17 -0.956 . . . . 0.0 109.715 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 29.4 mttm -87.36 127.85 35.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.354 -0.841 . . . . 0.0 109.394 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.482 ' HA ' HG12 ' A' ' 85' ' ' VAL . 23.3 t70 -126.62 138.87 53.5 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 36.9 ttt180 -141.06 150.09 42.49 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.171 -0.956 . . . . 0.0 109.54 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 49' ' ' GLY . 12.8 p -97.73 135.22 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.304 -0.873 . . . . 0.0 109.523 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -81.96 -43.92 17.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.369 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 86.1 tt0 -168.2 149.49 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.302 -0.874 . . . . 0.0 109.322 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 81' ' ' TYR . 48.4 t -125.85 130.51 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.547 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -115.85 99.82 7.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.199 -0.938 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -67.8 -41.86 82.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.187 -0.945 . . . . 0.0 109.349 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 89.0 m -65.63 -40.86 93.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.368 -0.832 . . . . 0.0 109.337 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -92.12 7.03 44.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.36 -0.837 . . . . 0.0 109.387 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 43.63 31.34 0.44 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.974 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 37.4 tttt -105.43 128.31 53.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.451 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.494 ' CD1' HG22 ' A' ' 74' ' ' VAL . 72.1 t80 -122.15 120.91 35.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.375 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -118.93 135.77 54.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.656 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.411 ' HB3' ' CE2' ' A' ' 81' ' ' TYR . 38.0 p90 -149.69 153.71 37.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.344 -0.848 . . . . 0.0 109.387 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 90.4 p -150.0 158.12 43.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 69' ' ' ASP . 27.6 m -105.23 144.49 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.307 -0.871 . . . . 0.0 109.535 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.507 HG13 ' N ' ' A' ' 87' ' ' GLU . 14.6 pt -107.82 -25.98 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.211 -0.931 . . . . 0.0 109.402 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.507 ' N ' HG13 ' A' ' 86' ' ' ILE . 76.9 mt-10 -135.04 107.88 7.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.34 -0.85 . . . . 0.0 109.227 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.66 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -121.23 167.58 14.16 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.498 ' HA3' ' HB3' ' A' ' 64' ' ' PHE . . . -57.83 -61.41 7.49 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 89' ' ' GLY . 51.1 Cg_endo -72.36 3.31 4.24 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.795 2.33 . . . . 0.0 111.899 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 97' ' ' LYS . 63.6 mt -117.78 139.57 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.128 -0.983 . . . . 0.0 109.214 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' CA ' HD12 ' A' ' 95' ' ' LEU . . . -128.46 -128.88 3.13 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -65.02 73.13 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.355 -1.085 . . . . 0.0 109.576 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER 52.59 60.97 3.44 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.315 -0.866 . . . . 0.0 109.088 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.527 HD12 ' CA ' ' A' ' 92' ' ' GLY . 5.2 mt -111.34 -14.85 13.72 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.499 -0.751 . . . . 0.0 109.437 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 71.0 tt0 -174.81 49.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 91' ' ' ILE . 3.5 ttmt -64.82 137.64 57.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.296 -0.878 . . . . 0.0 109.017 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.475 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 34.3 mt -120.75 128.22 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.119 -0.988 . . . . 0.0 110.04 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 50.2 m -118.78 126.23 51.4 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.314 -0.866 . . . . 0.0 108.862 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.423 ' HA ' ' O ' ' A' ' 117' ' ' SER . 23.4 t-20 -112.92 139.15 48.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.11 -0.994 . . . . 0.0 110.218 -179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.6 mt-10 -119.7 127.67 53.08 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.373 -0.829 . . . . 0.0 108.841 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.415 ' O ' ' N ' ' A' ' 81' ' ' TYR . 59.0 mt -112.98 135.24 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.112 -0.993 . . . . 0.0 110.323 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 15.8 tttt -133.91 123.54 24.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.885 HG22 ' CB ' ' A' ' 15' ' ' ALA . 41.2 mt -110.5 134.42 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.085 -1.01 . . . . 0.0 110.065 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 4.7 m -133.38 144.21 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.26 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.96 149.11 26.01 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.552 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.477 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 11.3 p -124.0 160.94 49.67 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.237 -0.914 . . . . 0.0 109.433 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.477 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.4 Cg_endo -70.97 -46.22 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.714 2.276 . . . . 0.0 112.221 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.434 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 82.9 m-20 -135.44 29.02 3.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 0.0 109.674 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -137.14 34.76 2.16 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 50.9 -150.43 6.24 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -113.66 148.92 35.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.22 -1.165 . . . . 0.0 109.45 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 69.8 mt -110.59 126.38 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.377 -0.827 . . . . 0.0 109.429 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.474 ' CD2' HG23 ' A' ' 104' ' ' ILE . 76.0 mt -100.15 139.77 35.35 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.551 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.6 mttt -128.18 116.6 20.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.513 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 67.2 mt -117.05 138.48 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.596 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 37.2 t -124.61 122.68 38.21 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.36 -0.837 . . . . 0.0 109.463 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.403 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 21.6 m120 -102.71 134.81 45.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.735 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 34.7 mttp -122.88 145.87 48.07 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.848 . . . . 0.0 108.978 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.581 ' CE1' HG13 ' A' ' 133' ' ' VAL . 98.9 m-85 -125.22 128.86 48.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.057 -1.027 . . . . 0.0 109.69 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.634 ' CE1' HG11 ' A' ' 2' ' ' VAL . 90.3 m-70 -113.86 128.75 56.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.286 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.82 HG21 HG23 ' A' ' 128' ' ' VAL . 30.3 p -126.01 142.82 51.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.539 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 94' ' ' THR . 28.6 tttt -55.02 -33.66 62.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.425 -0.797 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 133.49 -50.81 0.86 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -59.71 -26.66 65.78 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.178 -1.19 . . . . 0.0 109.46 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -112.77 137.68 50.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.372 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -110.98 161.44 15.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.82 HG23 HG21 ' A' ' 122' ' ' THR . 38.2 t -105.16 133.88 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.368 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -89.65 150.52 22.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.549 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -58.35 -42.56 87.19 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.28 -0.887 . . . . 0.0 109.404 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -52.86 -47.74 67.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 109.522 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -52.64 -41.9 64.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 120' ' ' TYR . 43.0 t -66.64 -41.27 87.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.216 -0.927 . . . . 0.0 109.549 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 54.2 mtpt -52.37 -45.27 65.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.314 -0.866 . . . . 0.0 109.592 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -60.97 -48.5 81.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.163 -0.961 . . . . 0.0 109.522 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 19.8 t -61.28 -39.99 92.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.564 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.492 ' HE2' ' HB3' ' A' ' 5' ' ' TYR . 19.2 mttt -62.32 -36.01 80.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.161 -0.962 . . . . 0.0 109.548 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -65.65 -38.76 90.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.403 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.9 mmm -63.09 -39.74 95.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.08 -43.28 99.0 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.55 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.2 mt-10 -66.31 -32.05 73.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -1.124 . . . . 0.0 109.483 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 m -70.92 -30.83 67.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.152 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.44 HD23 ' HA ' ' A' ' 143' ' ' LEU . 22.2 mt -74.37 -46.72 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.319 -0.863 . . . . 0.0 109.348 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 144' ' ' LEU . 4.0 pp -73.25 -32.78 64.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.592 ' N ' HD12 ' A' ' 144' ' ' LEU . 32.8 ttt180 -68.04 -37.19 81.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.748 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.88 -43.27 83.93 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.37 -0.831 . . . . 0.0 109.402 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 70.8 t -61.67 -48.66 87.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.402 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.0 tt0 -54.12 -50.41 66.95 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.28 -0.888 . . . . 0.0 109.584 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 70.2 m -51.61 -38.26 53.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.114 -0.992 . . . . 0.0 109.072 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 66.8 t80 -60.05 -42.3 94.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.193 -0.942 . . . . 0.0 109.211 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -63.0 -36.07 82.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.257 -0.902 . . . . 0.0 109.308 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.546 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.1 mm? -72.05 -25.37 61.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.309 -0.869 . . . . 0.0 109.424 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -57.48 -37.72 73.38 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 109.434 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -53.09 -30.45 36.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.561 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 30.6 m -61.59 -29.95 70.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.216 -0.928 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -75.15 -9.5 58.6 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.28 -0.887 . . . . 0.0 109.684 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.428 ' O ' ' C ' ' A' ' 158' ' ' TYR . . . -78.04 148.44 34.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.903 . . . . 0.0 109.455 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.428 ' C ' ' O ' ' A' ' 157' ' ' ALA . 13.8 t80 -44.61 -46.59 10.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.299 -0.875 . . . . 0.0 109.207 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 56.3 m-20 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.446 179.782 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 120' ' ' TYR . 48.5 t -133.37 142.83 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -1.148 . . . . 0.0 109.518 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.596 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 77.9 m-85 -96.26 145.11 25.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.27 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.7 t30 -133.5 109.04 9.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.736 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 87.9 m-85 -116.55 120.18 37.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.205 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 26.9 tt0 -108.01 148.08 30.23 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.132 -0.98 . . . . 0.0 109.369 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.9 p -132.2 154.03 49.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.324 -0.86 . . . . 0.0 109.239 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -126.74 128.14 46.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 109.712 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.464 ' O ' ' N ' ' A' ' 114' ' ' LEU . 27.9 m -139.7 139.3 36.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 109.312 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.632 HG22 HG23 ' A' ' 113' ' ' ILE . 34.6 p -113.8 159.07 20.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.137 -0.977 . . . . 0.0 109.544 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 63.1 m -147.78 143.6 27.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.259 -0.9 . . . . 0.0 109.487 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -68.46 -23.41 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.232 -0.918 . . . . 0.0 109.512 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.844 HG21 HD13 ' A' ' 151' ' ' LEU . 40.8 mm -60.5 143.76 89.55 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.291 -0.881 . . . . 0.0 109.476 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.732 ' HD2' HG23 ' A' ' 13' ' ' ILE . 48.4 Cg_endo -70.27 145.38 54.03 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.562 2.175 . . . . 0.0 111.679 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.621 ' HB3' ' HB2' ' A' ' 106' ' ' ALA . . . -67.21 -28.04 67.74 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.936 . . . . 0.0 109.598 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.72 -45.22 75.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.161 -0.962 . . . . 0.0 109.656 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.483 ' HB3' ' HG2' ' A' ' 14' ' ' PRO . 42.3 ttt85 -75.21 -44.23 47.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -0.907 . . . . 0.0 109.639 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.572 HD23 HD13 ' A' ' 104' ' ' ILE . 2.5 tp -67.46 -38.36 84.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.189 -0.945 . . . . 0.0 109.63 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 79' ' ' PHE . 79.3 t80 -62.38 -46.87 86.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 19.6 mttp -65.31 -47.97 74.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.45 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -73.8 -36.44 65.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.175 -0.953 . . . . 0.0 109.829 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 71.6 t80 -74.85 -24.15 58.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.162 -0.961 . . . . 0.0 109.726 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.7 mm -102.19 -63.17 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.781 -179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.23 -35.92 78.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.743 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 40.5 m-20 -108.35 16.92 22.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -0.935 . . . . 0.0 109.633 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.77 68.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.517 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 96.9 m-20 -73.25 -42.66 62.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.288 -1.125 . . . . 0.0 109.494 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.429 ' HB3' ' HE3' ' A' ' 32' ' ' LYS . 25.2 m-20 -86.26 -44.9 11.76 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.192 -0.942 . . . . 0.0 109.517 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.93 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.3 tp -58.41 -32.79 68.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.242 -0.911 . . . . 0.0 109.632 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.3 m-85 -55.7 -63.78 2.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.139 -0.976 . . . . 0.0 109.569 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.2 Cg_endo -70.96 -32.92 12.81 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.694 2.263 . . . . 0.0 111.877 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.429 ' HE3' ' HB3' ' A' ' 28' ' ' ASN . 76.0 mttt -65.76 -43.53 88.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.68 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.93 HG22 ' O ' ' A' ' 29' ' ' LEU . 15.7 m -80.4 -32.8 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.861 . . . . 0.0 109.636 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.36 72.21 44.97 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.237 -0.914 . . . . 0.0 109.616 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.27 -18.57 39.23 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.663 2.242 . . . . 0.0 111.696 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 54.5 mt-30 -73.29 -21.36 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.908 . . . . 0.0 109.389 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -87.54 -48.32 8.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.414 HD13 HG23 ' A' ' 56' ' ' ILE . 93.4 mt -126.7 125.39 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -0.926 . . . . 0.0 109.428 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.494 ' N ' ' HD3' ' A' ' 59' ' ' PRO . 73.6 m -65.88 -36.33 83.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.181 -0.949 . . . . 0.0 109.408 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 p -173.82 153.56 2.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.384 -0.823 . . . . 0.0 109.519 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.512 HG11 ' CA ' ' A' ' 27' ' ' ASP . 14.4 p -121.88 130.64 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.384 -0.823 . . . . 0.0 109.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 55' ' ' LYS . 67.4 tt0 -121.71 152.96 38.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.318 -0.864 . . . . 0.0 109.341 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -99.71 105.43 17.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.546 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.036 HD11 ' HB2' ' A' ' 55' ' ' LYS . 17.3 mm -61.22 -58.34 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.396 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.76 ' O ' HG23 ' A' ' 52' ' ' THR . 80.5 tt0 -145.54 154.47 42.22 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.479 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 92.72 166.87 39.01 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 -118.52 30.1 7.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 109.522 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.475 ' H ' HG21 ' A' ' 52' ' ' THR . . . 102.55 -10.98 56.46 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.65 -166.75 41.86 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 46.2 Cg_endo -67.91 137.47 41.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.848 2.366 . . . . 0.0 111.778 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.93 18.95 60.27 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.416 -1.473 . . . . 0.0 109.416 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.76 HG23 ' O ' ' A' ' 45' ' ' GLU . 93.8 m -98.6 138.51 35.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -1.163 . . . . 0.0 109.498 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 44' ' ' ILE . 98.2 mt -115.11 128.21 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.276 -0.89 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.6 mttm -119.49 139.77 51.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.581 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 1.036 ' HB2' HD11 ' A' ' 44' ' ' ILE . 76.2 tttt -96.68 136.1 37.68 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.733 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 66' ' ' TYR . 80.5 mt -115.94 142.26 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.229 -0.919 . . . . 0.0 109.651 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.41 ' O ' ' HA ' ' A' ' 38' ' ' ILE . 25.8 t -109.9 154.92 22.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.902 . . . . 0.0 109.266 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -136.86 112.75 9.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.197 -0.939 . . . . 0.0 109.738 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 39' ' ' SER . 52.4 Cg_endo -72.12 53.06 1.97 Allowed 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.697 2.265 . . . . 0.0 111.588 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -125.21 165.31 18.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 109.583 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -83.31 2.59 86.86 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.462 ' CB ' ' HD2' ' A' ' 63' ' ' PRO . 1.4 m-85 -46.45 171.64 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.211 -1.17 . . . . 0.0 109.338 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 62' ' ' PHE . 46.6 Cg_endo -68.84 -29.86 27.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.662 2.241 . . . . 0.0 111.533 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 97.7 m-85 -111.6 145.93 38.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.335 -0.853 . . . . 0.0 109.247 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 42.4 mttp -104.47 -18.44 14.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.179 -0.951 . . . . 0.0 109.858 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.599 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 41.3 p90 -143.25 163.06 34.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.612 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.592 HG13 ' HA2' ' A' ' 88' ' ' GLY . 22.1 t -134.03 157.59 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.394 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 1.034 ' O ' HG13 ' A' ' 85' ' ' VAL . 50.6 mttt -95.27 130.92 41.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.523 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -129.86 142.31 50.69 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.917 . . . . 0.0 109.449 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -129.7 151.61 50.1 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.519 ' CG2' ' OH ' ' A' ' 81' ' ' TYR . 41.1 t -103.99 132.78 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.268 -0.895 . . . . 0.0 109.434 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.3 t0 -77.05 -48.59 17.45 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 0.0 109.476 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.8 tt0 178.74 136.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.895 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.0 p -115.27 127.99 72.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -98.91 103.01 14.92 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.189 -0.944 . . . . 0.0 109.495 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -62.52 -42.98 99.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.192 -0.942 . . . . 0.0 109.515 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.4 m -61.25 -42.32 98.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.261 -0.899 . . . . 0.0 109.592 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -91.62 7.76 39.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.591 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 80.2 m-85 45.33 28.79 0.49 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 41.4 tttt -100.99 128.79 46.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.578 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.519 ' OH ' ' CG2' ' A' ' 71' ' ' VAL . 83.3 t80 -119.65 121.84 40.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.238 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 70.4 m-20 -122.28 131.41 53.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.283 -0.886 . . . . 0.0 109.658 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 71' ' ' VAL . 36.9 p90 -143.96 161.78 37.84 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.223 -0.923 . . . . 0.0 109.245 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.444 ' HB3' ' OG ' ' A' ' 99' ' ' SER . 75.0 p -154.27 158.74 40.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 1.034 HG13 ' O ' ' A' ' 68' ' ' LYS . 59.2 t -104.58 134.25 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.291 -0.881 . . . . 0.0 109.459 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.519 ' HA ' ' CE ' ' A' ' 97' ' ' LYS . 24.2 pt -108.05 -30.26 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.193 -0.942 . . . . 0.0 109.37 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.47 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 87.1 tt0 -128.41 118.69 23.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.407 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.592 ' HA2' HG13 ' A' ' 67' ' ' VAL . . . -138.36 158.11 24.77 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -53.15 -66.23 2.86 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.86 -2.95 11.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.845 2.363 . . . . 0.0 111.957 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 96' ' ' GLU . 48.2 mt -111.69 139.23 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.189 -0.944 . . . . 0.0 109.566 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.56 -150.93 18.22 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -52.36 -44.15 65.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.131 -1.217 . . . . 0.0 109.234 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.523 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.59 20.85 0.22 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.475 -179.918 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.706 HD22 ' HD2' ' A' ' 126' ' ' HIS . 98.3 mt -65.99 -32.15 73.47 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.155 -0.966 . . . . 0.0 109.937 -179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.523 ' O ' HD13 ' A' ' 91' ' ' ILE . 87.7 mt-10 -159.6 51.09 0.34 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.088 -1.008 . . . . 0.0 110.027 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.519 ' CE ' ' HA ' ' A' ' 86' ' ' ILE . 17.1 tttt -65.09 132.38 49.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.134 -0.979 . . . . 0.0 108.774 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 61.4 mt -115.01 133.93 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.987 . . . . 0.0 110.006 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 84' ' ' SER . 27.9 t -130.4 119.95 23.51 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.482 ' HA ' ' O ' ' A' ' 117' ' ' SER . 45.2 m-20 -117.03 142.06 47.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.138 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.4 mt-10 -119.64 130.23 54.98 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.403 ' O ' ' N ' ' A' ' 81' ' ' TYR . 62.8 mt -115.18 136.34 52.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.027 -1.045 . . . . 0.0 110.072 -179.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 23.0 tttt -132.52 129.19 38.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.395 -0.815 . . . . 0.0 109.056 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.572 HD13 HD23 ' A' ' 18' ' ' LEU . 59.3 mt -110.22 129.29 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.141 -0.974 . . . . 0.0 109.791 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 18.6 t -120.87 139.97 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.328 -0.857 . . . . 0.0 109.262 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -105.27 130.1 53.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.142 -0.974 . . . . 0.0 109.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 111' ' ' GLY . 1.3 p -132.37 122.48 18.08 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.3 -0.875 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.62 -21.51 29.38 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.721 2.28 . . . . 0.0 111.93 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -111.45 19.8 17.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.191 -0.943 . . . . 0.0 109.615 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -168.62 31.4 0.17 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.43 ' O ' ' OG1' ' A' ' 107' ' ' THR . . . 56.12 -146.29 32.71 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' A' ' 13' ' ' ILE . 81.4 p -109.77 150.43 28.35 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.301 -1.117 . . . . 0.0 109.428 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.632 HG23 HG22 ' A' ' 10' ' ' THR . 74.1 mt -113.54 133.14 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.282 -0.886 . . . . 0.0 109.375 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.819 HD21 ' CD1' ' A' ' 116' ' ' ILE . 0.4 OUTLIER -108.96 142.84 39.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.295 -0.878 . . . . 0.0 109.545 -179.876 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.524 ' N ' ' HG ' ' A' ' 114' ' ' LEU . 27.9 mttp -133.48 112.39 11.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.355 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.819 ' CD1' HD21 ' A' ' 114' ' ' LEU . 65.8 mt -115.34 134.3 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.31 -0.869 . . . . 0.0 109.623 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 57.3 p -119.62 135.08 54.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.229 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -111.09 143.01 42.48 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.249 -0.907 . . . . 0.0 109.674 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 9.6 mtpt -138.41 136.03 35.87 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.316 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.69 ' O ' HG13 ' A' ' 2' ' ' VAL . 87.8 m-85 -119.92 133.79 55.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.707 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.549 ' CE1' HG11 ' A' ' 2' ' ' VAL . 88.4 m-70 -117.49 134.47 54.81 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.227 -0.92 . . . . 0.0 109.248 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.63 HG21 HG23 ' A' ' 128' ' ' VAL . 31.9 p -131.5 137.84 48.71 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.138 -0.977 . . . . 0.0 109.673 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 94' ' ' THR . 63.5 tttm -49.4 -36.47 22.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.815 . . . . 0.0 109.431 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 136.1 -49.36 0.88 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -61.21 -32.06 71.83 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -1.158 . . . . 0.0 109.505 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.706 ' HD2' HD22 ' A' ' 95' ' ' LEU . 98.5 m-70 -107.83 138.06 44.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -115.43 162.13 17.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.63 HG23 HG21 ' A' ' 122' ' ' THR . 37.5 t -106.44 135.17 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 109.459 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 67.6 mttt -85.42 147.93 26.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.83 -38.92 83.4 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.483 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -56.38 -43.67 79.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.214 -0.929 . . . . 0.0 109.552 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -54.35 -39.1 66.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.382 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.663 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -69.97 -36.11 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.284 -0.885 . . . . 0.0 109.442 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -56.57 -42.17 78.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.184 -0.947 . . . . 0.0 109.534 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.53 -45.08 92.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 24.1 t -63.39 -41.46 98.77 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.428 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.571 ' HE3' HG12 ' A' ' 133' ' ' VAL . 41.7 mttt -62.4 -39.58 93.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.271 -0.893 . . . . 0.0 109.473 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.43 -43.52 90.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.28 -0.887 . . . . 0.0 109.472 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.445 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 94.8 mmm -64.51 -39.08 93.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.474 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -61.79 -41.63 99.65 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.0 mt-10 -68.33 -34.33 75.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 88.1 m -68.53 -31.18 70.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.488 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 139' ' ' MET . 24.8 mt -71.49 -47.75 53.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.561 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.8 pp -71.91 -31.43 66.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.121 -0.987 . . . . 0.0 109.507 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.413 ' N ' ' HG ' ' A' ' 144' ' ' LEU . 40.0 ttm180 -63.3 -42.81 99.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.608 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.66 -35.89 81.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.232 -0.917 . . . . 0.0 109.397 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.853 HG13 HD21 ' A' ' 29' ' ' LEU . 65.2 t -61.53 -48.11 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.469 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.434 ' HA ' HD12 ' A' ' 151' ' ' LEU . 88.1 tt0 -58.47 -53.02 62.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.8 t -51.81 -43.39 63.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -0.926 . . . . 0.0 109.544 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.541 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 75.9 t80 -57.23 -40.82 78.32 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -0.916 . . . . 0.0 109.394 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.844 HD13 HG21 ' A' ' 13' ' ' ILE . 47.0 mt -63.24 -40.56 97.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 109.457 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.553 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -64.65 -25.57 68.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.199 -0.938 . . . . 0.0 109.464 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.77 96.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.441 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.541 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 58.7 m-70 -58.11 -39.95 79.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 23.0 t -59.85 -29.76 68.51 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.452 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -70.5 -20.01 62.88 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -63.77 -24.39 67.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.399 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -114.48 131.28 56.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.3 t30 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.984 -1.007 . . . . 0.0 109.531 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 120' ' ' TYR . 54.9 t -136.41 140.46 43.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -1.151 . . . . 0.0 109.382 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.605 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 61.6 m-85 -91.31 151.56 20.83 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.192 -0.942 . . . . 0.0 109.649 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -136.88 112.96 9.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -0.948 . . . . 0.0 109.693 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.605 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 55.4 m-85 -118.93 114.22 22.24 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.317 -0.865 . . . . 0.0 109.232 179.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.52 ' OE2' ' CA ' ' A' ' 117' ' ' SER . 15.3 tp10 -104.46 148.84 26.0 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.2 -0.938 . . . . 0.0 109.232 -179.714 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.463 ' O ' ' OE1' ' A' ' 6' ' ' GLU . 22.2 p -133.94 165.85 24.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.391 -0.818 . . . . 0.0 109.472 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -126.74 138.22 53.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.479 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.2 m -137.54 140.19 40.93 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.913 . . . . 0.0 109.396 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.7 m -124.4 144.97 49.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.472 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -147.02 141.29 26.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.284 -0.885 . . . . 0.0 109.409 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 17.6 m -65.99 -27.5 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.927 . . . . 0.0 109.534 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.556 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 22.3 mm -55.62 142.0 63.03 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.144 -0.972 . . . . 0.0 109.403 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.05 144.66 47.77 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.58 2.186 . . . . 0.0 111.832 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.646 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -64.73 -25.22 67.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 0.0 109.604 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.85 -44.08 74.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.166 -0.958 . . . . 0.0 109.716 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.458 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 56.3 mtt-85 -76.61 -41.49 45.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.705 HD23 HD13 ' A' ' 104' ' ' ILE . 1.0 OUTLIER -69.49 -34.53 74.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 0.0 109.417 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE2' HG13 ' A' ' 23' ' ' ILE . 57.6 t80 -66.57 -46.04 77.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.49 ' HA ' HD13 ' A' ' 24' ' ' LEU . 22.9 mttp -67.45 -40.05 85.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.185 -0.947 . . . . 0.0 109.694 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.563 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -81.28 -35.71 30.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.304 -0.873 . . . . 0.0 109.953 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 75.2 t80 -79.75 -23.26 42.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.501 HG13 ' CE2' ' A' ' 19' ' ' PHE . 34.9 mm -99.04 -58.97 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 110.02 -179.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.617 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.6 mp -76.46 -34.19 58.71 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.141 -0.974 . . . . 0.0 109.807 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.551 ' O ' HD12 ' A' ' 29' ' ' LEU . 45.7 m-20 -108.27 25.0 12.16 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.116 -0.99 . . . . 0.0 109.402 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 30' ' ' PHE . . . -74.9 -42.85 29.32 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.87 -30.25 62.54 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -1.128 . . . . 0.0 109.53 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -81.91 -40.37 22.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.211 -0.931 . . . . 0.0 109.388 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.99 ' O ' HG22 ' A' ' 33' ' ' VAL . 29.4 mt -74.74 -34.53 62.54 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.26 -0.9 . . . . 0.0 109.391 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.527 ' CD1' ' O ' ' A' ' 26' ' ' GLY . 1.0 OUTLIER -41.27 -63.06 0.87 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.397 -0.815 . . . . 0.0 109.809 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.527 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.5 Cg_endo -70.34 -46.01 1.11 Allowed 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.63 2.22 . . . . 0.0 111.999 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -58.97 -45.97 89.24 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.187 -0.946 . . . . 0.0 109.759 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.99 HG22 ' O ' ' A' ' 29' ' ' LEU . 6.8 m -77.55 -28.03 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.068 -1.02 . . . . 0.0 109.703 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.22 71.1 16.3 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.169 -0.957 . . . . 0.0 109.712 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.42 ' N ' ' O ' ' A' ' 31' ' ' PRO . 49.5 Cg_endo -69.93 -16.89 37.0 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.661 2.24 . . . . 0.0 111.736 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.526 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 94.4 mt-30 -77.72 -17.4 57.65 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.502 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.501 ' O ' ' CD2' ' A' ' 58' ' ' PHE . . . -92.28 -46.24 7.81 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.923 . . . . 0.0 109.454 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.695 HD13 HG23 ' A' ' 56' ' ' ILE . 97.0 mt -131.98 120.6 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.424 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.5 m -58.96 -38.33 78.81 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.298 -0.876 . . . . 0.0 109.448 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.3 m -167.21 156.4 10.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -0.905 . . . . 0.0 109.5 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.5 t -116.77 141.34 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.91 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.409 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.3 mt-10 -134.63 152.58 51.88 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.446 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.0 m-20 -103.12 109.82 21.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.982 HD11 ' HB2' ' A' ' 55' ' ' LYS . 25.6 mm -62.51 -57.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.277 -0.89 . . . . 0.0 109.297 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.894 ' O ' HG23 ' A' ' 52' ' ' THR . 96.3 mt-10 -138.72 159.35 42.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.312 -0.868 . . . . 0.0 109.442 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.7 -174.05 51.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.1 t-20 -156.54 47.01 0.44 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -1.126 . . . . 0.0 109.443 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.64 7.51 50.95 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -103.5 -176.85 26.14 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.37 140.08 39.59 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.763 2.308 . . . . 0.0 111.832 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.7 18.68 72.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.894 HG23 ' O ' ' A' ' 45' ' ' GLU . 98.1 m -86.94 139.41 30.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.185 -1.185 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' A' ' 44' ' ' ILE . 68.5 mt -113.01 133.99 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.446 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 60.6 mttt -124.47 145.02 49.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.341 -0.849 . . . . 0.0 109.459 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.982 ' HB2' HD11 ' A' ' 44' ' ' ILE . 18.6 tttm -101.63 134.78 44.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.9 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.695 HG23 HD13 ' A' ' 38' ' ' ILE . 79.8 mt -109.84 135.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.47 ' O ' HG23 ' A' ' 38' ' ' ILE . 48.8 m -109.09 154.84 21.71 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.162 -0.961 . . . . 0.0 109.486 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.526 ' HE1' HG23 ' A' ' 67' ' ' VAL . 27.2 m-85 -124.71 141.24 37.47 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 0.0 109.492 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.38 151.5 65.55 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.715 2.277 . . . . 0.0 111.723 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.29 141.32 15.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.486 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 102.03 11.39 37.14 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.526 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.6 m-85 -113.69 169.86 6.01 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.482 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.47 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 50.3 Cg_endo -70.61 -49.48 0.44 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.649 2.233 . . . . 0.0 111.724 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.529 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 97.9 m-85 -113.71 152.45 30.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.237 -0.914 . . . . 0.0 109.463 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 58' ' ' PHE . 24.0 mttt -83.39 -36.39 24.34 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -0.918 . . . . 0.0 109.51 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.453 ' CD2' ' HE2' ' A' ' 55' ' ' LYS . 37.1 p90 -155.74 160.66 40.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.526 HG23 ' HE1' ' A' ' 58' ' ' PHE . 7.2 t -135.0 162.32 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.962 ' O ' HG13 ' A' ' 85' ' ' VAL . 79.2 tttt -114.65 135.31 54.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.246 -0.909 . . . . 0.0 109.547 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.1 p30 -138.96 162.2 35.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -142.23 155.98 45.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.915 . . . . 0.0 109.573 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 12.7 p -106.04 134.81 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 49.7 t0 -77.13 -45.66 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.252 -0.905 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.8 tt0 -179.87 151.94 0.45 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 81' ' ' TYR . 44.0 t -119.82 131.24 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.206 -0.934 . . . . 0.0 109.474 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -109.78 95.68 5.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -62.36 -42.76 99.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -0.913 . . . . 0.0 109.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 90.4 m -61.38 -39.04 89.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 109.496 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -94.94 6.69 48.34 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.446 ' HA ' ' CE2' ' A' ' 19' ' ' PHE . 71.9 m-85 44.34 30.3 0.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 24.7 tttt -105.66 135.18 47.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.521 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.53 ' CD2' HG22 ' A' ' 74' ' ' VAL . 76.6 t80 -121.23 120.06 34.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.316 -0.865 . . . . 0.0 109.242 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.401 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.6 m-20 -117.69 129.07 55.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.208 -0.932 . . . . 0.0 109.733 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.495 ' HB3' ' CE1' ' A' ' 81' ' ' TYR . 35.2 p90 -142.84 164.5 29.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.406 -0.809 . . . . 0.0 109.212 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 86.5 p -153.88 157.35 39.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.165 -0.96 . . . . 0.0 109.636 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 68' ' ' LYS . 47.5 t -105.32 128.54 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.262 -0.899 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.603 HG22 ' CE ' ' A' ' 97' ' ' LYS . 29.1 pt -104.48 -29.24 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.555 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LYS . 84.4 tt0 -129.44 114.37 16.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.554 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -133.7 147.19 18.95 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -49.6 -57.97 8.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 52.0 Cg_endo -72.49 -5.37 17.02 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.622 2.214 . . . . 0.0 111.924 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.481 HD13 ' O ' ' A' ' 96' ' ' GLU . 42.7 mt -114.67 150.05 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 109.557 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.83 -153.88 14.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -52.5 -45.69 66.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -1.184 . . . . 0.0 109.44 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -157.98 21.07 0.26 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -0.874 . . . . 0.0 109.398 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.793 HD22 ' CD2' ' A' ' 126' ' ' HIS . 93.5 mt -66.6 -31.24 71.8 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 110.133 -179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 79.3 mt-10 -159.25 50.91 0.36 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.962 -1.087 . . . . 0.0 110.075 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.603 ' CE ' HG22 ' A' ' 86' ' ' ILE . 9.2 tttt -65.12 132.23 48.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.115 -0.991 . . . . 0.0 108.755 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 60.8 mt -115.82 128.11 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.085 -1.009 . . . . 0.0 110.023 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.4 m -115.99 128.28 55.6 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 117' ' ' SER . 37.7 t-20 -124.98 137.67 54.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 110.161 -179.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.0 mt-10 -118.73 136.67 53.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.417 -0.802 . . . . 0.0 108.985 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.426 ' O ' ' N ' ' A' ' 81' ' ' TYR . 65.2 mt -119.7 136.87 55.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.097 -1.002 . . . . 0.0 109.919 -179.545 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 55.7 tttp -133.58 127.4 33.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.146 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.705 HD13 HD23 ' A' ' 18' ' ' LEU . 48.8 mt -107.98 137.95 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.77 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 112' ' ' SER . 11.8 t -133.62 136.16 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.444 -0.785 . . . . 0.0 109.206 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.449 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -95.41 139.22 32.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 0.0 109.614 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 111' ' ' GLY . 1.2 p -154.21 121.92 2.94 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.237 -0.915 . . . . 0.0 109.592 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -70.88 -1.08 8.84 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.771 2.314 . . . . 0.0 111.823 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -86.8 -35.11 19.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.204 -0.935 . . . . 0.0 109.636 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.94 33.71 0.8 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 82.43 -146.26 24.68 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 13.0 p -106.91 143.87 34.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -1.131 . . . . 0.0 109.434 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.7 mt -106.62 136.46 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.636 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.1 mp -116.81 132.74 56.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.748 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 86.1 mttt -114.86 119.57 37.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.348 -0.845 . . . . 0.0 109.123 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 69.5 mt -111.06 129.73 65.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.163 -0.961 . . . . 0.0 109.776 -179.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.52 ' CA ' ' OE2' ' A' ' 6' ' ' GLU . 24.2 t -109.23 137.35 47.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' TYR . 23.8 m120 -119.88 139.94 51.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.911 -179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -138.83 140.23 38.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.363 -0.836 . . . . 0.0 109.136 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.7 ' O ' HG13 ' A' ' 2' ' ' VAL . 97.2 m-85 -118.02 134.4 55.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.968 . . . . 0.0 109.767 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.506 ' CE1' HG11 ' A' ' 2' ' ' VAL . 80.8 m-70 -117.56 132.51 56.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.332 -0.855 . . . . 0.0 109.255 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.763 HG21 HG23 ' A' ' 128' ' ' VAL . 46.6 p -130.59 137.78 49.82 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.285 -0.884 . . . . 0.0 109.593 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.3 ttpp -50.15 -36.03 28.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.548 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.52 -51.11 0.84 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -61.01 -28.17 68.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -1.184 . . . . 0.0 109.381 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.793 ' CD2' HD22 ' A' ' 95' ' ' LEU . 85.8 m-70 -113.09 142.21 46.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.313 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -116.81 156.73 26.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.614 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.763 HG23 HG21 ' A' ' 122' ' ' THR . 38.7 t -92.24 140.56 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.89 . . . . 0.0 109.428 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 14.7 mtpt -90.17 140.83 29.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.444 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -56.01 -39.36 71.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.46 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -58.98 -39.25 81.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.921 . . . . 0.0 109.484 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -59.92 -33.76 72.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.884 . . . . 0.0 109.481 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.668 HG22 ' CZ ' ' A' ' 120' ' ' TYR . 74.4 t -71.01 -37.52 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 22.1 tttt -59.28 -45.16 91.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.04 -47.18 87.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -60.52 -39.63 88.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.437 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -61.68 -40.3 94.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.283 -0.886 . . . . 0.0 109.367 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -65.95 -38.57 88.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.309 -0.87 . . . . 0.0 109.413 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.417 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 51.3 ttm -64.41 -41.78 96.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.255 -0.903 . . . . 0.0 109.376 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.73 -43.93 98.54 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.542 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -71.2 -31.88 68.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -1.133 . . . . 0.0 109.436 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 91.4 m -66.88 -31.38 71.94 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.252 -0.905 . . . . 0.0 109.45 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.439 ' HA ' HD23 ' A' ' 143' ' ' LEU . 32.5 mt -72.62 -50.96 21.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.581 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.7 pp -68.47 -33.29 73.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.475 ' N ' HD12 ' A' ' 144' ' ' LEU . 61.6 ttp85 -59.89 -46.3 89.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.201 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.452 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -62.95 -43.75 97.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.359 -0.838 . . . . 0.0 109.28 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 78.7 t -58.95 -48.73 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.315 -0.865 . . . . 0.0 109.258 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -53.88 -46.63 71.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.308 -0.87 . . . . 0.0 109.326 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.601 ' HA ' HD12 ' A' ' 152' ' ' LEU . 19.2 m -53.33 -38.62 63.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.61 -45.28 94.75 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.286 -0.884 . . . . 0.0 109.378 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.3 mm? -64.68 -34.12 77.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.198 -0.939 . . . . 0.0 109.35 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.601 HD12 ' HA ' ' A' ' 149' ' ' SER . 20.1 mt -71.24 -23.2 61.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.504 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.28 -42.48 99.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.283 -0.885 . . . . 0.0 109.435 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -49.26 -38.8 28.12 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.276 -0.89 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.8 t -56.86 -32.25 65.62 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.503 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -75.09 -13.75 60.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.556 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -73.18 140.84 47.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.369 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 18.0 t80 -46.16 -55.46 7.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.202 -0.936 . . . . 0.0 109.273 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.429 179.842 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.1 t -132.6 144.01 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.211 -1.17 . . . . 0.0 109.597 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.545 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 82.8 m-85 -100.91 133.76 44.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.332 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.469 ' HA ' ' HG2' ' A' ' 119' ' ' LYS . 56.2 t30 -115.43 118.34 32.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.545 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 97.4 m-85 -121.69 132.25 54.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.373 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -122.54 142.14 50.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.401 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 17.6 p -132.4 154.74 49.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.389 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -128.07 135.9 50.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.465 ' O ' ' N ' ' A' ' 114' ' ' LEU . 44.7 m -137.82 141.29 40.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.6 m -117.38 138.87 51.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 54.0 p -138.37 157.35 46.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.887 . . . . 0.0 109.436 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.2 m -77.33 -20.92 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.387 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.904 HG21 HD13 ' A' ' 151' ' ' LEU . 5.0 mt -61.38 141.95 94.06 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.469 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.555 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 51.1 Cg_endo -71.36 150.86 59.18 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.509 2.14 . . . . 0.0 111.591 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.686 ' CB ' HG22 ' A' ' 104' ' ' ILE . . . -65.2 -24.74 67.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.276 -0.89 . . . . 0.0 109.694 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.0 -49.48 28.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.54 ' CG ' ' HG2' ' A' ' 14' ' ' PRO . 90.3 mtt-85 -71.91 -40.83 68.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.191 -0.943 . . . . 0.0 109.45 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.545 HD23 HD12 ' A' ' 104' ' ' ILE . 2.7 tp -65.29 -47.34 76.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.548 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 73.3 t80 -54.26 -46.34 72.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 24' ' ' LEU . 36.4 mttp -69.51 -61.4 1.8 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.192 -0.943 . . . . 0.0 110.024 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.689 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -58.49 -36.37 73.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.864 -179.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.659 ' CE1' HD13 ' A' ' 102' ' ' ILE . 75.1 t80 -76.84 -42.88 38.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.09 -1.006 . . . . 0.0 109.678 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 19' ' ' PHE . 40.7 mm -92.15 -63.97 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.1 -1.0 . . . . 0.0 109.725 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.512 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.6 mp -56.97 -46.82 81.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.189 -0.945 . . . . 0.0 109.73 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.471 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 6.6 m-20 -101.53 23.25 11.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.179 -0.951 . . . . 0.0 109.548 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 30' ' ' PHE . . . -71.78 -34.75 62.37 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.435 ' OD1' ' NZ ' ' A' ' 54' ' ' LYS . 88.2 m-20 -74.03 -29.05 61.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.289 -1.124 . . . . 0.0 109.609 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.441 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 91.0 m-20 -92.09 -49.73 6.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 109.562 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.891 ' O ' HG22 ' A' ' 33' ' ' VAL . 59.4 mt -63.2 -36.18 82.78 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.578 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.551 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 2.0 m-30 -46.38 -63.96 1.14 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.142 -0.974 . . . . 0.0 109.581 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.551 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.8 Cg_endo -71.86 -38.23 4.32 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.741 2.294 . . . . 0.0 111.92 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 96.2 mttt -66.02 -42.31 89.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.634 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.891 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.0 m -78.11 -30.29 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -0.943 . . . . 0.0 109.469 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -145.71 73.4 13.81 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.469 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -69.54 -17.22 38.7 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.65 2.233 . . . . 0.0 111.765 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.562 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 95.5 mt-30 -75.12 -19.91 59.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.281 -0.887 . . . . 0.0 109.421 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.0 -49.46 7.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.903 . . . . 0.0 109.382 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.523 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 mt -124.85 119.91 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.175 -0.953 . . . . 0.0 109.298 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 20.8 t -57.85 -43.95 86.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.249 -0.907 . . . . 0.0 109.524 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.1 p -164.33 157.13 17.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.496 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.03 140.01 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.519 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 55' ' ' LYS . 95.7 mt-10 -138.74 156.9 46.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.445 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.437 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 82.7 m-20 -100.44 105.94 17.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.499 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.799 HG22 ' HG3' ' A' ' 45' ' ' GLU . 84.5 mt -62.11 -53.2 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.799 ' HG3' HG22 ' A' ' 44' ' ' ILE . 95.7 mt-10 -146.54 157.34 43.72 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.165 -0.959 . . . . 0.0 109.489 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' HG23 ' A' ' 52' ' ' THR . . . 89.9 172.59 45.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 41.9 p-10 -126.64 28.22 5.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.471 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 108.33 -17.35 34.28 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.633 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -73.91 -170.87 22.87 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -70.18 140.58 41.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.636 2.224 . . . . 0.0 111.75 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.69 -1.6 85.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.763 HG23 ' O ' ' A' ' 45' ' ' GLU . 91.5 m -74.31 139.2 44.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.156 -1.203 . . . . 0.0 109.497 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.727 HG22 HD12 ' A' ' 44' ' ' ILE . 66.3 mt -117.01 126.19 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.437 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 91.7 mttt -112.21 137.95 49.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.252 -0.905 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 41.4 tttp -90.64 131.46 36.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.468 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.523 HG23 ' CG2' ' A' ' 38' ' ' ILE . 71.5 mt -112.71 132.06 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.466 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 48.7 m -111.35 154.79 24.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.246 -0.909 . . . . 0.0 109.414 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.476 ' N ' ' O ' ' A' ' 65' ' ' LYS . 29.6 m-85 -118.42 148.7 44.55 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.484 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.481 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.5 Cg_endo -70.3 145.98 55.53 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.669 2.246 . . . . 0.0 111.764 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.08 144.26 12.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.217 -0.927 . . . . 0.0 109.352 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.85 16.43 41.88 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.562 ' CZ ' ' O ' ' A' ' 36' ' ' GLN . 2.5 m-85 -114.69 161.65 27.75 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.335 -1.097 . . . . 0.0 109.425 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.93 -30.17 21.92 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.595 2.197 . . . . 0.0 111.829 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.57 ' CD2' ' HD3' ' A' ' 90' ' ' PRO . 45.5 m-85 -118.69 164.33 15.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.658 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 58' ' ' PHE . 34.9 mttt -104.78 -62.81 1.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 38.4 p90 -147.8 166.01 28.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.44 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.498 HG22 ' HB ' ' A' ' 56' ' ' ILE . 30.6 m -148.8 148.68 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.243 -0.91 . . . . 0.0 109.459 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 85' ' ' VAL . 34.0 mttp -86.23 113.19 22.04 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 53' ' ' ILE . 59.3 t0 -91.51 127.37 36.92 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.454 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -119.36 138.93 52.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 49' ' ' GLY . 13.9 p -97.44 133.73 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.481 ' HB2' ' OD1' ' A' ' 82' ' ' ASN . 74.5 m-20 -80.98 -48.15 12.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.594 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.443 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.5 tt0 178.73 127.68 0.06 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 74' ' ' VAL . 7.6 p -110.14 126.55 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.527 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.8 m-20 -105.67 104.82 14.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.582 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -59.49 -46.76 87.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.265 -0.897 . . . . 0.0 109.46 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 m -60.66 -42.52 97.18 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 79' ' ' PHE . 78.4 m-20 -91.34 5.9 47.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.172 -0.955 . . . . 0.0 109.678 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.445 ' N ' ' O ' ' A' ' 75' ' ' ASP . 91.4 m-85 44.11 26.46 0.15 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.279 -0.888 . . . . 0.0 109.51 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.42 ' HB3' ' HE2' ' A' ' 80' ' ' LYS . 31.3 ttpt -98.26 131.13 44.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.521 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 52.9 t80 -130.75 119.65 22.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.506 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 72' ' ' ASP . 2.4 t-20 -120.19 138.29 53.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.94 . . . . 0.0 109.553 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 100' ' ' ASN . 41.0 p90 -145.24 146.84 31.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.238 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.1 m -136.58 147.64 47.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.195 -0.941 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -93.64 125.95 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.429 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 44.0 pt -94.8 -23.62 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.24 -0.912 . . . . 0.0 109.519 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -135.47 124.11 23.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.552 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -148.34 146.14 15.38 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.532 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -46.39 -54.42 8.68 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 64' ' ' PHE . 54.9 Cg_endo -75.56 -6.01 17.19 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.69 2.26 . . . . 0.0 112.054 -179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.472 HD13 ' HA ' ' A' ' 97' ' ' LYS . 55.7 mt -119.29 137.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.144 -0.973 . . . . 0.0 109.852 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -109.01 -135.04 7.26 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -61.75 -44.41 96.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.207 -1.172 . . . . 0.0 109.059 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.693 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -161.07 22.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.395 -0.816 . . . . 0.0 109.275 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 95' ' ' LEU . 7.1 mp -63.79 -40.91 97.79 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.171 -0.955 . . . . 0.0 110.253 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 81.5 tt0 -154.33 52.34 0.66 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.974 -1.079 . . . . 0.0 110.12 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 0.1 OUTLIER -64.79 132.38 49.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.015 -1.053 . . . . 0.0 108.587 179.329 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.518 HG12 ' CD2' ' A' ' 120' ' ' TYR . 62.8 mt -117.97 133.26 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.033 -1.042 . . . . 0.0 110.386 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.4 m -118.01 142.23 47.6 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.479 ' HA ' ' O ' ' A' ' 117' ' ' SER . 47.5 m-20 -134.07 136.7 44.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.99 -1.069 . . . . 0.0 110.194 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 82' ' ' ASN . 94.0 mt-10 -118.71 129.7 55.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.003 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.659 HD13 ' CE1' ' A' ' 22' ' ' PHE . 68.5 mt -115.29 137.49 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.127 -0.983 . . . . 0.0 109.775 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.48 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 84.8 tttt -133.65 134.2 42.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.191 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.686 HG22 ' CB ' ' A' ' 15' ' ' ALA . 26.9 mm -111.94 126.9 69.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.157 -0.964 . . . . 0.0 109.56 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.408 HG21 ' NZ ' ' A' ' 115' ' ' LYS . 22.7 t -118.17 139.15 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.311 -0.868 . . . . 0.0 109.473 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . . . -104.79 139.5 39.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.271 -0.893 . . . . 0.0 109.575 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.459 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 11.0 p -109.36 160.06 29.09 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.249 -0.907 . . . . 0.0 109.394 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.0 Cg_endo -69.94 -23.58 29.8 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.647 2.231 . . . . 0.0 111.818 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -169.23 27.31 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.422 ' N ' ' OG1' ' A' ' 107' ' ' THR . . . -130.19 30.49 3.49 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 107' ' ' THR . . . 67.72 -146.43 46.86 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.2 p -125.07 154.67 41.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.358 -1.084 . . . . 0.0 109.508 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 85.6 mt -111.74 122.77 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.314 -0.866 . . . . 0.0 109.458 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.891 ' CD2' HD13 ' A' ' 144' ' ' LEU . 16.0 tp -90.07 149.8 22.35 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.198 -0.939 . . . . 0.0 109.885 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 24.7 mttt -140.78 110.97 6.63 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.701 HD11 HD21 ' A' ' 114' ' ' LEU . 67.0 mt -120.24 135.86 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.125 -0.984 . . . . 0.0 110.085 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 83.5 p -126.4 136.33 52.55 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.424 -0.797 . . . . 0.0 108.884 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 100' ' ' ASN . 90.5 m-20 -121.86 147.55 45.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 109.988 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 44.4 mttp -134.78 141.72 46.52 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.418 -0.801 . . . . 0.0 108.936 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.735 ' CE1' HG13 ' A' ' 133' ' ' VAL . 95.7 m-85 -114.24 132.18 56.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.086 -1.008 . . . . 0.0 109.71 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.476 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 78.3 m-70 -115.41 132.11 56.72 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.345 -0.847 . . . . 0.0 109.404 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.719 HG21 HG23 ' A' ' 128' ' ' VAL . 44.3 p -131.17 138.12 49.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.161 -0.962 . . . . 0.0 109.585 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.693 ' HB2' HG23 ' A' ' 94' ' ' THR . 35.4 tttm -53.04 -33.12 50.48 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.496 -0.753 . . . . 0.0 109.458 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.09 -47.49 1.01 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -62.72 -26.92 68.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.286 -1.126 . . . . 0.0 109.579 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.408 ' CD2' HD23 ' A' ' 95' ' ' LEU . 96.7 m-70 -112.41 139.68 47.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.43 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -110.18 164.84 12.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.51 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.719 HG23 HG21 ' A' ' 122' ' ' THR . 33.7 t -103.85 132.57 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.897 . . . . 0.0 109.513 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.404 ' HE2' ' OE1' ' A' ' 131' ' ' GLU . 25.6 tttt -76.27 133.08 40.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.41 66.79 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.198 -0.939 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.404 ' OE1' ' HE2' ' A' ' 129' ' ' LYS . 93.6 mt-10 -59.14 -43.67 92.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.914 . . . . 0.0 109.372 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.446 ' NE2' ' OE2' ' A' ' 96' ' ' GLU . 63.9 tt0 -52.48 -35.28 52.45 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.076 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.735 HG13 ' CE1' ' A' ' 120' ' ' TYR . 56.3 t -73.65 -34.39 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.316 -0.865 . . . . 0.0 109.399 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 70.7 mttt -65.83 -37.74 87.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 109.427 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.97 -44.17 93.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.295 -0.878 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.8 t -62.64 -39.22 93.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.316 -0.865 . . . . 0.0 109.474 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.401 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 55.0 tttt -60.89 -43.22 98.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.431 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -63.37 -42.28 98.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.207 -0.933 . . . . 0.0 109.394 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.443 ' O ' ' HG ' ' A' ' 143' ' ' LEU . 48.9 ttm -62.17 -41.53 98.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.351 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.479 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.19 -44.7 93.15 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -70.0 -37.41 75.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.258 -1.142 . . . . 0.0 109.267 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 30.9 m -54.1 -31.71 52.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.31 -0.869 . . . . 0.0 109.16 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 139' ' ' MET . 27.2 mt -73.87 -38.41 64.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.36 -0.838 . . . . 0.0 108.765 179.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.891 HD13 ' CD2' ' A' ' 114' ' ' LEU . 5.8 mt -74.02 -33.91 63.94 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -65.96 -41.67 90.92 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -71.93 -41.84 67.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.298 -0.876 . . . . 0.0 109.203 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 143' ' ' LEU . 53.7 t -64.05 -48.6 85.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.253 -0.904 . . . . 0.0 109.169 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.749 ' HA ' HD11 ' A' ' 13' ' ' ILE . 99.5 mt-10 -57.57 -40.51 79.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.336 -0.852 . . . . 0.0 109.288 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.8 m -65.98 -39.87 90.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.341 -0.849 . . . . 0.0 109.311 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 75.2 t80 -63.19 -47.47 82.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.346 -0.846 . . . . 0.0 109.283 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.904 HD13 HG21 ' A' ' 13' ' ' ILE . 36.3 mt -63.11 -36.81 84.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.333 -0.854 . . . . 0.0 109.315 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.6 mm? -68.71 -26.48 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.292 -0.88 . . . . 0.0 109.299 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.427 ' O ' ' C ' ' A' ' 154' ' ' HIS . . . -63.07 -34.2 77.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.363 -0.836 . . . . 0.0 109.392 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.563 ' CD2' ' HA ' ' A' ' 151' ' ' LEU . 37.6 m-70 -44.2 -32.48 1.26 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.244 -0.91 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 84.6 p -58.4 -30.85 67.16 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.327 -0.858 . . . . 0.0 109.262 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.418 ' N ' ' O ' ' A' ' 153' ' ' ALA . 81.5 m-20 -70.54 -20.19 62.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.513 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -107.71 139.4 42.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.616 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.59 ' CD2' ' HB2' ' A' ' 159' ' ' ASN . 3.3 t80 -72.59 131.48 42.52 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.303 -0.873 . . . . 0.0 109.175 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . 0.59 ' HB2' ' CD2' ' A' ' 158' ' ' TYR . 56.7 t30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.529 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.522 HG13 ' O ' ' A' ' 120' ' ' TYR . 49.1 t -134.05 146.26 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.149 -1.206 . . . . 0.0 109.44 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.597 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 89.3 m-85 -99.61 136.57 39.35 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.195 -0.941 . . . . 0.0 109.54 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -117.95 120.04 36.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.3 -0.875 . . . . 0.0 109.441 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -121.76 133.81 54.92 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.15 -0.969 . . . . 0.0 109.389 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -120.69 143.41 48.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.187 -0.946 . . . . 0.0 109.552 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.464 ' CG2' ' HE3' ' A' ' 137' ' ' LYS . 24.0 p -132.64 154.37 50.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.414 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -123.77 134.09 53.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.281 -0.887 . . . . 0.0 109.562 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.407 HG21 HD13 ' A' ' 144' ' ' LEU . 56.4 m -138.99 140.19 38.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.353 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 16.4 m -115.8 146.2 42.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.2 m -143.38 138.66 29.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.426 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 13' ' ' ILE . 12.3 m -65.15 -35.15 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.181 -0.949 . . . . 0.0 109.558 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.754 HD11 ' HA ' ' A' ' 148' ' ' GLU . 4.1 mt -50.52 142.27 15.73 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.562 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.5 Cg_endo -70.6 148.18 59.11 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.468 2.112 . . . . 0.0 111.737 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.488 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -61.7 -34.12 75.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.318 -0.864 . . . . 0.0 109.932 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -61.77 -49.41 76.46 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.091 -1.006 . . . . 0.0 109.545 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.469 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 49.7 mtt-85 -77.09 -37.82 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.29 -0.881 . . . . 0.0 109.161 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 18' ' ' LEU . 3.4 tm? -70.18 -45.99 65.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.76 ' CD1' HD12 ' A' ' 104' ' ' ILE . 53.7 t80 -58.92 -40.23 83.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.57 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 24' ' ' LEU . 29.7 mttt -73.11 -63.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.345 -0.847 . . . . 0.0 110.119 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -59.55 -33.27 71.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.943 -1.098 . . . . 0.0 110.284 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.52 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 67.5 t80 -74.14 -31.89 62.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.983 -1.073 . . . . 0.0 109.697 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.57 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 55.9 mt -110.44 -63.88 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.083 -1.011 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 20' ' ' LYS . 8.5 mp -51.27 -48.52 62.19 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.545 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 63.9 m-20 -111.47 20.22 17.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.094 -1.004 . . . . 0.0 109.466 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -66.61 -29.23 74.43 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.59 ' O ' HG21 ' A' ' 41' ' ' VAL . 95.3 m-20 -70.68 -34.2 71.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.309 -1.112 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.438 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 93.6 m-20 -83.45 -44.53 14.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.91 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.764 ' O ' HG22 ' A' ' 33' ' ' VAL . 5.8 mp -69.48 -31.57 69.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.238 -0.914 . . . . 0.0 109.528 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.7 m-30 -46.91 -63.8 1.24 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.917 . . . . 0.0 109.505 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 51.6 Cg_endo -71.8 -35.1 7.97 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.74 2.294 . . . . 0.0 111.756 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 64.1 mttm -66.19 -42.79 88.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.212 -0.93 . . . . 0.0 109.646 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.5 m -78.75 -34.68 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.664 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -140.77 74.84 26.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.598 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.67 -16.17 33.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.745 2.297 . . . . 0.0 111.788 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -78.99 -13.99 59.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 109.437 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.447 ' O ' ' CE1' ' A' ' 58' ' ' PHE . . . -93.44 -46.34 7.37 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.32 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.594 ' CG2' HG23 ' A' ' 56' ' ' ILE . 91.5 mt -129.65 119.94 49.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.343 -0.848 . . . . 0.0 109.363 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.6 m -58.05 -40.33 80.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.471 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.8 p -167.93 160.79 12.51 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.273 -0.892 . . . . 0.0 109.53 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.59 HG21 ' O ' ' A' ' 27' ' ' ASP . 35.2 m -128.4 148.01 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.211 -0.931 . . . . 0.0 109.519 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -145.84 154.85 42.45 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -99.87 106.97 18.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.592 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.796 HD12 HG22 ' A' ' 53' ' ' ILE . 86.0 mt -61.18 -52.95 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.854 ' O ' HG23 ' A' ' 52' ' ' THR . 97.9 mt-10 -148.07 155.21 41.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.83 . . . . 0.0 109.372 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.65 168.25 42.15 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -122.94 31.45 6.03 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.263 -1.139 . . . . 0.0 109.493 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.16 -12.42 48.57 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.16 -169.28 41.55 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.452 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 48.3 Cg_endo -68.98 142.53 51.7 Favored 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 122.755 2.303 . . . . 0.0 111.9 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.69 15.86 74.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.854 HG23 ' O ' ' A' ' 45' ' ' GLU . 95.1 m -94.46 134.36 37.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -1.18 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.796 HG22 HD12 ' A' ' 44' ' ' ILE . 57.8 mt -110.25 135.1 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -0.951 . . . . 0.0 109.512 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.439 ' O ' ' OD2' ' A' ' 69' ' ' ASP . 78.5 mttt -120.06 133.9 55.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.596 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -94.48 121.48 36.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.881 . . . . 0.0 109.364 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.594 HG23 ' CG2' ' A' ' 38' ' ' ILE . 94.4 mt -105.93 135.01 45.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.285 -0.885 . . . . 0.0 109.507 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.0 m -105.29 154.91 19.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.534 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.675 ' CD2' ' CE1' ' A' ' 64' ' ' PHE . 12.9 m-85 -128.12 139.72 36.22 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.301 -0.874 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.81 166.01 29.09 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.684 2.256 . . . . 0.0 111.78 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -63.62 139.49 58.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 108.27 13.33 19.59 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.606 ' CD1' ' CD1' ' A' ' 58' ' ' PHE . 1.5 m-85 -117.03 172.95 3.43 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.308 -1.113 . . . . 0.0 109.357 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.587 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 47.4 Cg_endo -68.22 -48.28 1.32 Allowed 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.652 2.235 . . . . 0.0 111.634 179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.675 ' CE1' ' CD2' ' A' ' 58' ' ' PHE . 40.4 p90 -124.33 153.53 41.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 109.328 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 58' ' ' PHE . 16.2 tttm -72.6 -44.25 62.25 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.913 . . . . 0.0 109.654 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -146.72 165.42 29.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.809 HG23 ' HA2' ' A' ' 88' ' ' GLY . 9.4 p -139.84 146.48 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 0.0 109.315 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.932 ' O ' HG13 ' A' ' 85' ' ' VAL . 77.0 tttt -98.13 137.18 37.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.613 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.599 ' O ' HG23 ' A' ' 53' ' ' ILE . 20.2 p30 -136.81 167.97 20.43 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.322 -0.861 . . . . 0.0 109.393 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -145.81 152.21 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 109.499 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.525 HG22 ' OH ' ' A' ' 81' ' ' TYR . 42.6 t -97.22 132.88 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.314 -0.866 . . . . 0.0 109.342 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.527 ' HB2' ' ND2' ' A' ' 82' ' ' ASN . 94.1 m-20 -77.13 -48.67 17.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.876 . . . . 0.0 109.536 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.9 tt0 178.37 141.6 0.1 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.185 -0.947 . . . . 0.0 109.582 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 74' ' ' VAL . 6.4 p -121.75 129.47 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -108.24 104.01 13.31 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.489 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -61.09 -43.79 98.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.491 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 49.8 m -61.07 -41.26 96.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.276 -0.89 . . . . 0.0 109.465 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 79' ' ' PHE . 8.3 m120 -91.54 5.08 50.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -0.867 . . . . 0.0 109.555 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.479 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 97.0 m-85 44.79 28.35 0.34 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.132 -0.98 . . . . 0.0 109.537 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -101.97 132.7 47.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.226 -0.921 . . . . 0.0 109.519 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.525 ' OH ' HG22 ' A' ' 71' ' ' VAL . 69.1 t80 -131.42 120.72 23.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.264 -0.898 . . . . 0.0 109.341 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.527 ' ND2' ' HB2' ' A' ' 72' ' ' ASP . 35.3 p-10 -125.49 144.34 50.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 35.1 p90 -147.35 158.31 43.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.292 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 92.9 p -144.23 155.44 43.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.295 -0.878 . . . . 0.0 109.548 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.932 HG13 ' O ' ' A' ' 68' ' ' LYS . 52.1 t -107.91 130.02 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.468 ' HA ' ' HD2' ' A' ' 97' ' ' LYS . 47.6 pt -103.24 -28.08 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.513 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.434 ' HG3' HG13 ' A' ' 86' ' ' ILE . 95.8 mt-10 -129.33 116.58 19.3 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.899 . . . . 0.0 109.355 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.809 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -134.85 171.18 22.5 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -64.99 -65.03 3.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -71.34 -0.74 8.6 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.802 2.335 . . . . 0.0 111.795 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.56 HD13 ' HA ' ' A' ' 97' ' ' LYS . 41.5 mt -115.04 149.06 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.154 -0.966 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.12 -135.33 4.8 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -61.85 -47.04 86.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -1.149 . . . . 0.0 109.202 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -158.45 21.78 0.23 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.405 -0.809 . . . . 0.0 109.203 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 122' ' ' THR . 96.8 mt -62.56 -46.99 85.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.233 -0.917 . . . . 0.0 110.047 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -152.69 48.83 0.74 Allowed 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.085 -1.009 . . . . 0.0 109.814 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.56 ' HA ' HD13 ' A' ' 91' ' ' ILE . 21.0 ttpt -64.71 132.28 49.21 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.152 -0.967 . . . . 0.0 108.644 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 120' ' ' TYR . 59.2 mt -117.55 134.84 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.11 -0.994 . . . . 0.0 110.255 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 32.7 t -118.72 122.93 43.63 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' A' ' 117' ' ' SER . 32.7 t-20 -110.41 143.9 39.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.097 -1.002 . . . . 0.0 110.081 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.5 mt-10 -127.35 125.48 40.82 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.504 HD13 ' HE2' ' A' ' 22' ' ' PHE . 52.6 mt -112.14 137.43 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.112 -0.992 . . . . 0.0 110.177 -179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 81.7 tttt -133.82 126.8 31.33 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.76 HD12 ' CD1' ' A' ' 19' ' ' PHE . 72.9 mt -109.95 136.43 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.926 -179.497 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.527 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 12.4 m -132.2 145.33 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.311 -0.868 . . . . 0.0 109.233 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.0 142.5 34.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.067 -1.021 . . . . 0.0 109.637 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.484 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 12.4 p -106.56 160.38 26.48 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.281 -0.887 . . . . 0.0 109.391 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.484 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 50.2 Cg_endo -70.65 -24.16 25.92 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.648 2.232 . . . . 0.0 111.867 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -170.35 28.01 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.213 -0.93 . . . . 0.0 109.507 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.69 29.11 4.07 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 71.96 -145.51 38.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 61.5 p -127.62 148.89 50.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.302 -1.116 . . . . 0.0 109.471 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.527 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 65.3 mt -110.87 135.9 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -0.879 . . . . 0.0 109.324 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.476 ' CD2' HG12 ' A' ' 104' ' ' ILE . 94.7 mt -110.92 136.0 50.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.6 mttt -122.79 122.19 38.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.473 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.9 mt -123.23 135.44 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.168 -0.957 . . . . 0.0 109.775 -179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 32.8 t -120.31 131.93 55.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.322 -0.861 . . . . 0.0 109.178 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.463 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 22.1 m120 -114.88 133.4 56.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 109.855 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 40.7 mttt -123.24 145.7 48.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.372 -0.83 . . . . 0.0 109.043 179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.528 ' CD2' HG12 ' A' ' 98' ' ' ILE . 95.8 m-85 -122.31 130.91 53.61 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.824 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.482 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 87.8 m-70 -114.19 134.74 54.71 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.34 -0.85 . . . . 0.0 109.201 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.675 HG21 HG23 ' A' ' 128' ' ' VAL . 50.6 p -133.1 137.66 46.41 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.111 -0.993 . . . . 0.0 109.731 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' A' ' 94' ' ' THR . 60.8 tttm -47.51 -37.52 12.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.495 -0.753 . . . . 0.0 109.467 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.05 -52.4 0.8 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -59.41 -26.75 65.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.321 -1.106 . . . . 0.0 109.607 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -112.21 138.29 49.11 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.466 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -115.11 162.06 17.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.961 . . . . 0.0 109.484 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.675 HG23 HG21 ' A' ' 122' ' ' THR . 41.1 t -106.92 136.28 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.183 -0.948 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.25 145.65 29.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.552 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.72 -36.65 79.37 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.565 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.86 -43.14 80.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.887 . . . . 0.0 109.584 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -57.31 -37.1 71.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.547 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 47.3 t -67.21 -38.49 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.183 -0.948 . . . . 0.0 109.593 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 53.1 mttm -59.01 -42.45 90.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.932 . . . . 0.0 109.583 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.03 -44.71 96.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.551 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.1 t -63.19 -37.03 85.63 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.213 -0.929 . . . . 0.0 109.453 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.464 ' HE3' ' CG2' ' A' ' 7' ' ' THR . 81.9 tttt -64.57 -37.9 89.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.886 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -63.17 -44.43 95.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.241 -0.912 . . . . 0.0 109.432 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 71.4 mtm -63.61 -40.22 96.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.212 -0.93 . . . . 0.0 109.329 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.02 -37.9 93.43 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.6 mt-10 -72.5 -32.41 66.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -1.134 . . . . 0.0 109.261 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.7 m -66.67 -31.02 71.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.27 -0.893 . . . . 0.0 109.464 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 143' ' ' LEU . 27.0 mt -69.42 -48.93 59.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.913 . . . . 0.0 109.812 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.539 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.4 pp -70.48 -30.85 67.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.081 -1.012 . . . . 0.0 109.599 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 33.6 mtt180 -65.51 -40.74 93.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.155 -0.966 . . . . 0.0 109.301 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.693 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -66.13 -40.66 90.83 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.313 -0.867 . . . . 0.0 109.414 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 77.8 t -59.77 -46.73 93.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.754 ' HA ' HD11 ' A' ' 13' ' ' ILE . 97.4 mt-10 -54.94 -47.58 74.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 84.1 p -55.37 -36.12 66.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.894 . . . . 0.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.589 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 69.3 t80 -61.65 -48.81 79.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.9 . . . . 0.0 109.432 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.607 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.4 mm? -59.21 -42.53 91.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.36 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.491 ' N ' HD12 ' A' ' 152' ' ' LEU . 7.4 mp -70.48 -25.66 63.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.593 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -60.14 -39.55 86.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.229 -0.919 . . . . 0.0 109.418 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.589 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 80.5 m-70 -55.7 -38.56 69.86 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 20.2 m -57.64 -31.14 65.99 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.929 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -73.26 -19.19 61.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.487 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.69 144.39 55.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.284 -0.885 . . . . 0.0 109.447 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -60.42 -33.06 71.97 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.33 -0.857 . . . . 0.0 109.524 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 31.3 t-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.435 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.38 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 78.8 t -134.16 146.25 31.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -1.157 . . . . 0.0 109.563 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.546 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 78.2 m-85 -100.67 138.11 38.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.399 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.405 ' CG ' ' HE3' ' A' ' 119' ' ' LYS . 51.4 t30 -124.78 116.8 22.87 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.546 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -120.03 135.16 55.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.274 -0.891 . . . . 0.0 109.382 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 92.0 mt-10 -122.29 139.8 53.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.151 -0.968 . . . . 0.0 109.584 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 22.3 p -127.59 157.84 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 0.0 109.395 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.64 136.41 47.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.642 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 34.3 m -137.74 144.71 41.81 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 109.278 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 113' ' ' ILE . 16.9 m -121.31 141.88 50.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.96 . . . . 0.0 109.693 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 27.4 p -144.42 155.76 43.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.452 HG23 HD13 ' A' ' 13' ' ' ILE . 19.3 m -73.94 -26.43 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.517 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 12.6 mm -55.62 140.86 65.87 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.513 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.517 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 48.8 Cg_endo -71.87 147.09 49.18 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.637 2.225 . . . . 0.0 111.501 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.508 ' HB1' HG22 ' A' ' 104' ' ' ILE . . . -61.39 -39.77 91.9 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 0.0 109.738 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.98 -46.72 78.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.142 -0.974 . . . . 0.0 109.484 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 ttm-85 -74.65 -40.88 61.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 109.567 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' CD1' ' HB2' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -67.13 -43.57 82.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 23' ' ' ILE . 60.0 t80 -64.94 -56.96 10.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.387 -0.821 . . . . 0.0 109.622 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 24' ' ' LEU . 51.0 mttt -56.36 -48.7 76.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.289 -0.882 . . . . 0.0 109.803 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.478 ' HB1' HD11 ' A' ' 29' ' ' LEU . . . -69.22 -47.89 63.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.134 -0.979 . . . . 0.0 109.831 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.574 ' CE2' HD13 ' A' ' 102' ' ' ILE . 67.8 t80 -66.14 -28.19 68.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.933 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 19' ' ' PHE . 32.6 mm -97.05 -62.18 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.088 -1.007 . . . . 0.0 109.687 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 20' ' ' LYS . 47.7 mt -67.53 -39.22 85.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.814 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 85.8 m-20 -106.6 23.13 14.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.119 -0.988 . . . . 0.0 109.498 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.71 -40.93 57.75 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.467 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 90.5 m-20 -65.36 -37.05 85.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -1.162 . . . . 0.0 109.376 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.464 ' O ' ' HB2' ' A' ' 32' ' ' LYS . 83.4 m-20 -83.37 -42.53 16.94 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.884 ' O ' HG22 ' A' ' 33' ' ' VAL . 51.7 mt -66.42 -37.57 85.51 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.642 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.543 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 1.4 m-85 -44.59 -63.55 1.1 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 108.953 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.543 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.71 -48.59 0.5 Allowed 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.674 2.249 . . . . 0.0 111.314 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' ASN . 10.0 tttt -51.34 -47.65 62.66 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.318 -0.864 . . . . 0.0 109.874 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.884 HG22 ' O ' ' A' ' 29' ' ' LEU . 3.6 m -78.21 -27.48 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.32 -0.863 . . . . 0.0 110.059 -179.245 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.92 75.73 10.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.957 -1.089 . . . . 0.0 109.919 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.56 -19.15 32.69 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.548 2.165 . . . . 0.0 111.482 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -77.39 -16.8 58.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.333 -0.854 . . . . 0.0 109.505 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -92.54 -40.45 10.79 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.284 -0.885 . . . . 0.0 109.48 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.561 ' CG2' HG23 ' A' ' 56' ' ' ILE . 83.1 mt -134.27 120.85 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.808 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 68.5 m -60.19 -41.67 93.42 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.241 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.0 t -166.79 154.2 9.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.585 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.468 ' O ' ' HG3' ' A' ' 42' ' ' GLU . 38.6 t -111.43 149.11 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.364 -0.835 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 55' ' ' LYS . 34.6 mp0 -147.48 150.39 34.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.19 -0.944 . . . . 0.0 109.808 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 55.8 m-20 -103.3 105.99 16.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.259 -0.901 . . . . 0.0 109.477 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.799 HD12 HG22 ' A' ' 53' ' ' ILE . 76.6 mt -59.19 -51.48 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.771 ' O ' HG23 ' A' ' 52' ' ' THR . 96.9 mt-10 -140.34 155.13 46.91 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.233 -0.917 . . . . 0.0 109.7 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 88.59 -166.98 34.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 35.5 t-20 -155.35 41.19 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -1.106 . . . . 0.0 109.565 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.46 ' H ' HG21 ' A' ' 52' ' ' THR . . . 97.8 11.48 50.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.832 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -109.16 -170.8 20.7 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -69.36 137.41 36.55 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.674 2.249 . . . . 0.0 111.88 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.05 4.98 88.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 45' ' ' GLU . 86.8 m -78.32 138.13 38.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -1.169 . . . . 0.0 109.506 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.799 HG22 HD12 ' A' ' 44' ' ' ILE . 62.8 mt -115.51 135.18 56.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.27 -0.894 . . . . 0.0 109.378 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 89.9 mttt -126.66 146.11 50.31 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 42' ' ' GLU . 8.0 pttt -107.42 137.1 46.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.217 -0.927 . . . . 0.0 109.364 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.561 HG23 ' CG2' ' A' ' 38' ' ' ILE . 89.0 mt -106.11 134.26 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 29.1 t -107.77 140.82 40.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.451 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.468 ' N ' ' O ' ' A' ' 65' ' ' LYS . 46.5 m-85 -109.44 143.4 27.69 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.02 144.06 51.5 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.666 2.244 . . . . 0.0 111.818 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -48.01 144.83 3.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.208 -0.933 . . . . 0.0 109.459 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.63 10.38 50.4 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.466 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 0.9 OUTLIER -111.7 164.94 13.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.245 -1.15 . . . . 0.0 109.509 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.466 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.2 Cg_endo -68.65 -35.09 17.59 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.757 2.304 . . . . 0.0 111.935 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.562 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 55.0 m-85 -118.85 166.73 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 109.467 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.468 ' O ' ' N ' ' A' ' 58' ' ' PHE . 67.4 mttt -100.22 -63.89 1.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.533 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.461 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 34.3 p90 -145.91 160.1 42.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 56' ' ' ILE . 25.4 m -141.65 145.08 24.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.428 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.7 ' O ' HG13 ' A' ' 85' ' ' VAL . 26.7 mttt -99.61 144.26 28.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.231 -0.918 . . . . 0.0 109.658 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.656 ' O ' HG23 ' A' ' 53' ' ' ILE . 37.1 p30 -136.98 167.56 21.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.361 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -143.04 145.6 33.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.232 -0.917 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.832 HG11 ' O ' ' A' ' 49' ' ' GLY . 11.8 p -90.55 138.13 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -81.51 -41.11 22.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 109.542 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -178.74 148.37 0.42 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.905 . . . . 0.0 109.475 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' TYR . 36.4 t -117.61 131.77 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -118.16 86.56 2.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.507 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -58.28 -41.02 83.45 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 109.512 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.6 m -64.21 -41.12 97.17 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.404 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' PHE . 77.8 m-20 -93.02 9.57 35.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.156 -0.965 . . . . 0.0 109.528 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.468 ' HB3' ' HB ' ' A' ' 104' ' ' ILE . 43.0 m-85 43.13 28.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.1 ttpt -105.79 133.22 50.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.597 ' CE2' HG22 ' A' ' 74' ' ' VAL . 71.6 t80 -127.94 127.98 44.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.26 -0.9 . . . . 0.0 109.412 179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.432 ' ND2' ' HB3' ' A' ' 101' ' ' GLU . 21.0 m120 -123.98 141.25 52.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.284 -0.885 . . . . 0.0 109.536 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.574 ' CZ ' ' HB3' ' A' ' 100' ' ' ASN . 34.9 p90 -155.93 158.68 38.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 84.1 p -148.13 161.61 41.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.483 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.7 HG13 ' O ' ' A' ' 68' ' ' LYS . 60.2 t -98.64 142.81 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.274 -0.891 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.42 ' HA ' ' HE2' ' A' ' 97' ' ' LYS . 41.1 pt -115.59 -23.87 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.192 -0.943 . . . . 0.0 109.544 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 68' ' ' LYS . 69.3 mm-40 -132.88 119.62 20.44 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.26 -0.9 . . . . 0.0 109.411 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -146.76 161.68 28.44 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -56.85 -63.95 4.85 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.562 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 50.8 Cg_endo -71.32 1.59 5.31 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.739 2.293 . . . . 0.0 112.062 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.543 HD11 HG12 ' A' ' 98' ' ' ILE . 26.6 mt -120.69 136.05 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.136 -0.977 . . . . 0.0 109.802 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.95 -116.51 2.76 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.14 -43.98 73.23 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.188 -1.183 . . . . 0.0 108.942 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.708 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.6 OUTLIER -169.4 25.86 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.926 HD23 ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -67.29 -34.19 76.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.233 -0.917 . . . . 0.0 110.025 -179.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 89.6 mt-10 -157.39 53.6 0.49 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.024 -1.048 . . . . 0.0 110.042 -179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 15.8 tttm -64.79 132.39 49.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 108.806 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.543 HG12 HD11 ' A' ' 91' ' ' ILE . 8.3 mm -106.52 135.01 46.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.107 -0.996 . . . . 0.0 110.083 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 39.3 t -131.05 116.9 18.39 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.574 ' HB3' ' CZ ' ' A' ' 83' ' ' TYR . 33.0 t-20 -112.56 139.6 48.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.109 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.432 ' HB3' ' ND2' ' A' ' 82' ' ' ASN . 94.8 mt-10 -119.1 127.89 53.8 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.574 HD13 ' CE2' ' A' ' 22' ' ' PHE . 47.1 mt -111.27 136.42 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.177 -0.952 . . . . 0.0 109.985 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 115' ' ' LYS . 20.4 tttt -132.25 123.73 27.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.431 -0.793 . . . . 0.0 109.087 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 114' ' ' LEU . 19.8 mm -104.89 131.92 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.166 -0.959 . . . . 0.0 109.803 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.53 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 13.6 m -129.8 144.22 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.359 -0.838 . . . . 0.0 109.38 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -104.71 135.63 45.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.452 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.6 HG23 ' O ' ' A' ' 111' ' ' GLY . 6.6 p -92.1 160.65 35.1 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.228 -0.92 . . . . 0.0 109.437 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 49.8 Cg_endo -69.9 -27.52 25.71 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.66 2.24 . . . . 0.0 111.776 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -168.58 27.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.271 -0.893 . . . . 0.0 109.552 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -129.41 28.33 4.05 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 107' ' ' THR . . . 77.42 -150.37 36.66 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 t -123.01 148.18 45.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.131 -1.217 . . . . 0.0 109.501 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 10' ' ' THR . 72.4 mt -108.48 138.78 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.49 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.627 ' CD2' HD12 ' A' ' 104' ' ' ILE . 86.5 mt -107.01 138.53 43.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.442 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 23.0 mttm -127.86 121.68 30.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 67.3 mt -123.06 139.51 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.214 -0.929 . . . . 0.0 109.661 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 6' ' ' GLU . 49.2 m -124.34 132.11 53.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.253 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -110.96 142.74 42.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.898 . . . . 0.0 109.703 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.405 ' HE3' ' CG ' ' A' ' 4' ' ' ASN . 37.9 mttp -134.45 131.8 38.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.261 -0.899 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 133' ' ' VAL . 87.2 m-85 -108.25 131.18 54.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.126 -0.984 . . . . 0.0 109.675 -179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 80.5 m-70 -117.07 133.23 56.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.391 -0.818 . . . . 0.0 109.25 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.523 HG22 ' O ' ' A' ' 95' ' ' LEU . 44.6 p -135.04 137.53 43.02 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.053 -1.03 . . . . 0.0 109.827 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.708 ' HB2' HG23 ' A' ' 94' ' ' THR . 22.3 ttpt -52.67 -35.86 55.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.537 -0.727 . . . . 0.0 109.485 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.87 -46.72 0.95 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -61.46 -28.93 69.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.174 -1.192 . . . . 0.0 109.664 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.926 ' CD2' HD23 ' A' ' 95' ' ' LEU . 97.7 m-70 -109.68 137.2 47.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.129 -0.982 . . . . 0.0 109.61 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -114.62 162.65 16.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.512 HG23 HG21 ' A' ' 122' ' ' THR . 18.3 t -109.53 135.88 47.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.22 -0.925 . . . . 0.0 109.381 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.43 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 47.8 mttt -84.42 141.8 30.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.37 -39.42 90.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 109.501 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.62 -42.87 79.53 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -0.935 . . . . 0.0 109.397 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.43 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 94.9 mt-30 -57.54 -36.6 71.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.288 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.535 HG22 ' CE2' ' A' ' 120' ' ' TYR . 93.8 t -65.68 -42.26 92.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -0.877 . . . . 0.0 109.45 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -55.44 -48.11 74.95 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.254 -0.904 . . . . 0.0 109.471 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -59.43 -42.33 91.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.207 -0.933 . . . . 0.0 109.309 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.9 t -59.67 -42.11 92.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.908 . . . . 0.0 109.382 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 44.3 tttt -57.83 -42.85 85.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -60.59 -40.47 91.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.372 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 89.7 mtp -59.58 -42.72 93.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.39 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.63 -44.2 94.04 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.539 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 83.4 tt0 -64.48 -37.02 86.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.236 -1.155 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 90.9 m -63.24 -32.11 73.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 109.307 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 25.7 mt -73.99 -48.78 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.295 -0.878 . . . . 0.0 109.362 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.619 ' C ' HD12 ' A' ' 144' ' ' LEU . 3.9 pp -72.77 -34.32 66.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.116 -0.99 . . . . 0.0 109.405 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.575 ' N ' HD12 ' A' ' 144' ' ' LEU . 48.0 ttt85 -60.14 -44.06 95.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.882 . . . . 0.0 109.156 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.53 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -64.9 -42.14 95.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.273 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.84 HG22 HG11 ' A' ' 33' ' ' VAL . 76.4 t -62.51 -48.0 90.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.407 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 98.0 mt-10 -54.46 -49.37 70.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.246 -0.909 . . . . 0.0 109.238 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 83.7 p -54.52 -35.89 63.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.303 -0.873 . . . . 0.0 109.223 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.527 ' CE1' ' CE1' ' A' ' 154' ' ' HIS . 68.2 t80 -59.5 -45.51 91.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.318 -0.864 . . . . 0.0 109.276 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.627 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -58.64 -42.45 88.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.324 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.663 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -75.86 -20.81 57.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.338 -0.851 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.8 -35.48 80.01 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -0.855 . . . . 0.0 109.464 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.527 ' CE1' ' CE1' ' A' ' 150' ' ' TYR . 76.0 m80 -49.38 -40.3 35.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.418 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 83.4 p -59.06 -30.65 68.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.941 . . . . 0.0 109.241 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -73.95 -16.52 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.364 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -67.7 145.09 55.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.956 . . . . 0.0 109.405 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.452 ' O ' ' CB ' ' A' ' 159' ' ' ASN . 69.9 m-85 -113.03 120.23 40.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.249 -0.907 . . . . 0.0 109.522 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . 0.452 ' CB ' ' O ' ' A' ' 158' ' ' TYR . 46.6 t30 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.687 HG13 ' O ' ' A' ' 120' ' ' TYR . 50.1 t -133.85 142.09 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.308 -1.113 . . . . 0.0 109.395 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.507 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 56.1 m-85 -94.8 139.85 30.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.135 -0.978 . . . . 0.0 109.313 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 47.1 t-20 -133.84 116.13 15.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.746 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 71.7 m-85 -119.78 120.83 37.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.165 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 28.9 tt0 -101.74 143.96 31.02 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.141 -0.974 . . . . 0.0 109.314 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.44 HG22 ' HE3' ' A' ' 137' ' ' LYS . 19.7 p -128.16 154.32 45.91 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.854 . . . . 0.0 109.25 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -121.06 137.42 54.66 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.182 -0.948 . . . . 0.0 109.822 -179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 51.6 m -139.6 145.41 38.51 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.389 -0.82 . . . . 0.0 109.408 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.2 m -121.62 145.82 47.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 25.1 m -145.54 142.09 28.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 26.3 m -70.66 -26.8 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.48 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.554 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 18.8 mm -55.03 141.44 59.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.368 -0.832 . . . . 0.0 109.432 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.554 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 50.1 Cg_endo -71.64 142.83 40.78 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.541 2.161 . . . . 0.0 111.817 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.489 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -58.27 -33.34 69.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.762 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.87 -49.52 77.45 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -78.39 -39.54 38.79 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.912 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -69.18 -36.0 76.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.315 -0.866 . . . . 0.0 109.427 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.696 ' CE2' HD12 ' A' ' 23' ' ' ILE . 59.3 t80 -69.59 -41.48 75.71 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.244 -0.91 . . . . 0.0 109.908 -179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 86.0 mttt -78.9 -38.95 36.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.158 -0.964 . . . . 0.0 109.9 -179.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.517 ' O ' HD12 ' A' ' 29' ' ' LEU . . . -75.09 -39.72 60.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.138 -0.976 . . . . 0.0 109.685 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.551 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 58.3 t80 -75.91 -23.21 55.51 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.188 -0.945 . . . . 0.0 109.815 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.696 HD12 ' CE2' ' A' ' 19' ' ' PHE . 51.9 mt -103.3 -63.93 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.963 . . . . 0.0 109.958 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 38.5 mt -65.43 -34.98 79.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB2' ' HA ' ' A' ' 21' ' ' ALA . 78.4 m-20 -110.48 20.82 17.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.423 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -72.33 -34.16 61.02 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 94.6 m-20 -73.98 -38.54 64.13 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -1.124 . . . . 0.0 109.412 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.443 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 84.2 m-20 -78.29 -42.53 30.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.879 . . . . 0.0 109.375 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.9 ' O ' HG22 ' A' ' 33' ' ' VAL . 77.2 mt -70.11 -33.74 72.23 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.248 -0.907 . . . . 0.0 109.449 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -44.06 -63.49 1.06 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.465 179.981 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.542 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.0 Cg_endo -71.13 -42.6 1.96 Allowed 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.753 2.302 . . . . 0.0 111.981 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 56.1 mttt -62.26 -43.29 99.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.203 -0.935 . . . . 0.0 109.723 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.9 HG22 ' O ' ' A' ' 29' ' ' LEU . 4.2 m -77.8 -29.53 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.915 . . . . 0.0 109.656 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.44 75.74 10.27 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.23 -0.919 . . . . 0.0 109.512 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.19 -14.98 35.33 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.635 2.224 . . . . 0.0 111.715 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -75.84 -18.52 59.42 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.869 . . . . 0.0 109.363 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -91.4 -47.18 7.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.203 -0.936 . . . . 0.0 109.501 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.614 ' CG2' HG23 ' A' ' 56' ' ' ILE . 77.6 mt -129.36 120.03 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.297 -0.877 . . . . 0.0 109.459 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.0 t -61.67 -38.92 89.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 26.4 t -159.85 149.83 18.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.493 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.502 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 96.7 t -117.59 130.03 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.565 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 55' ' ' LYS . 44.2 tt0 -132.87 150.42 52.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.867 . . . . 0.0 109.32 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 94.2 m-20 -97.19 118.07 32.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.227 -0.92 . . . . 0.0 109.504 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.838 HG22 ' HG3' ' A' ' 45' ' ' GLU . 86.1 mt -67.31 -52.65 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.449 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 52' ' ' THR . 93.8 mt-10 -148.56 162.39 39.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -0.976 . . . . 0.0 109.429 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.33 169.44 43.59 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -121.2 28.62 7.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -1.137 . . . . 0.0 109.473 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 52' ' ' THR . . . 107.98 -18.08 34.45 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.698 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -68.53 -170.98 6.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 49.8 Cg_endo -70.22 138.74 37.03 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.76 2.306 . . . . 0.0 111.797 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 84.88 8.44 82.52 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.859 HG23 ' O ' ' A' ' 45' ' ' GLU . 88.2 m -83.65 136.84 34.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.177 -1.19 . . . . 0.0 109.388 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.798 HG22 HD12 ' A' ' 44' ' ' ILE . 45.8 mt -106.55 129.56 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.247 -0.908 . . . . 0.0 109.433 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.502 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 10.9 ttpt -111.99 129.75 56.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.528 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.512 ' HB2' ' CG1' ' A' ' 44' ' ' ILE . 79.6 tttt -92.39 132.54 36.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.206 -0.934 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.614 HG23 ' CG2' ' A' ' 38' ' ' ILE . 79.4 mt -115.59 133.79 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.329 -0.857 . . . . 0.0 109.472 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 50.0 m -103.44 147.27 27.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.553 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.459 ' HB2' ' O ' ' A' ' 65' ' ' LYS . 3.1 m-30 -106.09 133.84 20.03 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.448 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.64 157.04 62.0 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.7 2.267 . . . . 0.0 111.719 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -54.47 141.62 30.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.479 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.62 9.36 52.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.541 ' CD2' ' HD2' ' A' ' 63' ' ' PRO . 1.3 m-85 -109.2 161.13 25.01 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.327 -1.101 . . . . 0.0 109.464 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.541 ' HD2' ' CD2' ' A' ' 62' ' ' PHE . 49.3 Cg_endo -70.07 -38.76 6.71 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.766 2.311 . . . . 0.0 111.696 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.56 ' CE2' ' HD3' ' A' ' 90' ' ' PRO . 98.0 m-85 -114.08 152.27 31.3 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.412 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB2' ' A' ' 58' ' ' PHE . 68.9 mttt -79.19 -36.69 39.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.656 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.454 ' HB2' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -159.29 165.12 34.13 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.614 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.3 t -136.55 157.6 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.339 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.997 ' O ' HG23 ' A' ' 85' ' ' VAL . 65.7 mttt -103.25 142.3 34.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.42 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -136.05 142.78 44.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.223 -0.923 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 71' ' ' VAL . 60.6 ttp180 -132.31 154.32 49.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.569 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.698 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.4 p -103.26 136.82 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.545 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -80.41 -45.72 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.502 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' HA ' ' HB3' ' A' ' 50' ' ' PRO . 85.8 tt0 -177.82 155.54 1.02 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -0.86 . . . . 0.0 109.526 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.416 ' N ' ' HG2' ' A' ' 73' ' ' GLU . 40.2 t -120.42 131.71 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.378 -0.827 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 -114.36 87.53 2.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.438 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -59.97 -40.69 89.97 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 84.9 m -59.83 -41.6 91.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.235 -0.915 . . . . 0.0 109.55 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -96.35 10.01 39.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.25 -0.906 . . . . 0.0 109.561 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.583 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 89.8 m-85 45.07 28.22 0.37 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.535 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 45.6 tttt -103.1 133.07 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.458 ' O ' ' N ' ' A' ' 102' ' ' ILE . 70.5 t80 -123.23 120.19 32.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.255 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' GLU . 78.8 m-20 -119.88 136.99 54.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.813 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.452 ' HE1' HD11 ' A' ' 102' ' ' ILE . 37.8 p90 -146.1 154.96 42.4 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.334 -0.854 . . . . 0.0 109.219 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.402 ' CB ' ' HA ' ' A' ' 99' ' ' SER . 87.0 p -145.71 157.39 43.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 68' ' ' LYS . 11.2 p -101.09 131.73 48.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.431 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.434 HG13 ' HG3' ' A' ' 87' ' ' GLU . 48.1 pt -103.16 -27.53 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -0.894 . . . . 0.0 109.51 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.477 ' OE1' ' HD2' ' A' ' 68' ' ' LYS . 96.7 mt-10 -131.91 115.69 16.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 109.461 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 91' ' ' ILE . . . -135.66 148.89 19.83 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.556 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -50.24 -57.13 10.65 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HD3' ' CE2' ' A' ' 64' ' ' PHE . 51.5 Cg_endo -72.52 -7.18 20.42 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.729 2.286 . . . . 0.0 111.893 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 97' ' ' LYS . 53.1 mt -114.32 140.57 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.569 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -104.63 -154.96 23.01 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -47.87 -45.03 29.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -1.177 . . . . 0.0 109.213 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.545 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.96 21.92 0.17 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 109.441 179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.622 HD22 ' HD2' ' A' ' 126' ' ' HIS . 99.2 mt -63.25 -40.74 98.26 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.127 -0.983 . . . . 0.0 110.013 -179.392 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 73.4 tt0 -155.29 51.42 0.59 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.971 -1.081 . . . . 0.0 109.857 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.503 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 31.0 ttpt -64.82 132.29 49.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.138 -0.976 . . . . 0.0 108.628 179.484 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.539 HG12 ' CD2' ' A' ' 120' ' ' TYR . 60.5 mt -115.32 130.28 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 110.127 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.402 ' HA ' ' CB ' ' A' ' 84' ' ' SER . 50.1 m -118.76 128.38 54.43 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.496 ' OD1' ' ND2' ' A' ' 118' ' ' ASN . 65.1 m-20 -120.47 136.76 54.66 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.011 -1.055 . . . . 0.0 110.239 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.459 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -115.84 124.59 51.06 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.551 HD13 ' CZ ' ' A' ' 22' ' ' PHE . 78.3 mt -108.21 137.89 37.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.17 -0.956 . . . . 0.0 110.052 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 21.5 tttm -130.76 131.15 44.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.448 -0.783 . . . . 0.0 109.108 179.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.525 HD12 ' HD1' ' A' ' 19' ' ' PHE . 64.6 mt -113.93 137.28 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 109.752 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 112' ' ' SER . 20.5 t -136.41 140.77 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.422 ' C ' ' CG2' ' A' ' 107' ' ' THR . . . -98.14 135.07 40.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.304 -0.873 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 111' ' ' GLY . 0.6 OUTLIER -153.52 125.04 3.67 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.51 -4.78 15.21 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.639 2.226 . . . . 0.0 111.72 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.23 -33.64 43.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.173 -0.954 . . . . 0.0 109.396 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -157.59 37.3 0.54 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 107' ' ' THR . . . 76.03 -143.9 30.38 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 65.8 p -103.9 148.21 26.43 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.324 -1.104 . . . . 0.0 109.18 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.1 mt -106.05 138.43 31.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.416 -0.803 . . . . 0.0 109.506 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.406 ' HA ' HD23 ' A' ' 114' ' ' LEU . 90.7 mt -108.99 130.86 55.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.316 -0.865 . . . . 0.0 109.63 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.412 ' HB2' ' HB3' ' A' ' 103' ' ' LYS . 12.0 mtpp -122.01 122.25 38.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.316 -0.865 . . . . 0.0 108.846 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 79.4 mt -121.62 118.19 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.033 -1.042 . . . . 0.0 110.095 -179.486 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 21.1 t -97.06 135.59 38.83 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 179.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.496 ' ND2' ' OD1' ' A' ' 100' ' ' ASN . 1.1 t-20 -116.13 141.59 47.93 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.361 -0.837 . . . . 0.0 109.995 -178.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.457 ' HA ' ' O ' ' A' ' 3' ' ' PHE . 36.1 mtmt -138.64 144.06 39.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.384 -0.823 . . . . 0.0 109.458 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.687 ' O ' HG13 ' A' ' 2' ' ' VAL . 89.0 m-85 -122.65 132.99 54.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.193 -0.942 . . . . 0.0 109.439 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.503 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 89.2 m-70 -114.73 134.8 54.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.312 -0.868 . . . . 0.0 109.43 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.804 HG21 HG23 ' A' ' 128' ' ' VAL . 62.5 p -129.63 137.79 50.87 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.607 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.545 ' HB2' HG23 ' A' ' 94' ' ' THR . 40.9 tttm -51.21 -37.83 48.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.444 -0.785 . . . . 0.0 109.504 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 137.69 -51.14 0.79 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -59.65 -28.05 66.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.48 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.622 ' HD2' HD22 ' A' ' 95' ' ' LEU . 98.6 m-70 -113.35 139.0 49.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 109.47 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -112.51 163.37 14.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.298 -0.876 . . . . 0.0 109.512 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.804 HG23 HG21 ' A' ' 122' ' ' THR . 26.0 t -103.09 135.08 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.488 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -88.66 146.34 25.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.57 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.54 -36.32 75.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -0.877 . . . . 0.0 109.495 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -59.04 -37.93 78.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.536 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -63.46 -33.35 75.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.245 -0.91 . . . . 0.0 109.459 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.445 HG11 ' CD1' ' A' ' 5' ' ' TYR . 45.4 t -73.48 -34.39 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.494 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 138' ' ' GLU . 22.8 mttt -64.58 -37.97 89.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.47 -42.75 74.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.205 -0.935 . . . . 0.0 109.566 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 22.8 t -68.8 -32.99 73.11 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.189 -0.944 . . . . 0.0 109.526 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.44 ' HE3' HG22 ' A' ' 7' ' ' THR . 19.9 tttt -66.04 -39.32 90.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.539 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.453 ' HG3' ' O ' ' A' ' 134' ' ' LYS . 95.6 mt-10 -65.47 -47.19 76.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 73.0 mtm -61.95 -38.17 87.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.416 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -60.47 -38.71 95.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.521 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 96.5 mt-10 -75.4 -31.5 60.45 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -1.15 . . . . 0.0 109.384 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 85.1 m -64.34 -30.98 72.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.326 -0.859 . . . . 0.0 109.35 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 143' ' ' LEU . 21.2 mt -69.46 -48.86 59.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.981 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.521 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.45 -31.1 68.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.993 -1.067 . . . . 0.0 109.769 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 89.1 mtt180 -63.99 -44.55 92.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.316 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.61 97.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.268 -0.895 . . . . 0.0 109.371 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 150' ' ' TYR . 77.7 t -60.01 -48.6 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 109.324 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 95.4 mt-10 -49.58 -54.99 15.15 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.491 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.6 m -51.8 -37.64 52.42 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.384 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.501 ' CE1' ' NE2' ' A' ' 154' ' ' HIS . 85.0 t80 -57.41 -41.33 80.12 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.309 -0.869 . . . . 0.0 109.262 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.665 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -65.94 -38.41 88.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.272 -0.893 . . . . 0.0 109.346 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.597 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -70.21 -18.95 63.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.3 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.404 ' O ' ' OD1' ' A' ' 156' ' ' ASP . . . -70.65 -28.37 64.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.327 -0.858 . . . . 0.0 109.349 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . 0.501 ' NE2' ' CE1' ' A' ' 150' ' ' TYR . 67.7 m-70 -92.16 -26.99 17.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 109.476 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 87.4 p -52.37 -31.92 36.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.194 -0.941 . . . . 0.0 109.361 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 156' ' ' ASP . 56.9 p30 -91.73 9.52 32.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -68.5 143.39 54.98 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.311 -0.868 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -61.23 -36.8 80.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.272 -0.893 . . . . 0.0 109.468 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.47 179.922 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.49 HG11 ' CE1' ' A' ' 121' ' ' HIS . 62.7 t -133.96 142.6 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.166 -1.197 . . . . 0.0 109.435 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 71.6 m-85 -96.1 136.97 35.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.879 . . . . 0.0 109.407 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.449 ' OD1' ' HE2' ' A' ' 119' ' ' LYS . 52.0 t30 -119.87 116.93 26.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.248 -0.907 . . . . 0.0 109.55 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.564 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 98.4 m-85 -119.73 132.17 55.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.439 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 94.3 mt-10 -122.45 140.54 52.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.194 -0.941 . . . . 0.0 109.576 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 p -126.21 157.51 38.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.261 -0.899 . . . . 0.0 109.339 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -123.84 135.29 53.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.454 HG21 HD13 ' A' ' 144' ' ' LEU . 48.0 m -134.45 141.57 46.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.416 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.519 HG23 HG12 ' A' ' 113' ' ' ILE . 15.5 m -118.01 141.48 48.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.529 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -141.65 151.4 43.03 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.479 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' O ' ' HA2' ' A' ' 111' ' ' GLY . 14.5 m -81.03 -20.05 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.563 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.7 mm -65.1 142.54 98.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.267 -0.896 . . . . 0.0 109.206 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.563 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 46.7 Cg_endo -68.43 146.32 68.05 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.543 2.162 . . . . 0.0 111.831 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.478 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -65.24 -26.47 68.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.292 -0.88 . . . . 0.0 109.74 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.01 -49.01 64.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.132 -0.98 . . . . 0.0 109.61 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.474 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 59.0 mtp180 -78.34 -38.7 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.214 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 18' ' ' LEU . 3.4 tm? -67.33 -37.0 82.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.345 -0.847 . . . . 0.0 109.36 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.885 ' HD2' HD12 ' A' ' 104' ' ' ILE . 65.3 t80 -69.79 -44.54 69.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.3 -0.875 . . . . 0.0 109.801 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 24' ' ' LEU . 18.7 mttt -66.82 -37.85 85.31 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.249 -0.907 . . . . 0.0 110.061 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 25' ' ' ASP . . . -82.19 -42.0 19.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.063 -1.023 . . . . 0.0 109.715 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.711 ' HE2' HD13 ' A' ' 102' ' ' ILE . 75.2 t80 -72.18 -25.62 61.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.851 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.58 HG13 ' CE2' ' A' ' 19' ' ' PHE . 26.3 mm -96.87 -63.55 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.053 -1.029 . . . . 0.0 109.704 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 20' ' ' LYS . 33.9 mt -68.49 -40.57 80.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 84.8 m-20 -102.65 26.69 7.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.27 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -78.69 -39.92 19.69 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.506 ' O ' ' CD ' ' A' ' 31' ' ' PRO . 84.3 m-20 -70.35 -35.42 73.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 109.398 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.487 ' ND2' ' HE3' ' A' ' 32' ' ' LYS . 10.4 t30 -84.58 -49.75 8.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.217 -0.927 . . . . 0.0 109.382 179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.818 ' O ' HG22 ' A' ' 33' ' ' VAL . 16.7 tp -63.0 -25.77 68.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.304 -0.873 . . . . 0.0 109.428 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 0.8 OUTLIER -55.59 -63.64 2.95 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 -179.954 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.529 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 50.4 Cg_endo -70.74 -34.4 11.36 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.623 2.215 . . . . 0.0 111.882 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.487 ' HE3' ' ND2' ' A' ' 28' ' ' ASN . 37.6 mttm -62.62 -39.93 95.37 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.948 . . . . 0.0 109.64 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.818 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.7 m -87.44 -35.82 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.924 . . . . 0.0 109.598 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.42 ' N ' HG23 ' A' ' 33' ' ' VAL . . . -133.64 73.68 71.88 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.31 -0.869 . . . . 0.0 109.441 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.87 -17.12 37.25 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.645 2.23 . . . . 0.0 111.784 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.507 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 96.4 mt-30 -77.17 -18.4 57.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.492 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -89.03 -47.45 8.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.213 -0.929 . . . . 0.0 109.51 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.547 ' CG2' HG23 ' A' ' 56' ' ' ILE . 88.1 mt -130.12 120.29 48.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.253 -0.904 . . . . 0.0 109.43 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.1 t -59.4 -36.92 76.73 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.881 . . . . 0.0 109.402 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 60.2 p -169.3 154.47 5.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.519 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HD2' ' A' ' 54' ' ' LYS . 58.9 t -116.99 138.63 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.269 -0.894 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -141.45 152.45 44.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.466 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 89.4 m-20 -101.92 106.59 17.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.472 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.875 HD12 HG22 ' A' ' 53' ' ' ILE . 83.4 mt -57.92 -55.93 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.248 -0.908 . . . . 0.0 109.34 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.756 ' O ' HG23 ' A' ' 52' ' ' THR . 76.1 tt0 -140.24 157.27 45.84 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.197 -0.939 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 81.49 -179.56 53.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 40.8 p-10 -131.12 28.5 4.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.195 -1.179 . . . . 0.0 109.489 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.697 ' H ' HG21 ' A' ' 52' ' ' THR . . . 109.91 -21.24 25.52 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -68.47 -169.24 5.31 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.48 147.31 64.35 Favored 'Trans proline' 0 C--O 1.217 -0.554 0 C-N-CA 122.71 2.274 . . . . 0.0 111.782 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.36 17.69 77.79 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.756 HG23 ' O ' ' A' ' 45' ' ' GLU . 92.9 m -91.65 140.4 29.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.259 -1.141 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.875 HG22 HD12 ' A' ' 44' ' ' ILE . 53.9 mt -108.49 134.84 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.512 ' HD2' ' CG1' ' A' ' 41' ' ' VAL . 32.7 ttpt -123.89 133.38 53.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.191 -0.943 . . . . 0.0 109.496 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 28.5 tttt -99.28 130.5 45.58 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.31 -0.869 . . . . 0.0 109.38 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.547 HG23 ' CG2' ' A' ' 38' ' ' ILE . 85.2 mt -111.41 129.5 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.547 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.6 t -106.87 146.32 31.11 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' LYS . 41.6 m-85 -109.84 150.08 40.85 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.458 ' HG2' ' CD2' ' A' ' 62' ' ' PHE . 49.8 Cg_endo -69.9 143.47 50.29 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.732 2.288 . . . . 0.0 111.838 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -51.23 143.89 10.39 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.343 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.39 8.35 57.57 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.527 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.1 m-85 -106.2 162.76 18.69 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.236 -1.155 . . . . 0.0 109.488 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.527 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 48.7 Cg_endo -68.92 -30.76 25.78 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.702 2.268 . . . . 0.0 111.795 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.528 ' CE1' ' HD3' ' A' ' 90' ' ' PRO . 41.0 m-85 -119.67 158.44 26.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 109.541 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 58' ' ' PHE . 66.7 tttt -96.58 -65.71 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -0.904 . . . . 0.0 109.402 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 37.7 p90 -144.41 169.26 18.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.488 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 56' ' ' ILE . 34.7 m -148.89 150.77 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.136 -0.978 . . . . 0.0 109.574 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.502 ' O ' HG13 ' A' ' 85' ' ' VAL . 93.6 mttt -106.75 141.05 38.62 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.46 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 85' ' ' VAL . 48.6 p30 -139.68 167.19 22.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.75 ' NE ' HD13 ' A' ' 86' ' ' ILE . 96.8 mtt180 -131.14 156.73 44.77 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.266 -0.897 . . . . 0.0 109.466 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.649 HG22 ' OH ' ' A' ' 81' ' ' TYR . 38.3 t -99.13 132.79 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 92.8 m-20 -76.9 -48.4 18.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.882 . . . . 0.0 109.59 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 85.0 tt0 177.91 151.54 0.24 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.639 HG22 ' CD1' ' A' ' 81' ' ' TYR . 34.8 t -117.83 131.73 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.24 -0.912 . . . . 0.0 109.558 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.6 m-20 -115.25 90.73 3.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.461 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -57.34 -43.36 83.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 0.0 109.53 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 63.0 m -58.38 -43.73 88.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.48 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' O ' ' C ' ' A' ' 79' ' ' PHE . 82.0 m-20 -96.81 6.28 48.98 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.557 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.506 ' N ' ' O ' ' A' ' 75' ' ' ASP . 87.8 m-85 45.0 38.53 3.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.204 -0.935 . . . . 0.0 109.338 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 32.2 tttm -108.84 125.85 52.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.294 -0.879 . . . . 0.0 109.626 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.649 ' OH ' HG22 ' A' ' 71' ' ' VAL . 75.3 t80 -118.36 122.08 41.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.328 -0.858 . . . . 0.0 109.325 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -118.33 136.71 53.56 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.915 . . . . 0.0 109.751 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.6 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 35.1 p90 -151.31 157.4 42.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.092 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.435 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 37.5 t -145.63 150.43 36.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.153 -0.967 . . . . 0.0 109.725 -179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 68' ' ' LYS . 40.2 t -89.67 136.92 22.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.325 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.75 HD13 ' NE ' ' A' ' 70' ' ' ARG . 37.3 pt -109.99 -26.13 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.243 -0.911 . . . . 0.0 109.615 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.443 ' OE2' ' HD2' ' A' ' 68' ' ' LYS . 82.4 tt0 -129.85 125.67 36.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.461 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -149.77 158.97 27.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.421 ' N ' ' HD2' ' A' ' 90' ' ' PRO . . . -57.2 -63.33 5.42 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -71.49 1.6 5.41 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.729 2.286 . . . . 0.0 111.813 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.6 mt -120.51 143.62 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.656 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.96 -124.44 3.3 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -69.84 -44.44 69.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -1.212 . . . . 0.0 109.181 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.533 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.1 OUTLIER -162.67 22.29 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.622 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.64 HD23 ' CD2' ' A' ' 126' ' ' HIS . 6.7 mp -65.48 -33.59 76.29 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.086 -1.009 . . . . 0.0 110.085 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.483 ' CG ' ' O ' ' A' ' 95' ' ' LEU . 82.1 mt-10 -159.24 48.38 0.31 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.133 -0.98 . . . . 0.0 110.055 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.489 ' HE2' ' HA ' ' A' ' 86' ' ' ILE . 14.7 tttm -64.99 132.31 48.91 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.033 -1.042 . . . . 0.0 108.632 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 71.1 mt -118.11 133.96 63.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.988 -1.07 . . . . 0.0 110.109 -179.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 32.9 t -118.79 125.61 49.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.331 -0.855 . . . . 0.0 109.049 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.6 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 78.8 m-20 -110.87 140.33 45.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.159 -0.963 . . . . 0.0 109.915 -179.622 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 94.7 mt-10 -121.2 134.69 55.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.423 -0.798 . . . . 0.0 109.051 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.711 HD13 ' HE2' ' A' ' 22' ' ' PHE . 67.7 mt -117.46 131.78 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.879 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 22.2 tttm -133.11 125.17 28.97 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.351 -0.843 . . . . 0.0 109.111 179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.885 HD12 ' HD2' ' A' ' 19' ' ' PHE . 60.0 mt -109.67 133.53 54.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.82 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 4.2 m -133.34 139.52 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.348 -0.845 . . . . 0.0 109.313 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -88.71 146.5 25.01 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 108' ' ' PRO . 1.3 p -109.26 163.84 16.11 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.387 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.3 Cg_endo -69.43 -17.62 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.535 2.157 . . . . 0.0 111.629 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.25 -23.63 59.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.354 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 126.81 -53.66 0.79 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 12' ' ' VAL . . . -62.46 -160.28 0.18 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.459 ' HA ' HG23 ' A' ' 107' ' ' THR . 83.6 p -147.18 157.75 43.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.227 -1.161 . . . . 0.0 109.381 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.519 HG12 HG23 ' A' ' 10' ' ' THR . 90.2 mt -106.3 147.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.195 -0.94 . . . . 0.0 109.541 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.514 ' CD2' HG12 ' A' ' 104' ' ' ILE . 95.6 mt -115.13 133.74 55.78 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.505 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 32.1 tttp -124.39 127.19 47.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 91.9 mt -124.78 139.55 50.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 109.696 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 41.5 m -125.26 137.42 54.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.328 -0.857 . . . . 0.0 109.203 179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -124.23 143.54 50.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.291 -0.881 . . . . 0.0 109.688 -179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 23.0 mttt -131.53 145.62 51.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.381 -0.824 . . . . 0.0 108.959 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.502 ' OH ' HG13 ' A' ' 133' ' ' VAL . 87.7 m-85 -117.75 126.22 52.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.127 -0.983 . . . . 0.0 109.789 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.49 ' CE1' HG11 ' A' ' 2' ' ' VAL . 84.6 m-70 -110.63 131.68 54.84 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.267 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.618 HG21 HG23 ' A' ' 128' ' ' VAL . 42.5 p -129.36 137.85 51.2 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.097 -1.002 . . . . 0.0 109.581 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.533 ' N ' ' O ' ' A' ' 94' ' ' THR . 27.8 tttt -53.35 -30.83 41.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.518 -0.739 . . . . 0.0 109.488 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 132.37 -49.29 0.93 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.7 -27.69 68.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.568 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . 0.64 ' CD2' HD23 ' A' ' 95' ' ' LEU . 97.7 m-70 -112.22 138.14 49.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -114.74 163.53 15.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.29 -0.881 . . . . 0.0 109.541 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.618 HG23 HG21 ' A' ' 122' ' ' THR . 39.5 t -108.22 137.27 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.48 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.464 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 49.0 mttt -85.31 142.47 29.32 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.936 . . . . 0.0 109.565 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.67 91.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.265 -0.897 . . . . 0.0 109.452 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -57.37 -40.41 78.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.185 -0.947 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.464 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 95.9 mt-30 -59.3 -37.3 77.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.502 HG13 ' OH ' ' A' ' 120' ' ' TYR . 43.7 t -67.36 -40.57 85.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.311 -0.868 . . . . 0.0 109.441 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.478 ' HA ' ' HE3' ' A' ' 137' ' ' LYS . 23.6 mttt -58.07 -41.23 82.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -68.27 -46.3 70.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.431 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.4 t -59.58 -45.75 90.95 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.27 -0.894 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.478 ' HE3' ' HA ' ' A' ' 134' ' ' LYS . 4.4 mtmp? -58.51 -43.08 88.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.267 -0.896 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -55.81 -47.94 76.29 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 87.5 mtp -56.07 -40.35 73.44 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.443 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.81 -41.86 94.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.54 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.3 mt-10 -66.42 -31.54 72.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.308 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 87.6 m -67.06 -31.77 72.51 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.283 -0.886 . . . . 0.0 109.237 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.455 ' HA ' HD23 ' A' ' 143' ' ' LEU . 37.0 mt -70.68 -50.05 40.67 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 109.339 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 3.7 pp -70.25 -33.01 71.11 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.205 -0.934 . . . . 0.0 109.46 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.431 ' N ' HD12 ' A' ' 144' ' ' LEU . 40.8 ttt180 -60.39 -43.88 96.22 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 0.0 109.412 179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.717 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -64.83 -38.38 90.78 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.866 . . . . 0.0 109.421 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 29' ' ' LEU . 53.6 t -60.61 -48.51 88.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.315 -0.865 . . . . 0.0 109.333 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.405 ' O ' HD23 ' A' ' 152' ' ' LEU . 84.5 tt0 -55.44 -52.39 63.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.274 -0.891 . . . . 0.0 109.482 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.3 m -51.63 -36.4 45.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.317 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -60.53 -43.55 97.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.371 -0.831 . . . . 0.0 109.23 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.624 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.5 mm? -62.09 -39.18 91.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.379 -0.825 . . . . 0.0 109.346 179.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.555 HD22 ' N ' ' A' ' 152' ' ' LEU . 4.0 mm? -66.95 -26.94 67.08 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.551 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.71 -44.57 95.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.506 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -90.75 -24.27 20.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 32.5 t -61.11 -29.06 69.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.595 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 57.7 p30 -105.93 18.33 22.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.92 . . . . 0.0 109.884 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -108.41 130.41 55.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.053 -1.029 . . . . 0.0 110.014 -179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 27.2 t80 -65.86 132.04 47.71 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.478 -0.764 . . . . 0.0 109.525 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 78.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.966 -1.016 . . . . 0.0 109.542 179.786 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 120' ' ' TYR . 58.2 t -132.05 145.9 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -1.157 . . . . 0.0 109.483 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.562 ' HB3' ' CE2' ' A' ' 5' ' ' TYR . 85.2 m-85 -99.43 137.07 38.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.398 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -121.84 119.75 32.53 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.571 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 3' ' ' PHE . 99.4 m-85 -123.5 133.94 53.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.214 -0.929 . . . . 0.0 109.449 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -124.54 137.97 54.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . 0.789 HG22 ' HE3' ' A' ' 137' ' ' LYS . 12.4 p -126.87 149.55 49.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -121.1 129.84 53.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.476 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 113' ' ' ILE . 37.5 p -135.68 157.39 46.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.343 -0.848 . . . . 0.0 109.495 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ILE . 64.1 p -117.28 157.29 26.33 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.536 ' OG ' HD12 ' A' ' 13' ' ' ILE . 17.3 t -146.02 142.04 28.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.534 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' O ' ' HA2' ' A' ' 111' ' ' GLY . 16.9 m -75.6 -23.89 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.362 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.846 HD13 HD12 ' A' ' 151' ' ' LEU . 2.9 mt -67.33 141.99 96.32 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.345 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.559 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 47.7 Cg_endo -70.0 141.23 43.71 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.482 2.121 . . . . 0.0 111.547 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' HB2' ' A' ' 19' ' ' PHE . . . -54.17 -32.3 55.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.326 -0.859 . . . . 0.0 109.816 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.98 -48.41 68.58 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.097 -1.002 . . . . 0.0 109.547 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.538 ' CB ' ' HG2' ' A' ' 14' ' ' PRO . 39.3 ttm-85 -71.82 -43.89 64.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.324 -0.86 . . . . 0.0 109.604 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.781 ' CD2' HD21 ' A' ' 114' ' ' LEU . 1.3 tp -67.6 -35.38 78.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.584 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 79' ' ' PHE . 69.4 t80 -62.53 -45.78 91.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.771 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HA ' HD13 ' A' ' 24' ' ' LEU . 29.2 mttt -64.18 -50.75 66.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.079 -1.013 . . . . 0.0 109.896 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.449 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -72.53 -38.34 68.05 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -0.945 . . . . 0.0 109.959 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.809 ' HZ ' HD13 ' A' ' 102' ' ' ILE . 72.8 t80 -73.63 -23.25 59.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.176 -0.953 . . . . 0.0 109.89 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' CE1' ' A' ' 19' ' ' PHE . 34.8 mm -102.5 -62.39 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.086 -1.009 . . . . 0.0 109.75 -179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 24' ' ' LEU . 6.7 mp -68.83 -37.38 79.12 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.624 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 65.8 m-20 -108.14 22.87 15.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.55 ' O ' ' CD2' ' A' ' 30' ' ' PHE . . . -73.29 -36.07 56.01 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.552 ' O ' HG21 ' A' ' 41' ' ' VAL . 82.6 m-20 -69.03 -42.58 76.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.294 -1.121 . . . . 0.0 109.595 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.409 ' O ' ' HG3' ' A' ' 32' ' ' LYS . 10.3 m-20 -82.25 -44.6 16.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.133 -0.979 . . . . 0.0 109.518 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 33' ' ' VAL . 14.1 tp -62.44 -20.62 64.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.599 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CD2' ' O ' ' A' ' 26' ' ' GLY . 1.6 m-30 -63.32 -64.01 3.44 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.205 -0.934 . . . . 0.0 109.416 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.55 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 52.7 Cg_endo -71.9 -33.25 10.19 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.652 2.235 . . . . 0.0 111.692 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 28' ' ' ASN . 76.6 mttt -62.56 -42.93 99.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.237 -0.914 . . . . 0.0 109.596 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 29' ' ' LEU . 11.6 m -83.77 -31.85 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.64 69.62 52.45 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.17 -0.956 . . . . 0.0 109.548 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.31 -13.45 33.29 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.697 2.265 . . . . 0.0 111.586 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -76.22 -18.86 58.85 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.872 . . . . 0.0 109.449 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.13 -46.71 7.3 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.255 -0.903 . . . . 0.0 109.288 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 56' ' ' ILE . 98.6 mt -126.44 125.76 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.519 ' OG ' ' CA ' ' A' ' 59' ' ' PRO . 67.1 m -65.96 -35.23 80.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.431 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.7 t -175.46 153.88 1.57 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.552 HG21 ' O ' ' A' ' 27' ' ' ASP . 26.0 m -122.96 136.03 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -127.59 149.83 49.99 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.454 ' OD1' ' HG2' ' A' ' 54' ' ' LYS . 93.5 m-20 -97.91 105.4 17.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.48 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 53' ' ' ILE . 81.9 mt -65.38 -56.0 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.194 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.847 ' O ' HG23 ' A' ' 52' ' ' THR . 76.0 tt0 -134.1 159.25 41.41 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.337 -0.852 . . . . 0.0 109.382 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.419 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 83.14 178.89 52.42 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -149.35 45.38 0.97 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.275 -1.132 . . . . 0.0 109.476 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.85 9.44 52.35 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.556 ' O ' HG11 ' A' ' 71' ' ' VAL . . . -110.56 -172.97 20.07 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.34 141.12 42.09 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.703 2.268 . . . . 0.0 111.84 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 81.74 11.22 83.17 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.847 HG23 ' O ' ' A' ' 45' ' ' GLU . 76.0 m -83.6 134.85 34.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.202 -1.175 . . . . 0.0 109.539 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.505 ' CD1' ' HG3' ' A' ' 70' ' ' ARG . 23.8 mm -106.36 132.53 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.938 . . . . 0.0 109.466 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.454 ' HG2' ' OD1' ' A' ' 43' ' ' ASN . 84.0 mttt -123.07 135.07 54.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.545 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 15.9 tttp -95.49 127.38 41.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.316 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 38' ' ' ILE . 78.7 mt -106.37 138.93 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.205 -0.935 . . . . 0.0 109.567 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.7 t -108.08 154.91 21.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.413 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.442 ' N ' ' O ' ' A' ' 65' ' ' LYS . 3.8 m-85 -116.95 126.79 27.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.699 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.519 ' CA ' ' OG ' ' A' ' 39' ' ' SER . 54.1 Cg_endo -74.24 -168.94 0.52 Allowed 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.709 2.273 . . . . 0.0 111.765 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' A' ' 59' ' ' PRO . 3.3 mt-10 50.56 177.48 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.849 . . . . 0.0 109.849 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 62' ' ' PHE . . . -88.73 26.87 7.72 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.139 -1.585 . . . . 0.0 109.139 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.468 ' O ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -42.1 165.99 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.452 -1.029 . . . . 0.0 109.701 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.98 -29.73 33.72 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.718 2.279 . . . . 0.0 111.911 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.578 ' CD2' ' HA3' ' A' ' 89' ' ' GLY . 79.6 m-85 -106.83 148.33 28.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.442 ' O ' ' N ' ' A' ' 58' ' ' PHE . 80.3 mttt -106.1 -40.85 5.53 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.74 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 56' ' ' ILE . 36.8 p90 -149.26 163.92 36.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.709 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.586 HG13 ' CA ' ' A' ' 88' ' ' GLY . 19.2 t -141.08 154.0 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.339 -0.851 . . . . 0.0 109.246 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 22.3 mttp -90.03 134.81 34.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.284 -0.885 . . . . 0.0 109.663 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.493 ' HA ' HG12 ' A' ' 85' ' ' VAL . 60.8 t0 -129.67 141.84 50.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.505 ' HG3' ' CD1' ' A' ' 53' ' ' ILE . 66.4 ttt180 -133.78 144.67 49.17 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.188 -0.945 . . . . 0.0 109.47 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 49' ' ' GLY . 14.0 p -100.31 134.76 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.459 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 54.8 t0 -77.84 -48.23 16.95 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 86.4 tt0 177.9 142.44 0.1 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.221 -0.925 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 81' ' ' TYR . 3.5 p -120.44 129.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -0.886 . . . . 0.0 109.56 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -100.23 106.24 17.89 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.437 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -64.35 -42.9 96.0 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.179 -0.951 . . . . 0.0 109.435 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.0 m -62.52 -42.71 99.7 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.887 . . . . 0.0 109.465 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 79' ' ' PHE . 12.5 m120 -91.03 7.62 39.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.552 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 82.6 m-85 44.2 28.92 0.31 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' LYS . 36.1 tttt -101.19 128.21 47.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.17 -0.956 . . . . 0.0 109.541 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.463 ' CD1' ' HB ' ' A' ' 74' ' ' VAL . 72.9 t80 -121.81 119.48 31.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.339 -0.851 . . . . 0.0 109.344 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -118.25 133.67 55.69 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 100' ' ' ASN . 36.7 p90 -146.35 159.24 43.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -0.847 . . . . 0.0 109.379 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 99' ' ' SER . 60.6 p -155.21 159.39 40.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.56 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 98' ' ' ILE . 27.0 m -105.74 150.4 8.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.385 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.809 ' N ' HD13 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -115.05 -54.25 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.394 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 43.8 tp10 -114.17 125.29 53.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.586 ' CA ' HG13 ' A' ' 67' ' ' VAL . . . -141.66 168.25 25.62 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.578 ' HA3' ' CD2' ' A' ' 64' ' ' PHE . . . -61.38 -58.04 15.26 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HB3' ' CE1' ' A' ' 64' ' ' PHE . 51.2 Cg_endo -72.15 -11.71 27.29 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.796 2.331 . . . . 0.0 111.819 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 97' ' ' LYS . 57.4 mt -114.47 143.63 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 109.568 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.485 ' HA3' HD13 ' A' ' 95' ' ' LEU . . . -104.54 -143.3 12.12 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.54 -42.53 99.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.129 -1.218 . . . . 0.0 109.242 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.532 ' O ' ' N ' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.2 21.41 0.19 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.353 -0.842 . . . . 0.0 109.439 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.626 HD12 ' N ' ' A' ' 95' ' ' LEU . 8.0 mp -65.33 -41.78 93.61 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.119 -0.988 . . . . 0.0 109.826 -179.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.422 ' HA ' ' O ' ' A' ' 121' ' ' HIS . 77.1 tt0 -155.65 51.2 0.56 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.119 -0.988 . . . . 0.0 109.865 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.57 ' HE2' HG22 ' A' ' 86' ' ' ILE . 0.1 OUTLIER -64.55 132.78 50.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.149 -0.969 . . . . 0.0 108.658 179.589 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 85' ' ' VAL . 66.9 mt -116.54 133.19 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.017 . . . . 0.0 110.272 -179.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 84' ' ' SER . 49.2 m -120.37 135.84 54.9 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 83' ' ' TYR . 93.8 m-20 -122.25 141.89 51.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.023 -1.048 . . . . 0.0 110.173 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 96.2 mt-10 -120.78 130.47 54.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.44 -0.787 . . . . 0.0 109.054 179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.809 HD13 ' HZ ' ' A' ' 22' ' ' PHE . 64.5 mt -116.32 131.82 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.144 -0.973 . . . . 0.0 109.973 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 80' ' ' LYS . 14.3 tttp -133.65 130.93 38.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.394 -0.816 . . . . 0.0 109.169 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.525 HD13 HD23 ' A' ' 18' ' ' LEU . 66.2 mt -111.33 130.61 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.09 140.27 48.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.269 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -87.27 141.66 28.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.497 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 112' ' ' SER . 1.5 p -103.01 163.24 17.92 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 109.42 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.49 ' HD2' ' HB ' ' A' ' 107' ' ' THR . 48.8 Cg_endo -69.9 -26.1 27.26 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.687 2.258 . . . . 0.0 111.754 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -70.85 -28.95 64.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.335 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 111' ' ' GLY . . . 132.85 -48.55 0.96 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.449 ' O ' ' O ' ' A' ' 110' ' ' GLY . . . -58.08 -156.54 0.02 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.636 ' HA ' HG23 ' A' ' 107' ' ' THR . 80.5 p -151.48 157.77 42.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -1.117 . . . . 0.0 109.463 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.574 HG13 HG22 ' A' ' 107' ' ' THR . 75.1 mt -107.92 147.93 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.332 -0.855 . . . . 0.0 109.238 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.781 HD21 ' CD2' ' A' ' 18' ' ' LEU . 94.0 mt -116.2 135.29 54.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.666 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 73.0 mttt -125.12 123.97 40.83 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.273 -0.892 . . . . 0.0 109.256 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 64.5 mt -124.61 138.67 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.166 -0.959 . . . . 0.0 109.684 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 40.4 m -124.68 134.84 52.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.266 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -113.49 143.52 44.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.79 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 76.7 mttt -133.3 139.1 46.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.356 -0.84 . . . . 0.0 109.037 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.613 ' O ' HG13 ' A' ' 2' ' ' VAL . 94.3 m-85 -117.38 131.97 56.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.049 . . . . 0.0 109.676 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 70.3 m-70 -115.72 131.64 56.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 109.367 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.6 HG21 HG23 ' A' ' 128' ' ' VAL . 68.0 p -132.63 137.65 47.09 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.212 -0.93 . . . . 0.0 109.666 179.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.532 ' N ' ' O ' ' A' ' 94' ' ' THR . 75.4 tttt -52.0 -34.29 41.99 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.494 -0.753 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.4 -47.38 0.99 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -60.5 -27.18 67.4 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.532 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -109.05 138.15 45.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -111.65 162.75 14.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.481 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.6 HG23 HG21 ' A' ' 122' ' ' THR . 23.6 t -110.91 133.65 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.246 -0.908 . . . . 0.0 109.459 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.458 ' HB2' ' HG3' ' A' ' 132' ' ' GLN . 78.3 mttt -89.16 146.14 24.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.487 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.08 -38.42 82.85 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.289 -0.882 . . . . 0.0 109.535 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -55.98 -44.36 78.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.458 ' HG3' ' HB2' ' A' ' 129' ' ' LYS . 23.7 mt-30 -57.9 -36.51 72.53 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.525 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.406 HG13 ' OH ' ' A' ' 120' ' ' TYR . 40.1 t -71.73 -35.6 55.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.232 -0.918 . . . . 0.0 109.598 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -60.61 -40.11 90.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.54 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -65.65 -50.31 65.43 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.207 -0.933 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.06 -38.85 87.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.927 . . . . 0.0 109.37 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.789 ' HE3' HG22 ' A' ' 7' ' ' THR . 53.1 tttt -61.63 -42.39 98.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -59.76 -42.56 93.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -0.92 . . . . 0.0 109.41 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 65.3 mtt -62.1 -38.5 89.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.388 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -58.6 -44.78 95.37 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.533 ' HA ' ' CD2' ' A' ' 144' ' ' LEU . 97.1 mt-10 -65.9 -31.86 73.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.279 -1.13 . . . . 0.0 109.497 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 86.1 m -66.64 -30.9 71.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.347 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 143' ' ' LEU . 31.6 mt -69.04 -49.03 61.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.319 -0.863 . . . . 0.0 109.733 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' A' ' 141' ' ' GLU . 2.3 pp -70.43 -30.98 67.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.179 -0.95 . . . . 0.0 109.709 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 75.5 mtt180 -67.5 -37.85 83.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -0.996 . . . . 0.0 109.431 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.532 ' HB1' ' HB ' ' A' ' 33' ' ' VAL . . . -68.29 -38.47 81.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.915 . . . . 0.0 109.425 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.846 HG13 HD21 ' A' ' 29' ' ' LEU . 65.3 t -61.72 -47.17 94.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.353 -0.842 . . . . 0.0 109.457 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.615 ' O ' HD23 ' A' ' 152' ' ' LEU . 98.6 mt-10 -59.23 -44.03 92.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.922 . . . . 0.0 109.548 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 20.0 m -58.33 -37.76 75.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.586 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -67.84 -52.39 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.901 . . . . 0.0 109.572 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.846 HD12 HD13 ' A' ' 13' ' ' ILE . 27.7 mt -63.5 -33.13 74.89 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 109.513 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 148' ' ' GLU . 3.7 mm? -73.58 -22.7 59.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.171 -0.955 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -61.7 -43.7 98.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -50.55 -39.25 48.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.875 . . . . 0.0 109.486 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 28.7 m -58.48 -29.49 66.25 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -72.43 -18.72 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.263 -0.898 . . . . 0.0 109.527 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -78.09 -10.64 59.71 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.154 -0.966 . . . . 0.0 109.513 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.539 ' CD1' ' C ' ' A' ' 158' ' ' TYR . 0.6 OUTLIER -50.15 -39.72 44.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.235 -0.915 . . . . 0.0 109.085 179.844 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . 0.462 ' OXT' ' OD1' ' A' ' 159' ' ' ASN . 28.7 t-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 117.909 -1.044 . . . . 0.0 109.493 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.535 HG13 ' O ' ' A' ' 120' ' ' TYR . 45.5 t -133.12 149.19 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -1.154 . . . . 0.0 109.565 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.577 ' HB3' ' CE1' ' A' ' 5' ' ' TYR . 83.2 m-85 -100.58 131.96 46.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.92 . . . . 0.0 109.408 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -115.63 121.52 42.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.612 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 3' ' ' PHE . 99.2 m-85 -123.2 134.79 54.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.394 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 117' ' ' SER . 93.9 mt-10 -120.38 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.193 -0.942 . . . . 0.0 109.578 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.7 p -129.56 158.95 37.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.245 -0.91 . . . . 0.0 109.424 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -134.81 127.37 30.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.315 -0.866 . . . . 0.0 109.573 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 27.4 m -133.67 137.6 45.42 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.328 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.709 HG22 HG23 ' A' ' 113' ' ' ILE . 36.4 p -124.09 155.39 38.45 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 109.515 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p -151.42 150.61 30.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.924 . . . . 0.0 109.422 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.9 m -67.79 -30.92 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' ' HD2' ' A' ' 14' ' ' PRO . 19.3 mm -53.62 141.86 43.82 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.411 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 13' ' ' ILE . 49.7 Cg_endo -70.7 141.23 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.482 2.121 . . . . 0.0 111.666 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.533 ' O ' ' CB ' ' A' ' 19' ' ' PHE . . . -60.92 -34.18 74.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.887 . . . . 0.0 109.784 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -58.11 -49.16 77.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.721 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.422 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 74.2 mtt85 -76.01 -43.86 42.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.778 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.738 ' CD2' HD21 ' A' ' 114' ' ' LEU . 2.3 tp -68.5 -36.83 79.47 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.669 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.86 ' HD1' HD12 ' A' ' 104' ' ' ILE . 67.8 t80 -62.84 -48.94 76.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 24' ' ' LEU . 76.1 mttt -63.03 -51.75 65.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.17 -0.957 . . . . 0.0 109.654 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.44 ' HA ' ' HB2' ' A' ' 25' ' ' ASP . . . -67.39 -37.49 83.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.107 -0.995 . . . . 0.0 109.73 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.522 ' CB ' ' O ' ' A' ' 18' ' ' LEU . 72.9 t80 -72.03 -26.55 62.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -0.922 . . . . 0.0 109.783 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 19' ' ' PHE . 35.1 mm -103.02 -58.42 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.944 . . . . 0.0 109.865 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 20' ' ' LYS . 6.5 mp -70.42 -33.99 71.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.846 -179.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' LEU . 64.7 m-20 -111.34 15.38 21.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.116 -0.99 . . . . 0.0 109.596 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.68 -30.95 70.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.496 ' CA ' HG21 ' A' ' 41' ' ' VAL . 94.9 m-20 -70.17 -43.81 70.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.482 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . 0.461 ' HB3' ' HE2' ' A' ' 32' ' ' LYS . 18.6 m-20 -86.14 -45.35 11.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.409 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.935 ' O ' HG22 ' A' ' 33' ' ' VAL . 13.5 tp -57.94 -31.7 67.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.353 -0.842 . . . . 0.0 109.649 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.535 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.9 OUTLIER -54.8 -63.67 2.68 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.591 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.535 ' CD ' ' CB ' ' A' ' 30' ' ' PHE . 49.4 Cg_endo -70.5 -34.46 12.06 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.697 2.265 . . . . 0.0 111.825 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.461 ' HE2' ' HB3' ' A' ' 28' ' ' ASN . 47.8 mttm -64.06 -42.82 96.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.935 HG22 ' O ' ' A' ' 29' ' ' LEU . 13.6 m -84.2 -31.64 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.624 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.14 72.54 39.23 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.229 -0.92 . . . . 0.0 109.576 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -15.04 35.63 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.631 2.22 . . . . 0.0 111.769 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.479 ' O ' ' CZ ' ' A' ' 62' ' ' PHE . 93.0 mt-30 -75.54 -18.64 59.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.402 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -90.96 -46.16 8.32 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.283 -0.886 . . . . 0.0 109.486 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.566 HG21 HG23 ' A' ' 56' ' ' ILE . 89.5 mt -134.0 121.49 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -60.05 -43.41 95.4 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.438 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 82.3 p -166.73 160.59 14.93 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.24 -0.913 . . . . 0.0 109.524 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.496 HG21 ' CA ' ' A' ' 27' ' ' ASP . 35.1 m -126.62 135.98 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' ASN . 41.1 tp10 -128.68 149.37 50.7 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.214 -0.929 . . . . 0.0 109.337 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 93.1 m-20 -95.46 107.52 19.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.19 -0.943 . . . . 0.0 109.566 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.851 HD12 HG22 ' A' ' 53' ' ' ILE . 80.3 mt -60.8 -61.92 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 109.416 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.818 ' O ' HG23 ' A' ' 52' ' ' THR . 81.6 tt0 -138.44 157.67 45.76 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.233 -0.917 . . . . 0.0 109.492 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.475 ' N ' ' HG2' ' A' ' 45' ' ' GLU . . . 89.53 168.49 43.4 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -115.51 25.96 10.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -1.147 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' H ' HG21 ' A' ' 52' ' ' THR . . . 104.66 -13.86 50.23 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -76.83 -167.78 27.53 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HB3' ' HA ' ' A' ' 73' ' ' GLU . 47.9 Cg_endo -68.24 140.79 49.98 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.797 2.331 . . . . 0.0 111.795 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 8.68 85.75 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 45' ' ' GLU . 94.9 m -86.53 141.03 29.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -1.134 . . . . 0.0 109.457 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.851 HG22 HD12 ' A' ' 44' ' ' ILE . 46.6 mt -111.62 128.86 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.532 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 43' ' ' ASN . 25.1 mttm -119.0 136.94 53.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.535 ' HE3' ' CD1' ' A' ' 66' ' ' TYR . 15.7 tttt -100.15 128.97 46.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.505 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.566 HG23 HG21 ' A' ' 38' ' ' ILE . 71.5 mt -108.22 139.33 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.312 -0.868 . . . . 0.0 109.493 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.407 ' O ' HG23 ' A' ' 38' ' ' ILE . 51.1 m -112.06 154.32 25.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 109.489 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PHE . . . . . 0.478 ' N ' ' O ' ' A' ' 65' ' ' LYS . 86.6 m-85 -121.85 141.74 34.64 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.472 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.68 155.35 66.43 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.751 2.301 . . . . 0.0 111.765 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -53.09 141.32 23.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.12 -0.987 . . . . 0.0 109.433 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.01 48.5 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.55 ' CD1' ' HD2' ' A' ' 63' ' ' PRO . 1.6 m-85 -108.41 169.87 6.1 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.296 -1.12 . . . . 0.0 109.491 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.55 ' HD2' ' CD1' ' A' ' 62' ' ' PHE . 49.2 Cg_endo -69.46 -49.7 0.57 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 111.791 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.551 ' CZ ' ' HD3' ' A' ' 90' ' ' PRO . 96.9 m-85 -119.64 148.86 42.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.247 -0.908 . . . . 0.0 109.495 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 58' ' ' PHE . 22.4 mttp -75.09 -44.79 45.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.186 -0.946 . . . . 0.0 109.698 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.535 ' CD1' ' HE3' ' A' ' 55' ' ' LYS . 36.0 p90 -151.41 165.29 34.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.166 -0.959 . . . . 0.0 109.702 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.587 HG23 ' HA2' ' A' ' 88' ' ' GLY . 13.9 p -145.94 147.51 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.351 -0.843 . . . . 0.0 109.33 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 1.015 ' O ' HG23 ' A' ' 85' ' ' VAL . 44.4 mttt -89.06 141.05 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.466 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.423 ' OD2' ' N ' ' A' ' 70' ' ' ARG . 60.3 t0 -139.55 146.17 39.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.181 -0.949 . . . . 0.0 109.527 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.443 ' HG2' HG12 ' A' ' 53' ' ' ILE . 46.7 mtp180 -126.47 152.76 46.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 83' ' ' TYR . 45.1 t -98.64 139.09 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 109.515 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 73' ' ' GLU . 52.3 t0 -80.0 -48.02 14.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 72' ' ' ASP . 84.7 tt0 178.68 151.98 0.32 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -0.92 . . . . 0.0 109.457 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 38.3 t -115.04 132.52 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.521 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 79' ' ' PHE . 93.5 m-20 -124.45 91.19 3.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.465 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -59.83 -44.45 94.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.884 . . . . 0.0 109.521 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 m -59.99 -41.91 93.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.489 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' PHE . 10.9 m120 -93.29 5.06 52.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 0.0 109.553 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.523 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 93.8 m-85 44.03 32.26 0.62 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.0 tttt -104.62 130.02 52.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.61 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -127.18 120.32 28.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.295 -0.878 . . . . 0.0 109.233 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 83' ' ' TYR . 12.0 t30 -124.32 140.75 52.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.742 -179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.59 ' CE1' ' HB3' ' A' ' 100' ' ' ASN . 40.4 p90 -142.5 144.94 33.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.019 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 21.4 m -132.42 154.52 49.76 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 109.868 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 1.015 HG23 ' O ' ' A' ' 68' ' ' LYS . 7.4 p -109.66 132.52 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.402 -0.811 . . . . 0.0 109.34 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.439 HG13 ' N ' ' A' ' 87' ' ' GLU . 46.0 pt -107.42 -28.17 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.25 -0.906 . . . . 0.0 109.503 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 68' ' ' LYS . 94.2 mt-10 -130.97 122.44 26.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.587 ' HA2' HG23 ' A' ' 67' ' ' VAL . . . -146.66 161.23 28.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.418 ' HA3' ' CD1' ' A' ' 64' ' ' PHE . . . -53.57 -63.4 5.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HD3' ' CZ ' ' A' ' 64' ' ' PHE . 53.1 Cg_endo -72.69 -2.7 12.26 Favored 'Trans proline' 0 C--O 1.216 -0.592 0 C-N-CA 122.762 2.308 . . . . 0.0 111.889 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.465 HG12 ' HB3' ' A' ' 96' ' ' GLU . 43.1 mt -118.28 143.61 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.755 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.43 -125.25 3.24 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -67.08 -47.58 70.82 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.125 -1.221 . . . . 0.0 109.116 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.635 HG23 ' HB2' ' A' ' 123' ' ' LYS . 0.0 OUTLIER -159.8 21.48 0.17 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.406 -0.809 . . . . 0.0 109.444 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 95' ' ' LEU . 6.8 mp -62.78 -40.27 96.78 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 110.203 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.465 ' HB3' HG12 ' A' ' 91' ' ' ILE . 76.7 tt0 -154.81 52.21 0.63 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.928 -1.107 . . . . 0.0 110.027 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.475 ' HB3' ' HB2' ' A' ' 121' ' ' HIS . 13.9 tttt -64.5 132.02 48.74 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.113 -0.992 . . . . 0.0 108.451 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 60.1 mt -119.95 132.23 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.124 -0.985 . . . . 0.0 110.345 -179.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 49.1 m -118.69 145.64 45.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 179.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.59 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 38.9 t-20 -137.73 132.7 33.19 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.924 -1.11 . . . . 0.0 110.295 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.455 ' O ' ' HA ' ' A' ' 116' ' ' ILE . 95.5 mt-10 -115.45 128.52 56.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.322 -0.862 . . . . 0.0 108.925 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 70.6 mt -113.45 135.12 54.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.087 -1.008 . . . . 0.0 109.961 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -133.66 125.94 29.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.127 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.86 HD12 ' HD1' ' A' ' 19' ' ' PHE . 66.2 mt -112.76 138.78 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.323 -0.861 . . . . 0.0 109.729 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.477 ' CG2' ' HB ' ' A' ' 113' ' ' ILE . 11.3 m -134.95 147.17 29.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -99.79 143.02 30.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.897 . . . . 0.0 109.501 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' THR . . . . . 0.421 HG23 ' O ' ' A' ' 111' ' ' GLY . 6.7 p -121.15 157.99 54.04 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.285 -0.884 . . . . 0.0 109.344 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.463 ' O ' ' OD2' ' A' ' 109' ' ' ASP . 48.8 Cg_endo -69.9 -48.02 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.744 2.296 . . . . 0.0 111.918 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.463 ' OD2' ' O ' ' A' ' 108' ' ' PRO . 92.1 m-20 -136.31 26.25 3.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.147 -0.971 . . . . 0.0 109.477 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.406 ' C ' ' OG1' ' A' ' 107' ' ' THR . . . -127.42 20.12 5.88 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.421 ' O ' HG23 ' A' ' 107' ' ' THR . . . 63.02 -147.47 50.47 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.2 p -112.84 146.73 38.36 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.241 -1.153 . . . . 0.0 109.394 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.709 HG23 HG22 ' A' ' 10' ' ' THR . 81.6 mt -115.8 129.65 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.199 -0.938 . . . . 0.0 109.462 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.738 HD21 ' CD2' ' A' ' 18' ' ' LEU . 4.8 mp -112.78 128.95 56.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.211 -0.93 . . . . 0.0 109.628 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -111.41 119.83 40.14 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.304 -0.872 . . . . 0.0 109.277 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 101' ' ' GLU . 73.2 mt -119.25 130.11 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.206 -0.934 . . . . 0.0 109.774 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 100' ' ' ASN . 51.1 m -117.74 138.33 52.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.342 -0.849 . . . . 0.0 109.082 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ASN . . . . . 0.471 ' ND2' ' CG ' ' A' ' 100' ' ' ASN . 26.0 m120 -119.62 141.4 49.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.16 -0.963 . . . . 0.0 109.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 98' ' ' ILE . 30.5 mttt -129.56 141.62 50.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.031 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.572 ' CE2' HG13 ' A' ' 133' ' ' VAL . 90.6 m-85 -118.93 126.41 51.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.109 -0.994 . . . . 0.0 109.749 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.475 ' HB2' ' HB3' ' A' ' 97' ' ' LYS . 84.5 m-70 -111.12 133.78 53.22 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.364 -0.835 . . . . 0.0 109.254 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.594 HG21 HG23 ' A' ' 128' ' ' VAL . 52.2 p -129.78 138.07 50.86 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.143 -0.973 . . . . 0.0 109.676 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' LYS . . . . . 0.635 ' HB2' HG23 ' A' ' 94' ' ' THR . 74.3 tttt -52.9 -35.36 58.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.464 -0.773 . . . . 0.0 109.377 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 135.87 -50.61 0.84 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -59.62 -30.53 68.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.236 -1.155 . . . . 0.0 109.567 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -110.03 137.6 47.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -115.13 162.73 16.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.245 -0.91 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.594 HG23 HG21 ' A' ' 122' ' ' THR . 39.8 t -110.39 133.69 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.191 -0.943 . . . . 0.0 109.438 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -80.38 143.35 33.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.523 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.39 -42.76 82.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -56.93 -42.56 80.22 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.215 -0.928 . . . . 0.0 109.372 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 60.0 tp60 -52.46 -36.56 55.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.077 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.572 HG13 ' CE2' ' A' ' 120' ' ' TYR . 25.6 t -73.49 -33.84 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.354 -0.841 . . . . 0.0 109.417 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -61.26 -38.85 88.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.516 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.82 -47.76 79.53 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.207 -0.933 . . . . 0.0 109.418 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 23.0 t -62.08 -37.53 85.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.5 tttm -58.36 -48.31 81.0 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.922 . . . . 0.0 109.505 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -59.66 -41.77 91.35 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.227 -0.921 . . . . 0.0 109.47 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 95.6 mmm -60.48 -41.2 93.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.3 -0.875 . . . . 0.0 109.433 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 144' ' ' LEU . . . -57.41 -46.0 92.34 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 91.7 mt-10 -69.34 -36.27 76.75 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.28 -1.13 . . . . 0.0 109.178 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 29.0 m -54.57 -32.15 57.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.367 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.492 ' O ' HG23 ' A' ' 147' ' ' VAL . 52.8 mt -73.07 -38.58 66.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.259 -0.901 . . . . 0.0 108.964 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.528 ' N ' HD23 ' A' ' 144' ' ' LEU . 5.6 mt -74.21 -33.03 63.26 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 38.1 ttp180 -66.67 -41.77 87.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.531 -0.731 . . . . 0.0 109.11 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -73.03 -43.6 61.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.323 -0.86 . . . . 0.0 109.35 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.922 HG13 HD21 ' A' ' 29' ' ' LEU . 57.7 t -61.65 -48.63 87.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.389 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.449 ' HG3' ' O ' ' A' ' 144' ' ' LEU . 96.2 mt-10 -55.23 -50.23 69.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.258 -0.901 . . . . 0.0 109.352 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 18.0 m -51.73 -38.63 56.12 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -0.9 . . . . 0.0 109.273 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -59.06 -44.72 91.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.395 -0.816 . . . . 0.0 109.414 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.7 mm? -60.03 -36.58 77.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.882 . . . . 0.0 109.499 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.601 HD22 ' N ' ' A' ' 152' ' ' LEU . 3.9 mm? -74.54 -21.03 59.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.236 -0.915 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -62.93 -31.25 72.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.31 -0.869 . . . . 0.0 109.485 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -56.38 -32.89 65.2 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' SER . . . . . . . . . . . . . 22.9 t -62.86 -21.15 65.76 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.575 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -85.65 5.96 29.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.22 -0.925 . . . . 0.0 109.646 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -95.1 125.62 39.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.107 -0.996 . . . . 0.0 109.499 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -58.23 129.56 42.56 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.481 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.423 179.954 . . . . . . . . 0 0 . 1 stop_ save_